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I 
 
Abstract 
 
 
The first total synthesis of (±)-janoxepin I, an antiplasmodial oxepine-pyrimidinone 
natural product isolated from the fungus Aspergillus janus is described herein. Chapter 
1 provides an introduction to janoxepin I and related natural products that have been 
reported in the literature. In Chapter 2, the available methods for the synthesis of 
oxepines and pyrimidinones are reviewed, before the preparation of dihydro-oxepine VI 
from readily available starting materials II-V is described. 
 
The enamine side-chain seen in janoxepin I was introduced by way of aldol-addition to 
the ketopiperazine ring. The development of methodology to achieve this efficiently, 
and its application to the synthesis of dihydro-janoxepin VII is described in Chapter 3. 
The synthesis of janoxepin I was completed by way of a novel dihydro-oxepine 
elaboration to construct the oxepine ring. This transformation was the subject of much 
investigation as discussed in Chapter 4.  
 
The proposed biosynthesis of janoxepin I from pyrazino[2,1-b]quinazoline-3,6-dione 
VIII was identified as an alternative strategy for oxepine synthesis. Chapter 5 first 
briefly reviews pyrazino[2,1-b]quinazoline-3,6-dione-containing natural products and 
the available methods for their synthesis. It then describes the preparation of the 
putative biosynthetic precursor of janoxepin VIII with a view to further investigation of 
biomimetic methods for oxepine synthesis.  
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Chapter 1.  Introduction: Oxepine-Pyrimidinone-Containing Natural 
Products – Janoxepin 
1.1  Isolation 
 
Janoxepin (1) is a novel tricyclic oxepine-containing secondary metabolite isolated from 
the fungus Aspergillus janus in 2005 by Sprogøe and co-workers (Figure 1.1).1 Also 
isolated from the same ethyl acetate extract was brevicompanine B (2) which has been 
isolated from other sources2 and was the subject of a total synthesis in 2001.2,3 
Aspergillus janus was first reported in 1940 by Raper and Thom;4 a component of the 
Panamanian microflora, it is so named because it possesses two distinct conidial head 
types.   
 
 
Figure 1.1. Janoxepin (1) and brevicompanine B (2). 
1.2  Structural Features and Assignment 
 
Sprogøe and co-workers describe janoxepin (1) as an orange crystalline powder with a 
melting point of 88-89 °C.1 The structure was determined through 1H and 13C-NMR 
spectroscopy (in conjunction with COSY, HMBC and nOe experiments) together with 
mass spectrometry.1 Key features include an unsaturated enamine side chain in the Z-
configuration (confirmed by nOe data),1 and a D-leucine derived stereocentre which was 
determined as (R) by Marfey’s method - derivatisation with 1-fluoro-2,4-dinitrophenyl-
5-L-alaninamide (FDAA) and HPLC analysis.5  
 
1.3 Biological Activity 
 
In a radio-isotope assay, janoxepin (1) was found to demonstrate antiplasmodial activity 
against the malaria parasite Plasmodium falciparum 3D7, exhibiting an IC50 value of 28 
mg/mL. It is suggested that the actual IC50 value is lower, as the compounds were 
observed to precipitate in the test media.1 
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1.4  Structurally Related Natural Products 
 
The oxepine-pyrimidinone system incorporated in janoxepin (1) is highly unusual, only 
found in a small family of closely related natural products. Before focussing on this 
small class of compound, a brief overview of natural products bearing the oxepine 
moiety is insightful. First however, the nomenclature of oxepines needs to be clarified. 
 
1.4.1 Oxepine Nomenclature   
 
The most recent reviews of the literature surrounding the synthesis of oxepines6-8 have 
classified any seven-membered ring containing a single oxygen atom as an ‘oxepine’, 
‘oxepene’ or ‘oxepin’. Given the differing levels of saturation that are possible in such 
structures, the different properties they exhibit, and the very different challenges that 
their synthesis presents, here ‘oxepines’ have been categorised and named according to 
this characteristic: 
 An ‘oxepine’ herein is defined as a fully unsaturated seven membered ring bearing a 
single oxygen atom. Therefore, three carbon-carbon double bonds will be present in 
the heterocycle (Figure 1.2, 3).  
 A ‘dihydro-oxepine’ has a higher level of saturation, bearing two double bonds in 
the ring (Figure 1.2, 4).  
 A ‘tetrahydro-oxepine’ bears a single double bond as part of the heterocycle (Figure 
1.2, 5). 
 An ‘oxepane’ is defined as a fully saturated seven membered ring bearing a single 
oxygen atom. No carbon-carbon double bonds will be present in the heterocycle 
(Figure 1.2, 6). 
 
Figure 1.2. ‘Oxepines’ defined according to the level of saturation. 
Where an aromatic group is fused to the heterocycle, the same definitions will apply 
(Figure 1.3). 
 
Figure 1.3. ‘Oxepine’ definition applied to substrates with fused aromatic groups. 
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1.4.1 Oxepine-Containing Natural Products 
 
Whilst numerous natural products containing dihydro- and tetrahydro-oxepine as well 
as oxepane moieties have been reported such as brevitoxin B,9 gambierol,10 
ptilomycalin A,11 aranotin12 and psammaplysin I,13 compounds based on an oxepine are 
less common. Dibenzo-oxepine compounds represent the largest class of oxepine-
containing natural product which includes artoristilbene (10),14 artocarpol A (11),15 
bauhinoxepin A (12)16 and bauhiniastatin 1 (13)17 as shown in Figure 1.4.      
 
Figure 1.4. Dibenzo-oxepine-containing natural products. 
 
Few oxepine-containing natural products lacking dibenzo-annelation (excluding the 
oxepine-pyrimidinone family) have been reported. Tenual (14) and tenucarb (14a),18 
perilloxin (15) and dehydroperilloxin (16),19 fusidienol (17),20 fusidienol A (18),21 
isofusidienol A-B (19-20)22 and microsphaeropsone C (21)23 remain the only examples 
(Figure 1.5), none of which bear the 2,3-disubstituted oxepine seen in janoxepin (1). 
 
Figure 1.5. Oxepine-containing natural products. 
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1.4.2  Oxepine-Pyrimidinone-Containing Natural Products 
 
Although small, the number of oxepine-pyrimidinone compounds isolated from natural 
sources is ever growing (Figure 1.6).   
 
Cinereain (22) was isolated by Cutler and co-workers from the fungus Botrytis cinerea 
in 1988 and its structure confirmed by X-ray crystallography.24 Structurally, it differs 
from janoxepin (1) only by the possession of a valine-derived saturated side chain 
which was subsequently reported to be derived from L-valine,1 although the absolute 
stereochemistry was not defined in the original publication.24  In bioassays, cinereain 
(22) demonstrated growth inhibition of wheat coleoptiles in the 10-4 – 10-3 M range, 
indicating wider potential as a plant growth regulator.24 
 
Belofsky, Köck and co-workers reported the isolation of oxepinamides A-C (23-25) 
from the culture broth and mycelia of an Acremonium sp. fungus found on the surface 
of the Caribbean tunicate Ecteinascidia turbinata in 2000.25 These compounds all 
possess an 11-methoxy substituent on the oxepine ring as well as an alanine-derived 
saturated side-chain (only relative stereochemistry reported). Oxygenated substituents 
were observed in place of the enamine moiety seen in janoxepin (1). Only oxepinamide 
A (23) showed notable biological activity, demonstrating good anti-inflammatory 
activity in a topical resiniferatoxin-induced mouse ear oedema assay.25 
 
Oxepinamide D (26) was reported in 2011, isolated from the fungus Aspergillus 
puniceus obtained from a Chinese soil sample.26 Whilst oxepinamide D (26) contains a 
related oxepine-pyrimidinone-ketopiperazine core to that seen in janoxepin (1), the 
closely related oxepinamides E-G (27-29) contain a 13-oxygenated dihydro-oxepine 
ring and a different pattern of conjugation through the pyrimidinone-ketopiperazine 
bicyclic system. The structure of oxepinamide E (27) was confirmed by X-ray 
crystallography. Oxepinamides D-G (26-29) were shown to be novel liver X receptor 
agonists with potential use in the treatment of atherosclerosis, diabetes and Alzheimer’s 
disease.26   
 
Zhang and co-workers isolated brevianamides O-P (30-31) from the harmful fungus 
Aspergillus versicolor in 2009/2010.27 Like oxepinamide D, these compounds have a 
close relative in brevianamide L (32)28 which contains a 13-oxygenated dihydro-
5 
 
oxepine ring. None of the brevianamides showed any notable activity in cytotoxicity 
assays.  
 
 
Figure 1.6. Oxepine-pyrimidinone-containing natural products. 
 
Protuboxepin A (33) and protuboxepin B (34) are very close relatives of brevianamide P 
(31) and were isolated by Oh and co-workers from the Aspergillus species SF-5044 
found in a Korean sediment sample.29 Protuboxepin A (33) displayed weak cell growth 
inhibition properties against a panel of cell lines.29  
 
The benzodiazepine oxepine alkaloids, circumdatin A30,31 [asperloxin A (35)32] and 
circumdatin  B (36)30 also possess the oxepine-pyrimidinone system seen in janoxepin 
(1). First isolated from the fungus Aspergillus ochraceus in 1999, they were only 
identified as oxepine-containing compounds following subsequent isolation of 
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circumdatin A (35) (also from Aspergillus ochraceus) by Zeeck and co-workers in 
200232 and a structural revision by Kusumi and co-workers in 2008.33 The isolation of 
asperloxin B (37)32 was reported with that of circumdatin A (35) and it was found to 
possess a dihydro-oxepine bearing ketone functionality at the 11-position.  
1.5  Proposed Biogenesis 
 
It was proposed by Sprogøe,1 Kiyota26 and Zeeck32 that janoxepin (1) (as well as the 
other oxepine-pyrimidinone-ketopiperazine containing natural products 22-37 in Figure 
1.6) might be derived from diketopiperazine 40, the product of the condensation of two 
amino acid residues. Cyclic dipeptide oxidase catalysed oxidation would then follow (as 
required) in analogy with the proposed biosynthesis of albonoursin (45) which occurs 
via the diketopiperazine (DKP) biosynthetic pathway.34 It is proposed that condensation 
with anthranilic acid 42 would then occur to form arene-derivative 43 which could 
undergo an intriguing epoxidation, rearrangement and electrocyclic ring opening 
sequence to form the oxepine ring (Scheme 1.1).  
 
 
Scheme 1.1. Proposed biogenesis of janoxepin (1). 
1.6  Strategy  
 
To the best of our knowledge there have been no reports of synthetic routes to janoxepin 
(1) or any of the aforementioned oxepine-containing natural products (14-37) that lack 
dibenzo-annelation. Furthermore, there have been no reported methods for the 
preparation of the unusual oxepine-pyrimidinone system incorporated in janoxepin (1). 
Focusing on the development of a synthetic route to janoxepin (1), preliminary studies 
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carried out by Jones in 2008 utilised a biosynthetically inspired retrosynthetic analysis 
of the oxepine-pyrimidinone system (Scheme 1.2).35 This relied on rearrangement and 
electrocyclic ring opening of epoxide 44 to form the oxepine ring. The alkene in 
epoxide 44 would be installed by allylic bromination of pyrimidinone 45 followed by 
elimination. A cyclocondensation between a suitable amidine such as 47 and 
cyclohexene carboxylate 48 would be used to generate the key pyrimidinone 
intermediate 46.  
 
Scheme 1.2. Initial retrosynthetic analysis of janoxepin (1). 
 
However, the synthetic challenges encountered in the preparation of model compounds 
of pyrimidinone 46 could not be overcome, and the alternative approach shown in 
Scheme 1.3 was devised. This strategy relied upon late stage elaboration of a dihydro-
oxepine such as 49 to construct the oxepine ring.35 It was proposed that the enamine 
side chain could be installed by means of an aldol addition to the ketopiperazine ring at 
a convenient point in the synthesis, whilst the dihydro-oxepine would be prepared by 
ring-closing metathesis (RCM) of advanced diallyl intermediate 50. Diallyl intermediate 
50 would be constructed by O-allylation of pyrimidinone 51, itself prepared from the 
condensation of amidine 52 and malonate 53 in analogy with the original strategy. 
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Scheme 1.3. Revised retrosynthetic analysis of janoxepin (1). 
1.7  Aims of the Project 
 
The core project aim was to develop a synthetic route to janoxepin (1) to enable a more 
thorough evaluation of its biological activity. Not only this, janoxepin (1) represents an 
excellent target for the elucidation of novel strategies to access the other oxepine-
pyrimidinone natural products (22-37) shown in Figure 1.6, some of which are of 
notable biological interest.  
 
Initial investigations would be focussed on developing methods for the construction of 
the oxepine-pyrimidinone system and the synthesis of a model compound. Attention 
would then turn to utilising the developed methodology to incorporate the 
ketopiperazine ring and synthesise the tricyclic core of janoxepin (1) before exploring 
the introduction of the enamine moiety by way of aldol addition to the ketopiperazine 
ring. 
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Chapter 2. Oxepine-Pyrimidinone Ring System Construction 
 
2.1  Oxepine-Pyrimidinone Synthesis: Literature Routes 
 
In order to highlight all the relevant literature examples that are available, the synthesis 
of oxepine-, dihydro-oxepine-, tetrahydro-oxepine- and oxepane-pyrimidinones is 
covered in this review. 
2.1.1 Intramolecular Cyclisation Strategies 
 
To the best of our knowledge Weisz and co-workers reported the only synthesis of an 
oxepine-pyrimidinone system in 1973. They observed the intramolecular 
cyclodehydrohalogenation of barbituric acid derived iodide 54 to dibenzo-oxepine 55 in 
low yield under photochemical conditions (Scheme 2.1).36 
 
Scheme 2.1. Photocyclodehydrohalogenation of iodide 54 to dibenzo-oxepine 55. 
 
There is more precedent for the intramolecular cyclisation of barbituric acid derivatives 
to furnish dihydro- or tetrahydro-oxepine-pyrimidinones. Majumdar and co-workers 
reported the 6-endo-trig cyclisation of cyclo-pentene 57 to bridged tetrahydro-oxepine 
58 upon treatment with a brominating agent such as pyridine hydrotribromide (Scheme 
2.2).37  
 
Scheme 2.2. 6-endo-trig cyclisation of cyclo-pentene 57. 
 
Williams and co-workers utilised an intramolecular Mitsunobu reaction to construct the 
oxepane ring in O-methyl guanine derivative 60 (Scheme 2.3).38 
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Scheme 2.3. Oxepane-pyrimidinone construction utilising Mitsunobu chemistry.  
2.1.2 Intermolecular Strategies 
 
The intermolecular cyclisation of barbituric acid derivatives to provide dihydro-
oxepine-pyrimidinone compounds has also been reported. Zoorob and co-workers 
observed the formation of bridged dihydro-oxepine 64 upon treatment of catechol 62 
with an excess of N,N’-dimethylbarbituric acid 61 in the presence of potassium 
ferricyanide, presumably via the intermediate furan 63 (Scheme 2.4).39 
 
Scheme 2.4. Intermolecular cyclisation of  N,N’-dimethylbarbituric acid 61 and catechol 62. 
 
Building on earlier work by Zoorob and co-workers,40 Singh and Paul observed the 
cyclisation of N,N’-dimethylbarbituric acid 61 with alkyl dihalides such as 65 under 
basic phase transfer conditions. In this case dihydro-oxepine 67 was isolated as the 
minor product, the spirocyclic barbituric acid derivative 66 predominating (Scheme 
2.5).41 
 
Scheme 2.5. Intermolecular cyclisation of  N,N’-dimethybarbituric acid 61 and alkyl dihalide 65. 
 
The substitution patterns of the oxepine-, dihydro-oxepine, tetrahydro-oxepine and 
oxepane-pyrimidinone products seen in these literature examples, as well as the 
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synthetic methods employed were clearly not applicable to the synthesis of janoxepin 
(1). It was therefore necessary to develop a novel approach having considered literature 
precedent for the synthesis of oxepines and pyrimidinones in isolation. 
2.2 Dibenzo-Oxepine Synthesis: Literature Examples 
 
The proposed synthetic strategy for construction of the oxepine ring of janoxepin (1) 
involved an uncommon elaboration of a dihydro-oxepine, the literature surrounding the 
synthesis of which will be reviewed in detail later (2.4).  The reported methods for the 
direct synthesis of oxepines, including dibenzo-oxepines, are first summarised. The 
literature surrounding methods for dibenzo-oxepine preparation is vast. Scheme 2.6 
summarises the most common approaches, where arene-oxide ring expansion 
transformations have long been known to give access to their oxepine isomers (reaction 
i).42 Synthetic strategies however have largely relied on the manipulation of keto-43,44 or 
halo-derivatives42,45 (reaction ii) and electrophilic aromatic substitution (reaction iii).43 
More recently, intra-molecular Buchwald reactions (reaction iv)46 and oxidative radical 
rearrangements47 (reaction v) have also been reported as convenient methods.  
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Scheme 2.6. Strategies for dibenzo-oxepine synthesis. 
2.3 Oxepine Synthesis: Literature Routes 
 
Only a limited number of strategies have been reported for the preparation of oxepines 
lacking dibenzo-annelation. Whilst most approaches rely upon the reversible 
isomerisation of arene-oxides to oxepines, a limited number of inter- and intramolecular 
cyclisation examples also exist. Of particular relevance to our planned strategy, the 
elaboration of dihydro-oxepines via eliminative transformations has also been reported, 
although such examples are rare.   
2.3.1 Arene-Oxide – Oxepine Isomerisation 
 
The reversible, photochemically or thermally-induced electrocyclic ring opening of 
arene-oxides to oxepines has been well documented.48 In particular, the isomerisation of 
arene-oxides of polycyclic aromatic hydrocarbons49 (including phenanthracene50) such 
as 79 as well compounds such as methyl benzoate derivatives51 have been the subject of 
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much investigation (Scheme 2.7). Boyd and O’Kane reported that in the absence of 
light, the arene-oxide:oxepine ratio of an anthryl-oxepine remained constant at 43:57 as 
shown by NMR analysis. Upon irradiation with UV light for 30 minutes the ratio shifted 
to 10:90 in favour of the oxepine.52 
 
 
Scheme 2.7. A representative reversible electrocyclic ring opening of arene-oxide 79 to oxepine 80. 
 
The isolation of oxepines resulting from the isomerisation of Dewar-benzene epoxides 
has also been reported. Warrener and co-workers observed the isomerisation (t0.5 = 77 
min at 30 °C) of Dewar-benzene epoxide 81 to oxepine 82 which existed in equilibrium 
with arene-oxide 83 in solution, although they did not report the ratio of the two 
products obtained (Scheme 2.8).53 
 
 
Scheme 2.8. Isomerisation of Dewar-benzene epoxide 81 to oxepine 82/arene-oxide 83. 
 
Although a convenient method, the reversibility of the transformation can lead to low 
yields of isolated oxepine product. This is often compounded by light54 or acid55 
induced aromatisation to phenol derivatives or oxygen rearrangement. It is proposed 
that the latter can occur via a diradical ‘oxygen walk’ (Scheme 2.9) or by [1,5]-
sigmatropic (Scheme 2.10) pathways leading to the isolation of isomeric species.52,53,56  
 
 
Scheme 2.9. Proposed ‘oxygen walk’ diradical mechanism for oxygen rearrangement. 
 
 
 
Scheme 2.10. Proposed [1,5]-sigmatropic mechanism for oxygen rearrangement. 
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Such transformations are well exemplified by the rearrangement followed by ring-
opening of dihydro-furan 91 to oxepine 93 upon irradiation with a mercury lamp 
(Scheme 2.11). In this case the oxepine can be isolated in excellent yield, although it is 
sensitive to acidic conditions.55  
 
 
Scheme 2.11. Oxygen rearrangement and ring opening in the synthesis of oxepine 93. 
 
This study also serves to demonstrate that arene-oxide electrocyclic ring-opening is not 
just limited to benzannelated systems. Sankaraman and co-worker’s synthesis of 
diethynyl oxepine 97 from its cyclohexadiene precursor 94 is another good example of 
this (Scheme 2.12).57  
 
Scheme 2.12. Synthesis of diethynyl oxepine 97 via arene-oxide ring opening. 
 
Friedrichsen and co-workers extended the scope of this methodology to the synthesis of 
more complex heterocyclces. They reported the synthesis of oxepine-isoxazole 101 
from the rhodium(II) acetate mediated cyclisation of diazo-diester 98 to furan 99 with 
subsequent cycloaddition of dimethyl acetylenedicarboxylate 100 (Scheme 2.13). The 
oxygen rearrangement required to generate a suitable epoxide for ring-opening is 
remarkable, and thus unambiguous proof of the products structure was provided by X-
ray crystallographic analysis.58 No comment is made on yield however, although 
Yamazaki and co-workers utilised the same approach for oxepine formation in the 
preparation of benzoxepines from benzofurans achieving 42-62% yields.59   
 
Scheme 2.13. Synthesis of oxepine-isoxazole 101. 
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Albini and co-workers reported the photochemical rearrangement of phenazine-5-oxide 
102 to the pyrazine-containing oxepine 104 in 1972. In this case, the yield of oxepine 
104 obtained was very low (6%), with greater quantities of azepinone 103 being 
isolated (38%) (Scheme 2.14).60 Similar observations were subsequently made by 
Niizuma and co-workers in 1985.61  
 
 
Scheme 2.14. Rearrangement of phenazine-5-oxide 102 to azepinone 103 and oxepine 104. 
 
A final example of the synthesis of oxepines in complex heterocyclic systems is the 
gold-catalysed synthesis of oxepine 110 from ω-alkynyl furan 105, first reported by 
Hashmi and co-workers in 2007 (Scheme 2.15).62 Subsequent mechanistic studies 
followed in 2008.63 It is proposed that the reaction proceeds via cyclopropyl carbenoid 
107 which undergoes ring-opening to intermediate 108. Cyclisation to arene-oxide 109 
followed by ring-opening to form oxepine 110 then occurs.  
 
 
Scheme 2.15. Gold catalysed synthesis of oxepine 110 via arene-oxide 109. 
 
The literature examples outlined above demonstrate that an arene-oxide electrocyclic 
ring-opening strategy could be applied to the synthesis of 2,3-disubstitued oxepines 
such as janoxepin (1). However, the challenges associated with preparing suitable 
substrates for such transformations, frequent requirement for poly-substitution around 
the oxepine ring and low yields do not make it an attractive synthetic option. 
 
 
 
16 
 
2.3.2 Other Intramolecular Pathways to Oxepines 
 
Examples of intra-molecular events leading to oxepine formation (not involving arene-
oxide ring-opening) are extremely rare. Langer and co-workers reported the synthesis of 
oxepines in low to moderate yields by the ring-opening of cyclopropane 111 under 
acidic conditions (Scheme 2.16).64 However, there is a requirement for an electron-
withdrawing group on the cyclopropane as well as ketone functionality on the pyran 
ring for this reaction to proceed. It is therefore hard to envisage the method being 
applicable to the synthesis of 2,3-disubstituted oxepines such as janoxepin (1).  
 
 
Scheme 2.16. Oxepine synthesis by ring-enlargement of cyclopropanes. 
 
The only other notable example is the intramolecular aldol condensation between the 
α,β-unsaturated ester and aldehyde functionalities of substrate 113 as reported by Zeitler 
and Mager in 2007 (Scheme 2.17).65 The apparently facile dehydration of hydroxyl-
intermediate 114, which the reaction presumably passes through, is particularly 
interesting in terms of possible eliminative strategies for oxepine formation. 
 
 
Scheme 2.17. Formation of oxepine 115 by intra-molecular aldol condensation. 
 
2.3.3 Intermolecular Cyclisation to Oxepines 
 
Oxepines have also been prepared via intermolecular cyclisation events. Lu and Liu 
reported the fascinating palladium catalysed [5+2] annelation reaction between boronic 
acid 117 and alkyne 116 as shown in Scheme 2.18. This involves nucleophilic attack of 
an intermediate vinyl-palladium species onto the ketone. Oxepine 119 was isolated in 
good yield following the in situ dehydration of hydroxy-derivative 118, a process which 
could be prevented by the addition of base to the reaction mixture.66 
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Scheme 2.18. [5+2] annelation reaction between boronic acid 117 and alkyne 116. 
 
The rhodium(I) catalysed reaction of alkyne 121 and cyclopropene 120 has also been 
reported as shown in Scheme 2.19. It is proposed that initial electrophilic attack of the 
rhodium(I) species on the cyclopropene gives metal carbene 122 which undergoes a 
[2+2]-cycloaddition with alkyne 121. The resulting metallocyclic intermediate 123 then 
undergoes rearrangement followed by reductive elimination of the rhodium(I) species to 
give oxepine 125 in good yield. It was noted that treatment of oxepine 125 with acid 
induced aromatisation to a phenolic derivative.67 
 
 
Scheme 2.19. Rhodium-catalysed cyclisation of cyclopropene 120 and alkyne 121. 
 
A final example of an intermolecular cyclisation leading to oxepine formation was 
reported by Tsuchiya and co-workers. In this reaction, pyridyne 127 is first generated 
from the treatment of aminotriazolopyridine 126 with lead tetra-acetate. This then 
undergoes cyclisation with pyridazine N-oxide 128 to afford oxepine 131. Mechanistic 
studies indicated that the reaction proceeds via cycloadduct 129 which undergoes N-O 
bond fission and a [1,3]-shift to give intermediate 130. The oxepine ring is then 
generated with the loss of nitrogen (Scheme 2.20).68,69  
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Scheme 2.20. Cyclisation of pyridazine N-oxide 128 and pyridine 126 to form oxepine 131. 
2.3.4 Dihydro-Oxepine Elaboration 
 
The direct oxidation of dihydro-oxepines to oxepines (Scheme 2.21) either via radical 
(e.g. DDQ) or dehydrogenative (e.g. Pd/C) approaches has not been reported. However, 
two examples of the preparation of oxepines from dihydro-oxepines through an 
eliminative approach exist. 
 
 
Scheme 2.21. Dihydro-oxepine elaboration. 
 
Hoffman and Djafari reported the synthesis of oxepine 133 by trapping the enol-
tautomer of enone 132 generated under basic conditions with acetic anhydride (Scheme 
2.22).70 
 
 
Scheme 2.22. Trapping enol tautomer of enone 132 as enol ester 133. 
 
They subsequently demonstrated that double bond migration of enone 132 followed by 
Luche reduction of the ketone gave alcohol 135. This could then be eliminated 
following activation as a tosylate using potassium tert-amylate as base to generate 
oxepine 136 (Scheme 2.23).71  
 
19 
 
 
Scheme 2.23. Elaboration of enone 132 to oxepine 136. 
 
Apart from these examples, the dehydration of hydroxy-dihydro-oxepine intermediates 
114 and 118 as seen in Schemes 2.1766 and 2.1865 respectively is also worthy of note. 
Given the potential utility of this eliminative approach, it is important to consider 
methods for the preparation of suitable dihydro-oxepine substrates. Again, few literature 
examples exist, however, epoxidation followed by base-induced ring-opening is one 
possible approach as demonstrated by the preparation of allylic alcohol 139 in Wijnberg 
and co-workers’ synthesis of pterulone (140) (Scheme 2.24).72 It is interesting to note 
that m-CPBA epoxidation was not possible in this case due to the m-chlorobenzoate 
anion formed during the reaction immediately opening epoxide 138. 
 
Scheme 2.24. Epoxidation followed by base-induced ring-opening to generate allylic alcohol 139. 
 
Allylic bromination of a dihydro-oxepine is also a reasonable strategy for preparing a 
substrate that could undergo dehydrobromination to an oxepine. However, this has only 
been reported on dibenzo-oxepine substrates such as 141, and as long ago as 1973 
(Scheme 2.25). No yield was reported for the reaction.42  
 
 
Scheme 2.25. Allylic bromination of dibenzo-dihydro-oxepine 141. 
 
Similarly, allylic oxidation could provide a suitable substrate for elimination to an 
oxepine. Chattopadhyay and co-workers prepared enone 144 from selenium dioxide 
oxidation at the allylic-benzylic position of dihydro-oxepine 143 (Scheme 2.26). A 
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reduction – activation – E2’ elimination sequence can be envisaged for subsequent 
elaboration to the corresponding oxepine.73 
 
 
Scheme 2.26. Allylic oxidation of dihydro-oxepine 143. 
 
2.4 Dihydro-Oxepine Synthesis: Literature Routes 
 
Synthetic approaches to the preparation of dihydro-oxepines have been well reviewed 
(alongside those of tetrahydro-oxepines) in recent years.6,7,74 In particular, the 2006 
review by Peczuh and co-workers covers an expansive cross-section of the literature, 
categorising syntheses according to carbon-carbon (C-C) and carbon-oxygen (C-O) 
bond-forming reactions (Figure 2.1).8 Since then, there have been a number of advances 
in both these categories as well as in ring-enlargement approaches to dihydro-oxepines.  
 
Figure 2.1. Categorisation of synthetic routes to dihydro-oxepines.8 
 
2.4.1 Carbon-Carbon Bond Forming Reactions 
 
Ring-closing metathesis (RCM) has been used effectively in numerous settings since the 
Peczuh review. Whilst examples such as Widhalm and co-workers’ synthesis of 
dihydro-oxepine-containing biheteroaryl compounds using RCM are notable,75 the 
application of RCM in natural product synthesis is of particular relevance here. An 
example of this is the synthesis of ptaeroxylinol (147) as reported by Moody and co-
workers in 2010. RCM of diallyl intermediate 145 using Grubbs second generation 
catalyst 148 followed by silyl deprotection completed the synthesis (Scheme 2.27). 
Another recent application of RCM in natural product synthesis is found in Yoshida’s 
synthesis of radulanin H.76 
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Scheme 2.27. RCM in the synthesis of dihydro-oxepine-containing ptaeroxylinol (147). 
 
Another advance in C-C forming reactions is the electrophilic carbocyclisation of aryl 
propargylic alcohols as reported by Liang and co-workers. Diiodo-dihydro-oxepine 
derivatives 150 were prepared in 44-72% yields by treatment of aryl propargylic alcohol 
149 with iodine in nitromethane at 80 °C (Scheme 2.28). Whilst the diiodides obtained 
might have application in subsequent coupling reactions, they have no direct utility in 
the synthesis of janoxepin (1).77  
 
 
Scheme 2.28. Electrophilic carbocyclisation of aryl propargylic alcohols 149 to dihydro-oxepines 150. 
 
A final recent example of a dihydro-oxepine being prepared via a C-C bond forming 
reaction is the synthesis of benzoxepinones through a silver-mediated Kondakov-
Darzens olefin acylation. Jarvo and Barczak reported that treatment of a range of O-allyl 
benzoic acids 151 with oxalyl chloride followed by silver(II) triflate gave access to 
benzo dihydro-oxepines 152 in 50-76% yields (Scheme 2.29).78 The potential 
application of benzoxepinones in dihydro-oxepine elaboration to oxepines has already 
been discussed. 
 
 
Scheme 2.29. Benzoxepinone synthesis via silver-mediated Kondakov-Darzens olefin acylation. 
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2.4.2 Carbon-Oxygen Bond Forming Reactions 
 
The transition metal-catalysed cycloisomerisation of alkynols for the synthesis of 
dihydro-oxepines has been the focus of many studies since the Peczuh review. For 
example, Saá and co-workers reported the osmium-mediated cycloisomerisation of 
aromatic alkynols 153 to dihydro-oxepines 154 in 56-69% yields (Scheme 2.30).79 
 
 
Scheme 2.30. Osmium-catalysed cycloisomerisation of alkynols. 
 
This methodology has also been applied to natural product synthesis. Reisman and co-
workers utilised a rhodium-catalysed cycloisomerisation of alkynol 155 to tetrahydro-
oxepine 156. A dehydrohalogenation then afforded the dihydro-oxepine 157 in their 
synthesis of the dihydro-oxepine epidithiodiketopiperazine natural product (–)-
acetylaranotin (158) (Scheme 2.31).80  These examples demonstrate that a wide 
substrate scope can be tolerated by such methodology making it a powerful C-O bond 
forming tool for the synthesis of dihydro-oxepines.  
 
 
 
Scheme 2.31. Rhodium-catalysed cycloisomerisation of alkynol 155 to tetrahydro-oxepine 156 in the 
synthesis of (–)-acetylaranotin (158). 
2.4.3 Ring-Expansion Methodology 
 
A novel ring-expansion method for dihydro-oxepine synthesis has also been reported 
since the 2006 review. Snapper and Leyhane demonstrated that epoxidation of strained 
cyclobutenes 159 followed by thermally-induced ring-expansion gave access to 
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diastereomeric dihydro-oxepines 161 and 162 (Scheme 2.32).81 The diastereomeric ratio 
obtained (believed to be due to fragmentation of the epoxide through diradical 
pathways) varies depending on the nature of the R1 and R2 substituents. 
 
 
Scheme 2.32. Epoxidation and ring expansion of cyclobutenes 159. 
 
Having considered the many different strategies for preparing dihydro-oxepines 
outlined above, RCM was identified as the most suitable method for the synthesis of 
janoxepin (1) in accordance with the retrosynthetic analysis outlined in Scheme 1.3. 
2.5 Pyrimidinone Synthesis: Literature Routes 
 
The literature surrounding dihydro-oxepine elaboration to oxepines was not extensive, 
however the planned RCM - dihydro-oxepine elaboration strategy was still an attractive 
one (Scheme 2.33). An efficient method for the preparation of a suitable pyrimidinone 
such as 163 would therefore be required.  
 
 
Scheme 2.33. Proposed strategy for oxepine construction. 
 
Reported approaches to the synthesis of this class of pyrimidinone utilise a narrow 
range of reactions. They exclusively rely on condensation of an amidine/amino-pyridine 
and a dicarbonyl compound to form the pyrimidinone ring. A subsequent substitution 
reaction to install the O-alkyl chain is then performed. For example, Urban and co-
workers prepared pyrimidinone 168 from the condensation of 2-aminopyridine 166 and 
commercially available malonate 167 using NaOEt as base. They then utilised the 
nucleophilic nature of the hydroxyl of the isolated enol tautomer 168 to perform an O-
allylation with allyl bromide (Scheme 2.34).82 
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Scheme 2.34. Condensation-O-allylation sequence to synthesis diallyl pyrimidinone 169. 
 
An almost identical approach was applied using a range of alkyl bromides by 
Venkatesan and co-workers in their synthesis of pyrimidinone 172.83 In this case the 
condensation reaction was performed in the absence of base but at high temperature 
with the continuous removal of ethanol (Scheme 2.35).83 No yields are reported for the 
reaction sequence, however Utley and co-workers demonstrated the efficient nature of 
such condensation reactions, achieving 74-96% yields on a range of substrates.84  
 
Scheme 2.35. Pyrimidinone preparation through condensation at high temperature in the absence of base 
followed by O-alkylation with alkyl bromides. 
 
The synthesis of dihydro-furan 176 is another interesting example highlighting the 
nucleophilicity of the enol-oxygen. Under acidic conditions pyrimidinone 175 (prepared 
from condensation of amino-pyridine 173 and malonate 174 but not discussed) is seen 
to readily cyclise to dihydro-furan 176 (Scheme 2.36).85 
 
 
Scheme 2.36. Preparation of pyrimidinone 175 and subsequent acid-mediated cyclisation to dihydro-
furan 176. 
 
An alternative strategy commonly used also relies on a condensation reaction to form 
the pyrimidinone ring. However, the polarity of the hydroxyl functionality is reversed 
by installing a good leaving group, thereby generating an electrophilic centre. 
Alkylation is then possible by nulceophilic attack. One such example shown in Scheme 
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2.37 uses POCl3 to generate chloride 180 from pyrimidinone 179 which is readily 
displaced by morpholine to furnish amine 181.56  
 
 
Scheme 2.37. Condensation followed by alkylation by addition of a nucleophile. 
 
E. Taylor and co-workers expanded on early work by Dox and Yoder,86 demonstrating 
that amidines and not just amino-pyridines could be used to prepare pyrimidinones via 
condensation with malonate derivatives. They employed malonyl dichloride 183 as an 
alternative to the commonly used malonate ester substrates in the synthesis of 
pyrimidinone 184. In this case the hydroxyl group is activated for elimination by 
forming triflate 185. This is then displaced by nucleophilic attack of a cyanocuprate to 
furnish the desired alkylated product 186 (Scheme 2.38).87   
 
 
 
Scheme 2.38. Condensation of amidine 182 and malonyl dichloride 183 followed by alkylation with 
a cyanocuprate. 
 
Ureas have also been employed to prepare pyrimidinones in condensation reactions. 
Lal and co-workers used a one-pot process to synthesise pyrimidinone chloride 192 
from urea 187 and malonic acid 188 in moderate yield (Scheme 2.39).88 It is 
proposed that initial cyclisation of urea 187 to cyclic amidine 189 is followed by 
condensation with the POCl3 activated malonic acid 190. Although an interesting 
transformation, the requirement of an activated aromatic species for cyclisation to 
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occur does limit its application. Morpholine was again used to demonstrate that 
nucleophilic substitution of chloride 192 was possible in good yield. 
 
 
Scheme 2.39. One pot synthesis of pyrimidinone 191 from urea 187 and malonic acid 188 followed 
by nucleophilic substitution with morpholine. 
 
Methods for pyrimidinone synthesis are not limited to the condensation of an amino-
pyridine or amidine with a malonate derivative. This is exemplified by the cyclisation of 
imidate 194  with aniline to furnish pyrimidinone 195 (Scheme 2.40).89 In this case, the 
required O-substitution was already installed whilst a range of primary alkyl amines 
were successfully used. 
 
 
Scheme 2.40. Pyrimidinone 195 preparation by condensation of aniline and imidate 194. 
 
2.6 Pyrimidinone-Oxepine Model Study 
 
In order to prove the viability of the planned strategy initial investigations were 
focussed on repeating the synthesis of a compound to model the oxepine-pyrimidinone 
system seen in janoxepin (1). The novel oxepine-pyrimidinone 196 had been identified 
as a suitable target molecule by Jones in 2008, a retrosynthetic analysis of which is 
shown in Scheme 2.41.35 As with the retrosynthetic analysis of janoxepin (1) (Scheme 
1.3) the oxepine ring would be generated through elaboration of dihydro-oxepine 197, 
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itself prepared by RCM of diallyl pyrimidinone 198. This key intermediate would be 
synthesised by condensation of amidine 200 and malonate 201.  
 
Scheme 2.41. Retrosynthetic analysis of model compound 196. 
 
Jones’ synthesis35 first required known amidine 20090 which was readily prepared from 
reaction of benzonitrile and n-propylamine in the presence of AlCl3.
91 This underwent 
condensation with the commercially available malonate 201 in the presence of NaOMe 
to provide pyrimidinone 199 in moderate, but acceptable yield. O-Allylation was 
effected by treatment of pyrimidinone 199 with KOH followed by the addition of allyl 
bromide to afford the diallyl pyrimidinone intermediate 198. This underwent a very 
efficient RCM with Grubbs second generation catalyst 148 to furnish the dihydro-
oxepine 197 (Scheme 2.42). Pleasingly when this was repeated the yields achieved 
compared very well with those reported by Jones.35 
 
 
Scheme 2.42. Synthesis of dihydro-oxepine 197. 
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Earlier attempts to elaborate dihydro-oxepine 197 to the desired oxepine via allylic 
bromination followed by dehydrobromination had been unsuccessful.35 Therefore Jones 
elected to convert dihydro-oxepine 197 to the racemic vicinal dibromide 202. A number 
of bases failed to mediate subsequent dehydrobromination to the desired oxepine 196. 
The screened bases comprised DBU, NaOMe, MTBD and t-BuOK, all in THF.35 
Elimination was eventually achieved by treatment of dibromide 202 with TBAF (1.0 M 
solution in THF) in DMSO at room temperature, affording the desired oxepine-
pyrimidinone 196 in an excellent 87% yield.35 Disappointingly though, this result could 
not be replicated in subsequent attempts. A consistently reproduced yield of 28-30% 
was instead achieved (Scheme 2.43).  
 
 
Scheme 2.43. Dihydro-oxepine elaboration: bromination – dehydrobromination. 
 
The structure of oxepine-pyrimidinone 196 was assigned by 1H and 13C-NMR 
spectroscopy in conjunction with HSQC and COSY experiments. Relevant signals for 
the spectra obtained compared favourably to those of janoxepin (1) but to provide 
unambiguous structural proof it was desirable to obtain an X-ray crystal structure. 
Dihydro-oxepine 197, dibromide 202 and oxepine 196 were not crystalline solids and 
therefore were unsuitable substrates for analysis. However, the study was expanded and 
hydrogenation of dihydro-oxepine 197 afforded tetrahydro-oxepine 203 as a colourless 
crystalline solid for which an X-ray crystal structure was obtained (Scheme 2.44). 
 
 
 
 
 
Scheme 2.44. Tetrahydro-oxepine 203: synthesis and X-ray crystal structure. ORTEP representation 
shown with ellipsoids at 50% probability. CCDC 862141. 
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Despite the low yield associated with dihydro-oxepine elaboration, the model study did 
demonstrate that the planned strategy for oxepine-pyrimidinone synthesis was viable. 
Attention now turned to investigation of ketopiperazine ring construction and 
subsequent incorporation into the developed methodology. 
2.7 Cyclic Amidine Synthesis 
 
As outlined in the retrosynthetic analysis of janoxepin (1) (Scheme 1.3), it was proposed 
that the key ketopiperazine-pyrimidinone 51 could be prepared from the condensation 
of cyclic amidine 52 and malonate 201 (Scheme 2.45).  
 
Scheme 2.45. Retrosynthetic analysis of pyrimidinone 51. 
 
Using a synthetic route reported by Isobe and co-workers,92 cyclic amidine 52 was 
efficiently prepared. Employing D-leucine 38 as the chiral starting material, Boc 
protection followed by coupling with aminoacetonitrile bisulfate via a mixed anhydride 
and then formic acid deprotection provided amine 206. This underwent a one-pot 
oximation – cyclisation – hydrogenation sequence to afford the desired novel cyclic 
amidine 52 on multi-gram scale in just 4 steps and 63% yield from D-leucine 38 (which 
compared favourably to that obtained by Isobe and co-workers (61%) for a similar 
reaction sequence) (Scheme 2.46).92  
 
 
Scheme 2.46. Synthesis of cyclic amidine 52. 
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The poor solubility of amidine 52 meant that chiral HPLC analysis to ascertain its ee 
could not be undertaken. However, optical rotation measurements ([α]D
22 –47 c = 1.0, 
MeOH) suggested that the configuration of the stereocentre may have been retained.  
2.8 Preparation of Pyrimidinone 51 
 
Cyclic amidine 52 was first subjected to the condensation conditions successfully used 
in the model study. Pleasingly, reaction of amidine 52 and dimethyl malonate 201 with 
NaOMe in refluxing MeOH furnished the desired pyrimidinone 51 in 58% yield (Table 
2.1, entry 1). However, it was desirable to improve the reaction efficiency for this 
critical step. Allowing for higher reaction temperatures, diethyl malonate 167 and 
ethanol as solvent were next investigated (Table 2.1, entry 2). Disappointingly, the yield 
achieved fell to just 32% of the desired pyrimidinone 51 with substantial quantities of 
malonate hydrolysis products 208 and 209 observed in the 1H-NMR spectrum of the 
crude product. The side-products also led to a difficult purification by flash column 
chromatography, further reducing the isolated yield.  
 
Steendam (an Erasmus visitor) investigated ways to minimise this problem in 2010.93 
He reported that using dimethyl malonate 201 in MeOH with a greater excess of Na 
could drastically reduce the reaction time. Together with implementing strictly 
anhydrous conditions - MeOH was dried over Mg(OMe)2,
94 glassware was flame-dried 
under vacuum and activated 3 Å molecular sieves were added to the reaction mixture - a 
much improved 72% yield of pyrimidinone 51 was achieved (Table 2.1, entry 3).93 
 
Entry Malonate Conditions Yield 51 
1 201 Na (3.0 eq.), MeOH, 66 °C, 18 h 58% 
2 167 Na (3.0 eq.), EtOH, 78 °C, 18 h 32% 
3 201 Na (6.0 eq.), MeOH, 3Å mol. sieves, 66 °C, 3 h 72% 
 
Table 2.1. Optimisation study for the condensation of cyclic amidine 52 with allyl malonates.93 
 
Steendam also explored the reaction of malonyl-dichloride 210 with cyclic amidine 
52.93 Dichloride 210 was prepared from the commercially available malonic acid 208 by 
heating with thionyl chloride and was used without purification. Two condensation 
31 
 
conditions were investigated. The use of triethylamine as base in THF at –78 °C to 
room temperature returned only a 17% yield of pyrimidinone 51 (Table 2.2, entry 1). 
Using NaHMDS as base furnished only 14% of the desired product (Table 2.2, entry 
2).93 It is proposed that the low yields are associated with the facile hydrolysis of 
malonyl dichloride 210 back to malonic acid 208 under the reaction conditions.  
 
 
Entry Conditions Yield 51 
1 NEt3 (2.0 eq.), THF, –78 °C - rt 17% 
2 NaHMDS (2.0 eq.), THF, –78 °C - rt 14% 
 
Table 2.2. Optimisation study for the condensation of cyclic amidine 52 with malonyl dichloride 210.93 
 
Again, the poor solubility of pyrimidinone 51 prevented chiral HPLC analysis to 
evaluate the ee of the product obtained. The optical rotation measurement observed 
([α]D
22 +0.8 c = 1.0, MeOH) suggested that racemisation of the substrate had occurred 
during the condensation step, however. An unambiguous evaluation of the ee of a 
subsequent intermediate was therefore critical. 
 
2.9 Preparation of Diallyl Pyrimidinone 50 
 
The conditions for O-allylation used in the model study were investigated first. 
Treatment of pyrimidinone 51 with KOH in DMF followed by the addition of allyl 
bromide 211 and heating provided diallyl pyrimidinone 50 but in a low 42% yield 
(Table 2.3, entry 1). Whilst this result produced material for investigation of subsequent 
steps, it was clear that such a low yield in a linear synthesis would not be sustainable. 
An extensive optimisation study was undertaken by Steendam93 who first investigated 
using allyl bromide 211 with K2CO3 as base in refluxing acetone. Diallyl pyrimidinone 
50 was isolated in 35% yield, whilst 7% of the intriguing bis-allylated compound 212 
was also isolated (Table 2.3, entry 2). The addition of TBAI in order to increase the rate 
of reaction by a Finkelstein-type mechanism offered a slight improvement in overall 
yield at lower temperatures (Table 2.3, entry 3). In order to minimise the amount of bis-
allylation observed using just one equivalent of allyl bromide 211 was investigated. 
This had the desired effect with respect to over alkylation – no bis-allylated compound 
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212 was isolated – but resulted in a small drop in yield of 50 (Table 2.3, entry 4). 
Changing the iodide source to NaI had a significant detrimental effect on yield (Table 
2.3, entry 5) whilst changing the solvent to THF offered a slight improvement (Table 
2.3, entry 6). Experimentation with Cs2CO3, Ag2CO2 and NaOMe as bases typically 
resulted in no reaction at all (Table 2.3, entries 7-10) whilst a formal deprotonation of 
pyrimidinone 51 with NaH in THF at –78 °C followed by addition of the alkylating 
agent was also unsuccessful.93 
 
 
Entry 
Equiv. 
211 
Base  
(1.5 eq.) 
Additive 
(1.5 eq.) 
Conditions Yield 50 
1 1.5 KOH - DMF, 60 °C, 2 d 41% 
2 1.5 K2CO3 - Acetone, 56 °C, 16 h 35% + 212 7% 
3 1.5 K2CO3 TBAI Acetone, 0 °C – rt, 2 h 41% + 212 7% 
4 1.0 K2CO3 TBAI Acetone, –78 °C – 0 °C, 18 h 37% 
5 1.0 K2CO3 NaI Acetone, 0 °C – rt, 3 d 21% 
6 1.0 K2CO3 TBAI THF, –78 °C – rt, 3 d 42% 
7 1.0 Cs2CO3 TBAI Acetone, 60 °C, 4 d 7% 
8 1.0 Cs2CO3 TBAI DMF, 60 °C, 4 d - 
9 1.0 Ag2CO3 TBAI Acetone, 60 °C, 6 d - 
10 1.0 NaOMe TBAI MeOH, rt, 3 d - 
11 1.0 NaH TBAI THF, –78 °C – rt, 2 d - 
 
Table 2.3. Optimisation study for O-allylation with allyl bromide 211.93 
 
It was clear that a different approach was required in order to achieve selectivity for O-
allylation and an acceptable yield for this transformation. Steendam proposed the 
Mitsunobu reaction of pyrimidinone 51 and allyl alcohol 213 with an azodicarboxylate 
214 and a phosphine as an alternative strategy.93 Initial experiments using diethyl 
azodicarboxylate (DEAD) with PPh3 and PBu3 returned similar yields to those achieved 
in the allyl bromide study (Table 2.4, entries 1-2). Using the sterically hindered di-tert-
butyl azodicarboxylate (DBAD) resulted in lower yields (Table 2.4, entry 3) whilst the 
more readily available di-iso-propyl azodicarboxylate (DIAD) was used with great 
success. With the addition of NEt3 as a base and a higher reaction temperature, diallyl 
pyrimidinone 50 was isolated in 73% yield after just 2 hours (Table 2.4, entry 4). This 
result could be reliably reproduced on an 8 g scale. 
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Entry 
Phosphine 
(2.2 eq.) 
Azodicarboxylate 
214 
Additive Conditions Yield 50 
1 PPh3 DEAD (R = Et) - THF, 10 °C – rt, 2 d 32% 
2 PBu3 DEAD (R = Et) - THF, 10 °C – rt, 2 d 30% 
3 PPh3 DBAD (R = t-Bu) - THF, 10 °C – rt, 2 d 21% 
4 PPh3 DIAD (R = i-Pr) 
NEt3 
(1.0 eq.) 
THF, 10 °C – 60 °C, 2 h 73% 
 
Table 2.4. Optimisation study for O-allylation using Mitsunobu conditions.93 
 
Chiral HPLC analysis (Chiralpak AD-H column) of diallyl pyrimidinone 50 was 
undertaken and confirmed that the material was essentially racemic (53:47 er). Optical 
rotation measurements ([α]D
22 +0.5 c = 1.0, MeOH) were in agreement with this 
outcome which is presumably a result of racemisation during the cyclocondensation 
step.  
2.10 Preparation of Dihydro-Oxepine 215 
 
Pleasingly, RCM of diallyl pyrimidinone 50 was as efficient as that observed in the 
model study. Initial experiments utilised the more thermally stable Grubbs-Hoyveda 
second generation catalyst 216, with dropwise addition of the catalyst in a single batch 
to the substrate 50 at high dilution. An acceptable 70% yield was achieved (Table 2.5, 
entry 1). This yield was considerably improved (88%) by addition of the catalyst in two 
batches separated by 2 h (Table 2.5, entry 2). Continuing to use this addition technique, 
it was shown that Grubbs second generation catalyst 148 not only gave similar yields 
(Table 2.5, entry 3) but also allowed for much reduced reaction times (Table 2.5, entry 
4). 
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Entry 
Catalyst 
(10 mol%) 
Catalyst addition 
(dropwise over 30 min) 
Conditions Yield 215 
1 216 1 batch DCM (2.5 mM), 45 °C, 18 h 70% 
2 216 2 batches, 1 h apart DCM (2.5 mM), 45 °C, 18 h 88% 
3 148 2 batches, 1 h apart DCM (2.5 mM), 45 °C, 18 h 90% 
4 148 2 batches, 1 h apart DCM (2.5 mM), 45 °C, 4 h 91% 
 
Table 2.5. Optimisation study for RCM of diallyl pyrimidinone 50. 
 
X-ray crystallography confirmed the structural assignment of dihydro-oxepine 215 and 
gave an insight into the conformation of the molecule (Figure 2.2). A planar central 
pyrimidinone ring can be clearly seen flanked by the dihydro-oxepine ring adopting a 
pseudo-boat conformation, and the ketopiperazine also adopting a boat conformation. 
Two enantiomers were present in the unit cell providing further evidence that 
racemisation had indeed occurred. 
 
 
Figure 2.2. X-ray crystal structure of dihydro-oxepine 215. Only a single (R) enantiomer is shown for 
clarity. ORTEP representations shown with ellipsoids at 50% probability. CCDC 848130, Appendix V. 
 
2.11 Dihydro-Oxepine Elaboration 
 
The elaboration of dihydro-oxepine 215 to its corresponding oxepine using the 
bromination – dehydrobromination methodology developed in the model study was 
investigated next. Bromination of dihydro-oxepine 215 proceeded in moderate yield 
using molecular bromine (Table 2.6, entry 1). This yield was much improved by using 
the easily handled pyridine hydrotribromide as a brominating agent (Table 2.6, entry 2).  
35 
 
Dibromide 217 was isolated as a racemic mixture of trans-diastereomers which could 
not be separated.  
 
 
Entry Brominating Agent Conditions Yield 217 
1 Br2 DCM, –48 °C, 40 min 55% 
2 PyHBr3  DCM, rt, 1.5 h 85% 
 
Table 2.6. Optimisation study for the bromination of dihydro-oxepine 215 (single diastereomer shown). 
 
Unfortunately dehydrobromination to oxepine 218 could not be achieved. Treatment of 
dibromide 217 with a range of bases (Table 2.7) gave a complex mixture of products. 
Whilst the presence of trace amounts of oxepine 219 could not be ruled out, analysis of 
the 1H-NMR spectrum of the unpurified product identified the isomer 218 as the major 
compound (approx. 25% yield in each case). A new singlet in the alkene region and loss 
of the ketopiperazine methylene proton signals indicated that deprotonation of the 
ketopiperazine had occurred to afford this conjugated isomer. Mass spectrometry also 
identified the mono-elimination product bromide 220.    
 
 
Entry Base (2.1 eq.) Conditions 
1 TBAF (1.0 M in THF) DMSO, rt, 30 min 
2 TBAF (1.0 M in THF) THF, –78 °C – rt, 4 h 
3 DBU THF, –78 °C – rt, 4 h 
4 t-BuOK THF, –78 °C – rt, 4 h 
5 t-BuOK (1 M in t-BuOH) DMF, 0 °C – rt, 4 h 
 
Table 2.7. Dehydrobromination conditions explored. 
 
Given the apparently facile deprotonation of the ketopiperazine it was clear that an 
elaboration of dihydro-oxepine 215 involving a base-induce elimination was not going 
to be an efficient transformation. 
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2.12 Summary 
 
Using methodology developed through the synthesis of the model compound 196 the 
tricyclic core of janoxepin (1) was efficiently constructed using condensation, 
Mitsunobu and RCM transformations. However, the acidic nature of the ketopiperazine 
methylene unit prevented thorough investigation of oxepine synthesis by elaboration of 
the dihydro-oxepine 215. It was proposed that this problem could be addressed by first 
installing the enamine side-chain required at this position. The investigation of this is 
described in Chapter 3.  
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Chapter 3. Enamine Installation: Ketopiperazine Substitution 
 
It was proposed that installation of the unsaturated enamine side-chain seen in 
janoxepin (1) could be achieved via an aldol-like condensation of iso-butyraldehyde 221 
and dihydro-oxepine 215 (Scheme 3.1).  
 
Scheme 3.1. Proposed aldol condensation. 
3.1 Ketopiperazine Substitution: Literature Examples 
 
Whilst the condensation of unprotected ketopiperazines (bearing an amide N-H) with 
aromatic aldehydes has been reported, a large excess of base and long reaction times 
were required.95 This is thought to be due to deprotonation of the amide rendering the 
neighbouring methylene protons much less acidic. Avendaño and co-workers 
demonstrated this through the alkylation of ketopiperazine-pyrimidinone 223 where, 
crucially, no epimerisation of the C-1 stereocentre was observed (80% ee matches the ee 
of the starting material), and instead alkylation occurs α- to the carbonyl (C-4). A large 
excess of LiHMDS (10 eq.) was required to achieve a moderate yield of the trans-
diastereomer 224 (95% de) (Scheme 3.2).96  
 
Scheme 3.2. No epimerisation at C-1 indicates poor reactivity of methylene protons to base when 
adjacent to amide N-H. 
 
Protection of the amide is therefore a requirement for efficient substitution at the 
ketopiperazine C-1 position. N-Acyl-, N-carbamate-, N-alkyl- and imidate-protection 
strategies have all been successfully used in aldol and alkylation approaches, whilst 
Mannich-Hoffmann and Horner-Wadsworth-Emmons (HWE) methodologies have also 
been applied.  
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3.1.1 Aldol Approaches Utilising N-Acyl- and N-Carbamate Protecting Groups 
 
Liberato and Gallina reported the efficient condensation of N-acyl-diketopiperazine 225 
with a number of aliphatic and aromatic aldehydes in 1973 (Scheme 3.3).97 They 
observed loss of the acyl group due to a kinetically favourable intra-molecular acyl 
transfer mechanism, resulting in the intermediate aldol addition species undergoing 
elimination to predominantly Z-alkenes (ratio not disclosed). Since then, this 
methodology has been used successfully in the synthesis of the structurally related 
natural product albonoursin (45)98 and a novel flutimide isomer.20 
 
Scheme 3.3. Aldol condensation of aliphatic and aromatic aldehydes with N-acyl-diketopiperazine 225. 
 
Of particular relevance to the synthesis of janoxepin (1), Menéndez and co-workers 
recently described the condensation of N-acyl-ketopiperazine-pyrimidinone 228 with 4-
chlorobenzaldehyde 229 using potassium tert-butoxide as base. A high yield of the de-
acylated Z-enamine 230 was achieved in excellent ee with the N-acyl group being 
removed during the reaction (Scheme 3.4).99  
 
Scheme 3.4. Aldol condensation of N-acyl-ketopiperazine-pyrimidinone 228 with 4-chlorobenzaldehyde 
229. 
 
Nishiyama and co-workers demonstrated that the condensation of N-Boc-protected 
ketopiperazines with benzaldehyde 232 also proceeded with great efficiency. As seen 
with N-acyl derivatives, the adjacent Boc group was lost through an acyl transfer 
mechanism to furnish an 84:16 mixture of Z/E enamine products 233 and 234 (Scheme 
3.5).100   
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Scheme 3.5. Aldol condensation of N-Boc-diketopiperazine 231 with benzaldehyde 232. 
 
Working with the similar substrate 235, Davies and co-workers reported that 
condensation with iso-butyraldehyde 221 using LiHMDS as the base at low temperature 
is also possible; the aldol adduct 236 was isolated in 52% yield as a single diastereomer 
(Scheme 3.6). The cis-configuration of substituents on the ketopiperazine ring was 
established by nOe studies, whilst the diastereoselective syn-aldol addition was 
tentatively assigned based upon a coupling constant between H-1 and H-2 of 2.4 Hz. 
This assignment assumed restriction of rotation about the new bond due to hydrogen 
bonding between the hydroxyl and carbonyl groups. Subsequent deprotonation with 
KHMDS effected elimination with acyl-transfer to furnish the Z-enamine 237 in 62% 
yield and excellent ee (Scheme 3.6).101  
 
Scheme 3.6. Aldol condensation using LiHMDS as base. 
3.1.2 Aldol Approaches Utilising N-Alkyl Protecting Groups 
 
N-Alkyl protecting groups have been widely used in the aldol condensation of 
aldehydes with ketopiperazine-containing substrates. Menéndez and co-workers 
described the condensation of N-methyl-ketopiperazine-pyrimidinone 238 with 4-
chlorobenzaldehyde 229 to furnish a mixture of enamines 239 and 240 (74:26) in a near 
quantitative yield (Scheme 3.7). In this case, however, partial epimerisation of the 
stereocentre is observed during the reaction.99   
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Scheme 3.7. Aldol condensation of N-methyl-ketopiperazine-pyrimidinone 238 and  
4-chlorobenzaldehyde 229. 
 
The para-methoxybenzyl (PMB) protecting group has also been widely used, and has 
the advantage of its (usually) facile removal using DDQ or CAN. One such example, as 
reported by Bartolomé and co-workers, is the addition of benzaldehydye 232 to N-
PMB-ketopiperazine-pyrimidinone 241 which led to the isolation of aldol adduct 242 in 
low yield (Scheme 3.8). Despite an extensive optimisation study, the yield could not be 
improved, possibly due a competing retro-aldol reaction. What is more, whilst giving 
good selectivity for relative syn-substitution across the ketopiperazine ring, the long 
reaction times required resulted in racemisation of the C-4 stereogenic centre. No 
comment as to the diastereoselectivity of aldol addition was made.102 Elimination to the 
enamine was not observed under these reaction conditions, although alcohol activation-
elimination has been reported as an efficient method for achieving this transformation 
(see Scheme 3.10). 
 
Scheme 3.8. Aldol addition of benzaldehyde 232 to N-PMB-ketopiperazine-pyrimidinone 241. 
 
Bartolomé and co-workers also reported an alternative approach for accessing similar 
aldol adducts. Treatment of N-PMB-ketopiperazine 241 with LiHMDS followed by the 
addition of pivaloyl chloride 243 provided ketone 244 in 80% yield, >95% de (in favour 
of the cis-isomer) and >95% ee. Subsequent reduction to the desired alcohol 245 was 
inefficient however, with substantial quantities of the decomposition product 246 also 
being isolated as a result of an auto-oxidation process (Scheme 3.9).102  
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Scheme 3.9. Addition of pivaloyl chloride 243 to N-PMB-ketopiperazine-pyrimidinone 241. 
 
Aldol addition to N-PMB-protected ketopiperazines has also had utility in natural 
product synthesis. The efficient aldol addition of iso-butyraldehyde 221 to N-PMB-
diketopiperazine 247 in the presence of LiHMDS was reported by Singh in the synthesis 
of flutimide (252) (Scheme 3.10). In this case, the enamine double bond was installed 
by activating the alcohol 248 as mesylate 249 followed by DBU-mediated elimination 
to afford a 2.5:1 mixture of Z/E alkenes 250 and 251.103  
 
Scheme 3.10. Aldol addition – alcohol activation – elimination in the synthesis of flutimide (252). 
3.1.3 Ketopiperazine Substitution Using Imidate Amide Protection 
 
The alkylation of bis-imidates such as 254 was first described by Schöllkopf and co-
workers in their diastereoselective synthesis of α-methyl-α-aminoesters 257 and 258 as 
shown in Scheme 3.11. The bis-imidate 254 was readily prepared from diketopiperazine 
253 by treatment with either triethyloxonium or trimethyloxonium tetrafluoroborate 
salts (‘Meerwein’s salt’). Imidates are readily hydrolysed under acid conditions.104  
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Scheme 3.11. Schöllkopf’s synthesis of α-methyl-α-aminoesters 257 and 258 using imidate-protected 
ketopiperazines. 
 
There are no examples of direct carbon-carbon double bond formation to imidate-
protected ketopiperazines at the C-1 position, but there are a number of procedures 
describing efficient alkylation and aldol addition reactions. Avendaño and co-workers 
reported the benzylation of ketopiperazine-pyrimidinone 259 in moderate yield in 2005 
(Scheme 3.12). In this case, the reaction was diastereoselective for the trans-product but 
smaller alkyl-halides (e.g. methyl iodide) gave poorer selectivity. The authors comment 
that epimerisation under the reaction conditions did not occur as readily as with N-alkyl 
substituted ketopiperazines, but was observed following prolonged work-up or 
chromatographic processes.105  
 
Scheme 3.12. Alkylation of imidate-protected ketopiperazine-pyrimidinone 259. 
 
Davies and co-workers utilised imidate protection for the alkylation of diketopiperazine 
substrates in 2007. Diastereoselective alkylation of imidate 262 by treatment with n-
BuLi followed by the addition of benzyl bromide 260 proceeded in excellent de and ee 
(Scheme 3.13). As reported by Avendaño,105 smaller alkyl halides were found to result 
in a lower de.106 
 
Scheme 3.13. Chiral diastereoselective alkylation of imidate-protected diketopiperazine 262. 
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Only a single report describes aldol addition of an aldehyde to an imidate-protected 
ketopiperazine. Sandri and co-workers demonstrated that addition of acetaldehyde 265 
to imidate 264, in the presence of LiHMDS, proceeded with modest diastereoselectivity 
for the trans-isomers (Scheme 3.14). In this case, the steric bulk of the benzyl group 
present at the ketopiperazine C-4 position is crucial for good diastereoselectivity – 
methyl substitution at this position significantly lowers the de achieved. No comment is 
made on the reaction yield, the diastereoselectivity of aldol addition, or on the ee of the 
products isolated.107 Application of an activation-elimination approach (as utilised by 
Singh103) to access the corresponding enamine can be envisaged. 
 
Scheme 3.14. Aldol addition of acetaldehyde 265 to imidate-protected diketopiperazine 264. 
3.1.4 Other Approaches 
 
The Mannich-Hofmann reaction was used efficiently by Avendaño and co-workers to 
introduce a carbon-carbon double bond onto ketopiperazine-pyrimidinones at the C-1 
position. As shown in Scheme 3.15, treatment of N-alkyl-ketopiperazine-pyrimidinone 
267 with diamine 268 in the presence of TFA furnished enamine 269 in high yield and 
ee (as shown by chiral HPLC analysis, although no figure is quoted).108  
 
Scheme 3.15. Mannich-Hofmann reaction of diamine 268 and N-alkyl-ketopiperazine-pyrimidinone 267. 
 
In the same report, the PCC-mediated oxidation of N-methyl-ketopiperazine-
pyrimidinone 238 is also described. Subsequent addition of methyl magnesium bromide 
occurs with regioselectively for the newly introduced, more electrophilic carbonyl and 
with good syn-diastereoselectivity. Treatment of alcohol 271 with p-TSA in refluxing 
methanol then mediated dehydration to provide enamine 272 in excellent yield (Scheme 
3.16).108 This methodology may not only have utility in the synthesis of janoxepin (1), 
44 
 
but also in the synthesis of the oxepine-pyrimidinone natural products bearing hydroxyl 
substitution on the ketopiperazine ring (e.g. oxepinamides A-C 23-25). 
 
Scheme 3.16. Ketopiperazine oxidation – Grignard addition – dehydration approach. 
 
The HWE reaction has also been used to introduce a carbon-carbon double bond to 
ketopiperazine substrates at C-1. Starting with N-PMB-diketopiperazine 273, Davies 
and co-workers first performed an electrophilic fluorination followed by trans-
halogenation to provide chloride 274. This was then converted into phosphonate 275 (as 
a mixture of diastereomers) upon treatment with triethylphosphite in an Arbuzov 
reaction. The cis-phosphonate 275 was isolated by chromatography and underwent 
HWE olefination with iso-butyraldehyde 221 to furnish the E-enamine 276 in good 
yield (Scheme 3.17).101 
 
Scheme 3.17. HWE approach for installing carbon-carbon double bonds onto ketopiperazines. 
3.2 Aldol Condensation/Addition: Strategy 
 
It was proposed to first establish whether amide protection was indeed required for 
successful aldol addition/condensation of iso-butyraldehyde 221 to either diallyl 
pyrimidinone 50 or dihydro-oxepine 215. This was important to ascertain as, if found to 
be successful, it would negate the need for extra protecting group manipulation steps. 
Subsequent investigations then focussed on finding the optimal method of amide 
protection: 
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1. N-Acyl/N-carbamate protecting groups.  
2. N-Alkyl protecting groups. 
3. Imidate protection. 
3.2.1 Aldol Addition/ Condensation Without Amide Protection 
 
Dihydro-oxepine 215 was the first substrate to be investigated, but on treatment with 
potassium tert-butoxide (as a solution in tert-butanol) and iso-butyraldehyde 221 in 
DMF at 0 °C, only aldehyde self-condensation and decomposition of the substrate 
occured (Table 3.1, entry 1). In order to eliminate the problem of aldehyde self-
condensation, the non-enolisable benzaldehyde 232 was employed, however, under the 
same reaction conditions, only decomposition of the starting material was seen (Table 
3.1, entry 2). When LiHMDS was used in THF at –78 °C with both iso-butyraldehyde 
221 and benzaldehyde 232 no reaction was observed (Table 3.1, entries 3-4).  
 
 
Entry 
Aldehyde 
(4.0 eq.) 
Base (2.1 eq.) Conditions Comment 
1 221  
t-BuOK 
(1.0 M in t-BuOH) 
DMF, 0 °C – rt, 2 h 
Self-condensed aldehyde and 
decomposition 
2 232  
t-BuOK 
(1.0 M in t-BuOH) 
DMF, 0 °C – rt, 2 h 
Self-condensed aldehyde and 
decomposition 
3 221  
LiHMDS 
(1.0 M in THF) 
THF, –78 °C – 0 °C, 18 h rsm 
4 232  
LiHMDS  
(1.0 M in THF) 
THF, –78 °C – 0 °C, 18 h rsm 
 
Table 3.1. Investigation of aldol condensation using unprotected dihydro-oxepine 215. 
 
Based on a concern that instability of the dihydro-oxepine ring might be responsible for 
the observed decomposition, diallyl pyrimidinone 50 was also subjected to both sets of 
reaction conditions. However, the same results were obtained, leading to the conclusion 
that protection of the amide was indeed required. 
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3.3 Aldol Condensation using N-Boc Protection: The First Synthesis of ‘Dihydro-
Janoxepin’ 49 
 
The N-Boc-substituted dihydro-oxepine 279 was first investigated as an alternative 
substrate for aldol addition/condensation. This was chosen in preference to the N-acyl-
substitution as the Boc protecting group could be removed under mild conditions 
(should aldol addition occur without subsequent acyl-transfer and elimination).  
3.3.1 Preparation of N-Boc Substrates 
 
Treatment of dihydro-oxepine 215 with di-tert-butyl dicarbonate in the presence of 
triethylamine and DMAP in DCM provided the desired Boc-protected substrate 279, 
however, the yield obtained for this transformation was only 50% (Scheme 3.18). 
 
 
Scheme 3.18. Boc-protection of dihydro-oxepine 215. 
 
Boc-protection of diallyl pyrimidinone 50 was found to be far more efficient (Scheme 
3.19), and it is reasonable to assume that subsequent RCM would also be high yielding. 
The proposed explanation for this observation is discussed later (Chapter 4.8).  
 
Scheme 3.19. Boc-protection of diallyl pyrimidinone 50. 
3.3.2 Aldol Condensation with iso-Butyraldehyde 
 
Given the observed sensitivity of dihydro-oxepine 215 to the Boc-protection conditions, 
an initial investigation used N-Boc-diallyl pyrimidinone 280 as the substrate for 
condensation with iso-butyraldehyde 221. However, when potassium tert-butoxide was 
used as base in DMF, decomposition of the substrate was observed (Table 3.2, entry 1). 
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When LiHMDS was used as the base no reaction was observed, but the starting material 
was recovered (Table 3.2, entry 2). 
 
Entry Base (2.1 eq.) Conditions Comment 
1 
t-BuOK 
(1.0 M in t-BuOH) 
DMF, 0 °C – rt, 3 h Self-condensed aldehyde and decomposition 
2 
LiHMDS 
(1.0 M in THF) 
THF, –78 °C – 0 °C, 18 h rsm 
 
Table 3.2. Investigation of aldol condensation using N-Boc-diallyl pyrimidinone 280. 
 
To our surprise, the condensation of N-Boc-dihydro-oxepine 279 with iso-
butyraldehyde 221 was successfully mediated using potassium tert-butoxide in DMF. 
The reaction proceeded with cleavage of the Boc group, presumably due to an acyl-
transfer process, to provide ‘dihydro-janoxepin’ 49 as a single enamine isomer (Table 
3.3, entry 1). However, the transformation was low yielding and unreliable; performing 
the reaction at a lower temperature using THF as solvent (Table 3.3, entry 2), and using 
a single equivalent of base (Table 3.3, entry 3), only led to the recovery of starting 
material whilst experimentation with the rate and order of reagent addition also offered 
no improvement.  
 
Entry t-BuOK eq. Conditions Yield 49 
1 2.1 DMF, 0 °C – rt, 3 h 21% 
2 2.1 THF, –78 °C – rt, 6 h rsm 
3 1.1 DMF, 0 °C – rt, 3 h rsm 
 
Table 3.3. Optimisation study for the aldol condensation of N-Boc-dihydro-oxepine 279 with  
iso-butyraldehyde 221. 
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3.3.3 Characterisation of ‘Dihydro-Janoxepin’ 49 
 
The structure of dihydro-janoxepin 49 was confirmed by the comparison of key NMR 
data with those of janoxepin (1) (Table 3.4).1 The Z-configuration of the enamine was 
confirmed by nOe experiments – nOe enhancements were seen between H-1 and H-4 
and, to a lesser extent, between H-1 and H-5/6. No enhancement was seen between H-1 
and H-3. All other characterisation data (mass spectrometry and IR) were also 
consistent with the structural assignment.  
 
# 
δH (ppm) (J in Hz) δC (ppm) 
49 1 49 1 
1 
8.98 
(br s) 
8.68 
(br s) 
- - 
2 - - 123.8 123.9 
3 
6.31 
(d, J 10.5) 
6.31 
(d, J 10.2) 
127.9 129.0 
4 
2.73 
(dsept. J 10.5, 6.5) 
2.66 
(dsept. J 10.2, 6.5) 
26.1 26.3 
5/6 
1.11 
(d, J 6.5) 
1.08 
(d, J 6.7) 
22.2 21.9 
5/6 
1.10 
(d, J 6.5) 
1.07 
(d, J 6.5) 
21.2 21.1 
 
Table 3.4. Selected NMR data for ‘dihydro-janoxepin’ 49 and janoxepin (1).1 Arrows indicate nOe 
enhancements observed. See Appendix I for 1H- and 13C-NMR spectra. 
3.4 Aldol Condensation Using N-Acyl Protection 
 
With the aim of improving the efficiency of the aldol condensation step, N-acyl 
protection was next investigated using a dihydro-oxepine derivative (based upon the 
previous success with N-Boc protection). 
 
N-Acyl-dihydro-oxepine 283 was prepared by the treatment of dihydro-oxepine 215 
with acetyl chloride in the presence of triethylamine and DMAP in DCM. As seen in the 
synthesis of N-Boc substrate 279 only a moderate yield was achieved (Scheme 3.20).  
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Scheme 3.20. N-Acyl protection of dihydro-oxepine 215. 
 
Disappointingly, condensation with, or the addition of iso-butyraldehyde 221 to N-acyl- 
dihydro-oxepine 283 was not possible. The successful conditions previously used 
resulted in the isolation of a complex mixture of side products (Table 3.5, entry 1). The 
same outcome was observed at a lower reaction temperature when THF was used as 
solvent (Table 3.5, entry 2) and when LiHMDS was used as the base (Table 3.5, entry 
3). Reducing the number of equivalents of base again resulted in no reaction (Table 3.5, 
entry 4). 
 
Entry Base Conditions Comment 
1 
t-BuOK (2.1 eq.) 
(1.0 M in t-BuOH) 
DMF, 0 °C – rt, 3 h 
Self-condensed aldehyde and 
decomposition 
2 
t-BuOK (2.1 eq.) 
(1.0 M in t-BuOH) 
THF, –78 °C – rt, 6 h 
Self-condensed aldehyde and 
decomposition 
3 
LiHMDS (2.1 eq.) 
(1.0 M in THF) 
THF, –78 °C – rt, 18 h rsm 
4 
t-BuOK (1.1 eq.) 
(1.0 M in t-BuOH) 
DMF, 0 °C – rt, 3 h rsm 
 
Table 3.5. Investigation of the aldol condensation of N-acyl-dihydro-oxepine 283 with  
iso-butyraldehyde 221. 
3.5 Aldol Addition Using N-PMB Protection 
 
Based upon literature precedent for its successful application in aldol addition reactions, 
and subsequent removal under mild conditions, N-protection using the PMB group was 
investigated next.  
 
 
50 
 
3.5.1 Preparation of N-PMB Dihydro-Oxepine 284 
 
As observed with N-Boc and N-acyl-protection, N-PMB-protection of dihydro-oxepine 
215 was only possible in moderate yield (Scheme 3.21). 
 
Scheme 3.21. Preparation of N-PMB dihydro-oxepine 284 from dihydro-oxepine 215. 
 
Protection of diallyl pyrimidinone 50 was found to be much more efficient, and 
subsequent RCM also proceeded in good yield (un-optimised), thus providing a much 
improved synthetic route to N-PMB-dihydro-oxepine 284 (Scheme 3.22).  
 
Scheme 3.22. Preparation of N-PMB-dihydro-oxepine 284 from diallyl pyrimidinone 50. 
3.5.2 Aldol Addition Optimisation Study 
 
An initial investigation of the conditions used for the successful aldol condensation of 
iso-butyraldehyde 221 with N-Boc-dihydro-oxepine 279 gave disappointing results. The 
treatment of N-PMB-dihydro-oxepine 284 with potassium tert-butoxide in both DMF 
and THF, followed by the addition of iso-butyraldehyde 221 gave only a complex 
mixture of decomposition products (Table 3.6, entries 1-2). However, the treatment of 
284 with LiHMDS in THF at –78 °C, followed by addition of iso-butyraldehyde 221, 
and quenching at –78 °C with AcOH furnished a promising 30% yield of the aldol 
adduct 286 (Table 3.6, entry 3). A modest increase in this yield was achieved following 
the in situ preparation of LiHMDS by the treatment of freshly distilled HMDS with n-
BuLi (Table 3.6, entry 4). When KHMDS was used as the base only a trace of aldol 
adduct 286 (<5%) was isolated along with a complex mixture of decomposition 
products (Table 3.6, entry 5). 
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Entry Deprotonation Aldehyde Addition Quench Yield 286 
1 
t-BuOK 
(2.1 eq., 1.0 M in t-BuOH), 
DMF, 0 °C, 1 h 
DMF, 0 °C – rt, 1 h Sat. NH4Cl (aq) 
Decomposition 
products isolated 
2 
t-BuOK 
(2.1 eq., 1.0 M in t-BuOH), 
THF, 0 °C, 1 h 
THF, 0 °C – rt, 1 h Sat. NH4Cl (aq) 
Decomposition 
products isolated 
3 
LiHMDS 
(2.1 eq., 1.0 M in THF), 
THF, –78 °C, 1 h 
THF, –78 °C, 1 h 
AcOH, –78 °C – rt, 
30 min 
30% 
4 
LiHMDS  
(2.1 eq., generated in situ), 
THF, –78 °C, 1 h 
THF, –78 °C, 1 h 
AcOH, –78 °C – rt, 
30 min 
35% 
5 
KHMDS  
(2.1 eq., 1.0 M in PhMe), 
THF, –78 °C, 1 h 
THF, –78 °C, 1 h 
AcOH, –78 °C – rt, 
30 min 
<5% 
 
Table 3.6. Optimisation study for the aldol addition of iso-butyraldehyde 221 to form 
N-PMB-dihydro-oxepine 284. (Relative stereochemistry shown). 
 
To ascertain if the poor yields were due to the self-condensation of iso-butyraldehyde 
221, benzaldehyde 232 was used under the optimal conditions. However, no reaction 
was observed, suggesting that the carbonyl centre of benzaldehye 232 was not 
sufficiently electrophilic to react with the intermediate ketopiperazine enolate.  
 
Warming the reaction mixture slowly to room temperature following addition of the 
aldehyde led to any aldol product initially formed, as observed by TLC, appearing to be 
converted back to the starting material; presumably as a result of a retro-aldol reaction. 
It was proposed that the forward reaction could be promoted by trapping the 
intermediate alkoxide with an electrophile. Thus, it was found that addition of TMS-Cl 
together with the aldehyde prevented the retro-aldol reaction and the intermediate silyl-
ether 287 was formed. This was not isolated, but hydrolysed in the same pot by the 
addition of TFA and water, with warming to room temperature, to reliably furnish the 
aldol adduct 286 in 44% yield (Scheme 3.23). Surprisingly, the addition of AcOH did 
not mediate the desired hydrolysis.  
52 
 
 
Scheme 3.23. Optimised synthesis of N-PMB aldol adduct 286. (Relative stereochemistry shown). 
 
Extensive experimentation with reaction time, as well as the order and rate of reagent 
addition, offered no improvement in the reliable, but moderate, 44% yield. This could 
be due to instability of the dihydro-oxepine under the harsh silyl-ether hydrolysis 
conditions used, but was not investigated further. 
3.5.3 Activation – Elimination: The Synthesis of N-PMB-Dihydro-Janoxepin 289 
 
The direct acid-mediated dehydration of aldol adduct 286 to enamine 289 was not a 
desirable strategy. No dehydration was observed under the silyl-ether hydrolysis 
conditions, and the low yield obtained was associated with stability of the dihydro-
oxepine in acidic media. Therefore, an activation-elimination approach was adopted. 
Aldol adduct 286 was treated with MsCl in the presence of triethylamine and DMAP to 
afford mesylate 288. Following work-up, this was immediately treated with potassium 
tert-butoxide in THF to provide N-PMB-dihydro-janoxepin 289, albeit in just 22% yield 
(Scheme 3.24).  
 
Scheme 3.24. Activation – elimination of aldol adduct 286. (Relative stereochemistry shown). 
 
The Z-configuration of the enamine was confirmed by nOe experiments showing 
enhancements between benzylic protons H-1 and iso-propyl proton H-3. No nOe 
enhancement was observed between H-1 and the alkene proton H-2 (Figure 3.1). 
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Figure 3.1. nOe enhancement observed for N-PMB-dihydro-janoxepin 289. 
 
The reaction sequence was not optimised further as it was first important to establish an 
efficient method for PMB group removal. 
3.5.4 N-PMB Deprotection 
 
To our disappointment, PMB group removal could not be achieved. A range of 
conditions were investigated as shown in Table 3.7, however only complex mixtures of 
side products were isolated. 
 
Entry Conditions Comment 
1 DDQ, PhMe, rt, 1 h Decomposition 
2 CAN, MeCN, H2O 0 °C – rt, 2 h Decomposition on warming 
3 AlCl3, anisole (solvent), rt, 1 h Decomposition 
4 TFA (solvent), anisole, rt, 1 h Decomposition 
5 H2SO4, TFA (solvent), rt, 30 min Decomposition 
6 NaI, DMF, rt – 110 °C, 16 h Decomposition upon heating 
 
Table 3.7. PMB group removal: reaction conditions screened. 
 
Unable to remove the PMB protecting group, the N-alkyl protection strategy was 
abandoned, and an imidate protection approach was investigated. 
3.6 Aldol Addition to an Imidate-Protected Ketopiperazine 
 
Although the literature precedent for aldol addition to imidate-protected ketopiperazines 
is limited (Chapter 3.1.3), it was proposed that such substrates would be suitable for 
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such a reaction. Furthermore, hydrolysis under mild conditions should provide a facile 
method for subsequent removal of this protecting group.  
3.6.1 Imidate Preparation 
 
Again, protection of dihydro-oxepine 215 directly was inefficient. When dihydro-
oxepine 215 was treated with triethyloxonium tetrafluoroborate and potassium 
carbonate in the presence of 4 Å molecular sieves, the desired imidate 290 was isolated 
in just 36% yield (Scheme 3.25). A substantial quantity of the intriguing bis-alkylated 
rearrangement product dihydro-furan 291 was also isolated, the characterisation of 
which, alongside mechanistic proposals is discussed later (Chapter 4.8). 
 
Scheme 3.25. Imidate protection of dihydro-oxepine 215. 
 
It was again found to be far more efficient to protect diallyl pyrimidinone 50 as imidate 
292. RCM then proceeded in excellent yield to provide the desired imidate-protected 
dihydro-oxepine 290 (Scheme 3.26). 
 
Scheme 3.26. Optimised preparation of imidate-protected dihydro-oxepine 290. 
3.6.2 Aldol Addition Optimisation 
 
Initial application of the optimal reaction conditions for the aldol addition of iso-
butyraldehyde 221 to N-PMB dihydro-oxepine 284 gave disappointing results. The 
acidic conditions required for hydrolysis of the intermediate silyl-ether also led to 
hydrolysis of the imidate, leading to the isolation of aldol adduct 293 in poor yield 
(Scheme 3.27). 
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Scheme 3.27. Application of previously optimal aldol conditions. (Relative stereochemistry shown). 
 
Performing the reaction at low temperature without the addition of TMS-Cl was found 
to be a more efficient strategy. Treatment of imidate 290 with LiHMDS (prepared in 
situ) at –78 °C for 1 h was followed by the addition of iso-butyraldehyde 221. The 
reaction mixture was stirred at –78 °C for 1 h before the addition of AcOH and warming 
to room temperature. The desired aldol adduct 294, with the imidate group intact, was 
isolated in a very promising 51% yield (Table 3.8, entry 1). The yield was further 
improved by reducing the reaction time for deprotonation and following aldehyde 
addition. At the same time, it was found that the number of equivalents of aldehyde 
used could be reduced without negative effect (Table 3.8, entry 2). 
 
Entry Deprotonation Aldehyde addition Quench Yield 294 
1 
LiHMDS (2.1 eq.), 
(generated in situ), THF, –78 °C, 
1 h 
221 (4.0 eq.), THF,  
–78 °C, 1 h 
AcOH, 
 –78 °C – rt, 1 h 
51% 
2 
LiHMDS (2.1 eq.), 
(generated in situ), THF, –78 °C, 
10 min 
221 (3.0 eq.), THF,  
–78 °C, 10 min 
AcOH,  
–78 °C – rt, 30 
min 
70% 
Table 3.8. Optimisation study for aldol addition to imidate 290. (Relative stereochemistry shown). 
 
As previously observed, no reaction took place when 1.1 equivalents of base was used, 
or when these conditions were applied to imidate protected diallyl pyrimidinone 292. 
3.6.3 Diastereoselectivity of Aldol Addition 
 
Aldol addition to both the N-PMB and imidate-protected ketopiperazines provided 
products as single diastereomers. It was assumed that addition in both cases occurred 
trans- to the bulky iso-butyl substituent at C-1 based upon steric considerations. 
However, further investigation involving nOe or X-ray crystallography experiments was 
not pursued.  
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A tentative assignment of whether syn- or anti-aldol addition had occurred was made 
based upon the 1H-NMR coupling constant between H-1 and H-2, in analogy with an 
assignment made previously by Davies and co-workers as described in Chapter 3.1.1.101 
 
In the case of the imidate-protected substrate 290 it is proposed that anti-aldol addition 
occurred (as expected) via an E-‘enolate’. Scheme 3.28 shows how the iso-propyl group 
of the aldehyde is able to adopt the preferred, equatorial position in a Zimmerman-
Traxler-like transition state 295. Assuming restricted rotation about the new bond, due 
to a hydrogen bonding interaction between the hydroxyl group and pyrimidinone 
nitrogen, H-1 and H-2 must adopt an anti-periplanar arrangement. This is consistent 
with the higher than usual coupling constant of 8.5 Hz between the two protons. 
However, this is surprising given that only the Z-enamine was isolated upon 
elimination, where the expected product would be the E-enamine. This perhaps suggests 
that reversible isomerisation of the enamine occurs, the thermodynamic outcome of 
which is driven by steric factors. 
 
Scheme 3.28. Imidate-protected ketopiperazine 295 undergoes anti-aldol addition based upon observed 
coupling constant between H-1 and H-2 (J 8.5 Hz). (Relative stereochemistry shown). 
 
In the case of the N-PMB-protected substrate 286 the observed coupling constant 
between H-1 and H-2 was much smaller (2.5 Hz). Using the same model, this can be 
explained by the bulky PMB group forcing the iso-propyl group of the aldehyde to 
adopt an axial position in the transition state 296 (Figure 3.2).  
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Figure 3.2. Bulky N-PMB group forces the iso-butyl chain of the aldehyde to adopt an axial position in 
the transition state. (Relative stereochemistry shown). 
 
Thus, syn-aldol addition occured, resulting in H-1 and H-2 adopting an eclipsed 
arrangement in the product (Scheme 3.29). This is a plausible explanation for the 
observed difference in J values; indeed Davies and co-workers reported an almost 
identical coupling of 2.4 Hz in their example of syn-aldol addition (Chapter 3.1.1).101 In 
this case of aldol adduct 286, the Z-enamine isolated upon elimination is the expected 
product.  
 
Scheme 3.29. N-PMB-protected ketopiperazine 284 undergoes syn-aldol addition based upon observed 
coupling constant between H-1 and H-2 (J 2.5 Hz). (Relative stereochemistry shown). 
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3.6.4 Enamine Synthesis: Activation – Elimination 
An activation – elimination strategy was again adopted, but application of the 
mesylation conditions previously used (MsCl, triethylamine and DMAP) gave a 
disappointing 31% yield of mesylate 297 (Table 3.9, entry 1). When pyridine was used 
as solvent, a mixture of mesylate 297 and enamine 298 was obtained. Addition of DBU, 
with heating to 50 °C, completed the elimination to furnish enamine 298 in a much 
improved 64% yield (Table 3.9, entry 2). Complete elimination could be achieved 
without the addition of DBU, but the prolonged reaction time required at 50 °C had a 
detrimental effect on the yield (Table 3.9, entry 3). 
 
Entry Conditions Yield 298 
1 MsCl (2.5 eq.), NEt3 (2.5 eq.), DMAP (0.1 eq), DCM, rt, 2 h 31% 
2 
i) MsCl (2.0 eq.), pyridine (solvent), rt, 18 h 
ii) DBU (2.0 eq), 50 °C, 1 h 
64% 
3 MsCl (2.0 eq.), pyridine (solvent), 50 °C, 18 h 50% 
Table 3.9. Mesylation – elimination optimisation study. (Relative stereochemistry shown). 
 
Further optimisation studies focussing on the reaction time and temperature offered no 
improvement in the yield of enamine 298. However, an intriguing observation was 
made when a large excess of DBU was used to investigate if elimination at room 
temperature was possible. The fascinating ring-contracted dihydro-pyran 299 was 
isolated in high yield as a single diastereomer (Scheme 3.30). The proposed mechanism 
for this rearrangement will be discussed in Chapter 4.8.  
 
Scheme 3.30. Unexpected rearrangement of dihydro-oxepine 294. (Relative stereochemistry shown). 
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3.6.5 Imidate Hydrolysis: A Second Generation Synthesis of  
Dihydro-Janoxepin 49 
 
Initially, an aqueous HCl/EtOAc system (1:3) for the hydrolysis of the imidate 
protecting group was investigated. Hydrolysis proceeded quickly, with the starting 
material being consumed within 40 min, but the isolated yield of dihydro-janoxepin 49 
was disappointing (Table 3.10, entry 1). Heating imidate 298 in AcOH and water (4:1) 
to 50 °C for 1 h was found to be the optimal conditions for hydrolysis, completing a 
second generation synthesis of dihydro-janoxepin 49 in 73% yield. The configuration of 
the enamine was again confirmed as Z by nOe experiments.  
 
Entry Conditions Yield 49 
1 3 M HCl, EtOAc (1:3), rt, 40 min 31% 
2 AcOH, H2O (4:1), 50 °C, 1 h 73% 
 
Table 3.10. Optimisiation of imidate hydrolysis: preparation of dihydro-janoxepin 49. 
3.7 Dihydro-Oxepine Hydrogenation:  
The Synthesis of Tetrahydro-Janoxepin 301 
 
Tetrahydro-janoxepin 301 was identified as an interesting analogue of janoxepin (1), 
and the model study (Chapter 2.6) had shown dihydro-oxepine hydrogenation to be an 
efficient process. However, selectivity for hydrogenation of the cyclic alkene over the 
enamine olefin presented an additional challenge for the synthesis of tetrahydro-
janoxepin 301 from either imidate 298 or dihydro-janoxepin 49. However, when 
imidate 298 was treated with palladium on carbon under an atmosphere of hydrogen, 
selective dihydro-oxepine hydrogenation was indeed observed to furnish tetrahydro-
oxepine 300. Subsequent imidate hydrolysis using the previously developed conditions 
then afforded tetrahydro-janoxepin 301 in 69% yield for the two-step sequence (Scheme 
3.31, see Appendix II for NMR spectra). A direct hydrogenation of dihydro-janoxepin 
49 was not subsequently investigated. 
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Scheme 3.31. Synthesis of tetrahydro-janoxepin 301. 
3.8 Summary 
 
The enamine side chain seen in janoxepin (1) was successfully introduced by aldol 
addition of iso-butyraldehyde 221 to imidate-protected dihydro-oxepine 290. Following 
extensive experimentation, a high and reliable yield of a single diastereomer was 
achieved which underwent elimination to exclusively the desired Z-enamine 298. This 
allowed for the synthesis of the novel janoxepin analogue dihydro-janoxepin 49 and, 
following a selective alkene hydrogenation, tetrahydro-janoxepin 301. The final 
transformation now required to complete the synthesis of janoxepin (1) was the 
elaboration of the dihydro-oxepine moiety to the required unsaturated oxepine. This is 
discussed in Chapter 4, alongside mechanistic proposals for the dihydro-oxepine 
rearrangements observed during this study. 
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Chapter 4.  Dihydro-Oxepine Elaboration:  
The Synthesis of (±)-Janoxepin (1) 
 
Literature precedent for the elaboration of dihydro-oxepines to oxepines (Scheme 4.1) is 
limited, as discussed in Chapter 2.3.4. However, a bromination followed by double 
dehydro-bromination sequence had been established as a viable method for effecting 
this transformation, and its utility demonstrated through the synthesis of the model 
compound, oxepine-pyrimidinone 196 (Chapter 2.6). This Chapter will first discuss the 
application of this methodology to the attempted synthesis of janoxepin (1) before 
describing alternative strategies that were subsequently explored.  
 
Scheme 4.1. Representative dihydro-oxepine 302 elaboration to oxepine 303. 
4.1 Bromination – Dehydrobromination 
4.1.1 Re-Cap: Model Study 
 
The bromination of dihydro-oxepine 197 to give dibromide 202, followed by a TBAF 
mediated double dehydrobromination to furnish the model oxepine-pyrimidinone 196 
(Scheme 4.2) was discussed in Chapter 2.6. Disappointingly, the elimination step was 
low yielding (28%) compared to the results initially reported by Jones in 2008 (87%),35 
and this yield could not be improved upon following a screen of different bases.   
 
Scheme 4.2. Bromination – dehydrobromination: synthesis of model oxepine-pyrimidinone 196. 
(Relative stereochemistry shown). 
4.1.2 Re-Cap: Application to Dihydro-Oxepine 215 
 
As discussed in Chapter 2.11, the bromination of dihydro-oxepine 215 was achieved in 
good yield, but dehydrobromination was not successful (Scheme 4.3). A complex 
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mixture of polar side-products was isolated, with the major product being identified as 
the isomeric species 218 which was formed as a result of deprotonation of the 
ketopiperazine. The mono-elimination product bromide 220 was also observed. 
 
Scheme 4.3. Bromination – dehydrobromination: application to dihydro-oxepine 215. 
4.1.3 Application to Dihydro-Janoxepin 49 
 
It was proposed that employing a dihydro-oxepine substrate bearing ketopiperazine 
substitution at C-1 would avoid deprotonation at this position as previously observed. 
Dihydro-janoxepin 49 was identified as the ideal substrate as, if successful, the 
synthesis of janoxepin (1) would be completed in just two further steps. However, 
bromination was favoured at the electron rich enamine double bond when a single 
equivalent of pyridine hydrotribromide was used. Dibromide 304 was isolated as a 
complex mixture of diastereomers which could not be separated and the mixture was 
not characterised (Scheme 4.4). 
 
Scheme 4.4. Bromination of dihydro-janoxepin 49. 
 
Treatment of dibromide 304 with a further equivalent of pyridine hydrotribromide did 
lead to bromination of the dihydro-oxepine olefin. Tetrabromide 305 was not isolated, 
but immediately treated with potassium tert-butoxide in an attempt to effect an unlikely 
global dehydrobromination (Scheme 4.5). This was unsuccessful, and following a brief 
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screen of different reaction conditions as described in Chapter 2.6, the approach was 
abandoned.  
 
Scheme 4.5. Synthesis of tetrabromide 305 from dibromide 304. Subsequent global elimination was 
unsuccessful. 
4.1.4 Application to Aldol Adduct 294 
 
Aldol adduct 294 was identified as a more suitable substrate for bromination–
dehydrobromination as the selectivity issue previously encountered would be negated. 
Following treatment with pyridine hydrotribromide in DCM, dibromide 306 was 
isolated in 68% yield as a 1:1 mixture of diastereomers that could not be separated 
(Scheme 4.6). 
 
Scheme 4.6. Bromination of aldol adduct 294. 
 
Dibromide 306 was next subjected to the optimal dehydrobromination conditions 
previously identified – TBAF in DMSO (Scheme 4.7). It was expected to obtain a 
mixture of aldol adduct 308 and enamine 309 (resulting from base induced elimination 
of the aldol adduct 308), but the isolation of aldehyde 307 in 47% yield was surprising. 
The characterisation of aldehyde 307, a possible mechanism for its formation and 
attempts to promote a subsequent cyclisation to oxepine 309 are discussed later 
(Chapter 4.8.2). 
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Scheme 4.7. Dehydrobromination of dibromide 306: isolation of aldehyde 307. (Relative stereochemistry 
shown). 
 
The dehydrobromination of dibromide 306 with DBU in DCM was also unsuccessful, 
but dehydration did occur and enamine 310 was isolated in moderate yield as a single 
diastereomer (Table 4.1, entry 1). The same transformation was also achieved in similar 
yield by treatment of dibromide 306 with mesyl chloride in pyridine as solvent (Table 
4.1, entry 2).  
 
Entry Conditions Yield 310 
1 DBU, DCM, rt, 30 min 38% 
2 MsCl, pyridine, 50 °C, 2 h 36% 
 
Table 4.1. Dehydration of aldol adduct 306 to enamine 310. (Relative stereochemistry shown). 
 
It was postulated that dibromide 310 would be a simplified substrate for further 
investigation of the double elimination to an oxepine. Therefore, dibromide 310 was 
subjected to three different reaction conditions, but in each case, only poor recovery of a 
complex mixture of products could be obtained (Table 4.2). Surprisingly, not even 
aldehyde 307 was seen upon treatment of dibromide 310 with TBAF in DMSO as 
previously observed (Scheme 4.7).  
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Entry Base (3.1 eq.) Conditions 
1 TBAF (1.0 M in THF) DMSO, rt, 30 min 
2 DBU PhMe, rt, 30 min 
3 t-BuOK THF, 0 °C – rt, 1 h 
 
Table 4.2. Reaction conditions screened for the dehydrobromination of dibromide 310. 
 
The double dehydrobromination strategy for dihydro-oxepine elaboration was now 
abandoned altogether and an alternative strategy relying upon allylic bromination was 
investigated. 
4.1.5 Allylic Bromination Strategy 
 
It was proposed that allylic bromination of a dihydro-oxepine 302 would be an efficient 
way to access an allylic bromide 311 or 312, which would then require only a single 
elimination in order to access the desired oxepine 303 (Scheme 4.8). Indeed, this 
strategy has been utilised in the preparation of dibenzo-oxepines as described by Griffin 
and Brightwell.42 The model dihydro-oxepine 197 was used for initial investigation 
owing to its relative ease of preparation. 
 
Scheme 4.8. Proposed allylic bromination – dehydrobromination strategy. 
 
Dihydro-oxepine 197 was treated with NBS and AIBN in degassed CCl4 at 80 °C for 1 
h (no reaction was observed at room temperature) (Scheme 4.9). Despite the starting 
material being consumed in the reaction, only traces of two possible bromination 
products 313 and 314 could be identified in the 1H-NMR spectrum of the unpurified 
material. Mass spectrometry was also inconclusive, as no [MH]+ peak or characteristic 
bromine isotope peaks were present, as would be expected for an allylic bromide. 
Instead, the mass for the methoxy derivative 315 was observed. It is proposed that this 
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was a result of nucleophilic substitution of methanol, used to inject the sample into the 
spectrometer.    
 
Scheme 4.9. Allylic bromination of dihydro-oxepine 197. 
 
An alternative approach was to prepare bromohydrin 316 and either: perform a double 
elimination following alcohol activation; or form epoxide 317 and open to allylic 
alcohol 318 upon treatment with base. Unfortunately, treatment of dihydro-oxepine 197 
with NBS and water in DMSO led to the isolation of a complex mixture of side 
products (Scheme 4.10). 
 
Scheme 4.10. Attempted bromhydrination of dihydro-oxepine 197 and proposed epoxide formation. 
 
Despite success in the model study, dihydro-oxepine elaboration via any bromination – 
dehydrobromination sequence could not be achieved for ketopiperazine-pyrimidinone-
containing substrates. A number of alternative approaches for dihydro-oxepine 
elaboration were therefore investigated. 
4.2 Dihydro-Oxepine Dihydroxylation 
 
It was envisaged that the osmium-catalysed dihydroxylation of a dihydro-oxepine 302 
followed by diol activation and elimination would provide an alternative method for 
elaboration to oxepines 303 (Scheme 4.11). Not only that, it was predicted that 
dihydroxylation would be selective for the least hindered dihydro-oxepine olefin, and 
therefore the strategy could be applied to advanced enamine-containing intermediates. 
A study using the model system was first undertaken to demonstrate the viability of the 
approach. 
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Scheme 4.11. Proposed dihydroxylation – elimination strategy. (Relative stereochemistry shown). 
4.2.1 Model Study 
 
Gratifyingly, application of standard Upjohn dihydroxylation conditions gave 
immediate success. Treatment of the model dihydro-oxepine 197 with osmium tetroxide 
(2.5 mol%) and N-methylmorpholine N-oxide (NMO) in acetone and water furnished 
the cis-diol 320 in excellent yield (Scheme 4.12).  
 
Scheme 4.12. Dihydroxylation of dihydro-oxepine 197. (Relative stereochemistry shown). 
 
Activation of diol 320 as a disulfonate for double elimination to an oxepine was 
investigated next. Conditions for the tosylation of diol 320 were initially explored 
without success. The treatment of diol 320 with TsCl, NEt3 and DMAP in DCM 
returned only starting material after a long reaction time at room temperature (Table 4.3, 
entry 1), whilst heating the reaction mixture also failed to promote any conversion to the 
desired ditosylate 321. Using TsCl in pyridine as solvent gave the same outcome (Table 
4.3, entry 2).  
 
Entry Conditions Comment 
1 NEt3, DMAP, DCM, rt, 24 h rsm 
2 Pyridine (solvent), rt, 24 h rsm 
 
Table 4.3. Ditosylate 321 formation: reaction conditions screened. (Relative stereochemistry shown). 
 
Mesylation was found to proceed efficiently, and dimesylate 322 was isolated in 95% 
yield following treatment with MsCl, NEt3 and DMAP in DCM (Scheme 4.13). Why 
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tosylation could not be achieved is unclear, but could be due to unfavourable steric 
interactions or the reduced reactivity of TsCl compared to MsCl. 
 
Scheme 4.13. Synthesis of dimesylate 322. (Relative stereochemistry shown). 
 
With dimesylate 322 in hand, a screen of elimination conditions was carried out. The 
successful dehydrobromination conditions previously described (TBAF in DMSO) gave 
optimal results, with the desired oxepine 196 being isolated in 30% yield (Table 4.4, 
entry 1). When DBU in DCM (Table 4.4, entry 2) and potassium tert-butoxide in THF 
(Table 4.4, entry 3) were employed, oxepine 196 was isolated in very low yields (<5%) 
from a complex mixture of other side-products. 
 
Entry Base (4.0 eq.) Conditions Yield 196 
1 TBAF (1.0 M in THF) DMSO, rt, 30 min 30% 
2 DBU DCM, 0 °C – rt, 16 h <5% 
3 t-BuOK THF, 0 °C – rt, 16 h <5% 
 
Table 4.4. Dimesylate 322 elimination to oxepine 196: reaction conditions screened. (Relative 
stereochemistry shown). 
 
Having demonstrated the viability of this strategy, no further optimisation studies were 
carried out on the model system. It was important to first ascertain that dihydroxylation 
of dihydro-janoxepin 49, or its imidate derivative 298, would proceed with the required 
selectivity.  
4.2.2 Selective Dihydroxylation of Dihydro-Janoxepin 49 
 
The dihydroxylation of dihydro-janoxepin 49 was indeed found to be selective for the 
dihydro-oxepine olefin. Following the treatment of dihydro-janoxepin 49 with 1.0 
mol% of osmium tetroxide and a stoichiometric amount of NMO in a solvent system of 
t-BuOH/THF/water (as reported by Panek109), the desired diol 323 was isolated in good 
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yield as a 1:1 mixture of diastereomers with the cis-diol syn and anti to the iso-butyl 
group respectively (Scheme 4.14). Increasing the loading of osmium tetroxide or 
extending the reaction time was found to be detrimental to the yield. 
 
Scheme 4.14. Dihydroxylation of dihydro-janoxepin 49. (Anti diastereomer shown). 
 
The same conditions were applied to the imidate 298 with similar results (Scheme 4.15). 
 
 
Scheme 4.15. Dihydroxylation of imidate 298. (Anti diastereomer shown). 
4.2.3 Mesylation of Diols 323 and 324 
 
The dimesylation of both diols 323 and 324 was investigated in order to compare any 
differences in reactivity, and thus quickly identify the optimal substrate to use. 
Application of the mesylation conditions previously employed (MsCl, NEt3, DMAP) 
gave disappointing results when applied to imidate-containing diol 324: only traces of 
dimesylate 325 could be identified in a complex mixture of side-products as shown by 
the 1H-NMR spectrum of the unpurified product (Table 4.5, entry 1). This problem was 
overcome by using MsCl in pyridine as solvent, which provided the desired dimesylate 
325 in 76% yield (Table 4.5, entry 2). 
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Entry Conditions Yield 325 
1 MsCl, NEt3, DMAP, DCM, rt, 4 h Trace – mainly decomposition products isolated 
2 MsCl, pyridine, rt, 4 h 76% 
 
Table 4.5. Synthesis of dimesylate 325: reaction conditions screened. (Anti diastereomer shown). 
 
Similar results were obtained when the dihydro-janoxepin derived diol 323 was 
subjected to the same reaction conditions (Table 4.6). 
 
Entry Conditions Yield 326 
1 MsCl, NEt3, DMAP, DCM, rt, 4 h Trace – mainly decomposition products isolated 
2 MsCl, pyridine, rt, 4 h 98% 
 
Table 4.6. Synthesis of dimesylate 326: reaction conditions screened. (Anti diastereomer shown). 
4.2.4 Dimesylate Elimination 
 
The double elimination of both dimesylates 325 and 326 to the respective oxepines 309 
and 1 was investigated next with the results obtained for each substrate being identical. 
When both the substrates were treated with TBAF in DMSO, no conversion to product 
was observed following prolonged reaction times with heating (Table 4.7, entry 1). The 
same outcome occurred when DBU was used in toluene (Table 4.7, entry 2) and 
NaOMe was used in DMF with heating (Table 4.7, entry 3). When stronger bases were 
employed, only a complex mixture of decomposition products was isolated: potassium 
tert-butoxide was used in both THF (Table 4.7, entry 4) and DMF (Table 4.7, entry 5) 
whilst potassium hydroxide in DMSO was also investigated (Table 4.7, entry 6). 
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Entry Base (3.1 eq.) Conditions Comment 
1 TBAF (1.0 M in THF) DMSO, rt – 60 °C, 2 h rsm 
2 DBU PhMe, rt – 60 °C, 2 h rsm 
3 NaOMe DMF, rt – 100 °C, rsm 
4 t-BuOK THF, –78 °C – rt, 2 h 
Decomposition of sm on 
warming to rt 
5 t-BuOK DMF, rt, 30 min Decomposition of sm 
6 KOH DMSO, rt – 100 °C, 2 h 
Decomposition of sm on 
heating 
 
Table 4.7. Elimination of dimesylates 325 and 326 to oxepines 309 or 1: reaction conditions screened. 
 
Both dehydrobromination and dihydroxylation studies provided clear evidence of 
ketopiperazine-pyrimidinone-oxepine instability under basic conditions. Therefore, 
strategies that would require a single elimination event to install the oxepine ring under 
mild conditions became the focus of further investigation. 
4.3 Epoxidation – Ring Opening Approach: Model Study 
 
As discussed in Chapter 2.3.4, Wijnberg and co-workers reported that a dihydro-
oxepine epoxidation followed by base induced ring-opening sequence could provide 
access to an allylic alcohol – in our case this would be 318.72 It was envisaged that an 
activation-elimination sequence, or indeed direct dehydration, would then provide 
access to the desired oxepine 303 under milder conditions to those required for a double 
elimination event (Scheme 4.16).  
 
Scheme 4.16. Proposed epoxidation – ring-opening strategy. 
 
A model study was undertaken to demonstrate that the approach would be viable for 
oxepine-pyrimidinone systems but, unfortunately, epoxidation of the model dihydro-
oxepine 197 proved very difficult. When conditions requiring the in situ generation of 
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DMDO from acetone using Oxone® as reported by Wijnberg and co-workers were 
applied,72 only a complex mixture of side-products was obtained (Table 4.8, entry 1). 
This poor result was attributed to the slow and unreliable formation of DMDO, and so 
Yang’s conditions for TFDO generation from trifluoroacetone using Oxone® were 
investigated,110 but with the same outcome (Table 4.8, entry 2).  
 
A m-CPBA mediated epoxidation had been avoided due to concerns that the benzoate 
anion formed would immediately open the newly formed epoxide.72 Indeed, when 
dihydro-oxepine 197 was treated with an excess of m-CPBA in DCM complete 
decomposition of the starting material was observed (Table 4.8, entry 3). It was 
proposed that the addition of an aqueous solution of NaHCO3 to the reaction would 
minimise any unwanted interaction of the substrate with the benzoate anion or benzoic 
acid. However, this modification resulted in the same outcome as previously obtained 
(Table 4.8, entry 4). 
 
Next, DMDO was prepared as a solution in acetone according the procedure of Singh 
and co-workers.111 Treatment of dihydro-oxepine 197 with the DMDO solution did lead 
to the isolation of epoxide 327 in low yield (Table 4.8, entry 5), but this result could not 
be repeated. Traces of diol 320 were observed by mass spectrometry suggesting that the 
epoxide was susceptible to ring-opening in the presence of water. Repeating the reaction 
in the presence of the desiccant Na2CO3 offered no improvement however. 
 
Entry Epoxidising agent Conditions Comment 
1 Oxone®/acetone 
NaHCO3, 18-crown-6, DCM, H2O, 0 °C, 
4 h 
Decomposition of sm 
2 Oxone®/trifluoroacetone 
NaHCO3, Na2EDTA, MeCN, 0 °C, 10 
min 
Decomposition of sm 
3 m-CPBA DCM, 0 °C – rt, 16 h Decomposition of sm 
4 m-CPBA Sat. NaHCO3 (aq.), DCM, 0 °C – rt, 16 h Decomposition of sm 
5 DMDO Acetone, –78 °C, 2.5 h 13% 327 
 
Table 4.8. Epoxidation of dihydro-oxepine 197: reaction conditions screened. 
 
The small quantities of epoxide 327 that could be isolated from the reaction of dihydro-
oxepine 197 with DMDO made further investigation impossible. It was therefore 
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decided to abandon this route: it seemed reasonable to suggest that other epoxidation 
conditions (e.g. Shi or Jacobsen methods) would also fail. Not only that, but it was 
deemed unlikely that dihydro-janoxepin 49, or a derivative, would prove a good 
substrate for epoxidation where the model system had already failed.  
4.4 Allylic Oxidation Strategy 
 
The allylic oxidation of a dihydro-oxepine 302 was identified as an alternative strategy 
for preparing an allylic alcohol 328, for either activation-elimination, or direct 
dehydration to an oxepine 303 (Scheme 4.17). 
 
Scheme 4.17. Proposed allylic oxidation strategy. 
4.4.1 Allylic Oxidation: Model Study 
 
The allylic oxidation of dihydro-oxepines was described by Chattopadhyay and co-
workers in 2007 (Chapter 2.3.4).112 Following their procedure, the model dihydro-
oxepine 197 was treated with 1.1 equivalents of selenium dioxide in xylenes, with 
heating at 125 °C for 18 h, to furnish the enone 329 in moderate yield (Scheme 4.18). 
The structure of enone 329 was assigned based upon the 1H-NMR spectrum which 
showed a doublet and doublet of doublets for the two alkene protons respectively and a 
singlet at 4.70 ppm corresponding to the O-methylene protons. The regioselectivity 
observed was surprising: it was expected that oxidation would occur at the benzylic-
allylic position. Instead, isomerisation of the alkene into conjugation with the 
pyrimidinone ring occured before oxidation at the now only available allylic position. 
 
Scheme 4.18. Selenium dioxide-mediated allylic oxidation of dihydro-oxepine 197 in xylenes. 
 
Enone 329 could also be prepared in comparable yield by pyridinium dichromate (PDC) 
and tert-butyl hydrogen peroxide (TBHP) mediated allylic oxidation of dihydro-oxepine 
197, a procedure previously used by the Taylor group (Scheme 4.19).113 The interesting 
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peroxy-intermediate 330 was also isolated, where addition of the TBHP radical had 
occurred at the expected benzylic-allylic position but subsequent oxidation to the 
respective enone had not proceeded. 
 
Scheme 4.19. PDC/TBHP-mediated allylic oxidation of dihydro-oxepine 197. 
Whilst enone 329 was a valuable intermediate, our initial interest was to utilise allylic 
alcohol 331. Thus, enone 329 was readily reduced using sodium borohydride in MeOH 
at 0 °C in near quantitative yield (Scheme 4.20). 
 
Scheme 4.20. Reduction of enone 329. 
It was more desirable to access allylic alcohol 331 directly, without the need for a 
subsequent reduction step. Pleasingly, it was discovered that treatment of dihydro-
oxepine 197 with selenium dioxide in dioxane as solvent at 100 °C for 30 min furnished 
the desired alcohol 331 in 39% yield and enone 330 in 14% yield (Table 4.9, entry 1). 
Reducing the reaction temperature to 75 °C with an increase in reaction time led to an 
improvement in the overall yield as well as the ratio of alcohol 331 to enone 329, with 
alcohol 331 isolated in 52% yield, and enone 329 in 10% yield (Table 4.9, entry 2). 
These conditions were found to be optimal - any further reduction in temperature 
resulted in extremely slow oxidation of dihydro-oxepine 197 (Table 4.9, entries 3 and 
4).   
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Entry Temperature (°C) Time (h) Yield 331 Yield 329 Overall Yield 
1 100 0.5 39% 14% 53% 
2 75 1.0 52% 10% 62% 
3 50 18 - - <10% 
4 rt 18 - - rsm 
 
Table 4.9. Selenium dioxide-mediated allylic oxidation of dihydro-oxepine 197 in dioxane:  
optimisation study. 
 
When methanol was investigated as an alternative solvent during the optimisation study, 
only the intriguing ring opened methoxy derivative 332 was isolated (Scheme 4.21). 
[This observation was also made in the absence of selenium dioxide]. The sensitivity of 
dihydro-oxepines to nucleophiles is indeed noteworthy; mechanistic proposals and the 
characterisation of 332 are discussed later (Chapter 4.8.3).  
 
Scheme 4.21. Unexpected synthesis of ring-opened methoxy-derivative 332. 
4.4.2 Allylic Oxidation of Dihydro-Oxepine 298 
 
The dihydro-janoxepin 49 imidate-protected precursor 298 was identified as the most 
suitable substrate for the investigation of allylic oxidation to alcohol 333. Its lower 
polarity compared to that of dihydro-janoxepin made it easier to handle, and amide 
nitrogen protection would preclude any complications arising from N-oxide formation.  
 
Application of the optimum conditions identified in the model study gave encouraging 
results, with the desired allylic alcohol 333 being isolated as a 1:1 mixture of 
diastereomers in 35% yield and enone 334 in 11% yield (Table 4.10, entry 1). The 
disappointing overall yield was attributed to decomposition of dihydro-oxepine 298 
under the reaction conditions. Increasing the reaction temperature to 90 °C, but halving 
the reaction time gave a much improved 58% yield of alcohol 333 and 13% yield of 
ketone 334 (Table 4.10, entry 2). A further increase in temperature to 100 °C had a 
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considerable detrimental effect on the overall yield (Table 4.10, entry 3), whilst lower 
temperatures gave very slow conversion to product (Table 4.10, entry 4). 
 
Entry Temperature (°C) Time (h) Yield 333 Yield 334 Overall Yield 
1 75 1.0 35% 11% 46% 
2 90 0.5 58% 13% 71% 
3 100 0.5 26% 15% 41% 
4 50 18 - - <10% 
 
Table 4.10. Allylic oxidation of dihydro-oxepine 298. 
 
As found in the model study, enone 334 could be readily reduced to alcohol 333 using 
sodium borohydride (Scheme 4.22). 
 
Scheme 4.22. Reduction of enone 334. 
 
With allylic alcohol 333 available in good yield directly from dihydro-oxepine 298, an 
investigation of methods for dehydration or elimination to provide the desired oxepine 
was undertaken next. Reaction conditions were applied to the model allylic alcohol 331 
in the first instance owing to its ready availability.   
4.4.3  Allylic Alcohol Dehydration: Model Study 
 
The acid-catalysed dehydration of alcohol 331 was initially investigated. 
Disappointingly, aqueous sulfuric acid (Table 4.11, entry 1) and p-toluenesulfonic acid 
(Table 4.11, entry 2) failed to promote any dehydration to oxepine 196. When TFA was 
used (10% v/v in DCM), the trifluoroacetate derivative 335 was observed in both mass 
and 1H-NMR spectra of the unpurified product. Following purification on silica gel 
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however, only a very poor recovery of the starting material was obtained (Table 4.11, 
entry 3).  
 
Entry Acid Conditions Comment 
1 H2SO4 (5% aq. solution) Dioxane, rt – 80 °C, 18 h rsm 
2 pTSA (0.5 eq.) PhMe, rt – 110 °C, 18 h rsm 
3 TFA (10% v/v) DCM, rt, 18 h 
335 present in unpurified 
material 
 
  Table 4.11. Acid-catalysed dehydration of alcohol 331: reaction conditions screened. 
 
Having observed no conversion to oxepine 196 this approach was abandoned and the 
utility of sulfur-containing dehydrating agents such as Burgess’ reagent114 336 and 
Martin’s sulfurane115 337 (Figure 4.1) was investigated.  
 
Figure 4.1. Structure of Burgess’ reagent 336 and Martin’s sulfurane 337. 
 
When alcohol 331 was heated with Burgess’ reagent 336 in both DMF (Table 4.12, 
entry 1) and toluene (Table 4.12, entry 2), complete consumption of the starting 
material was observed by TLC, but to a complex mixture of baseline material. Using 
Martin’s sulfurane 337 at room temperature also gave no conversion to the desired 
oxepine 196, but the intermediate species 338 could be seen in both mass and 1H-NMR 
spectra of the unpurified product (Table 4.12, entry 3). This indicated that initial 
activation of the alcohol was occurring, but that subsequent deprotonation of the α-
proton with elimination was an unfavourable process - heating the reaction mixture was 
not sufficient to promote this. 
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Entry Dehydrating Agent (2.0 eq.) Conditions Comment 
1 Burgess’ reagent 336 DMF, 80 °C, 3 h Decomposition 
2 Burgess’ reagent 336 PhMe, 110 °C, 18 h Decomposition 
3 Martin’s sulfurane 337 DCM, rt, 2 h 
Intermediate 338 
observed in crude 
material 
 
Table 4.12. Dehydrating agent-mediated dehydration of alcohol 331: reaction conditions screened. 
 
Two further alternative methods for the dehydration of alcohol 331 were investigated. 
Alcohol 331 was treated with Ph3P and DIAD in THF, it being proposed that the loss of 
Ph3P(O) may provide a driving force for elimination, but only decomposition of the 
starting material was observed as the reaction mixture was warmed to room temperature 
(Table 4.13, entry 1). When alcohol 331 was treated with SOCl2 in pyridine for 1 h, the 
allylic chloride 339 was isolated in 57% yield (Table 4.13, entry 2). Unfortunately, 
heating the reaction mixture was not sufficient to promote subsequent 
dehydrochlorination.  
 
Entry Conditions Comment 
1 PPh3, DIAD, THF, 0 °C – rt, 1.5 h Decomposition 
2 SOCl2, pyridine (solvent), 0 °C – rt, 1 h 57% 339 
 
Table 4.13. Alternative dehydration conditions investigated. 
4.4.4 Chlorination – Dehydrochlorination: Model Study 
 
An activation-elimination sequence for the conversion of an allylic alcohol 318 to an 
oxepine 303 was investigated next. It was proposed that a mesylate 340 would be a 
suitable intermediate for elimination (Scheme 4.23).  
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Scheme 4.23. Proposed activation – elimination sequence. 
 
Surprisingly, treatment of alcohol 331 with MsCl in pyridine (as used to prepare 
dimesylates 325 and 326) resulted in no conversion to product, with complete recovery 
of the starting material (Table 4.14, entry 1). When MsCl was used with NEt3 and 
DMAP, complete conversion to a product was observed in 4 h, however, no singlet 
corresponding to the mesyl group protons was present in the 1H-NMR spectrum. The 
product was eventually identified as chloride 339 (characterisation discussed below) 
which was isolated in 98% yield (Table 4.14, entry 2). When TsCl was used under the 
same reaction conditions, chloride 339 was again isolated, but a longer reaction time 
was required and a lower yield obtained (Table 4.14, entry 3). 
 
Entry Conditions Yield 339 
1 MsCl, pyridine (solvent), rt, 18 h rsm 
2 MsCl, NEt3, DMAP, DCM, rt, 4 h 98% 
3 TsCl, NEt3, DMAP, DCM, rt, 18 h 59% 
 
Table 4.14. Synthesis of chloride 339: reaction conditions screened. 
 
The ESI mass spectrum of chloride 339 did show the corresponding molecular ion (with 
chlorine isotope peaks), but at low intensity. The major peak corresponded to that of 
alcohol 331, presumably as a result of hydrolysis under the spectrometer conditions. IR 
spectroscopy of the product clearly showed the absence of an absorption band at a 
frequency corresponding to an O-H stretch, whilst NMR spectroscopy provided further 
evidence for the structural assignment. In the 1H-NMR spectrum of chloride 339 the 
signal for H-3 had clearly shifted downfield with respect to alcohol 331 whilst the 
diastereotopic protons H-1 and H-2 had also shifted downfield and had very distinct 
chemical shifts (Table 4.15). In the 13C-NMR spectrum the signal corresponding to the 
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H-3 carbon had shifted upfield (Table 4.15). These observations were consistent with 
the predicted NMRs generated by ACD© and ChemDraw©.  
 
# 
δH (J in Hz) δC 
339 331 339 331 
1 4.64 (ddd, J 12.0, 3.0, 1.0) 4.37 (ddd, J 11.5, 5.0, 1.0) 
72.3 73.5 
2 4.35 (dd, J 12.0, 7.0) 4.31 (dd, J 11.5, 2.0) 
3 4.86 (dddd, J 7.0, 4.0, 3.0, 1.5) 4.50 (app. td, J 5.0, 2.0, 1.0) 54.9 68.3 
4 6.11 (ddd, J 12.0, 4.0, 1.0) 6.17 (dd, J 12.0, 5.0) 129.9 132.5 
 
Table 4.15. Selected NMR data for chloride 339 and alcohol 331. 
 
With chloride 339 in hand, dehydrochlorination to oxepine 196 was investigated. The 
treatment of chloride 339 with TBAF in DMSO resulted in the isolation of oxepine 196 
in 41% yield, an improvement on previous eliminations (Table 4.16, entry 1). A brief 
optimisation study was subsequently undertaken. When 1.1 equivalents of base were 
used, no reaction at all was observed. Changing the base to potassium tert-butoxide 
(used in THF), and DBU (used in DCM), resulted in decomposition of the substrate to a 
complex mixture of side-products (Table 4.16, entries 2-3). Heating chloride 339 in 
pyridine to 50 °C also failed to effect elimination (Table 4.16, entry 4). 
 
Entry Base (2.1 eq.) Conditions Yield 196 
1 TBAF (1.0 M in THF) DMSO, rt, 30 min 44% 
2 t-BuOK THF, 0 °C – rt, 2 h Decomposition 
3 DBU DCM, rt – 45 °C Decomposition on heating 
4 Pyridine (solvent) 50 °C, 18 h rsm 
 
Table 4.16. Elimination of chloride 339: reaction conditions screened. 
 
Although the yield for TBAF-mediated elimination was encouraging, it was still 
desirable to improve the efficiency of this key transformation. It was proposed that 
installing a better leaving group than chloride might achieve this and so alcohol 331 was 
treated with Ms2O in place of MsCl to avoid rapid substitution of chloride (Scheme 
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4.24). Disappointingly, only alcohol 331 was isolated following work-up of the reaction 
mixture, suggesting that mesylate 341 was an unstable intermediate and not easily 
handled. 
 
Scheme 4.24. Attempted synthesis of mesylate 341 with Ms2O. 
 
Another strategy was to use a Finkelstein reaction to install an iodide leaving group. 
However, when chloride 339 was treated with NaI in acetone only alcohol 331 was 
isolated following work-up of the reaction mixture (Scheme 4.25). 
 
Scheme 4.25. Attempted Finkelstein reaction with chloride 339. 
 
An attempt was also made to prepare iodide 342 from alcohol 331 using TMSCl and 
NaI in a procedure reported by Kanai and co-workers (Scheme 4.26).116 However, this 
too was unsuccessful, with only the starting material being recovered. 
 
Scheme 4.26. Attempted preparation of iodide 342 from alcohol 331. 
 
Despite its moderate efficiency, chlorination of allylic alcohol 331 followed by 
dehydrochlorination was a viable alternative strategy for oxepine construction. The 
methodology was next applied to allylic alcohol 333 in order to focus further 
optimisation studies on that system. 
4.4.5 Chlorination – Dehydrochlorination of Allylic Alcohol 333 
 
Chloride 343 was readily prepared from alcohol 333 using MsCl, NEt3 and DMAP in 
excellent yield, as a 1:1 mixture of inseparable diastereomers (Scheme 4.27).  
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Scheme 4.27. Synthesis of chloride 343. 
 
The characterisation of chloride 343 was found to be more challenging than in the case 
of the model study, as the [MH]+ peak could not be seen in the ESI mass spectrum - 
only the mass of alcohol 333 was observed. This problem was overcome by the 
development of an APCI method whereby the substrate was injected in acetonitrile. In 
the absence of water and methanol the expected [MH]+ was then observed. IR 
spectroscopy showed the loss of an absorption band at a frequency corresponding to an 
O-H stretch from alcohol 333 to chloride 343, whilst NMR experiments again provided 
further evidence for the structural assignment. The data showed in Table 4.17 compared 
well with those of the model study despite the complex nature of the 1H-NMR spectrum 
as a result of the two diastereomers present. 
 
# 
δH (J in Hz) δC 
343 333 343 333 
1 4.61 (dd, J 12.0, 3.0) 4.38-4.21 (m) 
72.4 73.4 
2 4.41 (dd, J 12.0, 6.0) 4.38-4.21 (m) 
3 4.87-4.82 (m) 4.51-4.44 (m) 54.8 68.3 
4 6.06-6.00 (m) 6.11 (dd, J 12.0, 4.0) 129.1 131.4 
 
Table 4.17. Selected NMR data for chloride 343 and alcohol 333. Data corresponds to that of a single 
diastereomer. 
 
To our delight, treatment of chloride 343 with TBAF in DMSO effected elimination to 
oxepine 309 (Table 4.18, entry 1), the structure of which was confirmed by comparison 
of relevant NMR data with that of janoxepin (1). Unfortunately, the transformation 
occurred in just 10% yield and this could not be improved by extending the reaction 
time (Table 4.18, entry 2) or heating the reaction mixture (Table 4.18, entry 3). No 
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reaction was observed at low temperatures using DMF (Table 4.18, entry 4) or THF 
(Table 4.18, entry 5) as solvent - conversion to product was only observed upon 
warming to room temperature. Again, using 1.1 equivalents of base resulted in no 
reaction at all.  
 
Entry Temperature (°C) Time (min) Solvent Yield 309 
1 rt 10 DMSO 10% 
2 rt 60 DMSO <5% 
3 50 10 DMSO Decomposition 
4 –40 - rt 240 DMF 9% 
5 –40 - rt 240 THF <5% 
 
Table 4.18. Dehydro-chlorination to of chloride 343 using TBAF: optimisation study. 
 
An extensive screen of alternative reaction conditions for the elimination of chloride 
343 to oxepine 309 followed, as outlined in Table 4.19. In summary, the only 
improvement in yield was achieved by using the dehydrochlorination conditions as 
described by Reisman and co-workers, whereby heating chloride 343 with LiCO3 and 
LiCl in DMF furnished oxepine 309 in 13% yield (Table 4.19, entry 1).80 The only other 
successful reaction conditions used DBU as base in DCM, returning oxepine 309 in just 
5% yield (Table 4.19, entry 2). All other attempts resulted in decomposition of the 
starting material (Table 4.19, entries 3-10). 
 
 
 
 
 
 
 
 
 
 
 
84 
 
 
Entry Base (2.1 eq.) Conditions Yield 309 
1 LiCO3 LiCl, DMF, 100 °C, 2 h 13% 
2 DBU DCM, rt, 30 min 5% 
3 DBU DMF, rt, 30 min - 
4 t-BuOK THF, –78 °C, 30 min - 
5 t-BuOK t-BuOH, rt, 30 min - 
6 t-BuOK DMF, rt, 30 min - 
7 Pyridine (solvent) rt – 50 °C, 1 h - 
8 LiHMDS THF, –78 °C, 30 min - 
9 NEt3 AgBF4, DCM, rt, 30 min - 
10 NaH DMSO, rt, 30 min - 
 
Table 4.19. Dehydrochlorination of chloride 343: optimisation study. 
 
To ascertain if one diastereomer was preferentially undergoing elimination, the two 
diastereomers of allylic alcohol 333 were separated (the diastereomers of chloride 343 
were inseparable by column chromatography). Unfortunately, when the two 
diastereomers were independently subjected to the chlorination conditions, chloride 343 
was again isolated as a 1:1 mixture of diastereomers.   
 
The preparation of oxepine 309 represented a significant milestone in the synthesis of 
janoxepin (1), however, the low yield achieved for the elimination step was 
disappointing. An extensive study of alternative methods for dihydro-oxepine 
elaboration via an allylic alcohol now ensued. 
4.4.6 Chugaev Elimination: Model Study 
 
It was proposed that oxepine 303 could be generated via Chugaev elimination of a 
xanthante ester 344 (Scheme 4.28), itself prepared in a single step from an allylic 
alcohol 318.  
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Scheme 4.28. Proposed Chugaev elimination strategy. 
 
Using a procedure reported by Ball and co-workers, alcohol 331 was deprotonated with 
sodium hydride before the addition of carbon disulfide and methyl iodide (Scheme 
4.29).117 Unfortunately, an inseparable mixture of xanthate ester 345 and dithioate 346 
was obtained, the latter a result of [2,3]-rearrangement of the intermediate sulfur anion, 
a process that has been observed previously in allylic systems.118 
 
Scheme 4.29. Preparation of xanthate ester 345. 
 
Attempts to utilise the uncharacterised mixture of products in a subsequent elimination 
step were unsuccessful. Thermolysis in toluene at 110 °C for 3 d as described by Ball 
and co-workers117 failed to provide any oxepine 196, with the same mixture of products 
being recovered (Table 4.20, entry 1). When the mixture of xanthate ester 345 and 
dithioate 346 was heated in xylenes at 138 °C for 24 h, only approx. 50% recovery of 
the starting material was obtained, presumably as a result of decomposition under the 
reaction conditions (Table 4.20, entry 2). Finally, the palladium(0)-mediated elimination 
of xanthate esters to alkenes as described by Kanematsu and co-workers was 
investigated, but again without success (Table 4.20, entry 3).118  
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Entry Conditions Comment 
1 PhMe, 110 °C, 3 d rsm 
2 Xylenes, 138 °C, 24 h rsm (~50%) 
3 Pd(PPh3)4, DCM, rt, 18 h rsm 
 
Table 4.20. Attempted Chugaev elimination: reaction conditions screened. 
4.4.7 Grieco Elimination: Model Study 
 
The elimination of a selenide to an alkene following oxidation, as reported by Grieco 
and co-workers,119 was another possible strategy for preparing an oxepine 303 from an 
alcohol 318 (Scheme 4.30). 
 
Scheme 4.30. Proposed Grieco elimination strategy. 
 
However, it is well known that oxidation of a selenide in an allylic system can result in 
a [2,3]-rearrangement to furnish the regioisomer 328 as opposed to effecting elimination 
to an alkene (Scheme 4.31).120,121 Nevertheless, this strategy was investigated as a 
regiomeric alcohol 328 was an interesting alternative substrate for the investigation of 
dehydration or E2’ elimination strategies. 
 
Scheme 4.31. [2,3] Selenide rearrangement in allylic systems. 
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Selenide 349 was prepared in 63% yield according to the Grieco procedure whereby 
alcohol 331 was treated with o-nitrophenyl selenocyanate 348 and tributylphosphine 
(Scheme 4.32).119  
 
Scheme 4.32. Synthesis of selenide 349. 
 
No elimination to oxepine 196 was observed upon oxidation of selenide 349. When m-
CPBA was used as the oxidant at low temperature (as described by Bonjoch and co-
workers),121 a mixture of the regiomeric alcohol 350 and intermediate selenate 351 was 
obtained (Table 4.21, entry 1). Complete conversion to alcohol 350 was observed when 
hydrogen peroxide was used as the oxidant in the presence of pyridine, in accordance 
with a procedure reported by Zakarian and co-workers (Table 4.21, entry 2).120 
 
Entry Oxidant Conditions Yield 
1 m-CPBA DCM, –78 °C, 1 h 15% 350, 33% 351 
2 H2O2 Pyridine, H2O, THF, 0 °C, 3 h 70% 350 
 
Table 4.21. Attempted Grieco elimination: conditions screened. 
 
Alcohol 350 was next subjected to the screen of dehydration conditions previously 
described in Chapter 4.4.3, but without success. However, it was proposed that 
activation followed by elimination in an E2’ fashion may be possible. Unfortunately, 
when alcohol 350 was treated with MsCl, NEt3 and DMAP, chloride 339 was isolated in 
near quantitative yield as a result of conjugate addition of chloride to the alkene, with 
elimination of the activated hydroxyl group (Scheme 4.33).  
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Scheme 4.33. Attempted activation of alcohol 350 with MsCl. 
4.4.8 Palladium-Mediated Acetate/Carbonate Elimination: Model Study 
 
Tsuji and Trost reported that 1,3-dienes such as that present in an oxepine 303 could be 
formed by the treatment of allylic acetates 352 or carbonates 353 with a palladium(0) 
species, providing a β-hydrogen was available for elimination and no suitable 
nucleophiles were present.122,123 This was more recently utilised in the synthesis of a 
germination stimulant reported by Stick and co-workers.124 As the necessary substrates 
could be readily prepared from an allylic alcohol 318, this methodology was 
investigated for the preparation of an oxepine 303 (Scheme 4.34). 
 
Scheme 4.34. Proposed palladium mediated elimination of acetate/carbonate 352 or 353. 
 
Acetate 354 was prepared in 54% yield by treating alcohol 331 with AcCl, NEt3 and 
DMAP.  The same conditions were used with ethyl chloroformate to synthesise ethyl 
carbonate 355 (Scheme 4.35). These transformations were not further optimised. 
 
Scheme 4.35. Synthesis of acetate 354 and carbonate 355. 
 
Both acetate 354 and carbonate 355 were next treated with Pd(PPh3)4 (20 mol%) in 
THF. In both cases, no reaction was observed at room temperature and the starting 
material could be recovered. When the reaction mixture was heated at reflux, slow 
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decomposition of the substrates to a complex mixture of baseline material occurred 
(Scheme 4.36). This approach was abandoned rather than committing further time and 
resource to a ligand and solvent screen.   
 
 
Scheme 4.36. Attempted palladium mediated acetate/carbonate elimination. 
4.4.9 Utilising Enone 329: Alkenyl Triflate Reduction 
 
It was postulated that deprotonation of an enone 356 α- to the oxygen would be more 
likely than for an allylic alchol-derived substrate. Trapping the resulting enolate as a 
triflate 357, followed by reduction to oxepine 303 was therefore worthy of investigation 
(Scheme 4.37). 
 
Scheme 4.37. Proposed alkenyl triflate reduction strategy. 
 
Formation of triflate 358 was not straightforward, however. Deprotonation of enone 329 
with LiHMDS at –78 °C followed by the addition of Comins’ reagent 359 as reported 
by Minehan and co-workers, resulted in complete recovery of the starting material 
(Table 4.22, entry 2).125 Instead, enone 329 was treated with KHMDS at –20 °C with 
subsequent addition of Tf2O, according to a procedure previously reported by the Taylor 
group.126 Triflate 358 was observed in small quantities by mass spectrometry and 1H-
NMR spectroscopy of the unpurified product, but the compound quickly decomposed 
upon purification (Table 4.22, entry 2).  
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Entry i) Deprotonation conditions ii) Triflation conditions Comment 
1 LiHMDS, THF, –78 °C, 40 min Comins’ reagent 359, DMPU, –78 °C, 1 h rsm 
2 KHMDS, DME, –20 °C, 30 min Tf2O, –20 °C, 2 h Trace 358  
 
Table 4.22. Triflate 358 formation: reaction conditions investigated. 
 
The unpurified product was therefore immediately subjected to the palladium-mediated 
triethylammonium formate reduction conditions as reported by Ortar and co-workers 
(Scheme 4.38).127 Unfortunately, this resulted in complete decomposition of the starting 
material and the approach was abandoned.  
 
Scheme 4.38. Attempted reduction of triflate 358. 
4.4.10 Utilising Enone 329: Shapiro and Bamford-Stevens Reactions 
 
The Shapiro or Bamford-Stevens reaction of a hydrazone 360 to access an oxepine 303 
was also investigated (Scheme 4.39). 
 
Scheme 4.39. Proposed Shapiro/Bamford-Stevens approach. 
 
Hydrazone 361 was prepared in excellent yield by treatment of enone 329 with trisyl-
hydrazine according to a procedure reported by Quayle and co-workers (Scheme 
4.40).128 
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Scheme 4.40. Preparation of hydrazone 361. 
 
Unfortunately, subsequent attempts to effect a Shapiro reaction by treatment of 
hydrazone 361 with n-BuLi in hexane/TMEDA as reported by Heathcock and co-
workers (Table 4.23, entry 1)129 and in THF/TMEDA (Table 4.23, entry 2) resulted in 
complete decomposition of the substrate to a complex mixture of polar side-products. 
When Na in ethylene glycol was used in order to promote a Bamford-Stevens reaction 
(as reported by Quayle and co-workers) the same outcome was again observed (Table 
4.23, entry 3).128 
 
Entry Base (3.0 eq.) Conditions Comment 
1 n-BuLi (1.6 M in hexanes) n-Hexane, TMEDA, –78 – 0 °C, 1.5 h Decomposition 
2 n-BuLi (1.6 M in hexanes) THF, TMEDA, –78 – 0 °C, 1.5 h Decomposition 
3 Na Ethylene glycol, rt – 100 °C, 3 h Decomposition 
 
Table 4.23. Shapiro and Bamford-Stevens reaction of hydrazone 361: conditions explored. 
 
Having explored a number of different approaches for converting allylic alcohol 331 or 
enone 329 into an oxepine without improvement on the chlorination-
dehydrochlorination method, two alternative approaches for dihydro-oxepine 
elaboration were explored. These involved the direct dehydrogenation of a dihydro-
oxepine and installing the vinyl ether alkene by isomerisation or O-vinylation with 
subsequent elaboration to an oxepine.  
4.5 Dihydro-Oxepine Dehydrogenation 
 
It was proposed that dihydro-oxepine dehydrogenation may provide direct access to an 
oxepine. DDQ or CAN have been known to mediate such an oxidative transformation, 
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whilst Pd/C in anisole was also successfully used by Martin and co-workers in their 
synthesis of cribrostatin 6.130 However, dehydrogenation is typically accompanied by 
aromatisation which provides a thermodynamic driving force for the reaction to 
proceed. When dihydro-oxepine 197 was treated with DDQ in toluene at room 
temperature no conversion into oxepine 196 was observed, whilst heating the reaction 
mixture resulted in decomposition of the substrate (Table 4.24, entry 1). When dihydro-
oxepine 197 was heated with Pd/C in anisole only the starting material was recovered 
(Table 4.24, entry 2).  
 
Entry Conditions Comment 
1 DDQ, PhMe, rt – 90 °C, 4 h Decomposition upon heating 
2 Pd/C, anisole, 90 °C, 3 d rsm 
 
Table 4.24. Direct dehydrogenation approach: reaction conditions explored. 
4.6 Alkene Isomerisation 
 
The isomerisation of allyl ether species to vinyl ethers is well known, and formed the 
basis of an alternative strategy for installing the double bond adjacent to oxygen before 
elaboration to an oxepine (Scheme 4.41). The isomerisation of both dihydro-oxepine 
197 and diallyl pyrimidinone 198 was investigated. 
 
Scheme 4.41. Proposed isomerisation – allylic oxidation – elimination strategy. 
4.6.1 Dihydro-Oxepine Allyl Ether Isomerisation 
 
Given the instability of dihydro-oxepines under basic conditions, the transition metal-
catalysed isomerisation of dihydro-oxepine 197 was initially explored. When 
RuCl2(PPh3)3 was employed as the catalyst in the presence of NaBH4 using a procedure 
reported by Frauenrath and Runsink,131 undesired isomerisation of the alkene into 
conjugation with the pyrimidinone ring occurred to furnish dihydro-oxepine 364 
(Scheme 4.42). 
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Scheme 4.42. Ru catalysed alkene isomerisation. 
 
Ruthenium catalysts have also been employed in one pot RCM – isomerisation 
processes. For example, Schmidt reported that isomerisation could be induced following 
RCM by the addition of NaBH4 to the reaction mixture.
132 When these conditions were 
applied to diallyl pyrimidinone 198 no isomerisation was observed, although the RCM 
product dihydro-oxepine 197 was isolated in moderate yield (Scheme 4.43). 
 
Scheme 4.43. Attempted one-pot RCM – isomerisation sequence. 
 
Wilkinson’s catalyst (RhCl(PPh3)3) and a sub-stoichiometric quantity of DBU (0.3 eq.) 
was used to mediate allyl ether isomerisation by Rainier and co-workers when working 
with tetrahydro-oxepine substrates.133 When these conditions were applied to dihydro-
oxepine 197 a fascinating rearrangement to dihydro-furan 365 and pyrimidinone 366 
occured, but with no isomerisation to the desired vinyl ether (Scheme 4.44). The 
characterisation of these compounds and proposed mechanisms for their synthesis will 
be discussed later (Chapter 4.8.1). 
 
Scheme 4.44. Rhodium-catalysed isomerisation. 
4.6.2 Allyl Ether Isomerisation 
 
To avoid dihydro-oxepine rearrangement, the isomerisation of a diallyl pyrimidinone 
substrate was explored next. For this, a butenyl pyrimidinone 367 would be required for 
subsequent RCM of vinyl ether 368 to a dihydro-oxepine 362 (Scheme 4.45). 
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Scheme 4.45. Proposed allyl ether isomerisation – RCM sequence. 
 
The proposed reaction sequence was investigated using the ‘real’ ketopiperazine-
pyrimidinone system. Butenyl pyrimidinone 370 was prepared by the condensation of 
cyclic amidine 52 with known butenyl malonate 369, itself prepared from dimethyl 
malonate and 4-bromo-1-butene according to a procedure reported by Poli and co-
workers.134 O-Allylation using the previously developed Mitsunobu procedure then 
followed to furnish the desired allyl-butenyl pyrimidinone 371 in an efficient process, 
which further demonstrated the utility of this methodology (Scheme 4.46). 
 
Scheme 4.46. Preparation of allyl-butenyl pyrimidinone 373. 
 
The conditions previously investigated for dihydro-oxepine isomerisation were applied 
first. When Wilkinson’s catalyst was used with DBU in refluxing ethanol, complete 
decomposition of the substrate was observed (Table 4.25, entry 1). The ruthenium-
catalysed isomerisation conditions did give some conversion to the isomerised product 
as shown by 1H-NMR spectroscopy of the unpurified product (Table 4.25, entry 2). 
However, the overall recovery of material was low (46%) due to decomposition of the 
substrate, and the product could not be efficiently purified. Most importantly, the 
observed transformation was not repeatable and therefore other conditions for the 
isomerisation of allyl ethers were explored. Crivello and Kong reported that efficient 
isomerisation could be achieved using sub-stoichiometric quantities of iron 
pentacarbonyl and sodium hydroxide.135 However, when allyl-butenyl pyrimidinone 
371 was subjected to these conditions, only a trace of the desired isomerised product 
was observed in the 1H-NMR spectrum of the unpurified product (Table 4.25, entry 3). 
Attempts to promote further conversion by heating the reaction mixture were 
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unsuccessful. A base-induced isomerisation using potassium tert-butoxide in DMSO (as 
reported by Langlois and co-workers)136 was also investigated, but no conversion to 
vinyl ether 372 was observed at room temperature and complete decomposition of the 
substrate occurred upon heating (Table 4.25, entry 4). 
 
Entry Conditions Comment 
1 
RhCl(PPh3)3 (0.1 eq.), DBU (0.3 eq.), EtOH, 78 °C, 3 
h 
Decomposition 
2 
RuCl2(PPh3)3 (0.02 eq.), NaBH4 (0.1 eq.), THF, rt, 1.5 
h 
46% recovery; some conversion to 
vinyl ether 372. Result not repeatable 
3 
Fe(CO)5 (0.05 eq.), NaOH (0.1 eq.), EtOH/H2O, rt, 1.5 
h 
Trace of vinyl ether 372 
4 t-BuOK (0.2 eq.), DMSO, rt – 80 °C, 18 h Decomposition upon heating 
 
Table 4.25. Allyl ether isomerisation: reaction conditions explored. 
4.7 O-Vinylation Strategy 
 
The O-vinylation of a pyrimidinone 373 was explored as an alternative strategy for 
installing a vinyl ether that would be suitable for subsequent RCM to a dihydro-oxepine 
362 (Scheme 4.47). Both transetherification and eliminative approaches were 
investigated.  
 
Scheme 4.47. Proposed vinylation – RCM strategy. 
4.7.1 Vinylation by Transetherification  
 
Three different transetherification conditions were explored using the model 
pyrimidinone 199. The iridium-catalysed methodology developed by Ishii and co-
workers was first investigated.137 Pyrimidinone 199 was treated with [Ir(cod)Cl]2 and 
sodium carbonate in vinyl acetate 377 as solvent, but no reaction was observed despite 
heating the reaction mixture as high as 100 °C (Table 4.26, entry 1).  A more common 
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approach (such as that reported by Williams and co-workers in the synthesis of 
lankacyclinol) requires the treatment of an alcohol with ethyl vinyl ether 378 in the 
presence of mercuric triflate.138 When these conditions were applied to pyrimidinone 
199, no vinyl ether 375 was isolated with acetal 376, an intermediate in the reaction, 
isolated in 37% yield with pyrimidinone 199 also being recovered in 12% yield (Table 
4.26, entry 2). A similar result was obtained when the gold-catalysed reaction reported 
by Tokunaga and Nakamura was utilised.139 When pyrimidinone 199 was treated with 
ethyl vinyl ether 378 in the presence of AuCl(PPh3)3 and Ag(O2CCF3)2 at room 
temperature, acetal 376 was isolated in 42% yield and pyrimidinone 199 recovered in 
9% yield (Table 4.26, entry 3). 
 
Entry Catalyst Conditions Yield 
1 [Ir(cod)Cl]2 (0.1 eq.) 377 (solvent), Na2CO3, PhMe, 50 – 100 °C, 3 h rsm 
2 Hg(O2CCF3)2 (0.5 eq.) 378 (solvent), NEt3 (0.6 eq.), 33 °C, 18 h 
37% 376 
 (49% 
brsm) 
3 AuCl(PPh3)3 (0.05 eq.) 378 (solvent), Ag(O2CCF3)2 (0.05 eq.), rt, 18 h 
42% 376  
(51% brsm) 
 
Table 4.26. Transetherification: reaction conditions screened. 
 
Despite the mixed acetal 376 failing to undergo elimination to vinyl ether 375 under 
these reaction conditions, it was thought possible to effect elimination using a procedure 
reported by Brown and co-workers.140 Thus, acetal 376 was treated with TMSOTf and 
NEt3 in the expectation that elimination of EtOTMS would be favoured to furnish the 
desired vinyl ether 375. Unfortunately, elimination of the substrate was observed, and 
pyrimidinone 199 was isolated in 70% yield along with ethyl vinyl ether 378 (Scheme 
4.48).  
 
Scheme 4.48. Unwanted conversion of acetal 376 to pyrimidinone 199. 
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Heating acetal 376 in toluene at 110 °C for 6 h also failed to effect any elimination to 
the desired vinyl ether. 
4.7.2 Vinylation by Dehydrohalogenation 
 
Another proposed strategy for introducing a vinyl ether was by dehydrohalogenation of 
a suitable alkyl halide 379 (Scheme 4.49). 
 
Scheme 4.49. Proposed dehydrohalogenation strategy to introduce a vinyl ether. 
 
The previously prepared pyrimidinone 370 was used for this investigation and was first 
subject to a Mitsunobu reaction with chloroethanol which proceeded in excellent yield 
(Scheme 4.50). 
 
Scheme 4.50. Preparation of chloride 380. 
 
The dehydrochlorination of chloride 380 to vinyl ether 381 was not possible. When 
potassium tert-butoxide was used in both DMF (Table 4.27, entry 1) and THF (Table 
4.27, entry 2) at –10 °C no reaction was observed, with decomposition of the substrate 
occurring upon warming to room temperature. The milder phase transfer conditions 
reported by Otsuji and co-workers were investigated next.141 However, when chloride 
380 was treated with aqueous NaOH in the presence of n-Bu4NHSO4 no elimination 
was observed, with only slow decomposition of the substrate occurring over longer 
reaction times or upon heating (Table 4.27, entry 3). 
 
98 
 
 
Entry Conditions Comment 
1 t-BuOK, DMF, –10 °C – rt, 3 h Decomposition upon warming to rt 
2 t-BuOK, THF, –10 °C – rt, 3 h Decomposition upon warming to rt 
3 NaOH (aq.), n-Bu4NHSO4, C6H6, rt, 8 d Slow decomposition 
 
Table 4.27. Dehydrochlorination to vinyl ether 381: reaction conditions explored. 
 
Having thoroughly investigated seven novel strategies for the elaboration of dihyro-
oxepines to oxepines, only a single route had been identified that was applicable to the 
synthesis of janoxepin (1): allylic oxidation – chlorination – dehydrochlorination. 
Despite the low yield associated with this transformation, it had been shown to be a 
reliable method, and no further research was carried out in this area. 
 
This Chapter will now summarise the many examples of dihydro-oxepine 
rearrangement that have already been highlighted. It will then describe the ‘end-game’ 
with respect to the synthesis of janoxepin (1).  
4.8 Dihydro-Oxepine Rearrangement Products 
 
A number of fascinating products have been isolated during the course of dihydro-
oxepine elaboration and enamine installation (Chapter 3) research. Such observations 
have largely been made following exposure of a dihydro-oxepine to excess base, but 
also as a result of reaction with nucleophiles.   
4.8.1 Dihydro-Oxepines: Base Sensitivity 
 
The base sensitivity of dihydro-oxepines is not unknown. Ramachary and co-workers 
reported the base-induced ring-opening (BIRO) of a range of dihydro-oxepines 382 to 
phenols 383 in 2008 (Scheme 4.51).142 
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Scheme 4.51. Base-induced ring-opening of dihydro-oxepines. 
 
Furthermore, they observed a thermal (A) or silica-induced (B) rearrangement of these 
products to corresponding chromenes 384 (Scheme 4.52).142 This methodology was 
later utilised in the synthesis of a range of highly functionalised chromenes via a multi-
catalysis cascade sequence.143 
 
Scheme 4.52. Rearrangement to chromenes. 
 
The proposed mechanism for these transformations is shown in Scheme 4.53 and 
involves initial BIRO of the dihydro-oxepine 382 to the ring-opened cis-diene 383. A 
[1,7]-sigmatropic hydrogen shift would then proceed to give intermediate 385 which 
immediately undergoes a rapid cyclisation to chromene 384 (Scheme 4.53).142  
 
Scheme 4.53. Proposed mechanism for BIRO and cyclisation to chromenes. 
 
It is proposed that the same mechanism applies in the base-induced rearrangement of 
dihydro-oxepine 294 to pyran 299 which was isolated as a single diastereomer, where 
elimination to form the enamine occurs independently (Scheme 4.54). This was 
observed whilst investigating methods for preparing enamine 298 as described in 
Chapter 3.6.3. 
 
Scheme 4.54. Dihydro-oxepine 294 rearrangement to pyran 299. (Relative stereochemistry shown). 
100 
 
The 1H-NMR spectrum of pyran 299 was key to its characterisation. A doublet (δ 1.50 
ppm, J 6.5 Hz) clearly corresponded to the new methyl group whilst the position of the 
alkene was assigned based upon the signals for H-1 and H-2 which were a doublet and 
doublet of doublets, respectively. 13C-NMR spectroscopy along with HSQC and COSY 
experiments provided further confirmation of the structural assignment.   
 
Dihydro-furan 365 and pyrimidinone 366 were isolated following treatment of dihydro-
oxepine 197 with DBU in the presence of Wilkinson’s catalyst (Scheme 4.55). This 
discovery was made whilst investigating methods to promote isomerisation of the 
dihydro-oxepine alkene (Chapter 4.6). 
 
Scheme 4.55. Isolation of furan 365 and pyrimidinone 366. 
 
The characterisation of pyrimidinone 366 was not straightforward. Mass spectrometry 
showed that hydrogenation of dihydro-oxepine 197 had occurred but IR spectroscopy 
showed an absorption band at 3061 cm-1 indicating the presence of a hydroxyl group, 
thus ruling out hydrogenation to a tetrahydro-oxepine. The 1H-NMR spectrum of 366 
showed signals characteristic of a terminal alkene, as well as two complex CH2 alkane 
signals which coupled to each other and the alkene. Following analysis of 13C-NMR, 
DEPT, HSQC and COSY spectroscopic data, a firm assignment as to the structure of 
pyrimidinone 366 could be made.    
 
The formation of pyrimidinone 366 is intriguing, and could be the result of 
hydrogenation of the BIRO intermediate 386. The presence of Wilkinson’s catalyst 
under an atmosphere of air could explain alkene hydrogenation, however, the selectivity 
for the cis-1,2-disubstituted alkene over the terminal alkene is surprising (Scheme 4.56). 
It could be argued that rhodium coordination to the electron rich cis-alkene is favoured 
initially but hydrogenation of terminal alkenes is typically favoured.  
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Scheme 4.56. Proposed mechanism for the generation of pyrimidinone 366. 
 
An alternative explanation may lie in the previously described formation of acyclic 
alkanes by hydrogenation of dihydro-oxepines in the absence of base, as reported by 
Kawase and co-workers. When dihydro-oxepine 387 was treated with Adams’ catalyst 
(PtO2) under an atmosphere of hydrogen, both tetrahydro-oxepine 388 and triphenol 
389 were isolated in similar yields (Scheme 4.57).144 Although no mechanistic 
proposals are made, this may suggest that the observed reaction could proceed via an 
alternative mechanism not involving the intermediate cis-diene 386. 
 
Scheme 4.57. Hydrogenation of dihydro-oxepine 389 to tetrahydro-oxepine 388 and triphenol 389. 
 
The 1H-NMR spectrum of dihydro-furan 365 provided conclusive evidence for its 
structure. Signals at 6.10 ppm (1 H, ddd, J 17.0, 10.5, 6.0), 5.26 (1 H, dd, J 10.5, 1.0) 
and 5.42 (1 H, dd, J 17.0, 1.0) corresponded clearly to the terminal alkene protons H-1, 
2 and 3 respectively, whilst a signal at 5.34 (1 H, ddd, J 10.0, 7.0, 6.0) related to the 
proton α- to the oxygen in the five-membered ring (H-4). This showed coupling to 
‘roofing’ signals at 3.36 ppm and 2.95 ppm corresponding to the diastereotopic protons 
at the unsubstituted position on the dihydro-furan ring. The structural assignment was 
further confirmed by the 13C-NMR spectrum along with DEPT, HSQC and COSY 
experiments.    
 
A highly speculative mechanism for the generation of dihydro-furan 365 first involves 
BIRO (in the presence of DBU) to provide the intermediate cis-diene 386. An unusual, 
5-endo-trig cyclisation (disfavoured according to Baldwin’s rules) would then be 
required to afford dihydro-furan 365 (Scheme 4.58). Whilst this seems highly unlikely, 
it is hard to envisage how a cationic species that would undergo the desired cyclisation 
can be derived from the intermediate cis-diene 386.  
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Scheme 4.58. A speculative mechanism for the generation of dihydro-pyran 365. 
 
No mechanistic studies have been undertaken, but it can be deduced that rhodium is not 
essential as a similar cyclisation has been observed in the absence of any transition 
metal species. When dihydro-oxepine 215 was treated with triethyloxonium 
tetrafluoroborate and excess potassium carbonate, the fascinating dihydro-furan 291 was 
isolated as a single diastereomer in 33% yield, together with imidate 290 in 36% yield 
(Scheme 4.59). This observation was made whilst developing methods for installing the 
enamine moiety by aldol addition (Chapter 3.6.1). 
 
Scheme 4.59. Isolation of dihydro-furan 291. (Relative stereochemistry shown). 
 
In this case, the mass spectrum showed that bis-alkylation had occurred, whilst the 1H-
NMR spectrum was again instructive. Disappearance of the diastereotopic 
ketopiperazine CH2 protons seen in the spectrum of dihydro-oxepine 215, and 
appearance of a singlet in the alkene region (5.87 ppm) indicated that deprotonation at 
this position had occurred. Signals corresponding to a terminal alkene and 
diastereotopic protons at the unsubstituted position on the 5-membered ring compared 
extremely closely with those seen in the spectrum of dihydro-furan 291. The only 
anomaly was that the signal corresponding to the proton α- to the oxygen was 
considerably more up-field compared to that for dihydro-furan 365 (2.47 ppm c.f. 5.34 
ppm), however, 13C-NMR spectroscopy with DEPT, HSQC and COSY experiments 
provided sufficient further evidence for firm structural assignment. 
  
The proposed mechanism for this transformation is again highly speculative. It is 
suggested that following initial formation of imidate 290, BIRO of the dihydro-oxepine 
takes place to afford the pyrimidinone intermediate 390. This would then undergo 
103 
 
alkylation in the presence of a second equivalent of triethyloxonium tetrafluoroborate to 
give the cis-diene intermediate 391. It is speculated that ketopiperazine deprotonation 
effects tautomerisation to 392 which, based upon the mechanistic proposal for the 
formation of dihydro-furan 365, would undergo a disfavoured 5-endo-trig cyclisation to 
dihydro-furan 291 (Scheme 4.60). Why 390 does not undergo a [1,7]-sigmatropic 
hydrogen shift followed by cyclisation to a pyran in this case is unclear.  
 
Scheme 4.60. A speculative mechanism for the generation of dihydro-furan 291. 
4.8.2 Dihydro-Oxepines: Hydrolysis 
 
Not all unexpected reactions of dihydro-oxepines are as a result of a BIRO processes. 
For example, whilst investigating the double dehydrobromination of dibromide 306 
using TBAF in DMSO (Scheme 4.61, see also, Chapter 4.1.4) aldehyde 307 was 
isolated in 47% yield (Scheme 4.61). Key to the characterisation of aldehyde 307 was 
the 1H-NMR spectrum which showed a low field doublet indicative of an aldehyde 
proton (9.49 ppm, d, J 8.0 Hz), and two alkene signals (H-1 and H-2) at 6.93 and 6.11 
ppm as a dt and dd, respectively. A coupling constant of 15.5 Hz between the alkene 
protons led to assignment of the E-configuration of the alkene. 
 
Scheme 4.61. Isolation of aldehyde 307. (Relative stereochemistry shown). 
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It is proposed that elimination to afford enamine 310 occurs independently to the ring-
opening event. While it would be expected to observe dehydrobromination to allylic 
bromide 395, the corresponding chloride 343 was found to be a reasonably stable 
compound, with only slow hydrolysis to allylic alcohol 333 observed when exposed to 
water or the air. It is therefore speculated that dehydrobromination to allylic bromide 
393 is rapidly followed by conjugate addition of water to give hemi-acetal 394 which 
exists in an equilibrium weighted in favour of aldehyde 307 (Scheme 4.62).  
 
Scheme 4.62. Proposed mechanism for the generation of aldehyde 307.  
 
It was envisaged that under mild acidic conditions, aldehyde 307 would undergo 
cyclisation followed by elimination to oxepine 309. Unfortunately, upon treatment with 
p-TSA in toluene only decomposition of aldehyde 307 was observed (Scheme 4.63). 
 
Scheme 4.63. Attempted cyclisation of aldehyde 307 followed by elimination to afford oxepine 309. 
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4.8.3 Dihydro-Oxepines: Nucleophilic Addition 
 
When methanol was used as a solvent during a study to optimise the allylic oxidation of 
dihydro-oxepine 197 (Chapter 4.4.1), the methoxy derivative 332 was unexpectedly 
isolated in 58% yield (Scheme 4.64).  
 
Scheme 4.64. Synthesis of methoxy-derivative 332. 
 
The structure of the compound was assigned based upon mass spectrometry, which 
clearly indicated the addition of methanol, and the 1H-NMR spectrum. This contained 
characteristic signals for a terminal alkene as well as a singlet integrating for three 
protons at 3.36 ppm corresponding to a methyl ether group. IR spectroscopy was also 
informative, with a broad absorption band at 3040 cm-1 indicating the presence of a 
hydroxyl group. 
 
In order to probe the mechanism of the reaction, dihydro-oxepine 197 was subject to the 
same reaction conditions but in the absence of selenium dioxide. The methoxy 
derivative 332 was again isolated, in similar yield following 18 h at reflux, 
demonstrating that methanol was the only reactant (Scheme 4.65). It is proposed that 
conjugate addition of methanol into the dihydro-oxepine alkene occurs with ring-
opening to furnish the observed methoxy-derivative 332 (Scheme 4.66). When ethanol 
was used in place of methanol only very slow conversion (approx. 10%) to the 
corresponding ethoxy-derivative was observed following 24 h at reflux.  
 
 
Scheme 4.65. Synthesis of methoxy-derivative 332 in the absence of SeO2. 
 
106 
 
 
Scheme 4.66. Proposed mechanism for the synthesis of methoxy-derivative 332. 
 
The novel transformations described here are worthy of further investigation, not only 
to establish mechanisms and potential applications of the transformations, but also to 
better understand the reactivity of dihydro-oxepines. 
4.9 ‘End-Game’: The First Synthesis of (±)-Janoxepin (1) 
 
Despite the failure to achieve efficient dihydro-oxepine elaboration to oxepines, at least 
in part due to the instability of dihydro-oxepines in basic media, and their susceptibility 
to hydrolysis and nucleophilic attack, a reliable (if low-yielding) method had been 
established. All that remained to complete the synthesis was hydrolysis of the imidate 
protecting group. 
4.9.1 Imidate Hydrolysis 
 
 The conditions previously developed for completing the synthesis of dihydro- and 
tetrahydro-janoxepin 49 and 301 were applied to imidate 309. Pleasingly, imidate 
hydrolysis proceeded in excellent yield (98%) to complete the first total synthesis of 
(±)-janoxepin (1) in 14 steps from D-leucine 38 (Scheme 4.67). 
 
Scheme 4.67. Imidate hydrolysis to complete the synthesis of (±)-janoxepin (1). 
4.9.2 Characterisation of (±)-Janoxepin (1) 
 
The 1H- and 13C-NMR spectral data for synthetic (±)-janoxepin (1) matched exactly 
with those reported by Sprogøe and co-workers for the isolated compound – see 
Appendix III for a detailed comparison and copies of NMR spectra.1 The only anomaly 
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between the two sets of data was that the melting point of the synthetic material (179-
180 °C) did not match the reported value (88-89 °C).1  This was attributed to 
polymorphism and the presence of two different oxepine conformers in the solid state as 
shown by X-ray crystallography (Figure 4.2). 
 
 
Figure 4.2. X-ray crystal structure of (±)-janoxepin (1). Only a single enantiomer (R) is shown for clarity. 
ORTEP representations shown with ellipsoids at 50% probability. CCDC 848130, see Appendix V. 
4.10 De-Racemisation Studies 
 
Enantioselective protonation of enolate 396 was identified as a possible strategy for 
accessing the naturally occuring R-enantiomer of janoxepin (1) directly from the 
racemic material already prepared (Scheme 4.68).  
 
 
Scheme 4.68. Proposed de-racemisation of (±)-janoxepin (1). 
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4.10.1 Enantioselective Protonation: Literature Examples 
 
The de-racemisation of ketones, carboxylic acids, amino acid derivatives and esters by 
enantioselective protonation of their enolates has been the subject of much study; the 
work of Fehr,145 Eames146 and Plaquevent147 is particularly noteworthy. More recently, 
catalytic methods have been developed. For example, Yamamoto and co-workers 
reported the de-racemisation of silyl enol ether 397 using a sub-stoichiometric quantity 
of the novel N-triflyl thiophosphoramide 399 in the presence of a stoichiometric amount 
of phenol as an achiral proton source (Scheme 4.69).148  
 
Scheme 4.69. Catalytic enantioselective protonation of silyl enol ether 399. 
 
The available methods for the de-racemisation of amides are limited, largely due to the 
harsh enolisation conditions required. Vedejs and co-workers reported that, following 
enolisation of di-iso-propyl amide 400 (which required an excess of sec-BuLi), 
enantioselective protonation using chiral aniline 404 gave access to the R-enantiomer of 
400 in excellent ee. The corresponding S-enantiomer could be accessed with similar 
efficiency and optical purity using aniline 404 (Scheme 4.70).149  
 
Scheme 4.70. De-racemisation of di-iso-propyl amide 400. 
 
Lasne and co-workers had previously utilised chiral aniline 403 in the de-racemisation 
of pipecolic acid derived amides but also employed ephedrine derivatives effectively as 
the chiral proton source.150 They subsequently expanded this study to investigate the 
effect of nitrogen substituents and identify optimal reaction conditions. Enolisation of 
amide 405 was found to be most efficient using an excess of sec-BuLi and lithium 
bromide in THF at –78 °C. Enantioselective protonation was then achieved in good ee 
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(93%) using (–)-ephedrine 407 (as well as other derivatives) to furnish the R-enantiomer 
of 405 (Scheme 4.71).151 
 
Scheme 4.71. De-racemisation of pipecolic acid derived amide 405 using (–)-ephedrine 407. 
4.10.2 De-Racemisation of (±)-Janoxepin (1) 
 
The conditions reported by Lasne and co-workers were chosen to investigate the de-
racemisaton of (±)-janoxepin (1), mindful that two equivalents of sec-BuLi would be 
required to effect enolisation due to the presence of the amide functionality. When (±)-
janoxepin (1) was treated with sec-BuLi and lithium bromide in THF at –78 °C, 
however, complete decomposition of the substrate was observed (Table 4.28, entry 1). 
The same outcome was obtained when n-BuLi was used as the base (Table 4.28, entry 
2). 
 
Entry i) Enolisation ii) Protonation Comment 
1 
sec-BuLi (2.1 eq.), LiBr (2.1 eq.), THF,  
–78 °C, 15 min 
407 (4.0 eq.), THF,  
–78 °C - –20 °C, 30 min 
Decomposition 
2 
n-BuLi (2.1 eq.), LiBr (2.1 eq.), THF,  
–78 °C, 15 min 
407 (4.0 eq.), THF,  
–78 °C - –20 °C, 30 min 
Decomposition 
 
Table 4.28. De-racemisation of (±)-janoxepin (1): reaction conditions explored. 
 
To establish that the excess of base required was responsible for the decomposition, 
imidate 309 was subjected to the same reaction conditions, where only 1.2 equivalents 
of sec-BuLi were required. In this case, approx. 30% material recovery was achieved 
following the addition of (–)-ephedrine 407, however, this was still in racemic form 
(Scheme 4.72). 
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Scheme 4.72. Attempted de-racemisation of imidate 309. 
 
The limited availability and base-sensitivity of (±)-janoxepin (1) and precursors led to 
the decision to halt further investigation into methods for its de-racemisation. Any 
future work would screen a range of alternative lithium bases (e.g. LiHMDS, LDA) and 
also prepare the N-carbamate substrate 409 in analogy to the pipecolic acid derived 
substrates used by Lasne and co-workers (Scheme 4.71). Thus, it could be established if 
enolate 410 is stabilised by the formation of a six-membered chelate and therefore 
reduce the level of substrate decomposition observed (Scheme 4.73).  
 
Scheme 4.73. Proposed de-racemisation of carbamate 409. 
4.11 Summary and Future Work 
 
The elaboration of dihydro-oxepine 298 to oxepine 309 via an allylic oxidation – 
chlorination – elimination sequence enabled the first total synthesis of (±)-janoxepin (1) 
to be completed in 14 steps from D-leucine 38; this was reported in a recent publication 
(see Appendix VI).152 Unfortunately, this transformation was found to be low-yielding 
and could not be improved despite a thorough investigation of alternative strategies. The 
utilisation of a biomimetic approach for oxepine construction is discussed in Chapter 5, 
whilst future work will focus on developing an alternative oxepine synthesis by way of 
alkyne cycloisomerisation (see Chapter 4.11.1). 
 
Attempts to de-racemise (±)-janoxepin (1) by enantioselective protonation of an enolate 
intermediate were unsuccessful owing to the instability of the oxepine substrates to the 
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conditions required for enolisation. The development of a chiral synthesis of the natural 
product and its derivatives will also be the subject of future work. 
4.11.1 Future Work: Alkyne Cycloisomerisation Route 
 
As already discussed, it was proposed that preparing a dihydro-oxepine substrate 362 
with the vinyl ether alkene in place before elaboration to the oxepine 303 would 
represent a more efficient synthetic route to janoxepin (1) (Scheme 4.74).  
 
Scheme 4.74. Dihydro-oxepine elaboration strategies. 
 
Attempts to implement this strategy by alkene isomerisation (Chapter 4.6) and O-
vinylation (Chapter 4.7) were unsuccessful, however, an alternative retrosynthesis of a 
dihydro-oxepine 362 constructed the vinyl ether alkene by cycloisomerisation of an 
alkyne 411 (Scheme 4.75). This methodology has recently been used in the synthesis of 
such dihydro-oxepines by both Reisman80 and Saá79 groups as described in Chapter 
2.4.2. 
 
Scheme 4.75. Alternative retrosynthetic analysis of dihydro-oxepine 362. 
 
The proposed route would therefore commence with the condensation cyclic amidine 52 
and known alkynyl malonate 412153 to access pyrimidinone 413. Cycloisomerisation 
would then be effected by rhodium (Reisman)80 or osmium (Saá)79 catalysis to provide 
the vinyl ether-containing dihydro-oxepine 414. Aldol condensation of iso-
butyraldehyde 221 using the imidate protection methodology described in Chapter 3 
would then follow to provide enamine 415. Dihydro-oxepine elaboration via allylic 
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oxidation – activation – elimination would then install the final alkene to give oxepine 
309, with imidate hydrolysis completing the second generation synthesis of (±)-
janoxepin (1) (Scheme 4.76). 
 
Scheme 4.76. Proposed alkyne cycloisomerisation route. 
4.11.2 Future Work: Asymmetric Routes to (–)-Janoxepin (1) 
 
In addition to the further investigation of chiral protonation methodology as outlined in 
Chapter 4.10, the development of a novel chiral synthesis of (–)-janoxepin (1) may be 
worthy of consideration. For example, introduction of the stereocentre by a 
chemoselective asymmetric hydrogenation of the conjugated alkene of ketopiperazine-
pyrimidinone-oxepine 417 may be possible as a final step in the synthesis. [It has 
already been shown that selective hydrogenation of a dihydro-oxepine in the presence of 
an enamine is possible (Chapter 3.7), although how the oxepine ring would be affected 
is unknown]. Elaboration of dihydro-oxepine 418 (or an isomer) would follow double 
aldol condensation of iso-butyraldehyde 221 to the unsubstituted ketopiperazine-
pyrimidinone 419, itself constructed using the condensation – O-allylation sequence 
already developed. Thus, the unsubstituted cyclic amidine 422 and malonate 201 would 
be employed as the starting materials (Scheme 4.77). 
113 
 
 
Scheme 4.77. Retrosynthetic analysis of (–)-janoxepin (1): proposed asymmetric hydrogenation route. 
 
Alternatively, introduction of the stereocentre via late stage asymmetric alkylation of 
the enamine-containing ketopiperazine-pyrimidinone-oxepine 423 can also be 
envisaged, with approach of the electrophile directed by a chiral auxiliary appended to 
the amide nitrogen. The key alkylation substrate 423 would be prepared by elaboration 
of dihydro-oxepine 424 followed by introduction of the auxiliary. Enamine installation 
would again be achieved by aldol addition of iso-butyraldehyde 221 to the unsubstituted 
ketopiperazine-pyrimidinone 420, a common intermediate to both proposed chiral 
syntheses (Scheme 4.78). A crucial concern with this route would be the efficiency of 
dihydro-oxepine 424 elaboration to oxepine 423 in the presence of an acidic 
ketopiperazine proton and the distance of the auxiliary from the reactive site.  
 
Scheme 4.78. Retrosynthetic analysis of (–)-janoxepin (1): proposed asymmetric alkylation route. 
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Chapter 5.  Biomimetic Oxepine Construction: Synthesis of a 
Janoxepin Biosynthetic Precursor 
5.1 Oxepine Biosynthesis: Recap 
 
As described in Chapter 1.5, it is proposed that the biosynthesis of janoxepin (1), and 
similar natural products, proceeds via an intriguing enzymatic epoxidation of the 
pyrazino[2,1-b]quinazoline-3,6-dione intermediate 43. This is followed by electrocyclic 
ring-opening of the resulting epoxide 44 to form the oxepine ring (Scheme 5.1).1,26,27,32 
 
Scheme 5.1. Proposed oxepine biogenesis. 
 
The electrocyclic ring-opening of arene-oxides to oxepines has been the subject of much 
study, as reviewed in Chapter 2.3.1. It was therefore decided to investigate the 
plausibility of using such a biomimetic approach as part of an on-going search for an 
efficient synthetic method of oxepine construction. Work would first focus on the 
synthesis of the pyrazino[2,1-b]quinazoline-3,6-dione intermediate 43 before 
investigating methods for its epoxidation to access 44. 
5.2 Pyrazino[2,1-b]quinazoline-3,6-dione-Containing Natural Products 
 
The pyrazino[2,1-b]quinazoline-3,6-dione core of the novel, key intermediate 43 can be 
found in a number of natural products with interesting biological activity. Whilst many 
examples lacking an enamine side-chain on the ketopiperazine ring have been the 
subject of total syntheses, none bearing such a moiety have been prepared synthetically. 
Thus, the methodology used in the preparation of pyrazino[2,1-b]quinazoline-3,6-dione 
43 may also have utility in natural product synthesis. 
5.2.1 Natural Product Examples Without an Enamine Side-Chain 
 
The isolation of numerous natural products bearing the pyrazino[2,1-b]quinazoline-3,6-
dione core lacking an enamine side-chain have been reported. Many, including the 
fumiquinazolines A-I,154-156 alantrypinone157-159 and glyantrypine156,160 have been 
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prepared synthetically, with 5-N-acetylardeemin (425),161 fiscalin B (426)155 and 
serantrypinone (427)162 the subject of the most recent studies (Figure 5.1).  
 
Figure 5.1. Pyrazino[2,1-b]quinazoline-3,6-dione-based natural product examples. 
 
5-N-Acetylardeemin (425) was isolated from a strain of the fungus Aspergillus fisheri 
obtained from a Brazilian soil sample in 1993 by McAlpine and co-workers.163 Its 
structure was determined using NMR spectroscopy and mass spectrometry, with further 
evidence for the assignment provided by X-ray crystallography. The compound was 
found to be a potent inhibitor of tumour cell ‘multiple drug resistance’ to anti-tumour 
agents such as vinblastine, taxol and doxorubicin.164,165 It has been the subject of total 
syntheses by Danishefsky and co-workers,166 Qin and co-workers and,167,168 most 
recently, Kawasaki and co-workers.161 
 
Fiscalin B (426) was first isolated from the fungus Neosartorya fischeri by Cooper and 
co-workers in 1993 and was found to inhibit the human neurokinin receptor (NK-1), 
thus having potential anti-depressant and anti-emetic properties.169 The compound was 
subsequently also isolated from the ascomycete Corynascus setosus by Yamazaki and 
co-workers in 1996.170 Its interesting biological activity has made fiscalin B (426) a 
popular synthetic target; Baldino and co-workers reported the most recent synthesis in 
2005,155 whilst Söllhuber and co-workers156 and Ganesan and co-workers171 have also 
completed total syntheses of the compound.  
 
The spirooxindole-containing, pyrazino[2,1-b]quinazoline-3,6-dione serantrypinone 
(427) was first isolated from the fungus Penicillium thymicola in 2001 by Barrero and 
co-workers.172 Its interesting structure was assigned based upon spectral similarities 
with the closely related natural product alantrypinone. In 2004, Ozoe and co-workers 
isolated the compound from the fungus Aspergillus terreus and reported it to have 
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insecticidal properties.173 Serantrypinone (427) is the subject of a single total synthesis 
by Hart and Oba as reported in 2007.162 
5.2.2 Natural Product Examples Bearing an Enamine Side-Chain 
 
Only three natural product examples bear an enamine moiety at the C-1 position of the 
pyrazino[2,1-b]quinazoline-3,6-dione core, none of which have been prepared 
synthetically. These comprise aurantiomide C (428),174 verrucine F (429),175 and 
quinadoline A (430) (Figure 5.2).176 
 
Figure 5.2. Pyrazino[2,1-b]quinazoline-3,6-dione natural product examples bearing an enamine moiety. 
 
The L-glutamine derived pyrazino[2,1-b]quinazoline-3,6-dione aurantiomide C (428) 
was isolated from the fungus Penicillium aurantiogriseum SP0-19, alongside two 
hydroxylated derivatives, aurantiomides B and C, by Zhu and co-workers in 2007.174 Its 
structure was elucidated from 1H- and 13C-NMR spectroscopic data, in conjunction with 
mass spectrometry. Aurantiomide C (428) was shown to have moderate cytotoxic 
activity against a panel of cell lines.    
 
Verrucine F (429) is also derived from L-glutamine, differing to aurantiomide C (428) 
only in its phenyl-substituted enamine side-chain. Isolated in 2008 by Broberg and co-
workers from the fungus Penicillium verrucosum, no investigation into the biological 
activity of the compound was undertaken.175 
 
Quinadoline A (430) was isolated from the fungus Aspergillus sp. FKI-1746 by Tomoda 
and co-workers in 2008. Its structure was determined by 1H- and 13C-NMR 
spectroscopy in conjunction with COSY, HSQC and HMBC experiments, although the 
stereochemistry was not defined.176 The compound was found to inhibit lipid droplet 
synthesis in mouse macrophages with no cytotoxic effects. 
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5.3 Strategy for the Preparation of the Janoxepin Biosynthetic Intermediate 43 
 
It was proposed that the enamine side-chain of the proposed biosynthetic intermediate 
43 be installed using the aldol addition methodology described in Chapter 3. The 
known177 pyrazino[2,1-b]quinazoline-3,6-dione 431 would be prepared from the readily 
available anthranilic acid 42, glycine 432 and D-leucine 38 using a choice of established 
procedures which are reviewed below (Chapter 5.4) (Scheme 5.2).  
Scheme 5.2. Retrosynthetic analysis of the janoxepin biosynthetic precursor 43. 
5.4 Literature Routes to Pyrazino[2,1-b]quinazoline-3,6-diones 
 
Approaches to the synthesis of pyrazino[2,1-b]quinazoline-3,6-diones can be 
categorised into three areas: 
 Aza-Wittig methods. 
 Cyclodehydration approaches. 
 Microwave-mediated cyclisations. 
5.4.1 Aza-Wittig Approach 
 
A number of syntheses of the natural products described above (Chapter 5.2.1) have 
relied upon an aza-Wittig-like reaction, as first developed by Eguchi and co-workers in 
1989.178 For example, Danishefsky and co-workers166 and Qin and co-workers167,168 
both use this methodology at a late stage in their syntheses of 5-N-acetylardeemin (425) 
(Scheme 5.3). A 1:1 mixture of azido intermediates 435 and 436 is prepared by 
condensation of ortho-azidobenzoic anhydride 434 with diketopiperazine 433 in the 
presence of a strong base. Cyclisation is promoted by treatment of the mixture with tri-
n-butylphosphine to furnish pyrazino[2,1-b]quinazoline-3,6-diones 437 and 438 as 
single diastereomers and in excellent yield (Scheme 5.3). 
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Scheme 5.3. Aza-Wittig approach to pyrazino[2,1-b]quinazoline-3,6-dione synthesis as applied to the 
synthesis of 5-N-acetylardeemin (425). 
 
Söllhuber and co-workers,96 Menéndez and co-workers160 and Snider and co-workers154 
also apply this strategy to their syntheses of fiscalin B (426), glyantrypine (442) and the 
fumiquinazolines, respectively. 
5.4.2 Cyclodehydration Approaches 
 
Ganesan and Wang prepared the pyrazino[2,1-b]quinazoline-3,6-dione natural product 
glyantrypine (442), as well as the fumiquinazolines F-G and fiscalin B (426), by 
cyclodehydration of an amide intermediate.179 As shown in Scheme 5.4, the treatment of 
amide 439 with triphenylphosphine and iodine (which are required in large excess) 
effects dehydration to oxazine 440. The intermediate amidine 441 is then formed upon 
piperidine-mediated Fmoc cleavage, and readily cyclises to the pyrazino[2,1-
b]quinazoline-3,6-dione natural product glyantrypine (442) upon heating in acetonitrile, 
with retention of configuration of the stereocentres (although no ee is reported). 
Ganesan and Wang developed this route into a solid phase procedure which was used to 
prepare the proposed pyrazino[2,1-b]quinazoline-3,6-dione 431, a key intermediate in 
the retrosynthetic analysis of the target molecule 43 (Chapter 5.3).177 The methodology 
has also been employed in Hart and Magomedov’s158 and Chen and co-workers’157 
syntheses of alantrypinone, and Sim and Wang’s synthesis of verrucines A-B.180  
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Scheme 5.4. Cyclodehydration methodology as applied to the synthesis of glyantrypine (442). 
 
An alternative procedure was reported by Kawasaki and co-workers in their synthesis of 
5-N-acetylardeemin (425). A successive Boc-cleavage, followed by phosphorus 
oxychloride mediated double cyclisation of amide 443 is used to construct the 
pyrazino[2,1-b]quinazoline-3,6-dione core structure in moderate yield (Scheme 5.5).  
 
Scheme 5.5. POCl3 mediated double cyclisation to construct the pyrazino[2,1-b]quinazoline-3,6-dione 
core of 5-N-acetylardeemin (425). 
5.4.3 Microwave-Promoted Cyclisations 
 
Liu and co-workers developed a microwave-promoted, three-component, one-pot 
procedure for pyrazino[2,1-b]quinazoline-3,6-dione construction, and applied this to the 
synthesis of fumiquinazoline F, fiscalin B (426) and glyantrypine (442).181 Thus, 
treatment of anthranilic acid 42 and a Boc-protected amino acid 444 with P(OPh)3 in 
pyridine, and microwave irradiation at 150 °C, 50 W for 10 min furnished an 
intermediate oxazine 445. Addition of an amino acid hydrochloride 446 with further 
microwave irradiation at 220 °C, 50 W for 1.5 min then provided the desired 
pyrazino[2,1-b]quinazoline-3,6-diones 447, with loss of the Boc-protecting group, in 
56-79% yields (Scheme 5.6). Unfortunately, this process leads to epimerisation of the 
stereogenic centres and large R2 groups are not well-tolerated, resulting in much lower 
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yields. Nishida and co-workers subsequently utilised this methodology in their synthesis 
of alantrypinone.159 
 
Scheme 5.6. Microwave promoted, three-component, one-pot synthesis of  
pyrazino[2,1-b]quinazoline-3,6-diones. 
 
A Lewis acid-mediated double cyclisation was developed by Chu and co-workers in 
2010.182 Thus, treatment of amine 448 with one equivalent of scandium triflate and 
microwave irradiation at 140 °C, 30 W for 1-2 min furnished a range of C-1 substituted 
pyrazino[2,1-b]quinazoline-3,6-diones 449 in 49-86% yield (Scheme 5.7). No 
racemisation of the stereocentre was observed under the reaction conditions, as shown 
by 1H-NMR spectroscopy using a chiral shift reagent, although examples bearing a C-4 
substituent were not investigated.  
 
Scheme 5.7. Lewis acid-mediated, microwave promoted double cyclisation of amines 448. 
5.5 Synthesis of Pyrazino[2,1-b]quinazoline-3,6-dione 431: Liu Microwave 
Methodology 
 
The solid-phase, dehydrative procedure for the synthesis of pyrazino[2,1-b]quinazoline-
3,6-dione 431 as reported by Ganesan required large excesses of triphenylphosphine and 
iodine, as well as long reaction times and thus was not an attractive synthetic 
strategy.177 It was also desirable to avoid handling an azide intermediate. Our initial 
focus was therefore the microwave promoted, three-component, one-pot methodology 
reported by Liu and co-workers which had the virtues of brevity and its use of readily 
available, inexpensive starting materials.  
 
N-Boc-glycine 450 and anthranilic acid 42 were treated with P(OPh)3 in DMF with 
microwave irradiation to 150 °C, 50 W for 10 min. As described by Liu and co-workers, 
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D-leucine methyl ester 452 was then added to the reaction mixture, with further 
microwave irradiation at 220 °C, 50 W for 1.5 min. Again, only a complex mixture of 
decomposition products was isolated (Scheme 5.8). 
 
Scheme 5.8. Attempted synthesis of pyrazino[2,1-b]quinazoline-3,6-dione 431 using Liu’s procedure. 
 
To establish if the bulky iso-butyl group of leucine was not well-tolerated, or if using a 
hydrochloride salt was essential, a reaction described in the Liu report, which proceeded 
in 64% yield, was repeated. Thus, N-Boc-glycine 450 and anthranilic acid 42 were 
treated with P(OPh)3 in DMF with microwave irradiation at 150 °C, 50 W for 10 min 
before L-alanine methyl ester hydrochloride 453 was added, with further microwave 
irradiation at 220 °C, 50 W for 1.5 min.181 However, only a complex mixture of 
products was isolated, with no trace of the desired pyrazino[2,1-b]quinazoline-3,6-dione 
454 (Scheme 5.9). 
 
Scheme 5.9. Unsuccessful repeat of the reaction of using L-alanine methyl ester hydrochloride as 
reported by Liu and co-workers.155 
 
In order to establish why the reaction failed, the oxazine intermediate 451 was prepared 
in 55% yield using conventional heating at 70 °C for 18 h (Table 5.1, entry 1). 
Surprisingly, when the microwave conditions reported were used, no oxazine 451 was 
isolated, with only a complex mixture of products being obtained (Table 5.1, entry 2) 
indicating that the reaction was failing in the first step. 
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Entry Conditions Yield 451 
1 70 °C (conventional), 18 h 55% 
2 μW, 150 °C, 50 W, 10 min Decomposition 
 
Table 5.1. Synthesis of oxazine 451: reaction conditions explored. 
 
It was therefore decided to abandon the three-component, one-pot process and 
investigate using the previously prepared oxazine 451 in a sequential manner. However, 
when oxazine 451 was treated with D-leucine methyl ester 452 in pyridine with 
microwave irradiation as before, only decomposition of the substrates was observed 
(Table 5.2, entry 1). This was again the case using L-alanine methyl ester hydrochloride 
455 (Table 5.2, entry 2, as reported by Liu). Furthermore, no reaction occurred upon 
conventional heating at reflux (Table 5.2, entry 3). 
 
Entry Amino methyl ester Conditions Comment 
1 452 μW, 220 °C, 50 W, 1.5 min Decomposition 
2 455 μW, 220 °C, 50 W, 1.5 min Decomposition 
3 452 115 °C (conventional), 1.5 h rsm 
 
Table 5.2. Pyrazino[2,1-b]quinazoline-3,6-dione preparation from oxazine 451:  
reaction conditions explored. 
 
As we were unable to repeat the published procedures, or use conventional heating 
methods, this strategy was abandoned, and the Lewis acid-mediated cyclisation 
methodology reported by Chu and co-workers was investigated. 
5.6 Synthesis of Pyrazino[2,1-b]quinazoline-3,6-dione 431: Chu Microwave 
Methodology 
 
As outlined in Chapter 5.4.3, this strategy first required the synthesis of amine 456 
which would undergo a double cyclisation to pyrazino[2,1-b]quinazoline-3,6-dione 431. 
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5.6.1 Synthesis of Amine 456 
 
The synthesis of the novel amine 456 began with the coupling of isatoic anhydride 457 
and D-leucine methyl ester 452 using a modified procedure (Scheme 5.10).182 EtOAc 
was used as solvent in place of DMF, resulting in a much improved yield of 87% of the 
known amide 458, compared to 32% previously reported.183 Amide 458 was then 
coupled with Fmoc-protected glycine chloride 459 to furnish the novel bis-amide 460, 
which was treated with piperidine to remove the Fmoc-protecting group and provide the 
required amine 456 in 47% yield over the three steps (Scheme 5.10). Chiral HPLC 
analysis (Chiralpak AD-H column) indicated that the configuration of the stereocentre 
had been retained, with the material being isolated in 95% ee. 
 
Scheme 5.10. Synthesis of amine 456. 
5.6.2 Lewis Acid-Mediated Cyclisation 
 
Pleasingly, the treatment of amine 456 with one equivalent of scandium triflate in DMF, 
with microwave irradiation at 140 °C, 50 W for 1.5 min, as according to the Chu 
procedure, did furnish pyrazino[2,1-b]quinazoline-3,6-dione 431, but in low yield 
(Table 5.3, entry 1). Heating for 3.5 min led to an improved yield (Table 5.3, entry 2), 
whilst heating for 10 min was found to be optimal, providing pyrazino[2,1-
b]quinazoline-3,6-dione 431 in 62% yield (Table 5.3, entry 3). When the reaction 
temperature was raised to 210 °C for 3.5 min, a complex mixture of decomposition 
products was obtained (Table 5.3, entry 4), whilst using conventional heating at 110 °C 
for 2.5 h provided a much lower yield of pyrazino[2,1-b]quinazoline-3,6-dione 431 
(Table 5.3, entry 5). Interestingly, it was found that a sub-stoichiometric amount (0.5 
equivalents) of scandium triflate could be used with an increased reaction time at 140 
°C, to obtain a 50% yield of pyrazino[2,1-b]quinazoline-3,6-dione 431 (Table 5.3, entry 
6). 
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Entry Sc(OTf)3 eq. Conditions Yield 431 
1 1.0 μW, 140 °C, 50 W, 1.5 min 18% 
2 1.0 μW, 140 °C, 50 W, 3.5 min 35% 
3 1.0 μW, 140 °C, 50 W, 10 min 62% 
4 1.0 μW, 210 °C, 50 W, 3.5 min Decomposition 
5 1.0 110 °C (conventional), 2.5 h 20% 
6 0.5 μW, 140 °C, 50 W, 15 min 50% 
 
Table 5.3. Lewis acid-mediated cyclisation of amine 431. 
 
This demonstrated that the Chu methodology did tolerate substitution at the C-4 
position, but that longer reaction times are required, and lower yields are obtained. 
Disappointingly, the reaction proceeded with racemisation of the stereogenic centre, as 
shown by chiral HPLC analysis (Chiralpak OD column). Although the overall yield for 
the preparation of  pyrazino[2,1-b]quinazoline-3,6-dione 431 from isatoic anhydride 
457 (29%) is lower than for the solid-phase procedure reported by Ganesan (53%),177 it 
is amenable to preparation on a 2 g scale.  The 1H- and 13C-NMR spectroscopic data for 
pyrazino[2,1-b]quinazoline-3,6-dione 431 compared exactly with those previously 
reported.177 
5.7 Aldol Introduction of the Enamine 
 
It was proposed that the enamine side-chain of the janoxepin biosynthetic intermediate 
43 be installed using the aldol methodology described in Chapter 3. Thus, pyrazino[2,1-
b]quinazoline-3,6-dione 431 was first treated with triethyloxonium tetrafluoroborate and 
potassium carbonate with heating to reflux in DCM to furnish imidate 461 in 67% yield. 
Aldol addition was effected by deprotonation with LiHMDS (prepared in situ) in THF 
at –78 °C for 10 min followed by the addition of iso-butyraldehyde 221. After 10 min, 
the reaction was quenched at –78 °C by the addition of acetic acid and the aldol adduct 
462 was isolated in 66% yield without any further optimisation. Elimination to enamine 
463 was achieved by treating aldol adduct 462 with MsCl in pyridine and heating to 50 
°C for 1.5 h. Finally, imidate hydrolysis using aqueous acetic acid furnished the 
proposed janoxepin biosynthetic intermediate 43 in 28% yield for the four-step 
sequence, albeit in racemic form (Scheme 5.11). 
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Scheme 5.11. Synthesis of the proposed janoxepin biosynthetic intermediate 43. (Relative 
stereochemistry shown). 
5.8 Characterisation of Biosynthetic Intermediate 43 
 
The structure of the biosynthetic intermediate 43 was confirmed by 1H- and 13C-NMR 
spectroscopy in conjunction with COSY and HSQC experiments (see Appendix IV for 
NMR spectra). The Z-configuration of the enamine was established by nOe studies 
which showed enhancements betweem H-1 and H-2 and, to a lesser extent, H-1 and H-3 
(Figure 5.3).  
 
Figure 5.3. nOe enhancements for the janoxepin biosynthetic intermediate 43. 
 
Further evidence for the structural assignment was provided by X-ray crystallographic 
analysis of 43 (Figure 5.4). 
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Figure 5.4. X-ray crystallography of (±)-43. ORTEP representations shown with ellipsoids at 50% 
probability. A single enantiomer (R) is shown for clarity. CCDC 862145; see Appendix V. 
 
Unfortunately, attempts deracemise the product using an asymmetric protonation of an 
intermediate enolate species as described in Chapter 4.10 were again unsuccessful. As 
with janoxepin (1) and its imidate precursor 309, treatment of 43 with sec-BuLi resulted 
in decomposition of the material and no further investigation was carried out. 
5.9 Epoxidation – Ring-Opening: Preliminary Studies 
 
A preliminary investigation into the proposed biomimetic epoxidation – electrocyclic 
ring-opening strategy for oxepine synthesis was undertaken. It was decided to use 
pyrazino[2,1-b]quinazoline-3,6-dione 431 as the substrate for an initial epoxidation 
study, thus avoiding any selectivity issues arising from epoxidation of the enamine 
alkene in 43 or 463.  When pyrazino[2,1-b]quinazoline-3,6-dione 431 was treated with 
m-CPBA (Table 5.4, entry 1), sodium hypochlorite (Table 5.4, entry 2) and DMDO 
(Table 5.4, entry 3), no epoxide 464 (or oxepine 1) was observed. Only a complex 
mixture of compounds including N-oxide species (as indicated by mass spectrometry 
and 1H-NMR spectroscopy of the unpurified products), and decomposition products was 
isolated. 
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Entry Oxidant Conditions 
1 m-CPBA DCM/aq. NaHCO3 (sat.), rt, 18 h 
2 NaOCl n-Bu4NHSO4, DCM, rt, 18 h 
3 DMDO acetone, 0 °C – rt, 18 h 
 
Table 5.4. Attempted epoxidation of pyrazino[2,1-b]quinazoline-3,6-dione 431:  
reaction conditions explored. 
 
To inhibit competing N-oxidation, the N-Boc derivative 465 was prepared by treatment 
of pyrazino[2,1-b]quinazoline-3,6-dione 431 with di-tert-butyl dicarbonate, 
triethylamine and DMAP. However, when this substrate was subjected to the same 
conditions shown in Table 5.4, again only complex mixtures of products were obtained 
(Scheme 5.12). 
 
Scheme 5.12. Boc-protection of pyrazino[2,1-b]quinazoline-3,6-dione 431. Subsequent epoxidation was 
not possible. 
5.10 Summary and Future Work 
 
In summary, the proposed janoxepin biosynthetic intermediate 43 has been prepared in 
an efficient eight-step synthesis in racemic form. The pyrazino[2,1-b]quinazoline-3,6-
dione core was constructed using a Lewis acid-mediated double cyclisation of amine 
456, and the enamine side-chain was installed using the previously described aldol 
addition methodology (Chapter 3), demonstrating its broader scope. This synthetic 
approach not only has potential utility in the synthesis of enamine-containing 
pyrazino[2,1-b]quinazoline-3,6-dione natural products 428-430, but has also allowed for 
preliminary investigations into the development of a biomimetic oxepine synthesis. This 
work has been the subject of a recent publication (see Appendix VI).184 
 
Future work will first focus on investigating the chemical epoxidation of 43 itself, as 
well as other intermediates, before exploring the possibility of utilising an enzymatic 
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biotransformation. At the same time, further investigation using asymmetric protonation 
methods to afford optically pure material will then allow this methodology to be applied 
to enantiopure syntheses of enamine-containing pyrazino[2,1-b]quinazoline-3,6-dione 
natural products. 
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Chapter 6. Experimental 
 
NMR spectra were recorded on a Jeol ECX-400 instrument at 400 MHz (1H) and 100 
MHz (13C). A Bruker AV-500 instrument was used for recording nOe correlations at 
500 MHz (1H). Chemical shifts (δ) are quoted in parts per million (ppm) calibrated to 
residual non-deuterated solvent. Coupling constants (J) are quoted in Hertz. Structural 
assignment was verified by HSQC and COSY spectroscopy where necessary. Infrared 
(IR) spectra were recorded on a ThermoNicolet IR100 spectrometer with NaCl plates. 
Specific rotation values were measured on a JASCO DIP-370 digital polarimeter using 
a sodium lamp. High resolution electrospray ionisation (ESI) and atmospheric pressure 
chemical ionisation (APCI) mass spectra were recorded on a Brüker MicroTOF 
instrument. Elemental analysis was conducted on an Exeter Analytical, Inc. CE-440 
Elemental Analyser with samples weighed using a Sartorius SE2 analytical balance. 
Melting points were recorded on a Gallenkamp apparatus and are uncorrected. 
Microwave reactions were performed in a CEM Discover system at the specified power. 
Thin layer chromatography was performed on aluminium plates coated with Merck 
Silica gel 60 F254. Flash column chromatography was performed using Fluka flash silica 
gel 60 with the specified eluent. Petroleum ether (PE) refers to the fraction boiling in 
the range 40-60 °C. Where required, diethyl ether, DCM and toluene were obtained dry 
from an Innovative Technology Inc. PureSolv Purification System. THF was distilled 
from sodium benzophenone ketyl immediately before use. Methanol was dried 
according to the method of Lund and Bjerrum.94 Degassed solvent refers to solvent 
which has been sparged with argon for at least 2 h. Except where specified, all reagents 
were purchased from commercial sources and used without further purification. 
Structural assignment was aided by the use of DEPT, COSY and HSQC spectroscopy. 
The atom numbering on structures is for assignment purposes and is independent of 
IUPAC nomenclature.  
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6.1 Chapter 2: Oxepine-Pyrimidinone Ring System Construction  
 
N-Propylbenzenecarboximidamide 200 
 
A mixture of benzonitrile (6.85 g, 66.0 mmol, 1.0 eq.) and n-
propylamine (3.96 g, 66.0 mmol, 1.0 eq.) was added dropwise over 
30 min to AlCl3 (8.93 g, 66.0 mmol, 1.0 eq.). A vigorous exotherm 
occurred on addition. The reaction mixture was heated at 200-220 °C 
for 45 min and then, while still molten, poured into an aqueous HCl solution (1.8% v/v, 
170 mL). After being allowed to cool to room temperature the mixture was filtered 
through Celite®. The filtrate was poured into 4 M NaOH (aq.) (120 mL) and the organic 
component extracted with DCM (3 × 50 mL), dried over MgSO4, filtered and 
concentrated in vacuo to furnish the crude product. Purification by distillation at 
reduced pressure gave the title compound 200 (6.58 g, 61%) as a colourless oil: bp 95-
100 °C @ 0.45 mmHg (Lit.185 110-112 °C @ 7.0 mmHg); δH (400 MHz, MeOD) 7.62-
7.39 (5 H, m, H-6, 7, 8), 3.22 (2 H, app. dd (dt), J 7.5, 7.0, H-3), 1.73-1.64 (2 H, m, H-
2), 1.01 (3 H, t, J 7.5, H-1). Data consistent with those in the literature.90  
Lab. Book:  RD01/010/B1 
 
5-Allyl-6-hydroxy-2-phenyl-3-propylpyrimidin-4(3H)-one 199 
 
A solution of NaOMe was prepared by the portionwise addition of 
Na (1.32 g, 58.0 mmol, 2.3 eq.) to MeOH (80 mL). An exotherm 
occurred. Once the Na had completely reacted and the solution 
cooled to room temperature, dimethyl 2-allylmalonate 201 (5.01 g, 
25.0 mmol, 1.0 eq.) in MeOH was added dropwise, over 5 min, 
followed by amidine 200 (4.89 g, 30.0 mmol, 1.2 eq.) in MeOH 
dropwise, over 5 min. The reaction mixture was heated at reflux for 24 h before 
quenching by the addition of water (300 mL), acidification to pH 1 (1 M HCl (aq.)) and 
extraction with DCM (3 × 150 mL). The combined organic phase was dried over 
MgSO4, filtered and concentrated in vacuo. Recrystallisation from cyclohexane gave the 
title compound 199 (4.13 g, 60%) as colourless needles: mp 144-146 °C (Lit.35 142-143 
°C); Rf  0.40 (1:1 PE/EtOAc); δH (400 MHz, CDCl3) 11.55 (1 H, br s, H-17), 7.57-7.37 
(5 H, m, H-8, 9, 10), 5.80 (1 H, ddt, J 17.0, 10.0, 7.0, H-15), 4.97 (1 H, dd, J 17.0, 2.0, 
H-16b), 4.92 (1 H, dd, J 10.0, 2.0, H-16a), 3.78 (2 H, t, J 7.5, H-11), 3.04 (2 H, d, J 7.0, 
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H-14), 1.59-1.51 (2 H, m, H-12), 0.72 (3 H, t, J 7.5, H-13). Data consistent with those 
previously reported.35 
Lab. Book:  RD01/018/B1 
 
5-Allyl-6-(allyloxy)-2-phenyl-3-propylpyrimidin-4(3H)-one 198 
 
To a solution of pyrimidinone 199 (2.00 g, 7.40 mmol, 1.0 eq.) in 
DMF (20 mL) was added KOH (0.560 g, 10.0 mmol, 1.4 eq.). The 
reaction mixture was heated at 70 °C for 2 h before a solution of 
allyl bromide (1.42 g, 11.8 mmol, 1.6 eq.) was added. The reaction 
mixture was heated at 70 °C for a further 3 d, cooled to room 
temperature and quenched by the addition of water (120 mL). The 
crude product was extracted with EtOAc (3 × 60 mL), the organic phase washed with 
water (3 × 75 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude 
product was purified by flash column chromatography on silica gel (4:1 n-
hexane/EtOAc) to furnish the title compound 198 (1.47 g, 64 %) as a pale yellow oil: Rf: 
0.56 (1:1 PE/EtOAc); δH (400 MHz, CDCl3) 7.51-7.41 (5 H, m, H-8, 9, 10), 6.03-5.90 
(2 H, m, H-18, 15), 5.36-4.99 (4 H, m, H-16, 17), 4.80 (2 H, dt, J 5.0, 1.5, H-17), 3.85 
(2 H, t, J 7.5, H-11), 3.29 (2 H, dt, J 6.5, 1.0, H-14), 1.65-1.55 (2 H, m, H-12), 0.73 (3 
H, t, J 7.5, H-13). Data consistent with those previously reported.35 
Lab. Book:  RD01/012/B2 
 
2-Phenyl-3-propyl-5,8-dihydrooxepino[2,3-d]pyrimidin-4(3H)-one 197 
 
To a solution of diallyl pyrimidinone 198 (0.310 g, 1.00 mmol, 1.0 
eq.) in degassed anhydrous DCM (400 mL) under an inert 
atmosphere was added a solution of Grubbs second generation 
catalyst 148 (0.0850 g, 0.100 mmol, 0.1 eq.) in degassed anhydrous 
DCM (20 mL) dropwise over 15 min. The reaction mixture was 
heated at reflux for 3 h, cooled to room temperature and before 
directly purified by flash column chromatography on silica gel (1:24 Et2O/DCM) to 
furnish the title compound 197 (0.219 g, 77%) as a yellow oil: Rf  0.31 (1:1 PE/EtOAc); 
υmax/cm
-1
  (neat) 3043 (aromatic C-H stretch), 2966 (C-H stretch), 2876 (C-H stretch), 
1645 (C=O stretch), 1549 (C=C stretch);  δH (400 MHz, CDCl3) 7.47-7.41 (5 H, m, H-8, 
9, 10), 6.25 (1 H, dt, J 10.0, 6.0, H-17), 6.07-6.01 (1 H, m, H-16), 4.78 (2 H, d, J 6.5, H-
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15), 3.83 (2 H, t, J 7.5, H-11), 3.55-3.53 (2 H, m, H-18), 1.59 ( 2 H, tq, J 7.5, 7.5, H-
12), 0.73 (3 H, t, J 7.5, H-13). Data consistent with those previously reported.35 
Lab. Book:  RD01/024/B1 
 
(6S*,7S*)-6,7-Dibromo-2-phenyl-3-propyl-5,6,7,8-tetrahydrooxepino[2,3-
d]pyrimidin-4(3H)-one 202 
 
A solution of dihydro-oxepine 197 (0.190 g, 0.670 mmol, 1.0 eq.) in 
CHCl3 was cooled to –48 °C (MeCN/CO2 bath) before the dropwise 
addition of bromine (1.12 mL, 0.6 M solution in CHCl3, 0.670 
mmol, 1.0 eq.). The reaction mixture was stirred at –48 °C for 25 
min and concentrated in vacuo. The crude material was purified by 
flash column chromatography on silica gel (7:3 PE/EtOAc) to 
furnish the title compound 202 (0.142 g, 51%) as a yellow oil: Rf 0.54 (1:1 PE/EtOAc); 
υmax/cm
-1
  (neat) 3059 (aromatic C-H stretch), 2966 (C-H stretch), 1657 (C=O stretch), 
1592 (aromatic C=C stretch), 1541 (C=C stretch); δH (400 MHz, CDCl3) 7.52-7.46 (5 
H, m, H-8, 9, 10), 4.72-4.68 (2 H, m, H-15a, 17), 4.65-4.63 (1 H, m, H-16), 4.46-4.41 (1 
H, m, H-15b), 3.93-3.87 (2 H, m, H-11), 3.63-3.49 (2 H, m, H-18), 1.66-1.59 (2 H, m, 
H-12), 0.78-0.74 (3 H, m, H-13). Data consistent with those previously reported.35 
Lab. Book:  RD01/026/B1 
 
2-Phenyl-3-propyloxepino[2,3-d]pyrimidin-4(3H)-one 196 
 
To a solution of dibromide 202 (0.0640 g, 0.160 mmol, 1.0 eq.) in 
DMSO (2.75 mL) at room temperature was added TBAF (0.610 mL, 
1 M solution in THF, 0.610 mmol, 3.9 eq.) dropwise over 5 min. The 
reaction mixture was stirred at room temperature for 30 min. The 
reaction was quenched by the addition of sat. NH4Cl (aq.) (10 mL) 
and the organic components extracted with EtOAc (3 × 10 mL). The 
combined organic phase was washed successively with sat. NH4Cl (aq.) (2 × 10 mL), 
sat. NaHSO3 (aq.) (2 × 10 mL), water (2 × 10 mL) and brine (2 × 10 mL), dried over 
MgSO4, filtered and concentrated in vacuo. The crude product was purified by flash 
column chromatography on silica gel (4:1 PE/EtOAc) to furnish the title compound 196 
(0.0110 g, 28%) as a yellow oil: Rf  0.51 (1:1 PE/EtOAc); υmax/cm
-1
 (neat) 3046 
(aromatic C-H stretch), 2963 (C-H stretch), 2919 (C-H stretch), 1665 (C=O stretch), 
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1529 (C=C stretch); δH (400 MHz, CDCl3) 7.52-7.46 (5 H, m, H-14, 15, 16), 6.81 (1 H, 
d, J 11.0, H-12), 6.17 (1 H, dd, J 11.0, 6.0, H-11), 6.07 (1 H, d, J 6.0, H-9), 5.62 (1 H, 
app. t, J 6.0, H-10), 3.92-3.88 (2 H, m, H-17), 1.63 (2 H, m, H-18), 0.76 (3 H, t, J 7.5, 
H-19). Data consistent with those previously reported.35 
Lab. Book:  RD01/029/C1, RD01/041/A1 
 
2-Phenyl-3-propyl-5,6,7,8-tetrahydrooxepino[2,3-d]pyrimidin-4(3H)-one 203 
 
To a solution of dihydro-oxepine 197 (0.0520 g, 0.180 mmol, 1.0 
eq.) in EtOAc (5 mL) was added 10% Pd/C (0.0050 g, 0.0050 
mmol, 2.5 mol%). The reaction mixture was placed under an 
atmosphere of hydrogen and stirred at room temperature for 1 h 
before being filtered through Celite® and concentrated in vacuo. 
The crude product was purified by flash column chromatography 
on silica gel (1:1 n-hexane/EtOAc) to furnish the title compound 203 (0.0380 g, 74%) as 
colourless needles: mp 103-104 °C; Rf  0.33 (1:1 n-hexane/EtOAc); Found: C, 71.55; H, 
7.07; N, 9.79; C17H20N2O2 requires: C, 71.81; H, 7.09; N, 9.85%; υmax/cm
-1 2963 (C-H 
stretch), 1650 (C=O stretch), 1586 (aromatic C=C stretch), 1542 (C=C stretch); δH (400 
MHz, CDCl3) 7.48-7.43 (5 H, m, H-8, 9, 10), 4.35-4.32 (2 H, m, H-15), 3.87-3.83 (2 H, 
m, H-11), 2.82-2.79 (2 H, m, H-18), 2.04-1.98 (2 H, m, H-16), 1.93-1.87 (2 H, m, H-
17), 1.61 (2 H, app. sext. (tq), J 7.5, H-12); 0.75 (3 H, t, J 7.5, H-13); δC (100 MHz, 
CDCl3) 167.8 (C-4), 164.8 (C-6), 157.2 (C-2), 134.6 (C-7), 129.9 (C-10), 128.5 (C-9), 
127.7 (C-8), 107.4 (C-5), 71.4 (C-15), 47.8 (C-11), 29.2 (C-16), 23.9 (C-17), 22.5 (C-
18), 22.0 (C-12), 11.0 (C-13); m/z (ESI) 285 [MH]+. Calcd. for C17H21N2O2: 285.1598. 
Found: [MH]+, 285.1600 (0.2 ppm error). X-Ray crystallography: CCDC 862141 
contains the supplementary crystallographic data for this compound, see Appendix V. 
Crystals were grown by slow diffusion (n-hexane/EtOAc). 
Lab. Book: RD07/027/C1 
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N-(tert-Butoxycarbonyl)-D-leucine 204 
 
D-Leucine 38 (9.45 g, 72.0 mmol, 1.0 eq.) and NaHCO3 (6.05 
g, 72.0 mmol, 1.0 eq.) were suspended in water (200 mL) and 
1,4-dioxane (100 mL). Aqueous NaOH solution (2 M, 36 mL) 
was added to obtain a solution which was cooled to 0 °C (ice) 
before di-tert-butyl dicarbonate (20.5 g, 94.0 mmol, 1.3 eq.) was added. The reaction 
mixture was allowed to warm to room temperature with stirring over 16 h. After 
concentration in vacuo to half the volume, the solution was cooled to 0 °C (ice) and 
carefully acidified to pH 1 using 3 M HCl (aq.). The resulting white precipitate was 
extracted with EtOAc (3 × 100 mL) and the combined organic phase washed with water 
(150 mL), brine (150 mL), dried over MgSO4, filtered and concentrated in vacuo to 
furnish the title compound 204 (16.4 g, 98%) as a colourless viscous oil which was used 
without further purification: Rf 0.18 (1:1 PE/EtOAc); υmax/cm
-1
  (neat) 3323 (broad, O-H 
stretch), 2962 (C-H stretch), 1712 (broad, C=O stretch), 1517 (N-H bend); [α]D
24 +21 (c 
= 1.02, MeOH); δH (400 MHz, CDCl3) 4.86 (1 H, d, J 8.0, H-7), 4.32-4.28 (1 H, m, H-
2), 1.78-1.64 (2 H, m, H-3), 1.57-1.50 (1 H, m, H-4), 1.45 (9 H, s, H-10, 11, 12), 0.95 (6 
H, d, J 6.0, H-5, 6). Data are consistent with those in the literature.186, 187 
Lab. Book:  RD03/040/A1 
 
N
2
-(tert-Butoxycarbonyl)-N-(cyanomethyl)-D-leucinamide 205
 
 
A solution of N-Boc-D-leucine 204 (16.4 g, 71.0 mmol, 1.0 
eq.) in THF (250 mL) was cooled to –25 °C (CO2/MeOH 
bath). N-Methyl morpholine (7.89 g, 78.0 mmol, 1.1 eq.) and 
iso-butylchloroformate (10.7 g, 78.0 mmol, 1.1 eq.) were 
added successively. A white precipitate formed immediately. After stirring for 15 min, 
solutions of aminoacetonitrile bisulfate (12.0 g, 78.0 mmol, 1.1 eq.) in water (15 mL) 
followed by 1 M aqueous NaOH (100 mL), pre-cooled to 0 °C (ice), were added. The 
reaction mixture was warmed to room temperature and stirred for 18 h. After 
concentration in vacuo to remove THF, the resulting aqueous solution was extracted 
with EtOAc (3 × 250 mL). The combined organic phase was washed with water (250 
mL), sat. NaHCO3 (aq.) (250 mL), brine (250 mL), dried over MgSO4, filtered and 
concentrated in vacuo to yield a colourless oil, which solidified under vacuum. The 
crude product was suspended in PE and the title compound 205 (14.3 g, 75 %) isolated 
by filtration as colourless needles: mp 112–114 °C (Lit.2 114 – 116 oC); Rf  0.40 (1:1 
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PE/EtOAc); (Found: C, 57.9; H, 8.5; N, 15.5; C13H23N3O3 requires C, 57.9; H, 8.6; N, 
15.6); [α]D
22 +26 (c = 0.99, MeOH);  δH (400 MHz, CDCl3) 7.34 (1 H, br s, H-7), 5.03 
(1 H, d, J 5.5, H-13), 4.15 (2 H, d, J 5.5, H-14), 4.16-4.14 (1 H, m, H-2), 1.67-1.62 (2 
H, m, H-3), 1.56-1.49 (1 H, m, H-4), 1.45 (9 H, s, H-10, 11, 12), 0.94 (3 H, d, J 6.0, H-
5/6), 0.92 (3 H, d, J 6.0, H-5/6). Data are consistent with those reported in the 
literature.188  
Lab. Book:  RD03/055/C1 
 
N-(Cyanomethyl)-D-leucinamide 206
 
 
N
2-(tert-Butoxycarbonyl)-N-(cyanomethyl)-D-leucinamide 205 
 (14.1 g, 53.0 mmol, 1.0 eq.) was taken up in formic acid (neat, 150 
mL) and stirred at room temperature for 16 h. The reaction mixture 
was concentrated in vacuo to furnish a colourless oil which was taken 
up in MeOH/aq. NH3 (9:1) to neutralise, concentrated in vacuo and purified by flash 
column chromatography on silica gel (85:14:1 DCM/MeOH/aqueous NH3) to furnish 
the title compound 206 (8.77 g, 98%) as a colourless oil: Rf  0.27 (90:9:1 
DCM/MeOH/aqueous NH3); υmax/cm
-1
  (neat) 3358 (N-H stretch), 2958 (C-H stretch), 
1660 (C=O stretch), 1525 (N-H bend); [α]D
22  –4 (c = 1.03, MeOH); δH (400 MHz, 
MeOD) 4.17 (1 H, d, J 17.5, H-8a), 4.16 (1 H, d, J 17.5, H-8b), 3.37-3.34 (1 H, m, H-2), 
1.71 (1 H, tsept., J 8.0, 6.5, H-4), 1.53 (1 H, ddd, J 14.0, 8.0, 6.0, H-3a), 1.40 (1 H, ddd, 
J 14.0, 8.0, 6.0, H-3b), 0.96 (3 H, d, J 6.5, H-5/6), 0.93 (3 H, d, J 6.5, H-5/6); δC (100 
MHz, MeOD) 178.6 (C-1), 117.6 (C-9), 54.4 (C-2), 45.5 (C-8), 27.9 (C-3), 25.8 (C-4), 
23.4 (C-5/6), 22.4 (C-5/6); m/z (ESI) 170 [MH]+. Calcd. for C8H16N3O: 170.1288. 
Found: [MH]+ 170.1286 (1.5 ppm error). Data are consistent with those in the 
literature.189 
Lab. Book:  RD03/061/B1 
 
(3R)-5-Amino-3-iso-butyl-3,6-dihydropyrazin-2(1H)-one 52 
 
To a solution of N-(cyanomethyl)-D-leucinamide 206 (9.97 g, 
59.0 mmol, 1.0 eq.) in MeOH (200 mL) was added 
hydroxylamine (4.52 mL, 50% w/w solution in water, 73.0 mmol, 
1.25 eq.). After stirring at room temperature for 4 h, Raney® 2800 
Nickel (slurry in water) (~ 5 g) was added and the reaction mixture placed under an 
atmosphere of hydrogen. After stirring at room temperature for 3 h the reaction mixture 
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was filtered through Celite® with MeOH washing and concentrated in vacuo. The crude 
product was purified by flash column chromatography on silica gel (55:42:3 
DCM/MeOH/aqueous NH3) to furnish the title compound 52 (8.10 g, 81%) as a pale 
yellow solid: mp 94-96 °C; Rf  0.21 (80:19:1 DCM/MeOH/aqueous NH3); υmax/cm
-1
 
(neat) 3333 (N-H stretch), 3201 (N-H stretch), 2953 (C-H stretch), 1660 (C=O stretch); 
[α]D
22 –47 (c = 1.00, MeOH); δH (400 MHz, DMSO d-6) 7.77 (1 H, br s, H-1), 3.78 (1 
H, dd, J 16.5, 1.0, H-6a), 3.71 (1 H, dd, J 16.5, 1.0, H-6b), 3.58 (1 H, dd, J 9.5, 5.0, H-
3), 1.88-1.78 (1 H, m, H-8), 1.47 (1 H, ddd, J 13.5, 8.5, 5.0, H-7a), 1.33 (1 H, ddd, J 
13.5, 9.5, 5.5, H-7b), 0.87 (3 H, d, J 7.5, H-9/10), 0.85 (3 H, d, J 7.5, H-9/10); δC (100 
MHz, DMSO d-6) 172.2 (C-2), 156.1 (C-5), 56.3 (C-3), 42.3 (C-7), 41.3 (C-6), 23.9 (C-
8), 23.3 (C-9/10), 21.6 (C-9/10); m/z (ESI) 170 [MH]+. Calcd. for C8H16N3O: 170.1288. 
Found: [MH]+, 170.1288 (0.7 ppm error). 
Lab. Book:  RD03/064/C1 
 
(6R*)-3-Allyl-2-hydroxy-6-iso-butyl-8,9-dihydro-4H-pyrazino[1,2-a]pyrimidine-
4,7(6H)-dione 51 
 
A solution of NaOMe was prepared by the portionwise 
addition of Na (6.66 g, 290 mmol, 6.0 eq.) to rigorously dried 
MeOH (100 mL) containing activated, powdered 3 Ǻ 
molecular sieves (20.0 g, 0.500 g/mmol). An exotherm 
occurred. Once the Na had completely reacted the solution was 
cooled to room temperature and dimethyl 2-allylmalonate 201 
(11.6 mL, 72.0 mmol, 1.5 eq.) followed by a solution of amidine 5 (8.10 g, 47.0 mmol, 
1.0 eq.) in MeOH (40 mL) were added. The reaction mixture was heated at reflux for 3 
h. After cooling to room temperature the reaction mixture was filtered through Celite® 
and concentrated in vacuo. The crude product was purified by flash column 
chromatography on silica gel (70:28:2 DCM/MeOH/aqueous NH3) before 
recrystallisation from MeOH afforded the title compound 51 (9.38 g, 72%) as pale 
yellow needles: mp 240-242 °C; Rf  0.33 (70:28:2 DCM/MeOH/aqueous NH3); υmax/cm
-
1
 (neat) 3211 (broad, O-H/N-H stretch), 2916 (C-H stretch), 1667 (C=O stretch), 1644 
(C=O stretch), 1547 (C=C stretch); [α]D
22 +0.5 (c = 1.01, MeOH); δH (400 MHz, DMSO 
d-6) 11.50 (1 H, br s, H-11), 8.50 (1 H, d, J 5.0, H-8), 5.75 (1 H, ddt, J 16.0, 10.0, 6.0, 
H-13), 4.94-4.84 (3 H, m, H-6, 14), 6.67 (1 H, d, J 17.5, H-9a), 3.97 (1 H, dd, J 17.5, 
5.0, H-9b), 2.99 (2 H, d, J 6.0, H-12), 1.72-1.57 (2 H, m, H-15a, 16), 1.44 (1 H, ddd, J 
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12.5, 8.0, 6.5, H-15b), 0.92 (3 H, d, J 6.5, H-17/18), 0.87 (3 H, d, J 6.5, H-17/18); δC 
(100 MHz, DMSO d-6) 167.7 (C-4/7), 164.4 (C-4/7), 161.1 (C-2), 152.0 (C-3/10), 
135.3 (C-14), 97.5 (C-3/10), 53.5 (C-6), 43.5 (C-9), 39.5 (C-15), 26.9 (C-12), 24.4 (C-
16), 22.1 (C-17/18), 21.6 (C-17/18); m/z (ESI) 278 [MH]+. Calcd. for C14H20N3O3: 
278.1499. Found: [MH]+, 278.1500 (0.2 ppm error). 
Lab. Book:  RD05/094/C1 
 
(6R*)-3-Allyl-2-(allyloxy)-6-iso-butyl-8,9-dihydro-4H-pyrazino[1,2-a]pyrimidine-4, 
7(6H)-dione 50 
 
A suspension of pyrimidinone 51 (9.04 g, 33.0 mmol, 1.0 eq.) 
and PPh3 (18.9 g, 72.0 mmol, 2.2 eq.) in THF (140 mL) was 
cooled to 0 °C (ice). To this was added allyl alcohol (5.83 mL, 
86.0 mmol, 2.6 eq.), NEt3 (4.59 mL, 33.0 mmol, 1.0 eq.) and 
DIAD (14.1 mL, 72.0 mmol, 2.2 eq.). The reaction mixture 
was allowed to warm to room temperature over 15 min before 
heating to 65 °C for 2 h. After cooling to room temperature, a 5% aq. HCl solution (180 
mL) was added and the organic phase separated.  The aqueous phase was further 
extracted with EtOAc (2 × 180 mL). The combined organic phase was washed with 
brine (180 mL), dried over MgSO4, filtered and concentrated in vacuo. The PPh3(O) 
side product was removed by crystallisation from PE/EtOAc (3:2) and filtration. The 
filtrate was concentrated in vacuo and purified by flash column chromatography on 
silica gel (1:1 PE/EtOAc) to give the title compound 50 (7.70 g, 73%, er 53:47) as a 
pale yellow solid: mp 125-127 °C; Rf  0.23 (1:1 PE/EtOAc); υmax/cm
-1
 (neat) 3230 (N-H 
stretch), 2959 (C-H stretch), 1666 (C=O stretch), 1602 (C=O stretch), 1542 (C=C 
stretch); [α]D
22 +1.0 (c = 1.01, MeOH); δH (400 MHz, CDCl3) 7.48 (1 H, d, J 4.5, H-8), 
5.99 (1 H, ddt, J 17.0, 10.5, 5.0, H-13), 5.89  (1 H, ddt, J 17.0, 10.0, 6.5, H-16), 5.40-
5.33 (2 H, m, H-6, 14a), 5.24 (1 H, dd, J 10.5, 1.5, H-14b), 5.09 (1 H, dd, J 17.0, 1.5, H-
17a), 4.99 (1 H, dd, J 10.0, 1.5, H-17b), 4.88-4.77 (2 H, m, H-12), 4.55 (1 H, d, J 17.5, 
H-9a), 4.33 (1 H, dd, J 17.5, 4.5, H-9b), 3.25 (2 H, d, J 6.5, H-15), 1.87-1.80 (1 H, m, 
H-19), 1.74 (1 H, ddd, J 14.0, 9.0, 6.0, H-18a), 1.65 (1 H, ddd, J 14.0, 9.0, 6.0, H-18b), 
1.09 (3 H, d, J 6.5, H-20/21), 0.99 (3 H, d, J 6.5, H-20/21); δC (100 MHz, CDCl3) 169.8 
(C-4/7), 163.9 (C-4/7), 161.6 (C-2), 150.4 (C-10), 134.6 (C-16), 132.9 (C-13), 117.4 (C-
14), 115.1 (C-17), 102.1 (C-3), 67.3 (C-12), 53.9 (C-6), 44.7 (C-9), 40.4 (C-15), 27.1 
(C-18), 24.6 (C-19), 23.1 (C-20/21), 21.5 (C-20/21); m/z (ESI) 318 [MH]+. Calcd. for 
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C17H23N3NaO3: 340.1632. Found: [MNa]
+, 340.1629 (0.7 ppm error); HPLC: Chiralpak 
AD-H (90:10 n-hexane/i-PrOH, 1.0 mL min-1) 4.99 min (52.96%), 5.84 min (47.04%).  
Lab. Book:  RD05/096/C1 
 
(6R*,9S*)-3,9-Diallyl-2-(allyloxy)-6-iso-butyl-8,9-dihydro-4H-pyrazino[1,2-
a]pyrimidine-4,7(6H)-dione 212 
 
To a solution of pyrimidinone 51 (1.64 g, 5.90 mmol, 1.0 eq.) 
and K2CO3 (1.02 g, 7.40 mmol, 1.25 eq.) in acetone (30 mL) 
was added allyl bromide (0.89 g, 7.40 mmol, 1.25 eq.). The 
reaction mixture was heated at reflux for 16 h, cooled to room 
temperature, filtered through Celite® and concentrated in 
vacuo. The resulting crude product was purified by flash 
column chromatography on silica gel (4:1 PE/EtOAc) to furnish diallyl pyrimidinone 50 
(0.700 g, 35%) and the title compound 212 (0.140 g, 7%) as a pale yellow solid: mp 
124-126 oC; Rf  0.43 (1:1 PE/EtOAc); υmax/cm
-1
 (neat) 3247 (N-H stretch), 2958 (C-H 
stretch), 1676 (C=O stretch), 1442 (C=C stretch), 1398 (C=C stretch); δH (400 MHz, 
CDCl3) 7.94 (1 H, d, J 5.0, H-8), 5.71 (1 H, ddt, J 17.0, 10.5, 5.5, H-13), 5.58 (2 H, m, 
H-16, 23), 5.48 (1 H, d, J 5.0, H-9), 5.19-5.24 (3 H, m, H-6, 14), 4.98-5.15 (4 H, m, H-
17, 24), 4.34 (2 H, d, J 5.5, H-12), 2.72 (2 H, m, H-15), 2.52 (2 H, d, J 7.5, H-22), 1.54-
1.43 (3 H, m, H-19, 18), 0.92 (3 H, d, J 6.5, H-20/21), 0.91 (3 H, d, J 6.5, H-20/21); δC 
(100 MHz, CDCl3) 167.4 (C-4/7), 167.1 (C-4/7), 166.5 (C-2), 132.6 (C-16/23), 131.4 
(C-13), 130.8 (C-16/23), 120.5 (C-10), 120.1 (C-17/24), 119.5 (C-17/24), 117.7 (C-14), 
95.7 (C-9), 56.7 (C-3), 52.6 (C-6), 45.9 (C-12), 42.9 (C-22), 39.6 (C-15), 38.9 (C-18), 
23.9 (C-19), 22.7 (C-20/21), 22.0 (C-20/21); m/z (ESI) 358 [MH]+. Calcd. for 
C20H28N3O3: 358.2125. Found: [MH]
+, 358.2121 (1.0 ppm error).   
Lab. Book:  RD03/072/B2 
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(8R*)-8-iso-Butyl-2,5,10,11-tetrahydro-6H-oxepino[2,3-d]pyrazino[1,2-
a]pyrimidine-6,9(8H)-dione 215 
 
To a solution of diallyl pyrimidindione 50 (0.318 g, 1.00 mmol, 
1.0 eq.) in degassed anhydrous DCM (400 mL) under an inert 
atmosphere was added a solution of Grubbs second generation 
catalyst x (0.0840 g, 0.100 mmol, 0.1 eq.) in degassed 
anhydrous DCM (20 mL) dropwise over 15 min in two 10 mL 
batches separated by 1 h. The reaction mixture was heated at reflux for 3 h, cooled to 
room temperature, directly loaded onto a column of silica gel and purified by flash 
column chromatography (EtOAc). The title compound 215 (0.263 g, 91%) was isolated 
as an off-white solid: mp 159-160 °C decomposed; Rf  0.22 (EtOAc); υmax/cm
-1
 (neat) 
3258 (broad, N-H stretch), 2959 (C-H stretch), 1663 (C=O stretch), 1605 (C=O stretch), 
1552 (C=C stretch); [α]D
23 -13 (1.01 gdL-1, MeOH); δH (400 MHz, CDCl3) 6.79 (1 H, d, 
J 5.0, H-8), 6.25 (1 H, dt, J 10.0, 6.0, H-14), 6.08-6.02 (1 H, m, H-13), 5.29 (1 H, ddd, J 
9.0, 6.0, 1.0, H-6), 4.84 (1 H, dd, J 13.5, 6.5, H-12a), 4.77 (1 H, dd, J 13.5, 6.5, H-12b), 
4.53 (1 H, d, J 17.0, H-9a), 4.30 (1 H, dd, J 17.0, 5.0, H-9b), 3.49 (2 H, d, J 6.0, H-15), 
1.85-1.79 (1 H, m, H-17), 1.72 (1 H, ddd, J 13.5, 9.0, 6.0, H-16a), 1.61 (1 H, ddd, J 
13.5, 9.0, 6.0, H-16b), 1.09 (3 H, d, J 6.5, H-18/19), 0.98 (3 H, d, J 6.5, H-18/19); δC 
(100 MHz, CDCl3) 168.5 (C-4/7), 166.3 (C-4/7), 162.2 (C-2), 150.2 (C-10), 135.0 (C-
14), 126.6 (C-13), 102.7 (C-3), 65.6 (C-12), 54.3 (C-6), 44.4 (C-9), 40.4 (C-16), 24.8 
(C-17), 23.0 (C-18/19), 22.4 (C-15), 21.6 (C-18/19); m/z (ESI) 290 [MH]+. Calcd. for 
C15H20N3O3: 290.1505. Found: [MH]
+, 290.1499 (2.2 ppm error). X-Ray 
crystallography: CCDC 848129 contains supplementary crystallographic data for this 
compound, see Appendix V. Crystals were grown by slow diffusion (DCM/n-hexane). 
Lab. Book:  RD03/074/B1 
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(3S*,4S*,8R*)-3,4-Dibromo-8-iso-butyl-2,3,4,5,10,11-hexahydro-6H-oxepino[2,3-
d]pyrazino[1,2-a]pyrimidine-6,9(8H)-dione 217 
 
To a solution of dihydro-oxepine 215 
(0.0970 g, 0.330 mmol, 1.0 eq.) in DCM (5 
mL) at room temperature was added 
pyridine hydrotribromide (0.113 g, 0.350 
mmol, 1.05 eq.). The reaction mixture was 
stirred at room temperature for 1.5 h, 
quenched by the addition of sat. NaHSO3 (aq.) (10 mL) and extracted with DCM (2 × 
10 mL). The combined organic phase was washed with water (10 mL), brine (10 mL), 
dried over MgSO4, filtered and concentrated in vacuo to yield the title compound 217 
(0.126 g, 85%) as a brown solid (1:1 mixture of diastereomers) which was used without 
further purification: mp 127-129 °C; Rf 0.36 (EtOAc); υmax/cm
-1
 (neat) 3244 (broad, N-
H stretch), 2960 (C-H stretch), 1665 (C=O stretch), 1602 (C=O stretch), 1555 (C=C 
stretch); δH (400 MHz, CDCl3) 6.60 (2 H, br s, H-8, 8’), 5.37-5.26 (2 H, m, H-6, 6’), 
4.69-4.34 (12 H, m, H-9, 9’, 12, 12’, 13, 13’, 14, 14’), 3.53-3.45 (4 H, m, H-15, 15’), 
1.86-1.69 (4 H, m, H-17, 17’), 1.67-1.55 (4 H, m, H-16, 16’), 1.11-1.06 (6 H, m, H-
18/19, 18’/19’), 1.00-0.98 (6 H, m, H-18/19, 18’/19’); δC (100 MHz, CDCl3) 169.1 (C-
4/7), 168.9 (C-4’/7’), 167.7 (C-4/7), 167.6 (C-4’/7’), 163.6 (C-2), 162.1 (C-2’), 152.7 
(C-10), 151.4 (C-10’), 105.0 (C-3), 104.8 (C-3’), 70.5 (C-12), 70.4 (C-12’), 54.4 (C-6), 
54.2 (C-6’), 53.7 (C-13/14), 52.9 (C-13’/14’), 52.6 (C-13/14), 49.7 (C-13’/14’), 44.4 
(C-9), 44.3 (C-9’), 40.1 (C-16), 40.0 (C-16’), 27.4 (C-15), 27.1 (C-15’), 24.6 (d, C-17, 
17’), 22.8 (C-18/19), 21.6 (C-18’/19’), 21.5 (C-18/19), 21.3 (C-18’/19’); m/z (ESI) 447 
[MH]+. Calcd. for C15H20
79Br2N3O3: 447.9871. Found: [MH]
+, 447.9866 (0.3 ppm 
error).     
Lab. Book:  RD04/010/B1 
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6.2 Chapter 3 - Enamine Installation: Ketopiperazine Substitution 
 
tert-Butyl (8R*)-8-iso-butyl-6,9-dioxo-2,5,6,8,9,11-hexahydro-10H-oxepino[2,3-d]py 
razino[1,2-a]pyrimidine-10-carboxylate 279 
 
To a solution of dihydro-oxepine 215 (0.0680 g, 0.240 mmol, 
1.0 eq.) in THF (3.5 mL) was added NEt3 (0.0330 mL, 0.240 
mmol, 1.0 eq.), Boc2O (0.0630 g, 0.290 mmol, 1.2 eq.) and 
DMAP (0.0030 g, 0.0200 mmol, 0.1 eq.). The reaction mixture 
was stirred at room temperature for 30 min before the addition 
of water (10 mL). The organic phase was separated and the 
aqueous phase extracted with EtOAc (2 × 10 mL). The 
combined organic phase was washed with sat. NH4Cl (aq.) (10 mL), water (10 mL), 
brine (10 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude 
material was purified by flash column chromatography on silica gel (7:3 PE/EtOAc) to 
furnish the title compound 279 (0.0470 g, 50%) as a pale yellow film: Rf 0.71 (EtOAc); 
υmax/cm
-1
 (neat) 2961 (C-H stretch), 1781 (C=O stretch), 1733 (C=O stretch), 1663 
(C=O stretch), 1607 (C=C stretch), 1551 (C=C stretch); δH (400 MHz, CDCl3) 6.26 (1 
H, dt, J 10.0, 6.0, H-14), 6.07 (1 H, app. dt (ddd), J 10.0, 6.5, H-13), 5.44 (1 H, dd, J 
9.0, 6.5, H-6), 5.09 (1 H, d, J 17.0, H-9a), 4.82 (1 H, dd, J 13.5, 6.5, H-12a), 4.75 (1 H, 
dd, J 13.5, 6.5, H-12b), 4.54 (1 H, d, J 17.0, H-9b), 3.49 (2 H, d, J 6.0, H-15), 1.83-1.75 
(2 H, m, H-16a, 17), 1.69-1.55 (1 H, m, H-16b), 1.53 (9 H, s, H-22), 1.08 (3 H, d, J 6.5, 
H-18/19), 1.01 (3 H, d, J 6.5, H-18/19); δC (100 MHz, CDCl3) 166.5 (C-4/7), 165.5 (C-
4/7), 161.8 (C-2), 149.9 (C-20), 149.7 (C-10), 134.9 (C-14), 126.6 (C-13), 103.2 (C-3), 
85.2 (C-21), 65.7 (C-12), 55.8 (C-6), 46.8 (C-9), 40.3 (C-12), 27.8 (C-22, 23, 24), 24.8 
(C-17), 22.8 (C-18/19), 22.3 (C-15), 21.6 (C-18/19); m/z (ESI) 390 [MH]+. Calcd. for 
C20H28N3O5: 390.2023. Found: [MH]
+, 390.2031 (1.7 ppm error).   
Lab. Book:  RD03/095/C1 
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tert-Butyl (6R*)-3-allyl-2-(allyloxy)-6-iso-butyl-4,7-dioxo-4,6,7,9-tetrahydro-8H- 
pyrazino[1,2-a]pyrimidine-8-carboxylate 280 
 
To a solution of diallyl pyrimidinone 50 (0.100 g, 0.310 mmol, 
1.0 eq.) in THF (5 mL) was added NEt3 (0.0430 mL, 0.310 
mmol, 1.0 eq.), Boc2O (0.137 g, 0.630 mmol, 2.0 eq.) and 
DMAP (0.0040 g, 0.0300 mmol, 0.1 eq.). The reaction mixture 
was stirred at room temperature for 2 h before being quenched 
by the addition of water (10 mL). The organic phase was 
separated and the aqueous phase extracted with EtOAc (2 × 10 
mL). The combined organic phase was washed with sat. NH4Cl (aq.) (10 mL), water (10 
mL), brine (10 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude 
material was purified by flash column chromatography on silica gel (17:3 PE/EtOAc) to 
furnish the title compound 280 (0.128 g, 98%) as a colourless oil: Rf 0.73 (EtOAc); 
υmax/cm
-1
 (neat) 2961 (C-H stretch), 1783 (C=O stretch), 1733 (C=O stretch), 1669 
(C=O stretch), 1606 (C=C stretch), 1544 (C=C stretch); δH (400 MHz, CDCl3) 6.00 (1 
H, ddt, J 17.0, 10.5, 5.5, H-13), 5.87 (1 H, ddt, J 16.5, 10.0, 6.5, H-16), 5.51 (1 H, dd, J 
9.0, 6.5, H-6), 5.38 (1 H, dd, J 17.0, 1.5, H-14a), 5.24 (1 H, dd, J 10.5, 1.5, H-14b), 5.08 
(1 H, dd, J 16.5, 1.5, H-17a), 5.08 (1 H, d, J 17.0, H-9a), 4.98 (1 H, dd, J 10.0, 1.5, H-
17b), 4.89-4.79 (2 H, m, H-12), 4.54 (1 H, d, J 17.0, H-9b), 3.23 (2 H, d, J 6.5, H-15), 
1.83-1.73 (2 H, m, H-18a, 19), 1.66-1.60 (1 H, m, H-18b), 1.57 (9 H, s, H-24), 1.08 (3 
H, d, J 6.5, H-20/21), 0.99 (3 H, d, J 6.5, H-20/21); δC (100 MHz, CDCl3) 165.5 (C-
4/7), 164.0 (C-4/7), 161.2 (C-2), 150.1 (C-22), 150.0 (C-10), 134.5 (C-16), 132.9 (C-
13), 117.5 (C-14), 115.3 (C-17), 102.7 (C-3), 85.2 (C-23), 67.5 (C-12), 55.6 (C-6), 46.9 
(C-9), 40.3 (C-18), 27.9 (C-24, 25, 26), 27.1 (C-15), 24.9 (C-19), 22.9 (C-20/21), 21.6 
(C-20/21); m/z (ESI) 418 [MH]+. Calcd. for C22H32N3O5: 418.2336. Found: [MH]
+, 
418.2336 (0.7 ppm error).   
Lab. Book:  RD04/035/C1 
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 (8R*)-10-Acetyl-8-iso-butyl-2,5,10,11-tetrahydro-6H-oxepino[2,3-d]pyrazino[1,2-
a]pyrimidine-6,9(8H)-dione 283 
 
To a solution of dihydro-oxepine 215 (0.0770 g, 0.270 mmol, 
1.0 eq.) in DCM (1.5 mL) was added NEt3 (0.300 mL, 2.14 
mmol, 8.0 eq.), acetyl chloride (0.152 mL, 2.14 mmol, 8.0 eq.) 
and DMAP (0.0060 g, 0.0500 mmol, 0.2 eq.). The reaction 
mixture was stirred at room temperature for 4 h before being 
quenched by the addition of water (5 mL). The organic phase 
was separated and the aqueous phase extracted with DCM (2 × 10 mL). The combined 
organic phase was washed with sat. NH4Cl (aq.) (10 mL), water (10 mL), brine (10 
mL), dried over MgSO4, filtered and concentrated in vacuo. The crude material was 
purified by flash column chromatography on silica gel (3:2 n-hexane/EtOAc) to furnish 
the title compound 283 (0.0530 g, 59%) as a pale yellow film: Rf 0.57 (EtOAc); υmax/cm
-
1
 (neat) 2961 (C-H stretch), 1717 (C=O stretch), 1662 (C=O stretch), 1607 (C=C 
stretch), 1551 (C=C stretch); δH (400 MHz, CDCl3) 6.24 (1 H, dt, J 10.0, 6.0, H-14), 
6.08-6.03 (1 H, m, H-13), 5.48 (1 H, dd, J 9.0, 6.0, H-6), 5.40 (1 H, d, J 17.5, H-9a), 
4.84 (1 H, dd, J 13.5, 6.5, H-12a), 4.76 (1 H, dd, J 13.5, 6.5, H-12b), 4.34 (1 H, d, J 
17.5, H-9b), 3.47 (2 H, d, J 6.0, H-15), 2.59 (3 H, s, H-21), 1.81-1.70 (2 H, m, H-16a, 
17), 1.66-1.63 (1 H, m, H-16b), 1.08 (3 H, d, J 6.0, H-18/19), 1.00 (3 H, d, J 6.0, H-
18/19); δC (100 MHz, CDCl3) 171.3 (C-20), 167.5 (C-4/7), 166.6 (C-4/7), 161.7 (C-2), 
150.0 (C-10), 134.9 (C-14), 126.6 (C-13), 103.1 (C-3), 65.6 (C-12), 55.8 (C-6), 44.4 (C-
9), 40.2 (C-16), 27.0 (C-21), 24.8 (C-17), 22.7 (C-18/19), 22.2 (C-15), 21.5 (C-18/19); 
m/z (ESI) 332 [MH]+. Calcd. for C17H22N3O4: 332.1605. Found: [MH]
+, 332.1606 (0.2 
ppm error).     
Lab. Book:  RD04/063/C1 
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(8R*)-8-iso-Butyl-10-(4-methoxybenzyl)-2,5,10,11-tetrahydro-6H-oxepino[2,3-
d]pyrazino[1,2-a]pyrimidine-6,9(8H)-dione 284 
 
 N-Substitution of Dihydro-Oxepine 215: 
A solution of dihydro-oxepine 215 (0.304 g, 1.05 mmol, 1.0 
eq.) in THF (3.5 mL) was cooled to 0 °C (ice). To this was 
added NaH (0.046 g, 60% dispersion in mineral oil, 2.26 
mmol, 1.1 eq.). The reaction mixture was stirred at 0 °C (ice) 
for 10 min before the addition of para-methoxy benzyl 
bromide (0.169 mL, 1.16 mmol, 1.1 eq.) and TBAI (0.428 g, 
1.16 mmol, 1.1 eq.). After stirring at 0 °C for 2 h the reaction 
mixture was quenched by the addition of water (10 mL). The organic phase was 
separated and the aqueous phase extracted with DCM (3 × 10 mL).  The combined 
organic phase was dried over MgSO4, filtered and concentrated in vacuo. The crude 
material was purified by flash column chromatography on silica gel (1:1 EtOAc/n-
hexane) to furnish the title compound 284 (0.219 g, 51%) as a pale yellow waxy solid. 
Lab. Book:  RD05/025/C1 
 
 Alternatively: RCM of N-PMB-Diallyl Pyrimidindione 285: 
To a refluxing solution of N-PMB-diallyl pyrimidindione 285 (0.437 g, 1.00 mmol, 1.0 
eq.) in degassed anhydrous DCM (400 mL) under an inert atmosphere was added a 
solution of Hoveyda-Grubbs second generation catalyst x (0.0630 g, 0.100 mmol, 0.1 
eq.) in degassed anhydrous DCM (20 mL) in two batches separated by 1 h, dropwise 
over 15 min. The reaction mixture was heated at reflux for 18 h before cooling to room 
temperature, direct loading onto a column of silica gel and purification by flash column 
chromatography (9:1 DCM/Et2O). The title compound 284 (0.305 g, 74%) was isolated 
as a pale yellow waxy solid: Rf  0.25 (9:1 DCM/Et2O); υmax/cm
-1
 (neat) 2958 (C-H 
stretch), 1664 (broad, C=O stretch), 1608 (C=C stretch), 1552 (C=C stretch); δH (400 
MHz, CDCl3) 7.17 (2 H, d, J 8.5, H-22), 6.86 (2 H, d, J 8.5, H-23), 6.24 (1 H, dt, J 10.0, 
6.0, H-14), 6.06-6.00 (1 H, m, H-13), 5.37 (1 H, dd, J 9.0, 6.0, H-6), 4.77 (2 H, 2 × dd 
(overlapping), J 13.5, 6.5, H-12), 4.68 (1 H, d, J 14.5, H-20a), 4.49 (1 H, d, J 14.5, H-
20b), 4.34 (1 H, d, J 17.5, H-9a), 4.11 (1 H, d, J 17.5, H-9b), 3.80 (3 H, s, H-26), 3.48 
(2 H, d, J 6.0, H-15), 1.87-1.77 (1 H, m, H-17), 1.68-1.54 (2 H, m, H-16), 1.08 (3 H, d, 
J 6.5, H-18/19), 0.98 (3 H, d, J 6.5, H-18/19); δC (100 MHz, CDCl3) 166.3 (C-4/7), 
166.1 (C-4/7), 161.9 (C-2), 159.5 (C-24), 150.1 (C-10), 135.0 (C-14), 129.7 (C-22), 
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127.0 (C-21), 126.6 (C-13), 114.4 (C-23), 102.8 (C-3), 65.6 (C-12), 55.2 (C-26), 54.6 
(C-6), 48.8 (C-20), 48.2 (C-9), 40.6 (C-16), 24.8 (C-17), 23.0 (C-15), 22.3 (C-18/19), 
21.7 (C-18/19); m/z (ESI) 410 [MH]+. Calcd. for C23H28N3O4: 410.2074. Found: [MH]
+, 
410.2065 (2.7 ppm error).  
Lab. Book: RD05/031/B1 
 
(6R*)-3-Allyl-2-(allyloxy)-6-iso-Butyl-8-(4-methoxybenzyl)-8,9-dihydro-4H-
pyrazino[1,2-a]pyrimidine-4,7(6H)-dione 285 
 
A solution of diallyl pyrimidindione 50 (1.00 g, 3.14 mmol, 
1.0 eq.) in THF (20 mL) was cooled to 0 °C (ice). To this 
was added NaH (0.138 g, 60% dispersion in mineral oil, 
3.46 mmol, 1.1 eq.). The reaction mixture was stirred at 0 
°C for 10 min before the addition of para-methoxy benzyl 
bromide (0.504 mL, 3.46 mmol, 1.1 eq.) and TBAI (1.27 g, 
3.46 mmol, 1.1 eq.). Following stirring at 0 °C for 2 h the 
reaction mixture was quenched by the addition of sat. NH4Cl (aq.) (10 mL). The organic 
phase was separated and the aqueous phase extracted with DCM (3 × 10 mL).  The 
combined organic phase was dried over MgSO4, filtered and concentrated in vacuo. The 
crude material was purified by flash column chromatography on silica gel (1:4 
EtOAc/n-hexane) to furnish the title compound 285 (1.17 g, 85%) as a pale yellow oil: 
Rf  0.64 (1:1 PE/EtOAc); υmax/cm
-1
 (neat) 2958 (C-H stretch), 1667 (broad, C=O stretch), 
1605 (C=C stretch), 1542 (C=C stretch); δH (400 MHz, CDCl3) 7.20 (2 H, d, J 8.5, H-
24), 6.89 (2 H, d, J 8.5, H-25), 5.95 (1 H, ddt, J 15.0, 9.5, 5.0, H-13), 5.87 (1 H, ddt, J 
16.5, 10.0, 6.5, H-16), 5.46 (1 H, dd, J 9.0, 6.0, H-6), 5.32 (1 H, dd, J 15.0, 1.5, H-14a), 
5.21 (1 H, dd, J 9.5, 1.5, H-14b), 5.08 (1 H, dd, J 16.5, 1.5, H-17a), 4.97 (1 H, dd, J 
10.0, 1.5, H-17b), 4.89 (1 H, d, J 14.5, H-22a), 4.80-4.71 (2 H, m, H-12), 4.37 (1 H, d, J 
17.5, H-9a), 4.36 (1 H, d, J 14.5, H-22b), 4.11 (1 H, d, J 17.5, H-9b), 3.81 (3 H, s, H-
27), 3.22 (2 H, d, J 6.5, H-15), 1.88-1.78 (1 H, m, H-19), 1.68-1.55 (2 H, m, H-18), 1.08 
(3 H, d, J 6.5, H-20/21), 0.97 (3 H, d, J 6.5, H-20/21); δC (100 MHz, CDCl3) 166.2 (C-
4/7), 163.8 (C-4/7), 161.3 (C-2), 159.5 (C-26), 150.4 (C-10), 134.6 (C-16), 132.8 (C-
13), 129.5 (C-24), 127.2 (C-23), 117.3 (C-14), 115.1 (C-17), 114.3 (C-25), 102.1 (C-3), 
67.2 (C-12), 55.2 (C-27), 54.2 (C-6), 48.8 (C-22), 48.7 (C-9), 40.6 (C-18), 27.1 (C-15), 
24.8 (C-19), 23.1 (C-20/21), 21.6 (C-20/21); m/z (ESI) 438 [MH]+. Calcd. for 
C25H32N3O4: 438.2387. Found: [MH]
+, 438.2386 (1.2 ppm error). 
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Lab. Book:  RD05/045/C1 
 
(8R*,11R*)-11-(1-Hydroxy-2-methylpropyl)-8-iso-butyl-10-(4-methoxybenzyl)-
2,5,10,11-tetrahydro-6H-oxepino[2,3-d]pyrazino[1,2-a]pyrimidine-6,9(8H)-dione 
286 
 
A solution of LiHMDS was prepared by the addition of n-
BuLi (0.900 mL, 1.6 M solution in n-hexane, 1.44 mmol, 
2.05 eq.) to a solution of HMDS (0.310 mL, 1.47 mmol, 2.1 
eq.) in THF (1 mL) at 0 °C (ice). Following stirring at 0 °C 
for 20 min the solution was diluted with THF (4 mL) and 
cooled to –78 °C (CO2/acetone). A solution of dihydro-
oxepine x (0.288 g, 0.700 mmol, 1.0 eq.) in THF (4 mL) was 
then added dropwise over 5 min. The reaction mixture was stirred at –78 °C for 45 min 
before the addition of iso-butyraldehyde 221 (0.128 mL, 1.40 mmol, 2.0 eq.) and 
TMSCl (0.177 mL, 1.40 mmol, 2.0 eq.). Following stirring at –78 °C for 1 h the 
reaction mixture was quenched by the addition of TFA (0.5 mL) and water (2 mL) and 
allowed to warm to room temperature over 2 h. The reaction mixture was partitioned 
between EtOAc (15 mL) and water (10 mL) and the organic phase washed with water (3 
× 10 mL), sat. NaHCO3 (aq.) (3 × 10 mL) and brine (10 mL), dried over MgSO4, 
filtered and concentrated in vacuo. The crude material was purified by flash column 
chromatography on silica gel (3:2 n-hexane/EtOAc) to furnish the title compound 286 
(0.136 g, 44%) as a pale yellow crystalline solid: mp 141-143 °C; Rf  0.26 (1:1 
PE/EtOAc); υmax/cm
-1
 (neat) 3422 (broad, O-H stretch), 2959 (C-H stretch), 1647 (C=O 
stretch), 1549 (C=C stretch), 1513 (C=C stretch); δH (400 MHz, CDCl3) 7.11 (2 H, d, J 
8.5, H-22), 6.80 (2 H, d, J 8.5, H-23), 6.24 (1 H, dt, J 10.0, 6.0, H-14), 6.02 (1 H, dt, J 
10.0, 6.5, H-13), 5.47 (1 H, d, J 15.0, H-20a), 5.16 (1 H, dd, J 10.0, 4.0, H-6), 4.74 (2 H, 
d, J 6.5, H-12), 4.35 (1 H, d, J 2.5, H-9), 3.77 (1 H, d, J 15.0, H-20b), 3.76 (3 H, s, H-
26), 3.56 (1 H, ddd, J 8.5, 5.5, 2.5, H-27), 3.46 (2 H, d, J 6.0, H-15), 2.20-1.99 (3 H, m, 
H-16a, 17, 28), 1.69 (1 H, ddd, J 13.5, 9.5, 4.0, H-16b), 1.14 (3 H, d, J 6.5, H-18/19), 
1.02 (3 H, d, J 6.5, H-18/19), 0.98 (3 H, d, J 6.5, H-29/30), 0.95 (3 H, d, J 6.5, H-
29/30); δC (100 MHz, CDCl3) 166.8 (C-4/7), 165.7 (C-4/7), 162.4 (C-2), 159.5 (C-24), 
150.3 (C-10), 135.6 (C-14), 129.7 (C-22), 127.2 (C-21), 126.7 (C-13), 114.4 (C-23), 
102.4 (C-3), 78.4 (C-27), 65.3 (C-12), 60.8 (C-9), 55.2 (C-26), 54.7 (C-6), 46.5 (C-20), 
43.1 (C-16), 30.7 (C-17), 25.6 (C-28), 23.5 (C-18/19), 22.3 (C-15), 21.2 (C-18/19), 19.8 
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(C-29/30), 18.3 (C-29/30); m/z (ESI) 482 [MH]+. Calcd. for C27H36N3O5: 482.2649. 
Found: [MH]+, 482.2651 (0.4 ppm error).  
Lab. Book: RD06/007/C1 
 
(8R*,11Z)-8-iso-Butyl-10-(4-methoxybenzyl)-11-(2-methylpropylidene)-2,5,10,11-
tetrahydro-6H-oxepino[2,3-d]pyrazino[1,2-a]pyrimidine-6,9(8H)-dione 289 
 
To a solution of alcohol 286 (0.0600 g, 0.120 mmol, 1.0 eq.) 
in DCM (2.5 mL) was added NEt3 (0.0430 mL, 0.310 mmol, 
2.5 eq.), MsCl (0.0240 mL, 0.310 mmol, 2.5 eq.) and DMAP 
(0.001 g, cat.). The reaction mixture was stirred at room 
temperature for 5 h before the addition of sat. NH4Cl (aq.) 
(10 mL). The organic phase was separated and the aqueous 
phase extracted with DCM (3 × 10 mL). The combined 
organic phase was dried over MgSO4, filtered and concentrated in vacuo. The crude 
material was taken in THF (2.5 mL) and to this was added t-BuOK (0.033 g, 0.31 
mmol, 2.5 eq.). The reaction mixture was stirred at room temperature for 1 h before the 
addition of sat. NH4Cl (aq.) (10 mL). The organic phase was separated and the aqueous 
phase extracted with EtOAc (3 × 10 mL). The combined organic phase was dried over 
MgSO4, filtered and concentrated in vacuo. The crude product was purified by flash 
column chromatography on silica gel (7:3 n-hexane/EtOAc) to furnish the title 
compound 289 (0.0120 g, 22%) as yellow film:  Rf  0.45 (1:1 PE/EtOAc); υmax/cm
-1
 
(neat) 2969 (C-H stretch), 1691 (C=O stretch), 1650 (C=O stretch), 1588 (C=C stretch); 
δH (400 MHz, CDCl3) 7.08 (2 H, d, J 8.5, H-22), 6.78 (2 H, d, J 8.5, H-23), 6.23 (1 H, 
dt, J 10.0, 6.0, H-14), 6.17 (1 H, d, J 11.0, H-27), 6.03 (1 H, dt, J 10.0, 6.0, H-13), 5.42 
(1 H, dd, J 9.0, 6.5, H-6), 5.17 (1 H, d, J 15.0, H-20a), 4.79 (2 H, d, J 6.0, H-12), 4.49 
(1 H, d, J 15.0, H-20b), 3.76 (3 H, s, H-26), 3.47 (2 H, ddd, J 6.0, 4.0, 1.0, H-15), 2.77 
(1 H, dsept., J 11.0, 6.5, H-28), 1.75-1.51 (3 H, m, H-16, 17), 1.14 (3 H, d, J 6.5, H-
29/30), 1.04 (3 H, d, J 6.5, H-29/30), 1.03 (3 H, d, J 6.5, H-18/19), 0.96 (3 H, d, J 6.5, 
H-18/19); δC (100 MHz, CDCl3) 166.7 (C-4/7), 166.6 (C-4/7), 161.9 (C-2), 159.1 (C-
24), 150.2 (C-10), 135.2 (C-27), 134.9 (C-13), 128.6 (C-22), 128.5 (C-9), 128.2 (C-21), 
126.6 (C-14), 114.1 (C-23), 102.7 (C-3), 65.6 (C-12), 55.2 (C-26), 54.9 (C-6), 50.1 (C-
20), 40.6 (C-16), 27.6 (C-28), 25.0 (C-17), 23.0 (C-18/19), 22.5 (C-15), 22.3 (C-18/19), 
21.7 (C-29/30), 21.6 (C-29/30); m/z (ESI) 464 [MH]+. Calcd. for C27H34N3O4: 
464.2544. Found: [MH]+, 464.2534 (2.5 ppm error). 
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Lab. Book:  RD06/025/C1 
 
(6R*)-3-Allyl-2-(allyloxy)-7-ethoxy-6-iso-butyl-6,9-dihydro-4H-pyrazino[1,2-a]pyri 
midin-4-one 292 
 
To a solution of diallyl pyrimidinone 50 (1.00 g, 3.14 mmol, 
1.0 eq.) and K2CO3 (1.73 g, 12.6 mmol, 4.0 eq.) in anhydrous 
DCM (30 mL) containing activated, powdered 4 Ǻ molecular 
sieves (1.50 g, 0.500 g/mmol), was added triethyloxonium 
tetrafluoroborate (1.19 g, 6.28 mmol, 2.0 eq.). The reaction 
mixture was stirred at room temperature for 2 h before 
filtration through Celite®. The filtrate was washed with water (30 mL), brine (30 mL), 
dried over MgSO4, filtered and concentrated in vacuo. The crude material was purified 
by flash column chromatography on silica gel (9:1 PE/EtOAc) to furnish the title 
compound 292 (0.939 g, 87%) as a colourless oil: Rf  0.70 (1:1 PE/EtOAc); υmax/cm
-1
 
(neat) 2958 (C-H stretch), 1668 (C=O stretch), 1600 (C=C stretch), 1536 (C=C stretch); 
δH (400 MHz, CDCl3) 5.99 (1 H, ddt, J 17.0, 10.5, 5.0, H-13), 5.87 (1 H, ddt, J 17.0, 
10.0, 6.5, H-16), 5.34 (1 H, dd, J 17.0, 1.5, H-14a), 5.28 (1 H, t, J 7.5, H-6), 5.21 (1 H, 
dd, J 10.5, 1.5, H-14b), 5.01 (1 H, dd, J 17.0, 1.5, H-17a), 4.96 (1 H, dd, J 10.0, 1.5, H-
17b), 4.84-4.80 (2 H, m, H-12), 4.58 (1 H, d, J 20.0, H-9a), 4.51 (1 H, d, J 20.0, H-9b), 
4.16 (2 H, q, J 7.0, H-22), 3.23 (2 H, d, J 6.5, H-15), 1.76-1.65 (1 H, m, H-19), 1.61 (2 
H, dd, J 7.5, 6.5, H-18), 1.30 (3 H, t, J 7.0, H-23), 1.05 (3 H, d, J 6.5, H-20/21), 0.92 (3 
H, d, J 6.5, H-20/21); δC (100 MHz, CDCl3) 164.7 (C-4/7), 164.2 (C-4/7), 161.8 (C-2), 
153.9 (C-10), 135.0 (C-16), 133.1 (C-13), 117.2 (C-14), 114.9 (C-17), 101.3 (C-3), 67.1 
(C-12), 62.1 (C-22), 50.7 (C-9), 50.3 (C-6), 40.3 (C-18), 27.1 (C-15), 25.1 (C-19), 23.3 
(C-20/21), 21.5 (C-20/21), 14.1 (C-23); m/z (ESI) 346 [MH]+. Calcd. for C19H28N3O3: 
346.2125. Found: [MH]+, 346.2129 (1.1 ppm error). 
Lab. Book: RD06/037/C1 
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(8R*)-9-Ethoxy-8-iso-butyl-8,11-dihydro-6H-oxepino[2,3-d]pyrazino[1,2-
a]pyrimidin-6-one 290 
To a refluxing solution of diallyl pyrimidinone 292 (0.345 g, 
1.00 mmol, 1.0 eq.) in degassed anhydrous DCM (400 mL) 
under an inert atmosphere was added a solution of Grubbs 
second generation catalyst 148 (0.085 g, 0.1 mmol, 0.1 eq.) in 
degassed anhydrous DCM (20 mL) in two 10 mL batches 
separated by 1 h, dropwise over 15 min. The reaction mixture 
was heated at reflux for a further 3 h before cooling to room temperature, direct loading 
onto a column of silica gel and purification by flash column chromatography (1:1 
DCM/Et2O). The title compound 290 (0.258 g, 81%) was isolated as a red/brown oil: Rf 
0.28 (1:1 PE/EtOAc); υmax/cm
-1
 (neat) 2958 (C-H stretch), 1655 (C=O stretch), 1598 
(C=C stretch), 1548 (C=C stretch); δH (400 MHz, CDCl3) 6.23 (1 H, dt, J 10.0, 6.0, H-
14), 6.03 (1 H, app. dt (ddd), J 10.0, 6.0, H-13), 5.19 (1 H, dd, J 8.5, 6.5, H-6), 4.78 (2 
H, 2 × dd (overlapping), J 15.5, 6.0, H-12), 4.59 (1 H, d, J 20.0, H-9a), 4.51 (1 H, d, J 
20.0, H-9b), 4.16 (2 H, q, J 7.0, H-21), 3.48 (2 H, d, J 6.0, H-15), 1.76-1.66 (1 H, m, H-
17), 1.63-1.58 (2 H, m, H-16), 1.30 (3 H, t, J 7.0, H-22), 1.06 (3 H, d, J 6.5, H-18/19), 
0.94 (3 H, d, J 6.5, H-18/19); δC (100 MHz, CDCl3) 166.7 (C-4/7), 164.3 (C-4/7), 162.4 
(C-2), 153.5 (C-10), 134.7 (C-14), 126.7 (C-13), 102.3 (C-3), 65.6 (C-12), 62.1 (C-21), 
50.5 (C-6), 50.3 (C-9), 40.3 (C-16), 25.0 (C-17), 23.2 (C-18/19), 22.3 (C-15), 21.6 (C-
18/19), 14.1 (C-22); m/z (ESI) 318 [MH]+. Calcd. for C17H24N3O3: 318.1812. Found: 
[MH]+, 318.1820 (1.9 ppm error). 
Lab. Book: RD06/024/C1 
 
(2S*,9R*)-4,8-Diethoxy-9-iso-butyl-2-vinyl-2,3,6,9-tetrahydro-5aH-furo[3,2-
e]pyrazino[1,2-a]pyrimidine 291 
 
 To a solution of dihydro-oxepine 215 (1.00 g, 3.14 mmol, 1.0 
eq.) and K2CO3 (1.73 g, 12.6 mmol, 4.0 eq.) in anhydrous 
DCM (30 mL) containing activated, powdered 4 Ǻ molecular 
sieves (1.50 g, 0.500 g/mmol), was added triethyloxonium 
tetrafluoroborate (1.19 g, 6.28 mmol, 2.0 eq.). The reaction 
mixture was stirred at room temperature for 2 h before 
filtration through Celite®. The filtrate was washed with water (30 mL), brine (30 mL), 
dried over MgSO4, filtered and concentrated in vacuo. The crude material was purified 
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by flash column chromatography on silica gel (7:3 PE/EtOAc) to furnish dihydro-
oxepine 290 (0.0230 g, 36%) and the title compound 291 (0.0230 g, 33%) as brown oil 
(single diastereomer): Rf  0.32 (4:1 n-hexane/EtOAc); υmax/cm
-1
 (neat) 2958 (C-H 
stretch), 1690 (lactim C-O stretch), 1667 (C=C stretch), 1640 (C=C stretch), δH (400 
MHz, CDCl3) 5.87 (1 H, s, H-9), 5.72 (1 H, ddd, J 17.0, 10.5, 9.0, H-24), 5.28 (1 H, dd, 
J 17.0, 1.5, H-25a), 5.18 (1 H, t, J 7.5, H-6), 5.13 (1 H, dd, J 10.5, 1.5, H-25b), 4.19 (2 
H, q, J 7.0, H-12), 3.87 (1 H, dq, J 14.0, 7.0, H-22a), 3.75 (1 H, dq, J 14.0, 7.0, H-22b), 
2.47 (1 H, dt, J 9.0, 8.5, H-15), 2.12 (1 H, dd, J 8.5, 4.0, H-14a), 2.07 (1 H, dd, J 8.5, 
4.0, H-14b), 1.55-1.44 (3 H, m, H-17, 18), 1.32 (3 H, t, J 7.0, H-13), 1.21 (3 H, t, J 7.0, 
H-23), 0.94 (6 H, app. d (2 × d), J 6.0, H-19, 20); δC (100 MHz, CDCl3) 166.5 (C-2/4/7), 
162.4 (C-2/4/7), 159.4 (C-2/4/7), 132.7 (C-24), 123.3 (C-10), 119.3 (C-25), 103.2 (C-9), 
62.4 (C-12), 48.5 (C-6), 39.7 (C-15), 38.8 (C-17), 36.2 (C-3), 35.2 (C-3), 24.1 (C-18), 
22.6 (C-19/20), 22.5 (C-19/20), 21.7 (C-14), 14.2 (C-13), 12.4 (C-23); m/z (ESI) 346 
[MH]+. Calcd. for C19H28N3O3: 346.2125. Found: [MH]
+, 346.2134 (2.8 ppm error). 
Lab. Book:  RD06/024/C1 
 
(8R*,11R*)-9-Ethoxy-11-(1-hydroxy-2-methylpropyl)-8-iso-butyl-2,5,8,11-
tetrahydro-6H-oxepino[2,3-d]pyrazino[1,2-a]pyrimidin-6-one 293 
 
A solution of LiHMDS was prepared by the addition of n-BuLi 
(1.34 mL, 2.5 M solution in n-hexane, 3.34 mmol, 2.10 eq.) to 
a solution of HMDS (0.727 mL, 3.42 mmol, 2.15 eq.) in THF 
(5 mL) at 0 °C (ice). Following stirring at 0 °C for 20 min the 
solution was diluted with THF (10 mL) and cooled to –78 °C 
(CO2/acetone) before a solution of imidate 290  (0.504 g, 1.59 
mmol, 1.0 eq.) in THF (5 mL) was added. The reaction mixture was stirred at –78 °C 
for 10 min before the addition of iso-butyraldehyde 221 (0.440 mL, 4.77 mmol, 3.00 
eq.) and then held for a further 10 min before the reaction mixture was quenched by the 
addition of AcOH (1 mL) and allowed to warm to room temperature. The reaction 
mixture was partitioned between EtOAc (20 mL) and water (25 mL), the organic phase 
separated, washed with sat. NaHCO3 (aq.) (2 × 25 mL), brine (25 mL), dried over 
MgSO4, filtered and concentrated in vacuo. The crude material was purified by flash 
column chromatography on silica gel (4:1 n-hexane/EtOAc) to furnish the title 
compound 293 (0.425 g, 70%) as a yellow oil: Rf  0.59 (1:1 PE/EtOAc); υmax/cm
-1
 (neat) 
3433 (br, O-H stretch), 2960 (C-H stretch), 1647 (C=O stretch), 1593 (C=C stretch), 
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1544 (C=C stretch); δH (400 MHz, CDCl3) 6.23 (1 H, dt, J 10.0, 6.0, H-14), 6.02 (1 H, 
dt, J 10.0, 6.5, H-13), 5.00 (1 H, dd, J 9.5, 4.5 H-6), 4.81 (1 H, dd, J 13.5, 6.5, H-12a), 
4.72 (1 H, dd, J 13.5, 6.5, H-12b), 4.42 (1 H, d, J 8.5, H-9), 4.17 (2 H, m, H-21), 3.46 (2 
H, d, J 6.0, H-15), 3.43 (1 H, ddd, J 8.5, 3.0, 2.5, H-23), 2.10 (1 H, sept.d, J 7.0, 3.0, H-
24), 1.91-1.82 (1 H, m, H-17), 1.73 (1 H, ddd, J 13.5, 9.5, 4.5, H-16a), 1.52 (1 H, ddd, J 
13.5, 9.5, 4.5, H-16b), 1.29 (3 H, t, J 7.0, H-22), 1.06 (3 H, d, J 6.5, H-18/19), 1.05 (3 
H, d, J 7.0, H-25/26), 1.01 (3 H, d, J 7.0, H-25/26), 0.90 (3 H, d, J 6.5, H-18/19); δC 
(100 MHz, CDCl3) 165.9 (C-4/7), 162.4 (C-4/7), 162.0 (C-2), 155.1 (C-10), 134.9 (C-
13), 126.6 (C-14), 102.1 (C-3), 78.8 (C-23), 65.5 (C-12), 62.3 (C-9), 61.8 (C-21), 50.1 
(C-6), 44.8 (C-16), 29.7 (C-24), 25.4 (C-17), 23.5 (C-18/19), 22.3 (C-15), 21.4 (C-
18/19), 19.8 (C-25/26), 14.7 (C-25/26), 14.1 (C-22); m/z (ESI) 390 [MH]+. Calcd. for 
C21H32N3O4: 390.2387. Found: [MH]
+, 390.2399 (1.1 ppm error). 
Lab. Book: RD06/054/C1 
 
(8R*,11Z)-9-Ethoxy-8-iso-butyl-11-(2-methylpropylidene)-2,5,8,11-tetrahydro-6H-
oxepino[2,3-d]pyrazino[1,2-a]pyrimidin-6-one 298 
 
To a solution of aldol adduct 294 (0.0970 g, 0.250 mmol, 1.0 
eq.) in pyridine (4 mL) at room temperature was added MsCl 
(0.0390 mL, 0.500 mmol, 2.0 eq.). The reaction mixture was 
stirred at room temperature for 18 h before the addition of 
DBU (0.0740 mL, 0.500 mmol, 2.0 eq.). The reaction mixture 
was heated at 50 °C for 1 h, cooled to room temperature and 
then diluted with EtOAc (10 mL), washed with 1 M HCl (aq.) (3 × 10 mL), brine (10 
mL), dried over MgSO4, filtered and concentrated in vacuo. The crude material was 
purified by flash column chromatography on silica gel (9:1 n-hexane/EtOAc) to furnish 
the title compound 298 (0.0590 g, 64%) as a yellow oil: Rf  0.69 (1:1 PE/EtOAc); 
υmax/cm
-1
 (neat) 2959 (C-H stretch), 1653 (C=O stretch), 1579 (C=C stretch), 1534 
(C=C stretch); δH (400 MHz, CDCl3) 6.49 (1 H, d, J 9.5, H-23), 6.24 (1 H, dt, J 10.0, 
6.0, H-14), 6.03 (1 H, dt, J 10.0, 6.0, H-13), 5.24 (1 H, app. t (dd), J 6.5, H-6), 4.85 (1 
H, dd, J 13.5, 6.0, H-12a), 4.76 (1 H, dd, J 13.5, 6.0, H-12b), 4.31 (2 H, m, H-21), 3.49 
(2 H, d, J 6.0, H-15), 3.18 (1 H, dsept., J 9.5, 6.5, H-24), 1.71-1.63 (1 H, m, H-17), 
1.61-1.59 (2 H, m, H-16), 1.34 (3 H, t, J 7.0, H-22), 1.09 (3 H, d, J 6.5, H-25/26), 1.03 
(3 H, d, J 6.5, H-18/19), 1.01 (3 H, d, J 6.5, H-25/26), 0.87 (3 H, d, J 6.5, H-18/19); δC 
(100 MHz, CDCl3) 166.8 (C-4/7), 162.6 (C-4/7), 161.8 (C-2), 148.9 (C-10), 137.8 (C-
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23), 134.8 (C-14), 131.2 (C-9), 126.7 (C-13), 101.9 (C-3), 65.4 (C-12), 62.4 (C-21), 
50.5 (C-6), 42.2 (C-16), 26.4 (C-24), 24.8 (C-17), 23.4 (C-18/19), 22.5 (C-15), 22.3 (C-
25/26), 21.9 (C-18/19), 21.7 (C-25/26), 14.1 (C-22); m/z (ESI) 372 [MH]+. Calcd. for 
C21H30N3O3: 372.2282. Found: [MH]
+, 372.2290 (2.2 ppm error). 
Lab. Book: RD06/047/C1 
 
(2S*,5R*)-6-Ethoxy-5-iso-butyl-2-methyl-8-[2-methyl-prop-(Z)-ylidene]-5,8,8a,9-
tetrahydro-2H-1-oxa-7,9,10a-triaza-anthracen-10-one 299 
 
To a solution of aldol adduct 294 (0.368 g, 0.950 mmol, 1.0 
eq.) in pyridine (5.0 mL) at room temperature was added 
MsCl (0.146 mL, 1.89 mmol, 2.0 eq.). The reaction mixture 
was stirred at room temperature for 2 h and then at 50 °C for 
30 min before the addition of DBU (0.710 mL, 4.75 mmol, 5.0 
eq.) and further stirring at 50 °C for 30 min. The reaction mixture was cooled to room 
temperature, diluted with EtOAc (20 mL) and washed with 1 M HCl (aq.) (3 × 20 mL), 
sat. NaHCO3 (aq.) (3 × 20 mL), brine (20 mL), dried over MgSO4, filtered and 
concentrated in vacuo. The crude material was purified by flash column 
chromatography on silica gel (12:1 n-hexane/EtOAc) to furnish the title compound 299 
(0.228 g, 70%) as a yellow oil: Rf  0.72 (1:1 PE/EtOAc); υmax/cm
-1
 (neat) 2959 (C-H 
stretch), 2870 (C-H stretch), 1663 (C=O stretch), 1517 (C=C stretch); δH (400 MHz, 
CDCl3) 6.56 (1 H, d, J 9.5, H-22), 6.55 (1 H, d, J 10.0, H-14), 5.41 (1 H, dd, J 10.0, 3.0, 
H-13), 5.29-5.23 (2 H, m, H-6, 12), 4.30 (2 H, m, H-20), 3.19 (1 H, dsept., J 9.0, 7.0, H-
23), 1.68-1.57 (3 H, m, H-15, 16), 1.50 (3 H, d, J 6.5, H-26), 1.33 (3 H, t, J 7.0, H-21), 
1.09 (3 H, d, J 7.0, H-24/25), 1.03 (3 H, d, J 7.0, H-24/25), 0.98 (3 H, d, J 6.5, H-
18/19), 0.86 (3 H, d, J 6.5, H-18/19); δC (100 MHz, CDCl3) 164.1 (C-4/7), 161.7 (C-
4/7), 158.6 (C-2), 151.1 (C-10), 138.9 (C-22), 131.5 (C-9), 121.4 (C-13), 117.9 (C-14), 
97.7 (C-3), 74.9 (C-12), 62.4 (C-20), 50.1 (C-6), 42.3 (C-15), 26.4 (C-23), 24.7 (C-16), 
23.2 (C-18/19), 22.2 (C-24/25), 21.8 (C-26), 21.8 (C-24/25), 21.7 (C-18/19), 14.0 (C-
21); m/z (ESI) 372 [MH]+. Calcd. for C21H30N3O3: 372.2282. Found: [MH]
+, 372.2287 
(1.1 ppm error). 
Lab. Book:  RD06/092/C1 
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(8R*,11Z)-8-iso-Butyl-11-(2-methylpropylidene)-2,5,10,11-tetrahydro-6H-
oxepino[2,3-d]pyrazino[1,2-a]pyrimidine-6,9(8H)-dione – ‘Dihydro-janoxepin’ 49 
 
A solution of imidate 298 (0.102 g, 0.270 mmol, 1.0 eq.) in 
AcOH (4 mL) and water (1 mL) was heated at 50 °C for 1 h. 
The reaction mixture was cooled to room temperature and 
concentrated in vacuo before purification by flash column 
chromatography on silica gel (1:1 n-hexane/EtOAc) to furnish 
the title compound 49 (0.0680 g, 73%) as a yellow solid: mp 
164-166 °C; Rf  0.39 (1:1 PE/EtOAc); υmax/cm
-1
 (neat) 3191 (N-H stretch), 2961 (C-H 
stretch), 1689 (C=O stretch), 1649 (C=O stretch), 1536 (C=C stretch); δH (400 MHz, 
CDCl3) 8.98 (1 H, br s, H-8), 6.31 (1 H, d, J 10.5, H-20), 6.25 (1 H, dt, J 10.0, 6.0, H-
14), 6.05 (1 H, dt, J 10.0, 6.5, H-13), 5.34 (1 H, ddd, J 9.0, 5.5, 1.0, H-6), 4.86 (1 H, dd, 
J 13.5, 6.5, H-12a), 4.77 (1 H, dd, J 13.5, 6.5, H-12b), 3.50 (2 H, dd, J 6.0, 4.5, H-15), 
2.73 (1 H, dsept., J 10.5, 6.5, H-21), 1.86-1.74 (1 H, m, H-17), 1.71-1.58 (2 H, m, H-
16), 1.11 (3 H, d, J 6.5, H-22/23), 1.10 (3 H, d, J 6.5, H-22/23), 1.07 (3 H, d, J 6.5, H-
18/19), 0.92 (3 H, d, J 6.5, H-18/19); δC (100 MHz, CDCl3) 166.8 (C-4/7), 166.4 (C-
4/7), 162.2 (C-2), 146.7 (C-10), 135.0 (C-13), 127.9 (C-20), 126.7 (C-14), 123.8 (C-9), 
102.7 (C-3), 65.5 (C-12), 54.1 (C-6), 42.5 (C-16), 26.1 (C-21), 24.8 (C-17), 23.2 (C-
18/19), 22.5 (C-15), 22.2 (C-22/23), 22.0 (C-22/23), 21.2 (C-18/19); m/z (ESI) 344 
[MH]+. Calcd. for C19H26N3O3: 344.1969. Found: [MH]
+, 344.1968 (0.1 ppm error). 
Lab. Book: RD06/083/C1 
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(8R*,11Z)-9-Ethoxy-8-iso-butyl-11-(2-methylpropylidene)-2,3,4,5,8,11-hexahydro-
6H-oxepino[2,3-d]pyrazino[1,2-a]pyrimidin-6-one 300 
 
To a solution of dihydro-oxepine 298 (0.0540 g, 0.140 mmol, 
1.0 eq.) in EtOAc (4 mL) was added 3% Pd/C (0.012 g, 0.004 
mmol, 2.5 mol%) and the reaction mixture was placed under 
an atmosphere of H2. After stirring at room temperature for 1 
h the reaction mixture was filtered through Celite® and 
concentrated in vacuo. The crude product was purified by 
flash column chromatography on silica gel (17:3 PE/EtOAc) to furnish the title 
compound 300 (0.0430 g, 82%) as a yellow oil: Rf 0.32 (4:1 PE/EtOAc); υmax/cm
-1 
(neat) 2958 (C-H stretch), 1651 (C=O stretch), 1579 (C=C stretch), 1531 (C=C stretch); 
δH (400 MHz, CDCl3) 6.50 (1 H, d, J 9.5, H-23), 5.25 (1 H, app. t (dd), J 6.5, H-6), 
4.35-4.24 (4 H, m, H-21, 12), 3.19 (1 H, dsept., J 9.5, 6.5, H-24), 2.75-2.72 (2 H, m, H-
15), 2.06-1.89 (2 H, m, H-14), 1.87-1.81 (2 H, m H-13), 1.70-1.57 (3 H, m, H-16, H-
17), 1.33 (3 H, t, J 7.0, H-22), 1.08 (3 H, d, J 6.5, H-25/26), 1.02 (3 H, d, J 6.5, H-
18/19), 0.99 (3 H, d, J 6.5, H-25/26), 0.85 (3 H, d, J 6.5, H-18/19); δC (100 MHz, 
CDCl3) 168.7 (C-4/7), 163.2 (C-4/7), 161.8 (C-2), 148.6 (C-10), 137.6 (C-23), 131.4 
(C-9), 105.9 (C-3), 71.2 (C-21), 62.4 (C-12), 50.4 (C-6), 42.2 (C-16), 29.0 (C-14), 26.4 
(C-24), 24.8 (C-17), 23.8 (C-13), 23.4 (C-18/19), 22.3 (C-15), 22.2 (C-25/26), 21.9 (C-
18/19), 21.7 (C-25/26), 14.1 (C-22); m/z (ESI) 374 [MH]+. Calcd. for C21H32N3O3: 
374.2438. Found: [MH]+, 374.2422 (4.5 ppm error).   
Lab Book: RD09/057/C1 
 
(8R*,11Z)-8-iso-Butyl-11-(2-methylpropylidene)-2,3,4,5,10,11-hexahydro-6H-
oxepino[2,3-d]pyrazino[1,2-a]pyrimidine-6,9(8H)-dione – ‘Tetrahydro-janoxepin’ 
301 
 
A solution of tetrahydro-oxepine 300 (0.0260 g, 0.0690 mmol, 
1.0 eq.) in AcOH (0.8 mL) and water (0.2 mL) was heated at 50 
°C for 1 h before being concentrated in vacuo. The crude 
product was purified by flash column chromatography on silica 
gel (3:2 PE/EtOAc) to furnish the title compound 301 (0.0200 g, 
84%) as a pale yellow crystalline solid: mp 169-170 °C; Rf 0.12 
(4:1 PE/EtOAc); υmax/cm
-1 (neat) 3189 (broad, N-H stretch), 2960 (C-H stretch), 1689 
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(C=O stretch), 1655 (C=O stretch), 1581 (N-H bend), 1533 (C=C stretch); δH (400 
MHz, CDCl3) 9.19 (1 H, br. s, H-8), 6.33 (1 H, d, J 10.5, H-20), 5.36 (1 H, dd, J 9.0, 
5.5, H-6), 4.41-4.31 (2 H, m, H-12), 2.80-2.71 (3 H, m, H-21, 15), 2.08-2.00 (1 H, m, 
H-13a), 1.98-1.92 (1 H, m, H-13b), 1.90-1.84 (2 H, m, H-14), 1.82-1.77 (1 H, m, H-17), 
1.71-1.59 (2 H, m, H-16), 1.11 (3 H, d, J 6.5, H-22/23), 1.10 (3 H, d, J 6.5, H-22/23), 
1.08 (3 H, d, J 6.5, H-18/19), 0.92 (3 H, d, J 6.5, H-18/19); δC (100 MHz, CDCl3) 168.3 
(C-4/7), 166.7 (C-4/7), 162.8 (C-2), 146.3 (C-10), 127.7 (C-20), 124.0 (C-9), 106.9 (C-
3), 71.4 (C-12), 54.0 (C-6), 42.6 (C-16), 28.9 (C-13), 26.1 (C-21), 24.8 (C-17), 23.7 (C-
14), 23.2 (C-18/19), 22.4 (C-15), 22.2 (C-22/23), 22.0 (C-22/23), 21.2 (C18/19); m/z 
(ESI) 346 [MH]+. Calcd. for C19H28N3O3: 346.2125. Found: [MH]
+, 346.2113 (3.5 ppm 
error).   
Lab Book: RD09/066/C1 
6.3 Chapter 4 – Dihydro-Oxepine Elaboration: The Synthesis of (±)-Janoxepin (1) 
 
(3S*,4S*,8R*,11R*)-3,4-Dibromo-9-ethoxy-11-[(1S)-1-hydroxy-2-methylpropyl]-8-
iso-butyl-2,3,4,5,8,11-hexahydro-6H-oxepino[2,3-d]pyrazino[1,2-a]pyrimidin-6-one 
306 
 
To a solution of dihydro-oxepine 294 
(0.0470 g, 0.120 mmol, 1.0 eq.) in DCM 
(2.0 mL) was added pyridine 
hydrotribromide (0.0420 g, 0.132 mmol, 
1.1 eq.). The reaction mixture was stirred 
at room temperature for 1 h, diluted with 
EtOAc (10 mL), washed with sat. NaHCO3 (aq.) (10 mL) and brine (10 mL), dried over 
MgSO4, filtered and concentrated in vacuo. The crude material was purified by flash 
column chromatography on silica gel (4:1 PE/EtOAc) to furnish the title compound 306 
(0.0450 g, 68%) as a pale yellow crystalline solid (1:1 mixture of diastereomers): mp 
75-77 °C; Rf 0.57 (4:1 PE/EtOAc); υmax/cm
-1
 (neat) 3454 (O-H stretch), 2961 (C-H 
stretch), 1663 (C=O stretch), 1596 (C=C stretch), 1545 (C=N stretch); δH (400 MHz, 
CDCl3) 5.07-4.97 (2 H, m, H-6, 6a), 4.70-4.55 (6 H, m, H-9, 9’, 12a, 12’a, 13, 13’), 
4.49 (2 H, m, H-14, 14’), 4.43-4.38 (2 H, m, H-12a, 12’a), 4.23-4.19 (4 H, m, H-21, 
21’), 3.55-3.39 (6 H, m, H-15, 15’, 23, 23’), 2.13 (1 H, sept.d, J 7.0, 3.5, H-24), 2.12 (1 
H, sept.d, J 7.0, 3.5, H-24’), 1.93-1.78 (2 H, m, H-17, 17’), 1.76-1.66 (2 H, m, H-16, 
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16’), 1.62-1.51 (2 H, m, H-16a, 16’a), 1.30 (6 H, app. t, J 7.0, H-22, 22’), 1.08-1.01 (18 
H, m, H-18, 18’, 25, 25’, 26, 26’), 0.91 (3 H, d, J 6.5, H-19), 0.90 (3 H, d, J 6.5, H-19’); 
δC (100 MHz, CDCl3) 167.4 (C-4/7), 167.3 (C-4’/7’), 162.6 (C-4/7), 162.5 (C-4’/7’), 
161.9 (C-2), 161.8 (C-2’), 156.8 (C-10), 156.7 (C-10’), 104.3 (C-3), 104.2 (C-3’), 79.0 
(C-23), 78.7 (C-23’), 70.8 (C-12), 70.5 (C-12’),  62.8 (C-13/14), 62.6 (C-13’/14’), 62.5 
(C-21), 62.0 (C-21’), 53.7 (C-13/14), 53.0 (C-13’/14’), 50.5 (C-6), 50.2 (C-6’), 50.2 (C-
9), 50.0 (C-9’), 45.0 (C-16), 44.8 (C-16’), 29.9 (C-24), 29.7 (C-24’), 27.9 (C-15), 27.2 
(C-15’), 25.4 (C-17), 25.3 (C-17’), 23.5 (C-18/19), 23.4 (C-18’/19’), 21.7 (C-18/19), 
21.7 (C-18’/19’), 21.4 (C-25/26), 21.3 (C-25’/26’), 19.9 (d, C-25/26), 19.8 (d, C-
25’/26’), 14.1 (d, C-22, 22’); m/z (ESI) 548 [MH]+. Calcd. for C21H32
79Br2N3O4: 
548.0754. Found: [MH]+, 548.0764 (1.8 ppm error).   
Lab. Book: RD07/005/C1 
 
 
(2E)-4-[(6R*,9Z)-7-Ethoxy-2-hydroxy-6-iso-butyl-9-(2-methylpropylidene)-4-oxo-
6,9-dihydro-4H-pyrazino[1,2-a]pyrimidin-3-yl]but-2-enal 307 
 
To a solution of dibromide 306 (0.0280 g, 0.0500 mmol, 1.0 
eq.) in DMSO (1 mL) was added TBAF (1 M solution in THF, 
0.210 mL, 0.210 mmol, 4.1 eq.). The reaction mixture was 
stirred at room temperature for 30 min and quenched by the 
addition of 1 M HCl (aq.) (10 mL) and extracted with EtOAc 
(3 × 10 mL). The combined organic phase was washed with 1 
M HCl (aq.) (3 × 10 mL), brine (10 mL), dried over MgSO4, 
filtered and concentrated in vacuo. The crude material was purified by flash column 
chromatography on silica gel (3:2 PE/EtOAc) to furnish the title compound 307 (0.0090 
g, 47%) as an orange film: Rf 0.57 (1:1 PE/EtOAc); υmax/cm
-1
 (neat) 2960 (C-H stretch), 
1691 (C=O stretch), 1656 (C=O stretch), 1523 (C=C stretch), 1446 (C=N stretch); δH 
(400 MHz, CDCl3) 9.49 (1 H, d, J 8.0, H-14), 6.93 (1 H, dt, J 15.5, 6.0, H-12), 6.34 (1 
H, dd, J 9.5, 2.5, H-22), 6.11 (1 H, ddt, J 15.5, 8.0, 1.5, H-13), 5.33 (1 H, dd, J 8.5, 5.5, 
H-6), 4.35-4.31 (2 H, m, H-20), 3.49 (2 H, ddd, J 6.0, 3.5, 1.5, H-11), 3.23 (1 H, dsept., 
J 9.5, 6.5, H-23), 1.70-1.63 (1 H, m, H-16), 1.61-1.54 (2 H, m, H-15), 1.36 (3 H, t, J 
7.0, H-21), 1.14 (3 H, d, J 6.5, H-24/25), 1.04 (3 H, d, J 6.5, H-24/25), 1.03 (3 H, d, J 
6.5, H-17/18), 0.90 (3 H, d, J 6.5, H-17/18); δC (100 MHz, CDCl3) 194.1 (C-14), 163.7 
(C-4/7), 162.9 (C-4/7), 160.8 (C-2), 155.3 (C-12), 150.9 (C-10), 139.6 (C-22), 132.8 (C-
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13), 130.0 (C-9), 96.5 (C-3), 63.0 (C-20), 50.6 (C-6), 41.9 (C-15), 26.6 (C-11), 26.5 (C-
23), 25.0 (C-16), 23.3 (C-17/18), 22.1 (C-24/25), 21.8 (C-24/25), 21.5 (C-17/18), 14.1 
(C-21); m/z (ESI) 388 [MH]+. Calcd. for C21H30N3O4: 388.2231. Found: [MH]
+, 
388.2239 (1.6 ppm error).   
Lab. Book: RD07/010/C1 
 
 
(3S*,4S*,8R*,11Z)-3,4-Dibromo-9-ethoxy-8-iso-butyl-11-(2-methylpropylidene)-
2,3,4,5,8,11-hexahydro-6H-oxepino[2,3-d]pyrazino[1,2-a]pyrimidin-6-one 310 
 
To a solution of dibromide 306 (0.0600 g, 0.110 mmol, 1.0 eq.) 
in DCM (2.0 mL) was added DBU (0.0670 mL, 0.450 mmol, 
4.1 eq.). The reaction mixture was stirred at room temperature 
for 30 min before being quenched by the addition of 10% HCl 
(aq.) (10 mL). The organic phase was separated and the 
aqueous phase extracted with DCM (3 × 10 mL). The 
combined organic phase was washed with 10% HCl (aq.) (3 × 10 mL) and brine (10 
mL), dried over MgSO4, filtered and concentrated in vacuo. The crude product was 
purified by flash column chromatography on silica gel (19:1 PE/EtOAc) to furnish the 
title compound 310 (0.0220 g, 38%) as an orange film (single diastereomer): Rf 0.32 
(19:1 PE/EtOAc); υmax/cm
-1
 (neat) 2959 (C-H stretch), 1657 (C=O stretch), 1587 (C=C 
stretch), 1537 (C=N stretch); δH (400 MHz, CDCl3) 6.60 (1 H, d, J 9.5, H-23), 5.23 (1 
H, dd, J 7.5, 6.0, H-6), 4.65 (1 H, ddd, J 5.0, 4.0, 2.5, H-13), 4.52 (1 H, dd, J 12.5, 2.5, 
H-12a), 4.39 (1 H, dd, J 12.5, 5.0, H-12b), 4.36-4.26 (2 H, m, H-21), 4.00 (1 H, dd, J 
11.5, 3.0, H-15a), 3.82 (1 H, dd, J 11.5, 8.0, H-15b), 3.52 (1 H, ddd, J 8.0, 4.0, 3.0, H-
14), 3.20 (1 H, dsept., J 9.5, 6.5, H-24), 1.73-1.63 (1 H, m, H-17), 1.60-1.57 (2 H, m, H-
16), 1.35 (3 H, t, J 7.0, H-22), 1.09 (3 H, d, J 6.5, H-25/26), 1.04 (3 H, d, J 6.5, H-
18/19), 1.01 (3 H, d, J 6.5, H-25/26), 0.87 (3 H, d, J 6.5, H-18/19); δC (100 MHz, 
CDCl3) 164.0 (C-4/7), 161.7 (C-4/7), 161.1 (C-2), 151.3 (C-10), 139.4 (C-23), 131.4 
(C-9), 95.2 (C-3), 68.1 (C-12), 62.6 (C-21), 50.2 (C-6), 44.0 (C-15), 42.5 (C-16), 42.4 
(C-14), 41.4 (C-13), 26.5 (C-24), 24.9 (C-17), 23.3 (C-18/19), 22.3 (C-25/26), 21.8 (C-
25/26), 21.6 (C-18/19), 14.1 (C-22); m/z (ESI) 530 [MH]+. Calcd. for C21H30
79Br2N3O3: 
530.0648. Found: [MH]+, 530.0668 (3.6 ppm error).   
Lab. Book: RD07/014/C2 
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(6R*,7S*)-6,7-Dihydroxy-2-phenyl-3-propyl-5,6,7,8-tetrahydrooxepino[2,3-
d]pyrimidin-4(3H)-one 320 
 
To a solution of dihydro-oxepine 197 (0.195 g, 0.690 mmol, 1.0 
eq.) in acetone (3.8 mL) and water (1.2 mL) was added NMO 
(0.105 g, 0.900 mmol, 1.3 eq.) and OsO4 (0.105 mL, 4% w/w 
solution in water, 0.0170 mmol, 0.025 eq.). The reaction mixture 
was stirred at room temperature for 20 min before being filtered 
through Celite® and concentrated in vacuo. The crude product 
was purified by flash column chromatography on silica gel (19:1 EtOAc/MeOH) to 
furnish the title compound 320 (0.185 g, 85%) as a pale yellow crystalline solid: mp 
142-144 oC; Rf  0.10 (19:1 EtOAc/MeOH); υmax/cm
-1
 (neat) 3397 (broad, O-H stretch), 
2967 (C-H stretch), 1641 (C=O stretch), 1592 (aromatic C=C stretch), 1539 (C=C 
stretch); δH (400 MHz, CDCl3) 7.51-7.43 (5 H, m, H-8, 9, 10), 4.31 (1 H, dd, J 11.0, 2.5, 
H-15a), 4.20-4.11 (3 H, m, H-15b, 16, 17), 3.86 (2 H, dd, J 9.5, 6.0, H-11), 3.24 (1 H, 
dd, J 16.0, 9.0, H-18a), 2.85 (1 H, dd, J 16.0, 2.0, H-18b), 1.65-1.59 (2 H, m, H-12), 
0.75 (3 H, t, J 7.5, H-13); δC (100 MHz, CDCl3) 167.5 (C-4), 165.0 (C-6), 158.2 (C-2), 
134.2 (C-7), 130.2 (C-10), 128.6 (C-9), 127.7 (C-8), 103.9 (C-5), 71.1 (C-15), 70.6 (C-
16), 68.5 (C-17), 48.2 (C-11), 26.3 (C-18), 21.9 (C-12), 11.1 (C-13); m/z (ESI) 317 
[MH]+. Calcd. for C17H21N2O4: 317.1496. Found: [MH]
+, 317.1483 (4.0 ppm error). 
Lab. Book: RD04/048/C1 
 
 (6R*,7S*)-4-Oxo-2-phenyl-3-propyl-3,4,5,6,7,8-hexahydrooxepino[2,3-
d]pyrimidine-6,7-diyl dimethanesulfonate 322 
 
To a solution of diol 320 (0.178 g, 0.560 mmol, 1.0 eq.) in DCM 
(8 mL) was added NEt3 (0.315 mL, 2.26 mmol, 4.0 eq.), MsCl 
(0.175 mL, 2.26 mmol, 4.0 eq.) and DMAP (0.007 g, 0.06 mmol, 
0.1 eq.). The reaction mixture was stirred at room temperature 
for 1 h before being quenched by the addition of sat. NaHCO3 
(aq.) (10 mL). The organic phase was separated and the aqueous 
phase extracted with DCM (3 × 10 mL). The combined organic 
phase was washed with water (15 mL), sat. NH4Cl (aq.) (15 mL) 
and brine (15 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude 
material was purified by flash column chromatography on silica gel (7:3 EtOAc/n-
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hexane) to furnish the title compound 322 (0.251 g, 95%) as a colourless crystalline 
solid: mp 65-68 °C; Rf  0.65 (9:1 EtOAc/MeOH); υmax/cm
-1
 (neat) 2968 (C-H stretch), 
1656 (C=O stretch), 1597 (aromatic C=C stretch), 1541 (C=C stretch); δH (400 MHz, 
CDCl3) 7.55-7.45 (5 H, m, H-8, 9, 10), 5.22 (1 H, ddd, J 9.0, 2.5, 1.5, H-17), 5.17 (1 H, 
ddd, J 8.0, 4.0, 2.5, H-16), 4.38 (1 H, d, J 13.0, 4.0, H-15a), 4.26 (1 H, dd, J 13.0, 8.0, 
H-15b), 3.88 (2 H, ddd, J 9.0, 6.5, 3.0, H-11), 3.56 (1 H, dd, J 16.0, 9.0, H-18a), 3.19 (3 
H, s, H-19/20), 3.16 (3 H, s, H-19/20), 2.93 (1 H, dd, J 16.0, 1.5, H-18b), 1.68-1.57 (2 
H, m, H-12), 0.77 (3 H, t, J 7.5, H-13); δC (100 MHz, CDCl3) 167.2 (C-4), 164.1 (C-6), 
159.2 (C-2), 133.9 (C-7), 130.3 (C-10), 128.7 (C-9), 127.5 (C-8), 103.4 (C-5), 76.4 (C-
16), 75.5 (C-17), 67.9 (C-15), 48.3 (C-11), 39.1 (C-19/20), 38.7 (C-19/20), 24.3 (C-18), 
21.8 (C-12), 10.9 (C-13); m/z (ESI) 517 [MHCOO]–. Calcd. for C20H25N2O10S2: 
517.0596. Found: [MHCOO]–, 517.0963 (1.8 ppm error). 
Lab. Book: RD04/061/C1 
 
(3R*,4S*,8R*,11Z)-3,4-Dihydroxy-8-iso-butyl-11-(2-methylpropylidene)-
2,3,4,5,10,11-hexahydro-6H-oxepino[2,3-d]pyrazino[1,2-a]pyrimidine-6,9(8H)-
dione 323 
 
To a solution of ‘dihydro-janoxepin’ 49 
(0.0680 g, 0.200 mmol, 1.0 eq.) in tert-
butanol (2.2 mL), THF (0.6 mL) and water 
(0.2 mL) at room temperature was added 
NMO (0.0240 g, 0.210 mmol, 1.05 eq.) 
followed by OsO4 (0.0120 mL, 4% w/w 
solution in water, 0.01 eq.). The reaction mixture was stirred at room temperature for 1 
h before the addition of sat. NaHSO3 (aq.) (10 mL). After 30 min the reaction mixture 
was extracted with EtOAc (3 × 10 mL) and the combined organic phase washed with 
brine (10 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude 
material was purified by flash column chromatography on silica gel (98:2 
EtOAc/MeOH) to furnish the title compound 323 (0.0440 g, 58%) as a colourless solid 
(1:1 mixture of diastereomers): mp 105-107 °C; Rf  0.16 (EtOAc); υmax/cm
-1
 (neat) 3396 
(broad, O-H/N-H stretch), 2961 (C-H stretch), 1689 (C=O stretch), 1646 (C=O stretch), 
1584 (C=C stretch), 1533 (C=C stretch); δH (400 MHz, CDCl3) 8.48 (1 H, s, H-8), 8.47 
(1 H, s, H-8’),  6.24 (1 H, d, J 10.5, H-20), 6.20 (1 H, d, J 10.5, H-20’), 5.35 (2 H, app. 
dt, J 9.0, 5.0, H-6, 6’), 4.22-3.96 (8 H, m, H-12, 12’, 13, 13’, 14, 14’), 3.21 (1 H, dd, J 
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16.0, 8.5, H-15a), 3.19 (1 H, dd, J 16.0, 8.5, H-15’a), 2.91-2.65 (4 H, m, H-21, 21’, 15b, 
15’b), 1.77-1.56 (6 H, m, H-16, 16’, 17, 17’), 1.10 (12 H, app. d, J 6.5, H-22/23, 
22’/23’), 1.03 (6 H, app. d, J 6.5, H-18/19), 0.92 (6 H, app. d, J 6.5, H-18’/19’); δC (100 
MHz, CDCl3) 168.2 (C-4/7), 168.1 (C-4’/7’), 166.7 (d, C-4/7, 4’/7’), 163.2 (C-2), 163.1 
(C-2’), 149.3 (C-10), 149.1 (C-10’), 130.1 (C-20), 130.0 (C-20’), 125.9 (C-9), 125.8 (C-
9’), 103.5 (C-3), 103.3 (C-3’), 71.5 (C-12), 71.0 (C-12’), 70.8 (C-13/14), 70.2 (C-
13’/14’), 68.4 (C-13/14), 68.3 (C-13’/14’), 54.4 (C-6), 54.2 (C-6’), 42.5 (C-16), 42.4 
(C-16’), 26.1 (d, C-15, 15’), 24.8 (d, C-21, 21’), 23.2 (d, C-17, 17’), 22.1 (d, C-18, 19), 
22.0 (d, C-22, 23), 21.3 (d, C-22’, 23’), 22.2 (d, C-18’, 19’); m/z (ESI) 378 [MH]+. 
Calcd. for C19H28N3O5: 378.2023. Found: [MH]
+, 378.2031 (1.9 ppm error).  
Lab. Book: RD06/084/C1 
 
(3R*,4S*,8R*,11Z)-9-Ethoxy-3,4-dihydroxy-8-iso-butyl-11-(2-methylpropylidene)-
2,3,4,5,8,11-hexahydro-6H-oxepino[2,3-d]pyrazino[1,2-a]pyrimidin-6-one 324 
 
To a solution of dihydro-oxepine 298 
(0.0670 g, 0.180 mmol, 1.0 eq.) in tert-
butanol (2.2 mL), THF (0.6 mL) and water 
(0.2 mL) was added NMO (0.0220 g, 0.190 
mmol, 1.05 eq.) and OsO4 (0.011 mL, 4% 
w/w solution in water, 0.002 mmol, 0.01 
eq.). The reaction mixture was stirred at 
room temperature for 1 h before the addition of sat. NaHSO3 (aq.) (10 mL). After 30 
min the reaction mixture was extracted with EtOAc (3 × 10 mL) and the combined 
organic phase washed with brine (10 mL), dried over MgSO4, filtered and concentrated 
in vacuo. The crude product was purified by flash column chromatography on silica gel 
(4:1 EtOAc/n-hexane) to furnish the title compound 324 (0.0450 g, 62%) as a pale 
yellow waxy solid (1:1 mixture of diastereomers): Rf  0.33 (EtOAc); υmax/cm
-1
 (neat) 
3414 (broad, O-H stretch), 2959 (C-H stretch), 1654 (C=O stretch), 1581 (C=C stretch), 
1530 (C=C stretch); δH (400 MHz, CDCl3) 6.53 (1 H, d, J 9.5, H-23), 6.51 (1 H, d, J 
9.5, H-23’), 4.39-4.26 (6 H, m, H-12a, 12’a, 21, 21’), 4.20-4.06 (6 H, m, H-12b, 12’b, 
H-13, 13’, H-14, 14’), 3.24-3.13 (4 H, m, H-24, 24’, H-15a, 15’a), 2.83-2.76 (4 H, m, 
H-15’b, 15’b, 27, 27’), 2.56 (1 H, d, J 4.0, H-28), 5.52 (1 H, d, J 4.0, H-28’), 1.70-1.64 
(2 H, m, H-17, 17’), 1.61-1.57 (4 H, m, H-16, 16’), 1.35 (6 H, app. t, J 7.0, H-22, 22’), 
1.11 (3 H, d, J 7.0, H-25/26), 1.10 (3 H, d, J 7.0, H-25’/26’), 1.04 (3 H, d, J 7.0, H-
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25/26), 1.03 (3 H, d, J 7.0, H-25’/26’), 1.01 (3 H, d, J 6.5, H-18/19), 1.00 (3 H, d, J 6.5, 
H-18’/19’), 0.87 (6 H, app. d, J 6.5, H-18/19, 18’/19’); δC (100 MHz, CDCl3) 168.6 (C-
4/7), 168.5 (C-4’/7’), 163.4 (d, C-4/7, 4’/7’), 161.7 (d, C-2, 2’), 149.7 (C-10), 149.5 (C-
10’), 138.5 (C-9), 138.4 (C-9’), 131.3 (C-23), 131.2 (C-23’), 102.4 (C-3), 102.1 (C-3’), 
71.3 (C-12), 70.9 (C-12’), 70.8 (C-13/14), 70.3 (C-13’/14’), 68.5 (C-13/14), 68.4 (C-
13’/14’), 62.5 (d, C-21, 21’), 50.8 (C-6), 50.7 (C-6’), 42.2 (C-16), 42.1 (C-16’), 26.4 (d, 
C-24, 24’), 26.3 (C-15), 26.2 (C-15’), 24.8 (d, C-17, 17’), 23.3 (d, C-18/19, 18’/19’), 
22.3 (d, C-25/26, 25’/26’), 21.8 (d, C-18/19, 18’/19’), 21.6 (d, C-25/26, 25’/26’), 14.1 
(d, C-22, 22’); m/z (ESI) 406 [MH]+. Calcd. for C21H32N3O5: 406.2336. Found: [MH]
+, 
406.2348 (1.8 ppm error). 
Lab. Book:  RD06/069/C2 
 
(3R*,4S*,8R*,11Z)-9-Ethoxy-8-iso-butyl-11-(2-methylpropylidene)-6-oxo-
2,3,4,5,8,11-hexahydro-6H-oxepino[2,3-d]pyrazino[1,2-a]pyrimidine-3,4-diyl 
dimethanesulfonate 325 
 
To a solution of diol 324 (0.0380 g, 
0.0940 mmol, 1.0 eq.) in pyridine 
(1.5 mL) was added MsCl (0.0360 
mL, 0.470 mmol, 5.0 eq.). The 
reaction mixture was stirred at 
room temperature for 4 h before 
being diluted with EtOAc (10 mL), 
washed with 1 M HCl (aq.) (3 × 10 mL), brine (10 mL), dried over MgSO4, filtered and 
concentrated in vacuo. The crude material was purified by flash column 
chromatography on silica gel (3:2 PE/EtOAc) to furnish the title compound 325 (0.0400 
g, 76%) as a pale yellow film (1:1 mixture of diastereomers): Rf  0.66 (EtOAc); υmax/cm
-
1
 (neat) 2960 (C-H stretch), 1656 (C=O stretch), 1586 (C=C stretch), 1531 (C=C 
stretch); δH (400 MHz, CDCl3) 6.57 (1 H, d, J 9.5, H-23), 6.54 (1 H, d, J 9.5, H-23’),  
5.25 (1 H, dd, J 8.0, 5.5, H-6), 5.24 (1 H, dd, J 8.0, 5.5, H-6’), 5.19-5.12 (4 H, m, H-13, 
13’, 14, 14’), 4.39-4.21 (8 H, m, H-12, 12’, 21, 21’), 3.47 (2 H, dd, J 16.0, 9.0, 1.0, H-
15a, 15’a), 3.24-3.15 (2 H, m, H-24, 24’), 3.18 (3 H, s, H-27/28), 3.17 (3 H, s, H-
27’/28’), 3.11 (3 H, s, H-27/28), 3.10 (3 H, s, H-27’/28’), 2.88 (1 H, dd, J 16.0, 2.0, H-
15b), 2.87 (1 H, dd, J 16.0, 2.0, H-15’b), 1.65-1.53 (6 H, m, H-16, 16’, 17, 17’), 1.35 (3 
H, t, J 7.0, H-22), 1.34 (3 H, t, J 7.0, H-22’), 1.11 (3 H, d J 6.5, H-25/26), 1.10 (3 H, d J 
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6.5, H-25’/26’), 1.05 (3 H, d, J 7.0, H-18/19), 1.04 (3 H, d, J 7.0, H-18’/19’), 1.01 (3 H, 
t, J 7.0, H-18/19), 0.99 (3 H, d, J 7.0, H-18’/19’), 0.88 (3 H, d J 6.5, H-25/26), 0.87 (3 
H, d J 6.5, H-25’/26’); δC (100 MHz, CDCl3) 168.4 (C-4/7), 168.3 (C-4’/7’), 162.8 (C-
4/7), 162.7 (C-4’/7’), 161.7 (d, C-2, 2’), 150.9 (C-10), 150.7 (C-10’), 139.6 (C-23), 
139.4 (C-23’), 131.4 (C-9), 131.3 (C-9’), 102.0 (C-3), 101.7 (C-3’), 76.6 (C-13/14), 
76.4 (C-13’/14’), 75.7 (C-13/14), 75.5 (C-13’/14’), 68.2 (C-12), 68.1 (C-12’), 62.8 (d, 
C-21, 21’), 51.0 (C-6), 50.9 (C-6’), 42.4 (C-16), 42.2 (C-16’), 39.3 (C-27/28), 39.1 (C-
27’/28’), 38.9 (d, C-27/28, 27’/28’), 26.6 (d, C-24, 24’), 25.0 (C-17), 24.9 (C-17’), 24.4 
(C-15), 24.3 (C-15’), 23.5 (C-18/19), 23.3 (C-18’/19’), 22.3 (d, C-25/26, 25’/26’), 22.0 
(C-18/19), 21.9 (C-18’/19’), 21.7 (d, C-25/26, 25’/26’), 14.2 (d, C-22, 22’); m/z (ESI) 
562 [MH]+. Calcd. for C23H36N3O9S2: 562.1887. Found: [MH]
+, 562.1886 (0.2 ppm 
error). 
Lab. Book: RD06/071/C1 
 
 
(3R*,4S*,8R*,11Z)-8-iso-Butyl-11-(2-methylpropylidene)-6,9-dioxo-
2,3,4,5,8,9,10,11-octahydro-6H-oxepino[2,3-d]pyrazino[1,2-a]pyrimidine-3,4-diyl 
dimethanesulfonate 326 
To a solution of diol 323 (0.0400 
g, 0.100 mmol, 1.0 eq.) in pyridine 
(1.5 mL) was added MsCl (0.0380 
mL, 0.500 mmol, 5.0 eq.). The 
reaction mixture was stirred at 
room temperature for 2 h before 
being diluted with EtOAc (10 mL), 
washed with 1 M HCl (aq.) (3 × 10 mL), sat. NaHCO3 (aq.) (3 × 10 mL) and brine (10 
mL), dried over MgSO4, filtered and concentrated in vacuo to furnish the title 
compound 326 (0.0530 g, 98%) as a colourless waxy solid (1:1 mixture of 
diastereomers) which was used without further purification: Rf  0.50 (EtOAc); υmax/cm
-1
 
(neat) 3402 (N-H stretch), 2961 (C-H stretch), 1689 (broad, C=O stretch), 1586 (C=C 
stretch), 1534 (C=C stretch); δH (400 MHz, CDCl3) 8.45 (1 H, s, H-8), 8.38 (1 H, s, H-
8’), 6.39 (1 H, d, J 10.0, H-20), 6.37 (1 H, d, J 10.0, H-20’),  5.36 (1 H, dd, J 9.0, 5.5, 
H-6), 5.35 (1 H, d, J 9.0, 5.5, H-6’), 5.20-5.14 (4H, m, H-13, 13’, 14, 14’), 4.39 (1 H, 
dd, J 12.5, 3.5, H-12a), 4.36 (1 H, dd, J 12.5, 3.5, H-12’a), 4.27 (1 H, dd, J 13.5, 6.0, H-
12b), 4.25 (1 H, dd, J 13.5, 6.0, H-12’b), 3.49 (1 H, 2 dd, J 16.0, 9.0, H-15a), 3.47 (1 H, 
dd, J 16.0, 9.0, H-15’a), 3.19 (6 H, br s, H-24/25, 24’/25’), 3.12 (3 H, s, H-24/25), 3.11 
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(3 H, s, H-24’/25’), 2.90 (2 H, app. dd, J 16.0, 3.5, H-15b, 15’b), 2.74-2.64 (2 H, m, H-
21, 21’), 1.82-1.61 (6 H, m, H-16, 16’, 17, 17’), 1.14 (6 H, app. d, J 6.5, H-22/23), 1.13 
(6 H, app. d, J 6.5, H-22’/23’), 1.07 (3 H, d, J 6.5, H-18/19), 1.05 (3 H, d, J 6.5, H-
18’/19’), 0.93 (3 H, d, J 6.5, H-18/19), 0.92 (3 H, d, J 6.5, H-18’/19’); δC (100 MHz, 
CDCl3) 168.0 (C-4/7), 167.9 (C-4’/7’), 165.9 (d, C-4/7, 4’/7’), 162.7 (C-2), 162.4 (C-
2’), 147.5 (C-10), 147.4 (C-10’), 128.7 (d, C-20, 20’), 123.8 (d, C-9, 9’), 102.6 (C-3), 
102.3 (C-3’), 78.7 (C-13/14), 77.2 (d, C-13’/14’), 70.2 (C-13/14), 69.9 (C-13’/14’), 67.6 
(d, C-12, 12’), 54.4 (C-6), 54.3 (C-6’), 42.8 (C-16), 42.6 (C-16’), 39.0 (C-24/25), 38.9 
(C-24’/25’), 38.8 (C-24/25), 38.7 (C-24’/25’), 26.3 (d, C-21, 21’), 24.8 (d, C-15, 15’), 
23.2 (C-17), 23.1 (C-17’), 22.1 (d, C-22/23, 22’/23’), 21.9 (d, C-22/23, 22’/23’), 21.5 
(d, C-18/19, 18’/19’), 21.3 (d, C-18/19, 18’/19’); m/z (ESI) 534 [MH]+. Calcd. for 
C21H32N3O9S2: 534.1574. Found: [MH]
+, 534.1579 (1.3 ppm error).  
Lab. Book: RD06/085/B1 
 
5-Phenyl-6-propyl-1a,6,8,8a-tetrahydrooxireno[5,6]oxepino[2,3-d]pyrimidin-7(2H)- 
one 327 
 
To a solution of dihydro-oxepine 197 (0.0500 g, 0.180 mmol, 1.0 
eq.) in acetone (0.25 mL) at –78 °C (CO2/acetone) was added 
DMDO (5.90 mL, 0.0610 M solution in acetone, 0.360 mmol, 2.0 
eq.). The reaction mixture was stirred at –78 °C for 2.5 h before 
being concentrated in vacuo. The crude material was purified by 
flash column chromatography on silica gel (3:2 EtOAc/PE) to 
furnish the title compound 327 (0.0070 g, 13%) as a yellow oil: Rf  0.13 (1:1 EtOAc/PE); 
υmax/cm
-1
 (neat) 2925 (C-H stretch), 1644 (C=O stretch), 1586 (aromatic C=C stretch), 
1547 (C=C stretch); δH (400 MHz, CDCl3) 7.48-7.41 (5 H, m, H-8, 9, 10), 4.61 (1 H, 
dd, J 13.0, 4.5, H-15a), 4.44 (1 H, dd, J 13.0, 8.0, H-15b), 3.85 (1 H, dd, J 13.5, 7.5, H-
11), 3.83 (1 H, dd, J 13.5, 7.5, H-11a), 3.54 (1 H, dd, J 17.0, 6.0, H-18a), 3.52 (1 H, 
app. dt (ddd), J 6.0, 4.5, H-17), 3.39 (1 H, app. dt (ddd), J 8.0, 4.5, H-16), 2.97 (1 H, dd, 
J 17.0, 6.0, H-18b), 1.64-1.55 (2 H, m, H-12), 0.74 (3 H, t, J 7.5, H-13); δC (100 MHz, 
CDCl3) 165.0 (C-4), 164.2 (C-6), 158.3 (C-2), 134.3 (C-7), 130.1 (C-10), 128.6 (C-9), 
127.7 (C-8), 100.2 (C-5), 68.3 (C-15), 52.6 (C-17), 50.2 (C-16), 48.0 (C-11), 23.5 (C-
18), 22.0 (C-12), 11.1 (C-13); m/z (ESI) 299 [MH]+. Calcd. for C17H19N2O3: 299.1390. 
Found: [MH]+, 299.1383. (2.8 ppm error).   
Lab. Book: RD06/001/C1 
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2-Phenyl-3-propyloxepino[2,3-d]pyrimidine-4,7(3H,8H)-dione 329 
 
To a solution of dihydro-oxepine 197 (0.103 g, 0.360 mmol, 1.0 
eq.) in xylenes (6.0 mL) at room temperature was added SeO2 
(0.0610 g, 0.550 mmol, 1.5 eq.). The reaction mixture was heated 
at 125 °C for 18 h, cooled to room temperature, filtered through 
Celite® and concentrated in vacuo. The crude product was 
purified by flash column chromatography on silica gel (4:1 
PE/EtOAc) to furnish the title compound 329 (0.0400 g, 38%) as a yellow oil: Rf  0.54 
(1:1 n-hexane/EtOAc); υmax/cm
-1 2967 (C-H stretch), 1660 (C=O stretch), 1604 
(aromatic C=C stretch), 1528 (C=C stretch);  δH (400 MHz, CDCl3) 7.72 (1 H, d, J 12.0, 
H-18), 7.55-7.48 (5 H, m, H-8, 9, 10), 6.45 (1 H, d, J 12.0, H-17), 4.70 (2 H, s, H-15), 
3.97-3.93 (2 H, m, H-11), 1.65 (2 H, app. sext. (tq), J 7.5, H-12), 0.78 (3 H, t, J 7.5, H-
13); δC (100 MHz, CDCl3) 191.9 (C-16), 168.5 (C-4), 163.1 (C-6), 161.4 (C-2), 136.3 
(C-7), 133.7 (C-17), 130.9 (C-10), 128.9 (C-9), 128.8 (C-18), 127.6 (C-8), 105.3 (C-5), 
76.0 (C-15), 48.5 (C-11), 21.9 (C-12), 11.0 (C-13); m/z (ESI) 297 [MH]+. Calcd. for 
C17H17N2O3: 297.1234. Found: [MH]
+, 297.1930 (1.3 ppm error). 
Lab. Book: RD08/002/C1 
 
5-(tert-Butylperoxy)-2-phenyl-3-propyl-5,8-dihydrooxepino[2,3-d]pyrimidin-4(3H)- 
one 330 
 
To a stirred solution of dihydro-oxepine 197 (0.0520 g, 0.180 
mmol, 1.0 eq.) in benzene (2.3 mL) at room temperature was 
added Celite® (0.300 g), pyridinium dichromate (0.280 g, 0.740 
mmol, 4.0 eq.) and tert-butyl hydrogen peroxide (5.5 M solution 
in decane, 0.130 mL, 0.740 mmol, 4.0 eq.). The reaction mixture 
was stirred at room temperature for 4 d before being filtered and 
concentrated in vacuo. The crude product was purified by flash 
column chromatography on silica gel (4:1 - 2:3 n-hexane/EtOAc) to furnish enone 329 
(0.0180 g, 33%) and the title compound 330 (0.0080 g, 12%) as a colourless oil: Rf  0.61 
(1:1 PE/EtOAc); υmax/cm
-1 2973 (C-H stretch), 1651 (C=O stretch), 1570 (aromatic C=C 
stretch), 1549 (C=C stretch); δH (400 MHz, CDCl3) 7.49-7.42 (5 H, m, H-8, 9, 10), 6.46 
(1 H, ddt, J 10.0, 7.0, 1.5, H-17), 6.17 (1 H, app. dtd (dddd), J 10.0, 7.0, 1.5, H-16), 
5.82 (1 H, dd, J 7.0, 1.5, H-18), 5.50 (1 H, ddd, J 12.5, 7.0, 1.5, H-15a), 4.49 (1 H, ddd, 
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J 12.5, 7.0, 1.5, H-15b), 3.92-3.78 (2 H, m, H-11), 1.67-1.56 (2 H, m, H-12), 1.32 (9 H, 
s, H-22, 23, 24), 0.74 (3 H, t, J 7.5, H-13); δC (100 MHz, CDCl3) 167.0 (C-4), 164.0 (C-
6), 160.2 (C-2), 135.8 (C-17), 134.4 (C-7), 130.1 (C-10), 128.6 (C-9), 127.9 (C-16), 
127.6 (C-8), 99.9 (C-5), 81.0 (C-21), 72.0 (C-18), 64.5 (C-15), 48.0 (C-11), 26.5 (C-22, 
23, 24), 22.0 (C-12), 11.0 (C-13); m/z (ESI) 371 [MH]+. Calcd. for C21H27N2O4: 
371.1965. Found: [MH]+, 371.1967 (0.4 ppm error).  
Lab. Book: RD07/096/C1 
 
7-Hydroxy-2-phenyl-3-propyl-7,8-dihydrooxepino[2,3-d]pyrimidin-4(3H)-one 331 
 
To a solution of dihydro-oxepine 197 (0.101 g, 0.360 mmol, 1.0 
eq.) in 1,4-dioxane (6 mL) at room temperature was added SeO2 
(0.0440 g, 0.390 mmol, 1.1 eq.). The reaction mixture was heated 
at 75 °C for 1 h, cooled to room temperature, filtered through 
Celite® and concentrated in vacuo. The crude product was 
purified by flash column chromatography on silica gel (3:2 
EtOAc/PE) to furnish enone xx (0.0110 g, 10%) and the title compound 331 (0.0560 g, 
52%) as an off-white foam: Rf  0.23 (1:1 n-hexane/EtOAc); υmax/cm
-1 3391 (O-H) 
stretch, 2968 (C-H stretch), 1649 C=O stretch), 1569 (aromatic C=C stretch), 1538 
(C=C stretch); δH (400 MHz, CDCl3) 7.52-7.44 (5 H, m, H-8, 9, 10), 6.89 (1 H, dd, J 
12.0, 1.0, H-18), 6.17 (1 H, dd, J 12.0, 5.0, H-17), 4.50 (1 H, app. tdd (dddd), J 5.0, 2.0, 
1.0, H-16), 4.37 (1 H, ddd, J 11.5, 5.0, 1.0, H-15a), 4.31 (1 H, dd, J 11.5, 2.0, H-15b), 
3.92-3.88 (2 H, m, H-11), 1.89 (1 H, br. s, H-19), 1.63 (2 H, app. sext. (tq), J 7.5, H-12), 
0.75 (3 H, t, J 7.5, H-13); δC (100 MHz, CDCl3) 166.1 (C-4), 163.8 (C-6), 158.2 (C-2), 
134.0 (C-7), 132.5 (C-17), 130.3 (C-10), 128.6 (C-9), 127.7 (C-8), 120.3 (C-18), 103.3 
(C-5), 73.5 (C-15), 68.3 (C-16), 48.1 (C-11), 21.9 (C-12), 11.0 (C-13); m/z (ESI) 299 
[MH]+. Calcd. for C17H19N2O3: 299.1390. Found: [MH]
+, 299.1397 (1.9 ppm error). 
Lab. Book: RD07/028/C1 
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6-Hydroxy-5-(2-methoxybut-3-en-1-yl)-2-phenyl-3-propylpyrimidin-4(3H)-one 332 
 
A solution of dihydro-oxepine 197 (0.0500 g, 0.180 mmol, 1.0 
eq.) in MeOH (3.0 mL) was heated at reflux for 5 h. The 
reaction mixture was cooled to room temperature and 
concentrated in vacuo. The crude product was purified by flash 
column chromatography on silica gel (1:1 n-hexane/EtOAc) to 
furnish the title compound 332 (0.0310 g, 55%) as a colourless 
waxy solid: Rf 0.20 (1:1 n-hexane/EtOAc); υmax/cm
-1 3040 (O-H 
stretch), 2967 (C-H stretch), 1627 (C=O stretch), 1533 (C=C stretch); δH (400 MHz, 
CDCl3) 10.29 (1 H, br. s, H-14), 7.51-7.43 (5 H, m, H-8, 9, 10), 5.73 (1 H, ddd, J 17.5, 
10.5, 8.0, H-17), 5.25 (1 H, ddd, J 10.5, 1.5, 0.5, H-18a), 5.27 (1 H, ddd, J 17.5, 1.5, 
1.0, H-18b), 3.91 (1 H, app. td (ddd), J 8.0, 3.5, H-16), 3.85 (1 H, app. t (dd), J 7.5, H-
11), 3.83 (1 H, app. t (dd), J 7.5, H-11a), 3.36 (3 H, s, H-19), 2.97 (1 H, dd, J 15.0, 3.5, 
H-15a), 2.75 (1 H, dd, J 15.0, 8.0, H-15b), 1.59 (2 H, app. sext. (tq), J 7.5, H-12), 0.73 
(3 H, t, J 7.5, H-13); δC (100 MHz, CDCl3) 165.0 (C-4), 163.8 (C-6), 158.7 (C-2), 136.9 
(C-17), 133.9 (C-7), 130.1 (C-10), 128.5 (C-9), 127.6 (C-8), 117.8 (C-18), 99.2 (C-5), 
83.0 (C-16), 56.2 (C-19), 47.7 (C-11), 29.3 (C-15), 22.1 (C-12), 11.0 (C-13); m/z (ESI) 
315 [MH]+. Calcd. for C18H23N2O3: 315.1703. Found: [MH]
+, 315.1698 (2.2 ppm error). 
Lab. Book: RD07/053/C1 
 
 
(3S*,8R*,11Z)-9-Ethoxy-3-hydroxy-8-iso-butyl-11-(2-methylpropylidene)-2,3,8,11-
tetrahydro-6H-oxepino[2,3-d]pyrazino[1,2-a]pyrimidin-6-one 333 
 
To a solution of dihydro-oxepine 298 
(0.188 g, 0.510 mmol, 1.0 eq.) in 1,4-
dioxane (8 mL) was added SeO2 (0.0620 
g, 0.560 mmol, 1.1 eq.). The reaction 
mixture was heated to 90 °C for 30 min 
before being cooled to room temperature, 
filtered through Celite® and concentrated in vacuo. The crude product was purified by 
flash column chromatography on silica gel (9:1 DCM/acetone) to afford enone 334 
(0.250 g, 13%) and the title compound 333 (0.116 g, 58%) as a yellow oil (1:1 mixture 
of diastereomers): Rf 0.26 (3:2 n-hexane/EtOAc); υmax/cm
-1 3400 (O-H stretch), 2959 
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(C-H stretch), 1658 (C=O stretch), 1524 (C=C stretch); δH (400 MHz, CDCl3) 6.80 (1 
H, d, J 12.0, H-15), 6.79 (1 H, d, J 12.0, H-15’), 6.57 (1 H, d, J 9.5, H-23), 6.55 (1 H, d, 
J 9.5, H-23’),  6.08 (1 H, dd, J 12.0, 4.0, H-14), 6.04 (1 H, dd, J 12.0, 4.0, H-14’), 5.25 
(1 H, dd, J 10.0, 6.0, H-6), 5.23 (1 H, dd, J 10.0, 6.0, H-6’),  4.51-4.44 (2 H, m, H-13, 
13’), 4.38-4.21 (8 H, m, H-12, 12’, 21, 21’), 3.26-3.16 (2 H, m, H-24, 24’), 1.83 (1 H, d, 
J 9.0, H-27), 1.80 (1 H, d, J 9.0, H-27’), 1.68-1.59 (6 H, m, H-16, 16’, 17, 17’), 1.35 (6 
H, app. t, J 7.0, H-22, 22’), 1.08 (3 H, d, J 6.5, H-25/26), 1.07 (3 H, d, J 6.5, H-25’/26’), 
1.02 (3 H, d, J 6.5, H-25/26), 1.01 (3 H, d, J 6.5, H-25’/26’), 0.96 (6 H, app. d, J 6.0, H-
018/19, 18’/19’), 0.84 (3 H, d, J 6.0, H-18/19), 0.83 (3 H, d, J 6.0, H-18’/19’); δC (100 
MHz, CDCl3) 167.7 (C-4/7), 167.2 (C-4’/7’), 162.4 (d, C-4/7, 4’/7’), 161.8 (d, C-2, 2’), 
149.6 (C-10), 149.5 (C-10’), 139.6 (C-23), 139.4 (C-23’), 131.5 (C-14), 131.4 (C-14’), 
131.3 (C-9), 131.0 (C-9’), 121.1 (C-15), 120.4 (C-15’), 102.4 (d, C-3, 3’), 73.8 (C-12), 
73.6 (C-12’), 68.9 (C-13), 68.6 (C-13’), 62.7 (d, C-21, 21’), 50.8 (C-6), 50.7 (C-6’), 
42.4 (C-16), 42.3 (C-16’), 26.6 (d, C-24, 24’), 24.9 (d, C-17, 17’), 23.5 (C-18/19), 23.4 
(C-18’/19’), 22.3 (d, C-25/26, 25’/26’), 21.9 (d, C-25/26, 25’/26’), 21.7 (d, C-18/19, 
18’/19’), 14.1 (d, C-22, 22’); m/z (ESI) 388 [MH]+. Calcd. for C21H30N3O4: 388.2231. 
Found: [MH]+, 388.2228 (1.4 ppm error).   
Lab Book: RD08/015/C1; RD07/068/C1 
 
Also isolated was (8R*,11Z)-9-ethoxy-8-iso-butyl-11-(2-
methylpropylidene)-8,11-dihydro-6H-oxepino[2,3-
d]pyrazino[1,2-a]pyrimidine-3,6(2H)-dione 334 (0.0250 g, 
13%) as a yellow oil: Rf 0.20 (4:1 n-hexane/EtOAc); υmax/cm
-1 
2960 (C-H stretch), 1659 (C=O stretch), 1514 (C=C stretch); 
δH (400 MHz, CDCl3) 7.65 (1 H, d, J 12.0, H-15), 6.73 (1 H, d, 
J 9.5, H-23), 6.38 (1 H, d, J 12.0, H-14), 5.31 (1 H, dd, J 7.5, 5.5, H-6), 4.68 (2 H, s, H-
12), 4.40-4.26 (2 H, m, H-21), 3.23 (1 H, dsept., J 9.5, 6.5, H-24), 1.67-1.60 (3 H, m, H-
16, 17), 1.37 (3 H, t, J 7.0, H-22), 1.12 (3 H, d, J 6.5, H-25/26), 1.07 (3 H, d, J 6.5, H-
18/19), 1.01 (3 H, d, J 6.5, H-25/26), 0.90 (3 H, d, J 6.5, H-18/19); δC (100 MHz, 
CDCl3) 192.0 (C-13), 169.4 (C-4/7), 161.6 (C-4/7), 161.5 (C-2), 152.3 (C-10), 142.0 
(C-23), 136.1 (C-15), 131.3 (C-9), 127.9 (C-14), 104.3 (C-3), 76.0 (C-12), 62.9 (C-21), 
50.8 (C-6), 42.4 (C-16), 26.8 (C-24), 24.9 (C-17), 23.2 (C-18/19), 22.1 (C-25/26), 21.8 
(C-18/19), 21.7 (C-25/26), 14.1 (C-22); m/z (ESI) 386 [MH]+. Calcd. for C21H28N3O4: 
386.2074. Found: [MH]+, 386.2075 (0.4 ppm error).   
Lab Book: RD08/008/A1, RD08/015/C1 
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7-Chloro-2-phenyl-3-propyl-7,8-dihydrooxepino[2,3-d]pyrimidin-4(3H)-one 339 
 
To a stirred solution of allylic alcohol 331 (0.0300 g, 0.100 
mmol, 1.0 eq.) in DCM (2 mL) was added NEt3 (0.0280 mL, 
0.200 mmol, 2.0 eq.), MsCl (0.0160 mL, 0.200 mmol, 2.0 eq.) 
and DMAP (0.001 g, 0.010 mmol, 0.1 eq.). The reaction mixture 
was stirred at room temperature for 4 h before being quenched by 
the addition of sat. NH4Cl (aq.) (10 mL) and extracted with DCM 
(2 × 10 mL). The combined organic phase was washed with water (10 mL) and brine 
(10 mL), dried over MgSO4 and concentrated in vacuo. The title compound 339 was 
isolated as a yellow film (0.031 g, 98%) and was used without further purification: Rf  
0.57 (1:1 PE/EtOAc); υmax/cm
-1 2967 (C-H stretch), 1658 (C=O stretch), 1567 (aromatic 
C=C stretch), 1538 (C=C stretch); δH (400 MHz, CDCl3) 7.51-7.44 (5 H, m, H-8, 9, 10), 
6.89 (1 H, dd, J 12.0, 1.5, H-18), 6.11 (1 H, ddd, J 12.0, 4.0, 1.0, H-17), 4.86 (1 H, 
dddd, J 7.0, 4.0, 3.0, 1.5, H-16); 4.64 (1 H, ddd, J 12.0, 3.0, 1.0, H-15a), 4.35 (1 H, dd, 
J 12.0, 7.0, H-15b), 3.96-3.83 (2 H, m, H-11), 1.62 (2 H, app. sext. (tq), J 7.5, H-12), 
0.75 (3 H, t, J 7.5, H-13); δC (100 MHz, CDCl3) 166.2 (C-4), 163.6 (C-6), 158.6 (C-2), 
134.1 (C-7), 130.4 (C-10), 129.9 (C-17), 128.7 (C-9), 127.7 (C-8), 120.9 (C-18), 102.8 
(C-5), 72.3 (C-15), 54.9 (C-16), 48.2 (C-11), 21.9 (C-12), 11.0 (C-13); m/z (ESI) 317 
[MH]+. Calcd. for C17H18ClN2O2: 317.1051. Found: [MH]
+, 317.1051 (0.1 ppm error). 
Lab. Book: RD07/032/C1 
 
(3S*,8R*,11Z)-3-Chloro-9-ethoxy-8-iso-butyl-11-(2-methylpropylidene)-2,3,8,11-
tetrahydro-6H-oxepino[2,3-d]pyrazino[1,2-a]pyrimidin-6-one 343 
 
To a solution of allylic alcohol 333 (0.236 
g, 0.610 mmol, 1.0 eq.) in DCM (9 mL) 
was added NEt3 (0.130 mL, 0.910 mmol, 
1.5 eq.), MsCl (0.0700 mL, 0.910 mmol, 
1.5 eq.) and DMAP (0.0070 g, 0.0610 
mmol, 0.1 eq.). The reaction mixture was 
stirred at room temperature for 1.5 h and then quenched by the addition of sat. NH4Cl 
(aq.) (10 mL) and extracted with DCM (3 × 10 mL). The combined organic phase was 
washed with water (15 mL) and brine (15 mL), dried over MgSO4, filtered and 
concentrated in vacuo to furnish the title compound 343 (0.230 g, 93%) as a yellow oil 
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(1:1 mixture of diastereomers) which was used without further purification: Rf 0.61 (1:1 
PE/EtOAc); υmax/cm
-1 2959 (C-H stretch), 1658 (C=O stretch), 1524 (C=C stretch); δH 
(400 MHz, CDCl3) 6.83 (1 H, dd, J 12.0, 1.0, H-15), 6.81 (1 H, dd, J 12.0, 1.0, H-15’), 
6.60 (2 H, app. d, J 9.5, H-23, 23’), 6.06-6.00 (2 H, m, H-14, 14’), 5.29-5.25 (2 H, m, 
H-6, 6’), 4.87-4.82 (2 H, m, H-13, 13’), 4.64 (1 H, ddd, J 12.0, 3.0, 1.0, H-12a), 4.58 (1 
H, ddd, J 12.0, 2.5, 1.0, H-12’a), 4.41 (1 H, dd, J 12.0, 6.0, H-12b), 4.40 (1 H, dd, J 
12.0, 6.0, H-12’b), 4.34-4.26 (4 H, m, H-21, 21’), 3.25-3.16 (2 H, m, H-24, 24’), 1.62-
1.56 (6 H, m, H-16, 16’, 17, 17’), 1.35 (3 H, t, J 7.0, H-22), 1.34 (3 H, t, J 7.0, H-22’), 
1.10 (6 H, app. d, J 7.0, H-25/26, 25’/26’), 1.04 (6 H, app. d, J 7.0, H-25/26, 25’/26’), 
1.00 (3 H, d, J 6.5, H-18/19), 0.99 (3 H, d, J 6.5, H-18’/19’), 0.88 (3 H, d, J 6.5, H-
18/19), 0.87 (3 H, d, J 6.5, H-18’/19’); δC (100 MHz, CDCl3) 167.2 (C-4/7), 167.0 (C-
4’/7’), 162.1 (d, C-4/7, 4’/7’), 161.7 (d, C-2, 2’), 149.7 (d, C-10, 10’), 139.7 (d, C-23, 
23’), 131.2 (d, C-9), 129.1 (C-14’), 128.7 (C-14’), 121.2 (C-15), 120.5 (C-15’), 101.7 
(C-3), 101.6 (C-3’), 72.4 (C-12), 72.3 (C-12’), 62.6 (d, C-21, 21’), 55.5 (C-13), 54.7 (C-
13’), 50.6 (C-6), 50.5 (C-6’), 42.2 (d, C-16, 16’), 26.6 (d, C-24, 24’), 24.8 (d, C-17, 
17’), 23.3 (C-18/19), 23.2 (C-18’/19’), 22.2 (d, C-25/26, 25’/26’), 21.8 (d, C-25/26, 
25’/26’), 21.7 (C-18/19), 21.6 (C-18’/19’), 14.1 (d, C-22, 22’); m/z (APCI, sample 
injected in MeCN) 406 [MH]+. Calcd. for C21H29
35ClN3O3: 406.1892. Found: [MH]
+, 
406.1882 (2.4 ppm error).   
Lab. Book: RD08/007/C1, RD09/097/B1 
 
(8R*,11Z)-9-Ethoxy-8-iso-butyl-11-(2-methylpropylidene)-8,11-dihydro-6H-
oxepino[2,3-d]pyrazino[1,2-a]pyrimidin-6-one 309 
 
To a solution of allylic chloride 343 (0.225 g, 0.550 mmol, 1.0 
eq.) in DMSO (9 mL) at room temperature was added TBAF (1 
M solution in THF, 1.17 mL, 1.17 mmol, 2.1 eq.). The reaction 
mixture was stirred at room temperature for 10 min, quenched 
by the addition of sat. NH4Cl (aq.) (10 mL) and extracted with 
EtOAc (3 × 10 mL). The combined organic phase was washed 
with water (3 × 10 mL) and brine (10 mL), dried over MgSO4, filtered and concentrated 
in vacuo. The crude product was purified by flash column chromatography on silica gel 
(19:1 PE/EtOAc) to furnish the title compound 309 (0.0200 g, 10%) as an orange oil: Rf 
0.47 (9:1 PE/EtOAc); υmax/cm
-1 2959 (C-H stretch), 1660 (C=O stretch), 1515 (C=C 
stretch); δH (400 MHz, CDCl3) 6.74 (1 H, d, J 11.0, H-15), 6.56 (1 H, d, J 9.0, H-23), 
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6.09 (1 H, dd, J 11.0, 5.5, H-14), 6.09 (1 H, d, J 5.5, H-12), 5.59 (1 H, app. t (dd), J 5.5, 
H-13), 5.30-5.27 (1 H, m, H-6), 4.41-4.27 (2 H, m, H-21), 3.21 (1 H, dsept., J 9.0, 6.5, 
H-24), 1.72-1.58 (3 H, m, H-16, 17), 1.35 (3 H, t, J 7.0, H-22), 1.12 (3 H, d, J 6.5, H-
25/26), 1.05 (3 H, d, J 7.0, H-18/19), 1.01 (3 H, d, J 6.5, H-25/26), 0.88 (3 H, d, J 6.5, 
H-18/19); δC (100 MHz, CDCl3) 163.5 (C-4/7), 161.7 (C-4/7), 160.9 (C-2), 151.8 (C-
10), 142.9 (C-12), 139.5 (C-23), 131.4 (C-9), 127.0 (C-14), 125.8 (C-15), 117.1 (C-13), 
109.4 (C-3), 62.7 (C-21), 50.6 (C-6), 42.2 (C-16), 26.6 (C-24), 24.9 (17), 23.3 (C-
18/19), 22.3 (C-25/26), 21.8 (C-18/19), 21.7 (C-25/26), 14.1 (C-22); m/z (ESI) 370 
[MH]+. Calcd. for C21H28N3O3: 370.2125. Found: [MH]
+, 370.2126 (0.5 ppm error).    
Lab. Book: RD09/098/C1 
 
7-[(2-Nitrophenyl)seleno]-2-phenyl-3-propyl-7,8-dihydrooxepino[2,3-d]pyrimidin-4 
(3H)-one 349 
 
To a solution of allylic alcohol 331 (0.0250 g, 0.0840 mmol, 
1.0 eq.) and 2-nitrophenyl selanocyanate (0.0380 g, 0.170 
mmol, 2.0 eq.) in degassed THF (1.0 mL) at room 
temperature was added tributyl phosphine (0.105 mL, 0.420 
mmol, 5.0 eq.). The reaction mixture was stirred at room 
temperature for 1 h before being concentrated in vacuo and 
purified by flash column chromatography on silica gel (1:1 n-
hexane/EtOAc) to furnish the title compound 349 (0.025 g, 
62%) as a yellow film: Rf  0.18 (1:1 n-hexane/EtOAc); υmax/cm
-1 2966 (C-H stretch), 
1655 (C=O stretch), 1566 (aromatic C=C stretch), 1535 (C=C stretch), 1513 (N-O 
asymmetric stretch); δH (400 MHz, CDCl3) 8.28 (1 H, dd, J 8.5, 1.5, H-22), 7.67 (1 H, 
dd, J 8.0, 1.5, H-25), 7.57 (1 H, ddd, J 8.0, 7.0, 1.5, H-24), 7.52-7.47 (5 H, m, H-8, 9, 
10), 7.38 (1 H, ddd, J 8.5, 7.0, 1.5, H-23), 6.97 (1 H, dd, J 12.0, 1.5, H-18), 6.26 (1 H, 
dd, J 12.0, 5.0, H-17), 4.67 (1 H, dd, J 12.0, 2.0, H-15a), 4.60 (1 H, dd, J 12.0, 6.0, H-
15b), 4.55-4.52 (1 H, m, H-16), 3.94-3.90 (2 H, m, H-11), 1.65 (2 H, app. sext. (tq), J 
7.5, H-12), 0.77 (3 H, t, J 7.5, H-13); δC (100 MHz, CDCl3) 166.0 (C-4), 163.7 (C-6), 
158.0 (C-2), 147.4 (C-20), 134.2 (C-7), 133.8 (C-24), 131.4 (C-21), 130.3 (C-10), 129.7 
(C-25), 128.7 (C-17), 128.6 (C-9), 127.8 (C-8), 126.6 (C-22), 126.3 (C-23), 122.3 (C-
18), 103.0 (C-5), 71.4 (C-15), 48.2 (C-11), 42.6 (C-16), 21.9 (C-12), 11.1 (C-13); m/z 
(ESI) 484 [MH]+. Calcd. for C23H22N3O4Se: 484.0771. Found: [MH]
+, 484.0770 (1.4 
ppm error). 
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Lab. Book: RD08/042/C1 
4-Oxo-2-phenyl-3-propyl-3,4,5,8-tetrahydrooxepino[2,3-d]pyrimidin-5-yl  
2-nitrobenzeneselenenate 351 
 
To a solution of selenide 349 (0.0430 g, 0.0900 mmol, 1.0 eq.) 
in DCM (3.5 mL) at –78 °C (CO2/acetone) was added m-
CPBA (0.0170 g, 0.0990 mmol, 1.1 eq.). The reaction mixture 
was stirred at –78 °C for 2 h before being quenched by the 
addition of sat. NaHCO3 (aq.) (5 mL) and extracted with DCM 
(3 × 10 mL). The combined organic phase was dried over 
MgSO4, filtered and concentrated in vacuo to give the crude 
product which was purified by flash column chromatography on silica gel (3:2 n-
hexane/EtOAc) to furnish allylic alcohol 350 (0.0040 g, 15%) and the title compound 
351 (0.015 g, 33%) as an orange waxy solid: Rf 0.43 (1:1 PE/EtOAc); υmax/cm
-1 2965 
(C-H stretch), 1644 (C=O stretch), 1569 (aromatic C=C stretch), 1547 (aromatic C=C 
stretch), 1501 (C=C stretch); δH (400 MHz, CDCl3) 8.42 (1 H, dd, J 8.5, 1.0, H-23), 
8.34 (1 H, dd, J 8.5, 1.0, H-26), 7.79 (1 H, ddd, J 8.5, 7.0, 1.5, H-25), 7.50-7.43 (5 H, 
m, H-8, 9, 10), 7.39 (1 H, ddd, J 8.5, 7.0, 1.5, H-24), 6.59 (1 H, ddt, J 10.0, 7.0, 1.5, H-
17), 6.27 (1 H, dtd, J 10.0, 7.0, 1.0, H-16), 5.61 (1 H, ddd, J 12.5, 7.0, 1.5, H-15a), 5.60 
(1 H, dd, J 7.0, 1.0, H-18), 4.59 (1 H, ddd, J 12.5, 7.0, 1.5, H-15b), 3.90-3.86 (2 H, m, 
H-11), 1.63 (2 H, app. sext. (tq), J 7.5, H-12), 0.77 (3 H, t, J 7.5, H-13); δC (100 MHz, 
CDCl3) 166.2 (C-4), 164.2 (C-6), 160.2 (C-2), 144.2 (C-22), 141.3 (C-21), 137.6 (C-
17), 134.8 (C-25), 134.3 (C-7), 130.3 (C-10), 128.6 (C-9), 128.5 (C-16), 127.6 (C-8), 
126.9 (C-23), 126.1 (C-24), 125.2 (C-26), 103.7 (C-5), 72.5 (C-18), 64.6 (C-15), 48.1 
(C-11), 22.0 (C-12), 11.1 (C-13); m/z (ESI) 500 [MH]+. Calcd. for C23H22N3O5Se: 
500.0270. Found: [MH]+, 500.0271 (1.5 ppm error). 
Lab. Book: RD08/051/C1 
 
5-Hydroxy-2-phenyl-3-propyl-5,8-dihydrooxepino[2,3-d]pyrimidin-4(3H)-one 350 
 
To a stirred solution of selenide 350 (0.0310 g, 0.0630 mmol, 1.0 
eq.) in THF (1.25 mL) at 0 °C (ice) was added pyridine (0.0360 
mL, 0.0690 mmol, 1.1 eq.) followed by hydrogen peroxide (30% 
w/v solution in water, 0.0720 mL, 0.640 mmol, 10.0 eq.). The 
reaction mixture was stirred at 0 °C for 3 h, diluted with EtOAc 
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(10 mL), washed with sat. NaHCO3 (aq.) (10 mL) and brine (10 mL), dried over 
MgSO4, filtered and concentrated in vacuo. The crude product was purified by flash 
column chromatography on silica gel (3:2 EtOAc/n-hexane) to furnish the title 
compound 350 (0.0140 g, 70%) as a colourless solid: mp 122-124 °C; Rf  0.17 (1:1 
PE/EtOAc); υmax/cm
-1 3410 (O-H stretch), 2965 (C-H stretch), 1635 (C=O stretch), 1572 
(aromatic C=C stretch), 1546 (C=C stretch); δH (400 MHz, CDCl3) 7.51-7.44 (5 H, m, 
H-8, 9, 10); 6.33 (1 H, ddd, J 10.5, 6.0, 0.5, H-17), 6.17 (1 H, app. dt (ddd), J 10.5, 6.5, 
H-16), 5.63 (1 H, d, J 6.0, H-18), 5.01 (1 H, ddd, J 13.0, 6.5, 0.5, H-15a), 4.60 (1 H, dd, 
J 13.0, 6.5, H-15b), 4.20 (1 H, br. s, H-19), 3.88-3.84 (2 H, m, H-11), 1.63 (2 H, app. 
sext. (tq), J 7.5, H-12), 0.76 (3 H, t, J 7.5); δC (100 MHz, CDCl3) 165.7 (C-4), 165.4 (C-
6), 158.8 (C-2), 137.1 (C-17), 134.0 (C-7), 130.3 (C-10), 128.6 (C-9), 127.7 (C-8), 
127.0 (C-16), 105.0 (C-5), 65.4 (C-15), 63.5 (C-18), 47.8 (C-11), 22.0 (C-12), 11.1 (C-
13); m/z (ESI) 299 [MH]+. Calcd. for C17H19N2O3: 299.1390. Found: [MH]
+, 299.1387 
(1.4 ppm error). 
Lab. Book: RD09/010/C1 
 
4-Oxo-2-phenyl-3-propyl-3,4,4a,7,8,9a-hexahydrooxepino[2,3-d]pyrimidin-7-yl  
acetate 354 
 
To a solution of allylic alcohol 331 (0.0430 g, 0.140 mmol, 1.0 
eq.) in DCM (2.0 mL) at room temperature was added NEt3 
(0.039 mL, 0.280 mmol, 2.0 eq.), AcCl (0.0120 mL, 0.170 
mmol, 1.2 eq.) and DMAP (cat.). The reaction mixture was 
stirred at room temperature for 30 min before being quenched by 
the addition of sat. NH4Cl (aq.) (5 mL) and extracted with DCM 
(2 × 10 mL). The combined organic phase was washed with 
water (15 mL) and brine (15 mL), dried over MgSO4, filtered 
and concentrated in vacuo. The crude product was purified by flash column 
chromatography on silica gel (3:2 n-hexane/EtOAc) to furnish the title compound 354 
(0.0260 g, 54%) as a colourless film: Rf 0.35 (1:1 PE/EtOAc); υmax/cm
-1 2967 (C-H 
stretch), 1738 (C=O stretch), 1659 (C=O stretch), 1568 (C=C stretch), 1538 (aromatic 
C=C stretch); δH (400 MHz, CDCl3) 7.51-7.44 (5 H, m, H-8, 9, 10), 7.01 (1 H, dd, J 
12.0, 1.0, H-18), 6.04 (1 H, dd, J 12.0, 4.5, H-17), 5.59 (1 H, app. tdd (dddd), J 4.5, 2.5, 
1.0, H-16), 4.41 (1 H, J 12.0, 4.5, H-15a), 4.37 (1 H, dd, J 12.0, 2.5, H-15b), 3.92-3.88 
(2 H, m, H-11), 2.11 (3 H, s, H-21), 1.62 (2 H, app. sext. (tq), J 7.5, H-12), 0.75 (3 H, t, 
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J 7.5, H-13); δC (100 MHz, CDCl3) 170.1 (C-20), 166.2 (C-4), 163.7 (C-6), 158.5 (C-2), 
134.2 (C-7), 130.3 (C-10), 128.6 (C-9), 127.7 (C-8), 127.7 (C-17), 122.7 (C-18), 102.8 
(C-5), 70.3 (C-15), 69.9 (C-16), 48.1 (C-11), 21.9 (C-12), 20.9 (C-21), 11.0 (C-13); m/z 
(ESI) 341 [MH]+. Calcd. for C19H21N2O4: 341.1496. Found: [MH]
+, 341.1494 (0.4 ppm 
error). 
Lab. Book: RD08/089/C1 
 
Ethyl 4-oxo-2-phenyl-3-propyl-3,4,7,8-tetrahydrooxepino[2,3-d]pyrimidin-7-yl  
carbonate 355 
 
To a solution of allylic alcohol 331 (0.0500 g, 0.170 mmol, 1.0 
eq.) in DCM (2.0 mL) at 0 °C (ice) was added NEt3 (0.0280 mL, 
0.200 mmol, 1.2 eq.), ethyl chloroformate (0.0240 mL, 0.250 
mmol, 1.5 eq.) and DMAP (cat.). The reaction mixture was 
stirred at 0 °C for 1 h before being quenched by the addition of 
sat. NH4Cl (aq.) (5 mL) and extracted with DCM (3 × 10 mL). 
The combined organic phase was dried over MgSO4, filtered, 
concentrated in vacuo and the resulting crude product purified 
by flash column chromatography on silica gel (65:35 n-hexane/EtOAc) to furnish the 
title compound 355 (0.0340 g, 54%) as a colourless film: Rf 0.46 (1:1 PE/EtOAc); 
υmax/cm
-1 2969 (C-H stretch), 1743 (C=O stretch), 1660 (C=O stretch), 1568 (C=C 
stretch), 1539 (C=C stretch), 1253 (C-O stretch); δH (400 MHz, CDCl3) 7.51-7.43 (5 H, 
m, H-8, 9, 10), 7.02 (1 H, dd, J 12.0, 1.5, H-18), 6.09 (1 H, dd, J 12.0, 4.0, H-17), 5.44 
(1 H, dddd, J 5.5, 4.0, 2.5, 1.5, H-16), 4.46 (1 H, dd, J 12.0, 2.5, H-15a), 4.41 (1 H, dd, 
J 12.0, 5.5, H-15b), 4.23 (2 H, q, J 7.0, H-22), 3.91-3.87 (2 H, m, H-11), 1.62 (2 H, app. 
sext. (tq), J 7.5, H-12), 1.32 (3 H, t, J 7.0, H-23), 0.75 (3 H, t, J 7.5, H-13); δC (100 
MHz, CDCl3) 166.1 (C-4), 163.6 (C-6), 158.6 (C-2), 154.3 (C-20), 134.2 (C-7), 130.3 
(C-10), 128.6 (C-9), 127.7 (C-8), 127.2 (C-17), 122.7 (C-18), 102.7 (C-5), 72.8 (C-16), 
69.9 (C-15), 64.5 (C-22), 48.1 (C-11), 21.9 (C-12), 14.2 (C-13), 11.0 (C-23); m/z (ESI) 
371 [MH]+. Calcd. for C20H23N2O5: 371.1601. Found: [MH]
+, 371.1590 (3.4 ppm error).    
Lab. Book: RD08/090/C1, RD09/003/C1 
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2,4,6-Tri-iso-propyl-N'-[(7E)-4-oxo-2-phenyl-3-propyl-3,4-dihydrooxepino[2,3-
d]pyrimidin-7(8H)-ylidene]benzenesulfonohydrazide 361 
 
To a solution of enone 329 (0.0330 g, 0.110 mmol, 1.0 
eq.) in THF (0.25 mL) at room temperature was added 
2,4,6-tri-iso-propylbenzenesulfonohydrazide (0.0410 g, 
0.140 mmol, 1.5 eq.). After 2 h the reaction mixture was 
concentrated in vacuo and purified by flash column 
chromatography on silica gel (1:1 n-hexane/EtOAc) to 
furnish the title compound 361 (0.0580 g, 91%) as a 
yellow oil: Rf  0.30 (3:2 PE/EtOAc); υmax/cm
-1 3198 (N-H 
stretch), 2962 (C-H stretch), 1647 (C=O stretch), 1601 
(aromatic C=C stretch), 1560 (aromatic C=C stretch), 
1530 (C=C stretch); δH (400 MHz, CDCl3) 7.96 (1 H, s, H-20), 7.53-7.43 (5 H, m, H-8, 
9, 10), 7.37 (1 H, d, J 12.0, H-18), 7.17 (2 H, s, H-24, 26), 6.45 (1 H, d, J 12.0, H-17), 
4.75 (2 H, s, H-15), 4.26-4.19 (1 H, m, H-26/34), 4.18-4.12 (1 H, m, H-26/34), 3.93-
3.90 (2 H, m, H-11), 2.95-2.86 (1 H, m, H-31), 1.63 (2 H, app. sext. (tq), J 7.0, H-12), 
1.27 (6 H, d, J 7.0, H-29/30), 1.26 (6 H, d, J 7.0, H-32/33), 1.25 (6 H, d, J 7.0, H-
35/36), 0.76 (3 H, t, J 7.0, H-13); δC (100 MHz, CDCl3) 167.6 (C-4), 163.5 (C-6), 159.7 
(C-2), 153.7 (d, C-16), 151.7 (C-23/27), 151.3 (C-23/27), 145.9 (C-22), 133.8 (C-7), 
131.1 (C-25), 130.6 (C-18), 129.0 (C-10), 128.7 (C-9), 127.7 (C-8), 123.9 (C-24/26), 
123.8 (C-24/26), 116.2 (C-17), 103.9 (C-5), 73.0 (C-15), 48.3 (C-11), 34.1 (C-31), 29.9 
(C-28/34), 29.7 (C-28/34), 24.9 (C-29/30), 24.7 (C-32/33), 23.5 (C-35/36), 21.9 (C-12), 
11.0 (C-13); m/z (ESI) 577 [MH]+. Calcd. for C32H41N4O4S: 577.2843. Found: [MH]
+, 
577.2837 (1.4 ppm error). 
Lab. Book: RD08/044/C1    
 
 
2-Phenyl-3-propyl-7,8-dihydrooxepino[2,3-d]pyrimidin-4(3H)-one 364 
 
A solution of dihydro-oxepine 197 (0.0510 g, 0.180 mmol, 1.0 
eq.) and RuCl2(PPh3)3 (0.0040 g, 0.0040 mmol, 0.02 eq.) in THF 
(1.0 mL) was heated in a sealed microwave tube at 60 °C for 4 
h. The reaction mixture was then cooled to room temperature, 
concentrated in vacuo and the crude product was purified by 
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flash column chromatography on silica gel (3:2 PE/EtOAc) to furnish dihydro-oxepine 
197 (0.0100 g, 20%) and the title compound 364 (0.0180 g, 35%) as a colourless 
crystalline solid: mp 107-109 °C; Rf  0.46 (1:1 PE/EtOAc); υmax/cm
-1 2966 (C-H stretch), 
1652 (C=O stretch), 1566 (C=C stretch), 1538 (aromatic C=C stretch); δH (400 MHz, 
CDCl3) 7.50-7.45 (5 H, m, H-8, 9, 10), 6.84 (1 H, dd, J 12.0, 1.5, H-18), 6.08 (1 H, dt, J 
12.0, 5.0, H-17), 4.42 (2 H, t, J 4.5, H-15), 3.91-3.87 (2 H, m, H-11), 2.69 (2 H, dtd, J 
5.0, 4.5, 1.5, H-16), 1.63 (2 H, app. sext. (tq), J 7.5, H-12), 0.76 (3 H, t, J 7.5, H-13); δC 
(100 MHz, CDCl3) 165.9 (C-4), 164.1 (C-6), 157.0 (C-2), 134.5 (C-7), 130.5 (C-17), 
130.1 (C-10), 128.5 (C-9), 127.8 (C-8), 120.3 (C-16), 103.3 (C-5), 69.5 (C-15), 48.0 (C-
11), 33.1 (C-16), 22.0 (C-12), 11.1 (C-13); m/z (ESI) 283 [MH]+. Calcd. for 
C17H19N2O2: 283.1441. Found: [MH]
+, 283.1444 (0.9 ppm error).    
Lab. Book: RD09/085/C1 
 
2-Phenyl-3-propyl-6-vinyl-5,6-dihydrofuro[2,3-d]pyrimidin-4(3H)-one 365 
 
To a solution of dihydro-oxepine 197 (0.0540 g, 0.190 mmol, 
1.0 eq.) in dry, degassed EtOH (5.0 mL) was added Rh(PPh3)3Cl 
(0.0180 g, 0.0190 mmol, 0.1 eq.) and DBU (0.0090 mL, 0.0570 
mmol, 0.3 eq.). The reaction mixture was heated at 78 °C for 1 h 
before being cooled to room temperature and concentrated in 
vacuo. The crude product was purified by flash column 
chromatography on silica gel (3:2 PE/EtOAc) to furnish the title 
compound 365 (0.0240 g, 44%) as a colourless film: Rf  0.26 (3:2 PE/EtOAc); υmax/cm
-1 
2965 (C-H stretch), 1679 (C=O stretch), 1606 (C=C stretch), 1516 (aromatic C=C 
stretch); δH (400 MHz, CDCl3) 7.50-7.42 (5 H, m, H-8, 9, 10), 6.01 (1 H, ddd, J 17.0, 
10.5, 6.0, H-17), 5.42 (1 H, dt, J 17.0, 1.0, H-18a), 5.34 (1 H, dddt, J 10.0, 7.0, 6.0, 1.0, 
H-15), 5.26 (1 H, dt, J 10.5, 1.0, H-18b), 3.94-3.82 (2 H, m, H-11), 3.36 (1 H, dd, J 
15.5, 10.0, H-16a), 2.95 (1 H, dd, J 15.5, 7.0, H-16b), 1.60 (2 H, app. sext. (tq), J 7.5, 
H-12), 0.74 (3 H, t, J 7.5, H-13); δC (100 MHz, CDCl3) 170.7 (C-4), 162.4 (C-6), 160.6 
(C-2), 136.1 (C-17), 135.0 (C-7), 130.1 (C-10), 128.6 (C-9), 127.6 (C-8), 117.1 (C-18), 
97.6 (C-5), 83.2 (C-15), 47.5 (C-11), 31.7 (C-16), 22.3 (C-12), 11.0 (C-13); m/z (ESI) 
283 [MH]+. Calcd. for C17H19N2O2: 283.1441. Found: [MH]
+, 283.1441 (0.0 ppm error).  
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Also isolated was 5-(but-3-en-1-yl)-6-hydroxy-2-phenyl-3-
propylpyrimidin-4(3H)-one 366 (0.0040 g, 7%) as a colourless 
film: Rf 0.13 (4:1 PE/EtOAc); υmax/cm
-1 3067 (O-H stretch), 2966 
(C-H stretch), 1656 (C=O) stretch, 1532 (aromatic C=C stretch), 
1444 (C=C stretch); δH (400 MHz, CDCl3) 7.56-7.39 (5 H, m, H-
8, 9, 10), 5.78 (1 H, ddt, J 17.0, 10.0, 6.5, H-16), 4.97 (1 H, ddt, J 
17.0, 2.0, 1.5, H-17a), 4.90 (1 H, ddt, J 10.0, 2.0, 1.0, H-17b), 
3.82-3.78 (2 H, m, H-11), 2.43-2.39 (2 H, m, H-14), 2.18-2.13 (2 H, m, H-15), 1.57 (2 
H, app. sext. (tq), J 7.5, H-12), 0.73 (3 H, t, J 7.5, H-13); δC (100 MHz, CDCl3) 163.3 
(C-4), 163.1 (C-2), 158.1 (C-2), 138.7 (C-16), 132.9 (C-7), 130.4 (C-10), 128.6 (C-9), 
127.6 (C-8), 114.3 (C-17), 102.3 (C-5), 47.5 (C-11), 31.6 (C-15), 22.7 (C-14), 22.2 (C-
12), 11.0 (C-3); m/z (ESI) 285 [MH]+. Calcd. for C17H21N2O2: 285.1598. Found: [MH]
+, 
285.1586 (3.3 ppm error). 
Lab. Book: RD09/091/C1 and C2; RD09/078/C1 
 
Dimethyl but-3-en-1-ylmalonate 369 
 
To a solution of NaH (60% dispersion in mineral oil, 1.89 g, 47.0 
mmol, 1.1 eq.) in DMF (100 mL) at 0 °C (ice) was added dropwise 
dimethyl malonate (5.00 mL, 43.0 mmol, 1.0 eq.). The reaction 
mixture was allowed to warm to room temperature before the 
addition of 4-bromo-1-butene (4.03 mL, 43.0 mmol, 1.0 eq.). The reaction mixture was 
stirred at room temperature for a further 18 h before being quenched by the addition of 
sat. NH4Cl (aq.) (100 mL) and the organic layer was separated. The aqueous phase was 
extracted with Et2O (3 × 100 mL) and the combined organic phase washed with water 
(3 × 100 mL) and brine (100 mL), dried over MgSO4, filtered and concentrated in 
vacuo. The crude product was purified by flash column chromatography on silica gel 
(9:1 PE/ Et2O) to furnish the title compound 369 (4.50 g, 56%) as a yellow oil: Rf  0.35 
(9:1 PE/Et2O); υmax/cm
-1 2955 (C-H stretch), 1736 (C=O stretch), 1437 (C-O stretch); δH 
(400 MHz, CDCl3) 5.76 (1 H, ddt, J 17.0, 10.0, 6.5, H-7), 5.06-4.99 (2 H, m, H-8), 3.73 
(6 H, s, H-1), 3.40 (1 H, t, J 7.5, H-4), 2.12-2.06 (2 H, m, H-5), 2.04-1.98 (2 H, m, H-6). 
Data in agreement with those in the literature.134 
Lab. Book: RD10/001/C1 
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(6R*)-3-(But-3-en-1-yl)-2-hydroxy-6-iso-butyl-8,9-dihydro-4H-pyrazino[1,2-
a]pyrimidine-4,7(6H)-dione 370 
 
A solution of NaOMe was prepared by the portionwise addition 
of Na (0.408 g, 17.0 mmol, 6.0 eq.), to rigorously dried MeOH 
(8.0 mL) containing activated, powdered 3Å molecular sieves 
(2.00 g, 0.500 g/mmol). An exotherm occurred. Once the Na 
had completely reacted the solution was cooled to room 
temperature and dimethyl but-3-en-1-ylmalonate 369 (0.825 g, 
4.43 mmol, 1.5 eq.) in MeOH (2.0 mL) followed by amidine 52 
(0.500 g, 2.96 mmol, 1.0 eq.) in MeOH (2.0 mL) were added. The reaction mixture was 
heated at 65 °C for 2 h. After cooling to room temperature the reaction mixture was 
filtered through Celite® and concentrated in vacuo. The crude product was purified by 
flash column chromatography on silica gel (70:28:2 DCM/MeOH/aq. NH3) before 
recrystallization from MeOH furnished the title compound 370 (0.564 g, 65%) as a 
colourless crystalline solid: mp 222-224 °C; Rf 0.30 (70:28:2 DCM/MeOH/aqueous 
NH3); Found: C, 61.52; H, 7.18; N, 14.29; C15H21N3O3 requires: C, 61.84; H, 7.27; N, 
14.42%; υmax/cm
-1 3065 (N-H/O-H stretch), 2925 (C-H stretch), 1684 (C=O stretch), 
1651 (C=O stretch), 1540 (C=C stretch); δH (400 MHz, DMSO d-6) 11.41 (1 H, br s, H-
11), 8.52 (1 H, d, J 5.0, H-8), 5.79 (1 H, ddt, J 17.0, 10.0, 6.5, H-14), 5.00-4.95 (2 H, m, 
H-6, 15a), 4.90 (1 H, ddt, J 10.0, 2.0, 1.0, H-15b), 4.69 (1 H, d, J 17.5, H-9a), 3.99 (1 H, 
d, J 17.5, 5.0, H-9b), 2.38 (2 H, t, J 7.5, H-12), 2.17-2.11 (2 H, m, H-13), 1.74-1.59 (2 
H, m, H-16a, 17), 1.45 (1 H, ddd, J 12.5, 7.5, 6.5, H-16b), 0.95 (3 H, d, J 6.5, H-18/19), 
0.91 (3 H, d, J 6.5, H-19); δC (100 MHz, DMSO d-6) 167.7 (C-4/7), 164.2 (C-4/7), 
161.3 (C-2), 151.6 (C-10), 138.4 (C-14), 114.6 (C-15), 99.1 (C-3), 53.2 (C-6), 43.4 (C-
9), 39.5 (C-16), 31.5 (C-13). 24.3 (C-17), 22.7 (C-18/19), 22.1 (C-12), 21.6 (C-18/19); 
m/z (ESI) 292 [MH]+. Calcd. for C15H22N3O3: 292.1656. Found: [MH]
+, 292.1647 (2.9 
ppm error).  
Lab. Book: RD10/013/D1    
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(6R*)-2-(Allyloxy)-3-(but-3-en-1-yl)-6-iso-butyl-8,9-dihydro-4H-pyrazino[1,2-a]pyr 
imidine-4,7(6H)-dione 371 
 
To a solution of pyrimidinone 370 (0.250 g, 0.860 mmol, 1.0 
eq.) and allyl alcohol (0.150 mL, 2.23 mmol, 2.6 eq.) in THF 
(10.0 mL) at 0 °C (ice) was added PPh3 (0.496 g, 1.89 mmol, 
2.2 eq.) followed by DIAD (0.370 mL, 1.89 mmol, 2.2 eq.). The 
reaction mixture was allowed to warm to room temperature and 
then stirred for a further 2 h. The reaction mixture was 
quenched by the addition of 5% HCl (aq.) (20 mL) and the organic phase separated. The 
aqueous phase was extracted with EtOAc (2 × 10 mL) and the combined organic phase 
washed with brine (40 mL), dried over MgSO4, filtered and concentrated in vacuo. The 
resulting crude product was purified by flash column chromatography on silica gel (1:1 
PE/EtOAc) to furnish the title compound 371 (0.180 g, 63%) as a colourless crystalline 
solid: mp 144-146 °C; Rf  0.23 (1:1 PE/EtOAc); υmax/cm
-1 3238 (N-H stretch), 2958 (C-
H stretch), 1665 (C=O stretch), 1602 (C=O stretch), 1542 (C=C stretch); δH (400 MHz, 
CDCl3) 7.42 (1 H, d, J 5.0, H-8), 5.99 (1 H, ddt, J 17.0, 10.5, 5.5, H-13), 5.85 (1 H, ddt, 
J 17.0, 10.0, 6.5, H-17), 5.38-5.32 (2 H, m, H-6, 14a), 5.24 (1 H, app. dq (ddd), J 10.0, 
1.5, H-14b), 4.99 (1 H, ddd, J 17.0, 3.5, 1.0, H-18a), 4.91 (1 H, ddd, J 10.0, 3.5, 1.5, H-
18b), 4.86-4.75 (2 H, m, H-12), 4.54 (1 H, d, J 17.0, H-9a), 4.31 (1 H, dd, J 17.0, 5.0, 
H-9b), 2.59 (2 H, t, J 7.5, H-15), 2.32-2.22 (2 H, m, H-16), 1.85-1.69 (2 H, m, H-19a, 
20), 1.64-1.59 (1 H, m, H-19b), 1.08 (3 H, d, J 6.5, H-21/22), 0.98 (3 H, d, J 6.5, H-
21/22); δC (100 MHz, CDCl3) 170.1 (C-4/7), 163.9 (C-4/7), 161.9 (C-2), 150.1 (C-10), 
138.3 (C-17), 133.0 (C-13), 117.3 (C-14), 114.6 (C-18), 103.7 (C-3), 67.2 (C-12), 53.9 
(C-6), 44.7 (C-9), 40.4 (C-19), 31.9 (C-16), 24.8 (C-20), 23.0 (C-21/22), 22.4 (C-15), 
21.6 (C-21/22); m/z (ESI) 332 [MH]+. Calcd. for C18H26N3O3: 332.1969. Found: [MH]
+, 
332.1963 (2.2 ppm error). 
Lab. Book: RD10/028/C1 
 
 
 
 
 
 
 
 
 
 
179 
 
5-Allyl-6-(1-ethoxyethoxy)-2-phenyl-3-propylpyrimidin-4(3H)-one 376 
 
To a solution of pyrimidinone 199 (0.0530 g, 0.190 mmol, 1.0 
eq.) in ethyl vinyl ether 378 (2.0 mL, solvent) was added NEt3 
(0.0160 mL, 0.110 mmol, 0.6 eq.) and Hg(O2CF3)2 (0.0420 g, 
0.0980 mmol, 0.5 eq.). The reaction mixture was heated in a 
sealed microwave tube at 40 °C for 18 h before being cooled to 
room temperature and concentrated in vacuo. The crude product 
was purified by flash column chromatography on silica gel (9:1 
PE/EtOAc) to furnish pyrimidinone 199 (0.0230 g, 43%) and the title compound 376 
(0.0240 g, 47%) as a colourless oil: Rf 0.50 (7:3 PE/EtOAc); υmax/cm
-1 2925 (C-H 
stretch), 1662 (C=O stretch), 1595 (C=C aromatic stretch), 1531 (C=C stretch), 1443 
(C-O stretch); δH (400 MHz, CDCl3) 7.52-7.41 (5 H, m, H-8, 9, 10), 6.18 (1 H, q, J 5.0, 
H-18), 5.95 (1 H, ddt, J 16.5, 10.0, 6.5, H-15), 5.16 (1 H, ddt, J 17.0, 2.0, 1.5, H-16a), 
5.00 (1 H, ddt, J 10.0, 2.0, 1.5, H-16b), 3.87-3.83 (2 H, m, H-11), 3.76 (1 H, dq, J 9.5, 
7.0, H-21a), 3.53 (1 H, dq, J 9.5, 7.0, H-21b), 3.29 (2 H, dt, J 6.5, 1.5, H-14), 1.67-1.57 
(2 H, m, H-12), 1.46 (3 H, d, J 5.0, H-19), 1.18 (3 H, t, J 7.0, H-23), 0.75 (3 H, t, J 7.5, 
H-13); δC (100 MHz, CDCl3) 163.6 (C-4), 162.9 (C-6), 157.4 (C-2), 135.2 (C-15), 135.1 
(C-7), 129.9 (C-10), 128.5 (C-9), 127.7 (C-8), 115.1 (C-16), 102.6 (C-5), 97.8 (C-18), 
63.8 (C-21), 47.7 (C-11), 27.4 (C-14), 22.2 (C-12), 21.2 (C-19), 15.1 (C-22), 11.1 (C-
13); m/z (ESI) 343 [MH]+. Calcd. for C20H27N2O3: 343.2016. Found: [MH]
+, 343.2021 
(0.3 ppm error).     
Lab. Book: RD10/007/C1 
 
(6R*)-3-(But-3-en-1-yl)-2-(2-chloroethoxy)-6-iso-butyl-8,9-dihydro-4H-
pyrazino[1,2-a]pyrimidine-4,7(6H)-dione 380 
 
To a solution of pyrimidinone 370 (0.0500 g, 0.170 mmol, 1.0 
eq.) and chloroethanol (0.0290 mL, 0.440 mmol, 2.6 eq.) in 
THF (2.0 mL) at 0 °C (ice) was added PPh3 (0.0990 g, 0.380 
mmol, 2.2 eq.) followed by DIAD (0.0740 mL, 0.380 mmol, 2.2 
eq.). The reaction mixture was allowed to warm to room 
temperature and then stirred for a further 2 h. The reaction 
mixture was quenched by the addition of 5% HCl (aq.) (20 mL) 
and the organic phase separated. The aqueous phase was extracted with EtOAc (2 × 10 
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mL) and the combined organic phase washed with brine (40 mL), dried over MgSO4, 
filtered and concentrated in vacuo. The resulting crude product was purified by flash 
column chromatography on silica gel (8:2 EtOAc/PE) to furnish the title compound 380 
(0.0470 g, 78%) as a colourless crystalline solid: mp 131-132 °C; Rf  0.35 (9:1 
EtOAc/PE); υmax/cm
-1 3229 (N-H stretch), 2959 (C-H stretch), 1664 (C=O stretch), 1604 
(C=O stretch), 1544 (C=C stretch); δH (400 MHz, CDCl3) 7.27 (1 H, d, J 5.0, H-8), 5.85 
(1 H, ddt, J 17.0, 10.0, 6.5, H-15), 5.36 (1 H, ddd, J 9.0, 6.0, 1.0, H-6), 4.99 (1 H, ddd, J 
17.0, 3.5, 1.5, H-16a), 4.92 (1 H, ddd, J 10.0, 3.5, 1.5, H-16b), 4.58-4.48 (3 H, m, H-9a, 
11), 4.31 (1 H, dd, J 17.0, 5.0, H-9b), 3.76 (2 H, t, J 6.0, H-12), 2.58 (2 H, t, J 7.5, H-
13), 2.31-2.21 (2 H, m, H-14), 1.87-1.78 (1 H, m, H-18), 1.76-1.69 (1 H, m, H-17a), 
1.66-1.59 (1 H, m, H-17b), 1.08 (3 H, d, J 6.5, H-19/20), 0.98 (3 H, d, J 6.5, H-19/20); 
δC (100 MHz, CDCl3) 169.9 (C-4/7), 163.5 (C-4/7), 161.8 (C-2), 150.3 (C-10), 138.3 
(C-15), 114.7 (C-16), 104.1 (C-3), 66.2 (C-11), 53.9 (C-6), 44.6 (C-9), 41.9 (C-12), 40.3 
(C-17), 31.9 (C-14), 24.8 (C-18), 23.0 (C-19/20), 22.3 (C-13), 21.6 (C-19/20); m/z (ESI) 
354 [MH]+. Calcd. for C17H25
35ClN3O3: 354.1579. Found: [MH]
+, 354.1572 (1.1 ppm 
error). 
Lab. Book: RD10/017/C1 
 
(8R*,11Z)-8-iso-Butyl-11-(2-methylpropylidene)-10,11-dihydro-6H-oxepino[2,3-
d]pyrazino[1,2-a]pyrimidine-6,9(8H)-dione – (±)–Janoxepin (1) 
 
A solution of imidate 309 (0.0190 g, 0.0510 mmol, 1.0 eq.) in 
AcOH (1.6 mL) and water (0.4 mL) was heated at 50 °C for 
1.5 h. The reaction mixture was cooled to room temperature, 
concentrated in vacuo and the crude product purified by flash 
column chromatography on silica gel (3:1 PE/EtOAc) to 
furnish the title compound 1 (0.0170 g, 98%, er 53:47) as an 
orange crystalline powder: mp 179-180 °C (Lit.1 88-89 °C); Rf  0.17 (7:3 PE/EtOAc); 
υmax/cm
-1 3193 (N-H stretch), 2961 (C-H stretch), 1689 (C=O stretch), 1567 (C=C 
stretch); δH (400 MHz, CDCl3) 8.38 (1 H, s, H-8), 6.74 (1 H, d, J 11.0, H-15), 6.38 (1 H, 
d, J 10.0, H-20), 6.14 (1 H, dd, J 11.0, 5.5, H-14), 6.08 (1 H, d, J 5.5, H-12), 5.63 (1 H, 
app. t (dd), J 5.5, H-13), 5.39 (1 H, ddd, J 9.0, 5.0, 1.0, H-6), 2.67 (1 H, dsept., J 10.0, 
6.5, H-21), 1.86-1.76 (1 H, m, H-17), 1.74-1.61 (2 H, m, H-16), 1.14 (3 H, d, J 6.5, H-
22/23), 1.14 (3 H, d, J 6.5, H-22/23), 1.08 (3 H, d, J 6.5, H-18/19), 0.93 (3 H, d, J 6.5, 
H-18/19); δC (100 MHz, CDCl3) 165.9 (C-7), 162.8 (C-2), 160.5 (C-4), 149.1 (C-10), 
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143.0 (C-12), 129.1 (C-20), 127.8 (C-14), 125.6 (C-15), 124.0 (C-9), 117.2 (C-13), 
110.4 (C-3), 54.2 (C-6), 42.7 (C-16), 26.3 (C-21), 24.9 (C-17), 23.2 (C-18/19), 22.1 (C-
18/19), 22.0 (C-22/23), 21.3 (C-22/23); m/z (ESI) 342 [MH]+. Calcd. for C19H24N3O3: 
342.1812. Found: [MH]+, 342.1810 (0.9 ppm error); HPLC: Chiralpak AD-H (95:5 n-
hexane/i-PrOH, 1.0 mL min-1) 14.15 min (47.28%), 15.10 (52.72%). X-Ray 
crystallography: CCDC 848130 contains the supplementary crystallographic data for 
this compound, see Appendix V. Crystals were grown by slow evaporation of MeOH. 
Lab. Book:  RD10/022/C1, RD10/003/C1    
 
6.4 Chapter 5 – Biomimetic Oxepine Construction: Synthesis of a Janoxepin 
Biosynthetic Precursor 
 
 
tert-Butyl [(4-oxo-4H-3,1-benzoxazin-2-yl)methyl]carbamate 451 
 
A suspension of anthranilic acid 42 (0.0550 g, 0.400 mmol, 1.0 eq.), 
N-Boc-glycine 450 (0.0700 g, 0.400 mmol, 1.0 eq.) and P(OPh)3 
(0.130 mL, 0.480 mmol, 1.2 eq.) in dry pyridine (2.0 mL) in a sealed 
microwave tube was heated at 70 °C for 18 h. The reaction mixture 
was cooled to room temperature, concentrated in vacuo and the crude 
product was purified by flash column chromatography on silica gel 
(4:1 PE/EtOAc) to furnish the title compound 451 (0.0610 g, 55%) as 
a colourless crystalline solid: 129-131 °C; Rf  0.20 (4:1 PE/EtOAc); υmax/cm
-1 3349 (N-
H stretch), 2979 (C-H stretch), 1764 (C=O stretch, 1697 (C=O stretch), 1525 (aromatic 
C=C stretch); δH (400 MHz, CDCl3) 8.19 (1 H, dd, J 8.0, 1.5, H-6), 7.81 (1 H, ddd, J 
8.0, 7.0, 1.5, H-4), 7.59 (1 H, d, J 8.0, H-3), 7.53 (1 H, ddd, J 8.0, 7.0, 1.5, H-5), 5.32 (1 
H, br s, H-12), 4.31 (2 H, d, J 5.5, H-11), 1.48 (9 H, s, H-16); δC (100 MHz, CDCl3) 
159.1 (C-8), 158.8 (C-10), 155.6 (C-13), 145.7 (C-2), 136.6 (C-4), 128.6 (C-6), 128.6 
(C-5), 126.7 (C-3), 116.9 (C-7), 80.3 (C-15), 42.3 (C-11), 28.3 (C-16); m/z (ESI) 299 
[MH]+. Calcd. for C14H16N2NaO4: 299.1002. Found: [MH]
+, 299.0995 (2.1 ppm error).  
Compound previously reported as an intermediate, but not isolated.155 
Lab. Book: RD10/062/C1     
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Methyl N-(2-aminobenzoyl)-D-leucinate 458 
 
A suspension of isatoic anhydride 457 (5.00 g, 0.0310 mol, 1.0 
eq.), methyl D-leucinate 452 (4.62 g, 0.0310 mol, 1.0 eq.) and 
NEt3 (8.60 mL, 0.0620 mol, 2.0 eq.) in EtOAc (200 mL) was 
heated at 77 °C for 18 h. The reaction mixture was cooled to 
room temperature, filtered through Celite® and washed with 
water (200 mL) and brine (200 mL). The organic phase was dried over MgSO4, filtered 
and concentrated in vacuo to furnish the title compound 458 (7.13 g, 87%) as a yellow-
brown solid which was used without further purification: mp 64-66 °C (Lit.183 42-46 
°C); Rf  0.26 (4:1 PE/EtOAc); [α]D
16 +7 (c = 2.00, DCM); δH (400 MHz, CDCl3) 7.39 (1 
H, dd, J 8.5, 1.5, H-6), 7.21 (1 H, ddd, J 8.0, 7.0, 1.5, H-4), 6.67 (1 H, d, J 8.0, H-3), 
6.68-6.64 (1 H, m, H-5), 6.41 (1 H, d, J 8.0, H-9), 5.47 (2 H, br s, H-1), 4.80 (1 H, app. 
td (ddd), J 8.0, 5.0, H-10), 3.76 (3 H, s, H-13), 1.77-1.62 (3 H, m, H-14, 15), 0.98 (3 H, 
d, J 6.0, H-16/17), 0.97 (3 H, d, J 6.0, H-16/17); m/z (ESI) 265 [MH]+. Calcd. for 
C14H21N2O3: 265.1547. Found: [MH]
+, 265.1545 (0.7 ppm error).  Data are consistent 
with those in the literature.183 
Lab. Book: RD10/077/C1 and RD10/093/C1 
 
Methyl N-[2-({N-[(9H-fluoren-9-ylmethoxy)carbonyl]glycyl}amino)benzoyl]-D-
leucinate 460 
 
To a solution of methyl N-(2-aminobenzoyl)-D-
leucinate 458 (3.79 g, 0.0140 mol, 1.0 eq.) in 
DCM (230 mL) at room temperature was added 
Fmoc-Gly-Cl 459 (4.89 g, 0.0160 mol, 1.1 eq.). 
The reaction mixture was stirred for 30 min 
before the addition of 1 M Na2CO3 (aq.) and 
stirring for a further 1 h. The organic phase was 
then separated over 18 h and the aqueous phase 
extracted with DCM (3 × 100 mL). The combined organic phase was dried over 
MgSO4, filtered and concentrated in vacuo to furnish the title compound 460 (6.05 g, 
79%) as an off-white crystalline solid which was used without further purification: mp 
61-63 °C; Rf  0.07 (4:1 PE/EtOAc); υmax/cm
-1 3332 (N-H stretch), 3020 (aromatic C-H 
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stretch), 2957 (C-H stretch), 1729 (C=O stretch), 1646 (C=O stretch), 1589 (C=O 
stretch), 1521 (aromatic C=C stretch), 1449 (C-O stretch), 1251 (aromatic C-H bend); 
[α]D
19 –9 (c = 1.00, CHCl3); δH (400 MHz, CDCl3) 11.42 (1 H, br s, H-1), 8.60 (1 H, d, J 
8.0, H-6), 7.77 (2 H, d, J 7.5, H-29), 7.66 (2 H, d, J 7.5, H-26), 7.55 (1 H, dd, J 8.0, 1.5, 
H-3), 7.51 (1 H, app. t (dd), J 8.0, H-4), 7.40 (2 H, app. t (dd), J 7.5, H-28), 7.32 (2 H, 
app. t (dd), J 7.5, H-27), 7.13 (1 H, app. t (dd), J 8.0, H-5), 6.62 (1 H, d, J 8.0, H-9), 
5.57 (1 H, t, J 5.5, H-20), 4.77-4.71 (1 H, m, H-10), 4.44 (1 H, dd, J 14.0, 7.5, H-23a), 
4.41 (1 H, dd, J 14.0, 7.5, H-23b), 4.28 (1 H, app. t (dd), J 7.5, H-24), 4.09 (1 H, dd, J 
5.5, 2.0, H-19), 3.72 (3 H, s, H-13), 1.73-1.60 (3 H, m, H-14, 15), 0.94 (6 H, app. d, J 
6.0, H-16, 17); δC (100 MHz, CDCl3) 173.3 (C-11), 168.4 (C-8), 167.7 (C-18), 156.4 
(C-21), 143.9 (C-25), 143.8 (C-30), 141.2 (C-2), 139.0 (C-7), 132.9 (C-4), 127.6 (C-28), 
127.0 (C-27), 126.7 (C-3), 125.2 (C-26), 123.2 (C-5), 121.4 (C-6), 119.9 (C-29), 67.3 
(C-23), 52.5 (C-13), 51.0 (C-10), 47.1 (C-24), 45.3 (C-19), 41.3 (C-14), 24.9 (C-15), 
22.7 (C-16/17), 21.9 (C-16/17); m/z (ESI) 566 [MH]+. Calcd. for C31H33N3NaO6: 
566.2262. Found: [MH]+, 566.2261 (0.2 ppm error).   
Lab. Book: RD10/083/C1 and RD11/014/C1 
 
 
Methyl N-[2-(glycylamino)benzoyl]-D-leucinate 456 
 
To a solution of Fmoc-amide 460 (6.05 g, 0.0110 mol, 1.0 
eq.) in DCM (80 mL) was added piperidine (20 mL). The 
reaction mixture was stirred at room temperature for 30 min 
and concentrated in vacuo. The resulting crude product was 
purified by flash column chromatography on silica gel (95:5 
DCM/MeOH) to furnish the title compound 456 (2.40 g, 68%, er 95:5) as colourless 
crystalline solid: mp 130-132 °C; Rf  0.32 (9:1 DCM/MeOH); υmax/cm
-1 3261 (N-H 
stretch), 2957 (C-H stretch), 1743 (C=O stretch), 1645 (C=O stretch), 1583 (C=O 
stretch), 1518 (aromatic C=C stretch), 1449 (C-O stretch), 1286 (aromatic C-H bend); 
[α]D
19 –13 (c = 1.02, CHCl3); δH (400 MHz, CDCl3) 11.57 (1 H, br s, H-19), 8.63 (1 H, 
dd, J 8.5, 1.0, H-6), 7.54 (1 H, dd, J 7.5, 1.5, H-3), 7.49 (1 H, ddd, J 8.5, 7.5, 1.5, H-5), 
7.11 (1 H, app. td (ddd), J 7.5, 1.0, H-4), 6.55 (1 H, d, J 8.0, H-9), 4.86 (1 H, dt, J 8.0, 
5.0, H-10), 3.77 (3 H, s, H-13), 3.51 (2 H, br s, H-20), 1.80-1.64 (3 H, m, H-14, 15), 
0.99 (3 H, d, J 7.0, H-16/17), 0.97 (3 H, d, J 7.0, H16/17); δC (100 MHz, CDCl3) 173.2 
(C-11), 168.3 (C-18), 138.6 (C-2), 132.5 (C-5), 126.9 (C-3), 122.9 (C-4), 121.4 (C-6), 
121.1 (C-7), 52.3 (C-13), 51.0 (C-10), 46.0 (C-19), 41.3 (C-14), 24.9 (C-15), 22.7 (C-
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16/17), 21.9 C-16/17); m/z (ESI) 322 [MH]+. Calcd. for C16H24N3O4: 322.1761. Found: 
[MH]+, 377.1749 (3.9 ppm error); HPLC: Chiralpak AD-H (80:20 n-hexane/i-PrOH, 1.0 
mL min-1) 7.25 min (94.91%), 9.09 min (5.09%).   
Lab. Book: RD10/091/C1 and RD11/053/C1   
 
(4R*)-4-iso-Butyl-2H-pyrazino[2,1-b]quinazoline-3,6(1H,4H)-dione 431 
 
A solution of amine 456 (0.200 g, 0.620 mmol, 1.0 eq.) and 
Sc(OTf)3 (0.306 g, 0.620 mmol, 1.0 eq.) in DMF (2.0 mL) in a 
sealed vial was irradiated in the microwave (50 W, 140 °C) for 
10 min. The reaction mixture was concentrated in vacuo and 
purified by flash column chromatography on silica gel 
(97:1.9:0.1 DCM/MeOH/aqueous NH3) to furnish the title compound 431 (0.105 g, 
62%, er 51:49) as a yellow/brown solid: mp 220-221 °C (MeOH); Rf  0.33 (96:3.8:0.2 
DCM/MeOH/aqueous NH3); υmax/cm
-1 3243 (N-H stretch), 2959 (C-H stretch), 1686 
(C=O stretch), 1609 (C=O stretch), 1471 (C=C stretch); [α]D
24 –0.5 (c = 1.02, CHCl3); 
δH (400 MHz, CDCl3) 8.28 (1 H, dd, J 8.0, 1.5, H-6), 7.77 (1 H, ddd, J 8.0, 7.0, 1.5, H-
4), 7.64 (1 H, dd, J 8.0, 1.0, H-3), 7.51 (1 H, ddd, J 8.0, 7.0, 1.0, H-5), 7.34 (1 H, br s, 
H-12), 5.51 (1 H, ddd, J 8.5, 6.5, 1.5, H-10), 4.69 (1 H, d, J 17.0, H-13a), 4.48 (1 H, dd, 
J 17.0, 5.5, H-13b), 1.87-1.79 (2 H, m, H-15a, 16), 1.69 (1 H, ddd, J 15.0, 8.5, 6.5, H-
15b), 1.10 (3 H, d, J 6.5, H-17/18), 1.02 (3 H, d, J 6.5, H-17/18); δC (100 MHz, CDCl3) 
170.1 (C-11), 160.3 (C-8), 148.2 (C-2), 147.0 (C-14), 134.8 (C-4), 127.2 (C-5), 127.0 
(C-3), 126.9 (C-6), 120.3 (C-7), 54.1 (C-10), 45.0 (C-13), 40.5 (C-15), 24.9 (C-16), 22.9 
(C-17/18), 21.8 (C-17/18); m/z (ESI) 272 [MH]+. Calcd. for C15H18N3O2: 272.1394. 
Found: [MH]+, 272.1391 (1.3 ppm error); HPLC: Chiralcel OD (80:20 n-hexane/i-
PrOH, 1.0 mL min-1) 9.71 min (50.59%), 18.83 min (49.41%). Data consistent with 
those in the literature.177 
Lab. Book: RD11/006/C1 and RD11/047/C1   
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(4R*)-3-Ethoxy-4-iso-butyl-1,2,3,4-tetrahydro-6H-pyrazino[2,1-b]quinazolin-6-one 
461 
 
To a solution of pyrazino[2,1-b]quinazoline-3,6-dione 431 
(0.572 g, 2.11 mmol, 1.0 eq.) in DCM (50 mL) was added K2CO3 
(1.16 g, 8.44 mmol, 4.0 eq.) and BF4OEt3 (0.802 g, 4.22 mmol, 
2.0 eq.). The reaction mixture was heated at 45 °C for 1 h. After 
cooling to room temperature, the reaction mixture was quenched 
by the addition of sat. NH4Cl (aq.) (50 mL) and the organic phase 
separated. The aqueous phase was extracted with DCM (2 × 30 mL) and the combined 
organic phase dried over MgSO4, filtered and concentrated in vacuo. The crude product 
was purified by flash column chromatography on silica gel (3:2 PE/EtOAc) to furnish 
the title compound 461 (0.423 g, 67%) as a pale yellow oil: Rf  0.22 (3:2 PE/EtOAc); 
υmax/cm
-1 2959 (C-H stretch), 1677 (C=O stretch), 1603 (aromatic C=C stretch), 1471 
(C-O stretch); δH (400 MHz, CDCl3) 8.26 (1 H, dd, J 8.0, 1.5, H-6), 7.74 (1 H, ddd, J 
8.0, 7.0, 1.5, H-4), 7.64 (1 H, dd, J 8.0, 1.0, H-3), 7.45 (1 H, ddd, J 8.0, 7.0, 1.0, H-5), 
5.40 (1 H, ddd, J 8.5, 6.0, 1.0, H-10), 4.78 (1 H, d, J 19.5, H-13a), 4.67 (1 H, dd, J 19.5, 
1.0, H-13b), 4.22-4.18 (2 H, m, H-20), 1.77-1.64 (3 H, m, H-15, 16), 1.33 (3 H, t, J 7.0, 
H-21), 1.07 (3 H, d, J 6.5, H-17/18), 0.97 (3 H, d, J 6.5, H-17/18); δC (100 MHz, 
CDCl3) 164.6 (C-8), 160.4 (C-11), 151.3 (C-14), 147.4 (C-2), 134.5 (C-4), 126.8 (C-3), 
126.6 (C-6), 126.5 (C-5), 120.2 (C-7), 62.1 (C-20), 50.9 (C-13), 50.3 (C-10), 40.3 (C-
15), 25.1 (C16), 23.1 (C-17/18), 21.7 (C-17/18), 14.1 (C-21); m/z (ESI) 300 [MH]+. 
Calcd. for C17H22N3O2: 300.1707. Found: [MH]
+, 300.1698 (3.1 ppm error). 
Lab. Book: RD11/020/C1    
 
  
 
(1R*,4R*)-3-Ethoxy-1-(1-hydroxy-2-methylpropyl)-4-iso-butyl-1,4-dihydro-6H-
pyrazino[2,1-b]quinazolin-6-one 462 
 
A solution of LiHMDS was prepared by the addition of n-BuLi 
(0.350 mL, 2.0 M solution in n-hexane, 0.700 mmol, 2.05 eq.) 
to a solution of HMDS (0.150 mL, 0.720 mmol, 2.10 eq.) in 
THF (1.0 mL) at 0 °C (ice). Following stirring at 0 °C for 20 
min the solution was diluted with THF (1.0 mL) and cooled to 
–78 °C (CO2/acetone). To this was added a solution of imidate 
461 (0.102 g, 0.340 mmol, 1.0 eq.) in THF (2.0 mL) pre-cooled to –78 °C. The reaction 
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mixture was stirred at –78 °C for 10 min before the addition of iso-butyraldehyde 221 
(0.0930 mL, 1.02 mmol, 3.0 eq.). Following stirring for a further 10 min the reaction 
mixture was quenched by the addition of AcOH (0.5 mL) and allowed to warm to room 
temperature. The reaction mixture was partitioned between EtOAc and water (30 mL) 
and the organic phase separated. This was washed with water (2 × 20 mL) and brine (20 
mL), dried over MgSO4, filtered and concentrated in vacuo. The crude product was 
purified by flash column chromatography on silica gel (85:15 PE/EtOAc) to furnish the 
title compound 462 (0.0830 g, 66%) as a pale yellow waxy solid (single diastereomer): 
mp 73-75 °C (n-hexane); Rf  0.32 (4:1 PE/EtOAc); υmax/cm
-1 3385 (O-H stretch), 2914 
(C-H stretch), 1657 (C=O stretch), 1568 (aromatic C=C stretch); δH (400 MHz, CDCl3) 
8.25 (1 H, dd, J 8.0, 1.5, H-6), 7.75 (1 H, ddd, J 8.0, 7.0, 1.5, H-4), 7.64 (1 H, dd, J 8.0, 
1.0, H-3), 7.46 (1 H, ddd, J 8.0, 7.0, 1.0, H-5), 5.22 (1 H, ddd, J 9.0, 4.5, 1.0, H-10), 
4.61 (1 H, d, J 9.0, H-13), 4.42 (1 H, br s, H-26), 4.25-4.21 (2 H, m, H-20), 3.56 (1 H, 
dd, J 9.0, 2.5, H-22), 2.17 (1 H, sept.d, J 7.0, 2.5, H-23), 1.94-1.84 (1 H, m, H-16), 1.76 
(1 H, ddd, J 13.5, 9.0, 4.5, H-15a), 1.58 (1 H, ddd, J 13.5, 9.0, 5.0, H-15b), 1.33 (3 H, t, 
J 7.0, H-21), 1.11-1.09 (9 H, m, H-17/18, 24, 25), 0.93 (3 H, d, J 6.5, H-17/18); δC (100 
MHz, CDCl3) 161.7 (C-8), 160.3 (C-11), 153.4 (C-14), 146.4 (C-2), 134.7 (C-4), 126.7 
(C-5), 126.7 (C-3), 126.6 (C-6), 120.0 (C-7), 78.4 (C-22), 62.5 (C-13), 61.7 (C-20), 49.6 
(C-10), 45.2 (C-15), 29.5 (C-23), 25.3 (C-16), 23.4 (C-17/18), 21.5, 19.2, 14.4 (C-
17/18/24/25), 14.2 (C-21); m/z (ESI) 372 [MH]+. Calcd. for C21H30N3O3: 372.2282. 
Found: [MH]+, 372.2278 (1.0 ppm error).   
Lab. Book: RD11/043/D1 
 
(1Z,4R*)-3-Ethoxy-4-iso-butyl-1-(2-methylpropylidene)-1,4-dihydro-6H-
pyrazino[2,1-b]quinazolin-6-one 463 
 
To a solution of aldol adduct 462 (0.0670 g, 0.180 mmol, 1.0 
eq.) in pyridine (2.0 mL) was added MsCl (0.0420 mL, 0.540 
mmol, 3.0 eq.). The reaction mixture was heated at 50 °C for 2 
h, cooled to room temperature and concentrated in vacuo. The 
crude product was purified by flash column chromatography on 
silica gel (95:5 PE/EtOAc) to furnish the title compound 463 
(0.0490 g, 77%) as a pale yellow oil: Rf  0.30 (9:1 PE/EtOAc); υmax/cm
-1 2958 (C-H 
stretch), 1662 (C=O stretch), 1579 (aromatic C=C stretch), 1560 (C=C stretch), 1469 
(C-O stretch); δH (400 MHz, CDCl3) 8.24 (1 H, dd, J 8.0, 1.5, H-6), 7.73 (1 H, ddd, J 
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8.5, 6.5, 1.5, H-4), 7.70 (1 H, dd, J 8.5, 1.5, H-3), 7.42 (1 H, ddd, J 8.0, 6.5, 1.5, H-5), 
6.57 (1 H, d, J 9.5, H-22), 5.45 (1 H, dd, J 8.0, 5.5, H-10), 4.37-4.33 (2 H, m, H-20), 
3.24 (1 H, dsept., J 9.5, 6.5, H-23), 1.70-1.59 (3 H, m, H-15, 16), 1.37 (3 H, t, J 7.0, H-
21), 1.19 (3 H, d, J 6.5, H-24/25), 1.08 (3 H, d, J 6.5, H-24/25), 1.02 (3 H, d, J 6.0, H-
17/18), 0.89 (3 H, d, J 6.0, H-17/18); δC (100 MHz, CDCl3) 161.9 (C-8), 160.7 (C-11), 
147.8 (C-14), 147.1 (C-2), 136.5 (C-22), 134.3 (C-4), 132.5 (C-13), 127.4 (C-3), 126.6 
(C-6), 126.1 (C-5), 119.9 (C-7), 62.4 (C-20), 50.1 (C-10), 42.1 (C-15), 26.4 (C-23), 24.9 
(C-16), 23.2 (C-17/18), 22.5 (C-24/25), 22.1 (C-24/25), 21.8 (C-17/18), 14.1 (C-21); 
m/z (ESI) 354 [MH]+. Calcd. for C21H28N3O2: 354.2176. Found: [MH]
+, 354.2183 (2.0 
ppm error).         
Lab. Book: RD11/023/C1 
 
(1Z,4R*)-4-iso-Butyl-1-(2-methylpropylidene)-2H-pyrazino[2,1-b]quinazoline-
3,6(1H,4H)-dione 43 
 
A solution of imidate 463 (0.107 g, 0.300 mmol, 1.0 eq.) in 
AcOH (8.0 mL) and water (2.0 mL) was heated at 50 °C for 1.5 
h. The reaction mixture was then cooled to room temperature 
and concentrated in vacuo. The crude product was purified by 
flash column chromatography on silica gel (7:3 PE/EtOAc) to 
furnish the title compound 43 (0.0820 g, 84%, er 50:50) as a 
colourless crystalline solid: mp 229-231 °C (MeOH/n-hexane); Rf  0.55 (1:1 
PE/EtOAc); Found: C, 69.89; H, 7.09; N, 12.81; C19H23N3O2 requires: C, 70.13; H, 
7.12; N, 12.91%; υmax/cm
-1 3187 (N-H stretch), 3078 (aromatic C-H stretch), 2960 (C-H 
stretch), 1686 (C=O stretch), 1582 (aromatic C=C stretch), 1562 (C=C stretch); δH (400 
MHz, CDCl3) 8.59 (1 H, br s, H-12), 8.27 (1 H, dd, J 8.0, 1.5, H-6), 7.76 (1 H, ddd, J 
8.5, 7.0, 1.5, H-4), 7.69 (1 H, d, J 8.5, 1.5, H-3), 7.47 (1 H, ddd, J 8.0, 7.0, 1.5, H-5), 
6.45 (1 H, d, J 10.0, H-22), 5.58 (1 H, ddd, J 8.5, 5.5, 1.0, H-10), 2.75 (1 H, dsept., J 
10.0, 6.5, H-23), 1.83-1.71 (2 H, m, H-15a, 16), 1.65 (1 H, ddd, J 13.5, 8.5, 5.5, H-16), 
1.21 (3 H, d, J 6.5, H-24/25), 1.18 (3 H, d, J 6.5, H-24/25), 1.08 (3 H, d, J 6.5, H-
17/18), 0.94 (3 H, d, J 6.5, H-17/18); δC (100 MHz, CDCl3) 167.4 (C-11), 160.4 (C-8), 
147.4 (C-14), 145.1 (C2), 134.6 (C-4), 127.8 (C-22), 127.4 (C-3), 126.8 (C-5), 126.8 
(C-6), 124.9 (C-13), 120.0 (C-7), 53.7 (C-10), 42.6 (C-15), 26.1 (C-23), 24.9 (C-16), 
23.1 (C-17/18), 22.4 (C-24/25), 22.3 (C-24/25), 21.5 (C-17/18); m/z (ESI) 326 [MH]+. 
Calcd. for C19H24N3O2: 326.1863. Found: [MH]
+, 326.1859 (0.9 ppm error). HPLC: 
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Chiralcel OD (95:5 n-hexane/i-PrOH, 1.0 mL min-1) 9.74 min (50.10%), 20.02 min 
(49.90%). X-Ray crystallography: CCDC 862145 contains the supplementary 
crystallographic data for this compound, see Appendix V. Crystals were grown by slow 
diffusion (Et2O/DCM). 
Lab. Book: RD11/025/C1 and RD11/049/D1 
 
tert-Butyl (4R*)-4-iso-butyl-3,6-dioxo-1,3,4,6-tetrahydro-2H-pyrazino[2,1-b]quinaz 
oline-2-carboxylate 465 
 
To a solution of pyrazino[2,1-b]quinazoline-3,6-dione 431 
(0.105 g, 0.390 mmol, 1.0 eq.) in THF (6.0 mL) at room 
temperature was added NEt3 (0.0540 mL, 0.390 mmol, 1.0 eq.) 
and Boc2O (0.170 g, 0.780 mmol, 2.0 eq.) followed by DMAP 
(0.0050 g, 0.0390 mmol, 0.1 eq.). The reaction mixture was 
stirred at room temperature for 2 h before being quenched by the 
addition of sat. NH4Cl (aq) (10 mL) and the organic phase 
separated. The aqueous phase was extracted with EtOAc (2 × 15 mL) and the combined 
organic phase washed with water (20 mL) and brine (20 mL), dried over MgSO4, 
filtered and concentrated in vacuo. The resulting crude product was purified by flash 
column chromatography on silica gel (4:1 PE/EtOAc) to furnish the title compound 465 
(0.107 g, 74%) as a colourless crystalline solid: mp 158-159 °C; Rf  0.25 (4:1 
PE/EtOAc); υmax/cm
-1 2962 (C-H stretch), 1780 (C=O stretch), 1732 (C=O stretch), 
1687 (C=O stretch), 1611 (aromatic C=C stretch), 1300 (aromatic C-H bend); δH (400 
MHz, CDCl3) 8.27 (1 H, dd, J 8.0, 1.5, H-6), 7.78 (1 H, ddd, J 8.0, 7.0, 1.5, H-4), 7.66 
(1 H, dd, J 8.0, 1.0, H-3), 7.51 (1 H, ddd, J 8.0, 7.0, 1.0, H-5), 5.64 (1 H, dd, J 8.5, 7.0, 
H-10), 5.27 (1 H, d, J 17.0, H-13a), 4.69 (1 H, d, J 17.0, H-13b), 1.90-1.78 (2 H, m, H-
15a, 16), 1.68 (1 H, app. td (ddd), J 13.0, 7.0, H-15b), 1.57 (9 H, s, H-22), 1.08 (3 H, d, 
J 6.5, H-17/18), 1.04 (3 H, d, J 6.5, H-17/18); δC (100 MHz, CDCl3) 165.9 (C-11), 
159.8 (C-8), 150.3 (C-19), 147.9 (C-14), 147.1 (C-2), 134.8 (C-4), 127.4 (C-5), 127.1 
(C-3), 126.9 (C-6), 120.4 (C-7), 85.1 (C-21), 55.6 (C-10), 47.4 (C-13), 40.7 (C-15), 27.9 
(C-22), 24.9 (C-16), 22.7 (C-17/18), 21.8 (C-17/18); m/z (ESI) 372 [MH]+. Calcd. for 
C20H26N3O4: 372.1918. Found: [MH]
+, 372.1908 (2.4 ppm error).  
Lab. Book: RD11/011/C1      
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Appendix I.  
1
H- and 
13
C-NMR Spectra for Dihydro-Janoxepin 49 
 
1H-NMR Spectrum of Dihydro-Janoxepin 49 
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13C-NMR Spectrum of Dihydro-Janoxepin 49 
 
 
 
 
191 
 
Appendix II.  
1
H- and 
13
C-NMR Spectra for Tetrahydro-
Janoxepin 301 
 
1H-NMR Spectrum of Tetrahydro-Janoxepin 301 
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13C-NMR Spectrum of Tetrahydro-Janoxepin 301 
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Appendix III.  
1
H- and 
13
C-NMR Data for (±)-Janoxepin (1) 
 
 
 
Table I. Comparison of 1H-NMR Spectral Data. 400 MHz, CDCl3 
 
Atom δ (ppm) Reported δ (ppm) Synthetic 
1 5.31 (ddd, 9.1, 5.5, 0.9) 5.38 (ddd, 9.0, 5.5, 1.0) 
2 - - 
3 8.68 (s, br) 8.26 (s) 
4 - - 
5 - - 
7 - - 
9 6.01 (d, 5.3) 6.08 (d, 5.5) 
10 5.55 (t, 5.3) 5.62 (t, 5.5) 
11 6.06 (dd, 10.7, 5.3) 6.13 (dd, 11.0, 5.5) 
12 6.67 (d, 10.7) 6.73 (d, 11.0) 
13 - - 
14 - - 
16 1.61 (m) 1.72-1.61 (m) 
17 1.75 (m) 1.86-1.76 (m) 
18 0.87 (d, 6.5) 0.92 (d, 6.5) 
19 1.02 (d, 6.4) 1.07 (d, 6.5) 
20 6.31 (d, 10.2) 6.37 (d, 10.0) 
21 2.66 (dsept, 10.2, 6.5) 2.65 (dsept, 10.0, 6.5) 
22 1.08 (d, 6.7) 1.13 (d, 6.5) 
23 1.07 (d, 6.5) 1.13 (d, 6.5) 
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Table II. Comparison of 
13
C-NMR spectral data. 100 MHz, CDCl3 
 
Atom δ (ppm) Reported δ (ppm) Synthetic 
1 54.1 54.3 
2 165.9 165.2 
4 123.9 124.0 
5 149.0 149.0 
7 162.7 162.8 
9 142.9 143.0 
10 117.1 117.2 
11 127.6 127.8 
12 125.5 125.6 
13 110.3 110.5 
14 160.4 160.4 
16 42.6 42.8 
17 24.8 24.8 
18 22.1 22.1 
19 23.1 23.1 
20 129.0 128.4 
21 26.3 26.3 
22 21.1 21.4 
23 21.9 21.9 
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1H-NMR Spectrum of (±)-Janoxepin (1) 
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13C-NMR Spectrum of  (±)-Janoxepin (1) 
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Appendix IV. 
1
H- and 
13
C-NMR Spectra for the Putative 
Janoxepin Biosynthetic Intermediate 43 
 
1H-NMR Spectrum of the Putative Janoxepin Biosynthetic Intermediate 43 
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13C-NMR Spectrum of the Putative Janoxepin Biosynthetic Intermediate 43 
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Appendix V.  X-Ray Crystallography Data 
 
Tetrahydro-Oxepine 203 (CCDC 862141) 
 
 
 
 
Identification code     rjt1012 
Empirical formula   C17H20N2O2 
Formula weight   284.35 
Temperature / K   110.0 
Crystal system   monoclinic 
Space group   P21/n 
a / Å, b / Å, c / Å   5.8281(3), 8.4825(14), 29.5706(13) 
α/°, β/°, γ/°   90.00, 92.203(4), 90.00 
Volume / Å3   1460.8(3) 
Z   4 
ρcalc / mg mm
-3   1.293 
μ / mm-1   0.085 
F(000)   608 
Crystal size / mm3   0.1669 × 0.1279 × 0.0382 
2Θ range for data collection   7.08 to 57.44° 
Index ranges   -6 ≤ h ≤ 7, -7 ≤ k ≤ 10, -39 ≤ l ≤ 22 
Reflections collected   5248 
Independent reflections   3173[R(int) = 0.0175] 
Data/restraints/parameters   3173/0/191 
Goodness-of-fit on F2   1.076 
Final R indexes [I>2σ (I)]   R1 = 0.0473, wR2 = 0.0950 
Final R indexes [all data]   R1 = 0.0594, wR2 = 0.1029 
Largest diff. peak/hole / e Å-3   0.248/-0.246 
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Dihydro-Oxepine 215 (CCDC 848129) 
 
 
 
 
Identification code  rjt0908m 
Empirical formula  C15 H19 N3 O3 
Formula weight  289.33 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 10.9526(16) Å a= 99.921(3)°. 
 b = 11.3040(17) Å b= 98.521(3)°. 
 c = 12.2597(19) Å g = 97.849(3)°. 
Volume 1458.0(4) Å3 
Z 4 
Density (calculated) 1.318 Mg/m3 
Absorption coefficient 0.093 mm-1 
F(000) 616 
Crystal size 0.22 x 0.05 x 0.02 mm3 
Theta range for data collection 1.71 to 25.02°. 
Index ranges -13<=h<=13, -13<=k<=13, -14<=l<=14 
Reflections collected 14953 
Independent reflections 5123 [R(int) = 0.0533] 
Completeness to theta = 25.02° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.998 and 0.872 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5123 / 0 / 391 
Goodness-of-fit on F2 0.983 
Final R indices [I>2sigma(I)] R1 = 0.0449, wR2 = 0.0945 
R indices (all data) R1 = 0.0874, wR2 = 0.1111 
Largest diff. peak and hole 0.181 and -0.197 e.Å-3 
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(±)-Janoxepin (1) (CCDC 848130) 
 
 
 
 
Identification code    rjkt1101  
Empirical formula    C19H23.00158N3O3  
Formula weight    341.41  
Temperature/K    110.0  
Crystal system    triclinic  
Space group    P-1  
a/Å    13.0580(5)  
b/Å    13.0653(5)  
c/Å    14.0770(6)  
α/°    97.904(4)  
β/°    105.810(4)  
γ/°    112.461(4)  
Volume/Å3    2055.13(18)  
Z    4  
ρcalcmg/mm
3    1.103  
m/mm-1    0.076  
F(000)    728  
Crystal size/mm3    0.3654 × 0.1716 × 0.1007  
2Θ range for data collection    5.68 to 61.32°  
Index ranges    -18 ≤ h ≤ 16, -17 ≤ k ≤ 18, -17 ≤ l ≤ 20  
Reflections collected    17882  
Independent reflections    11009[R(int) = 0.0225]  
Data/restraints/parameters    11009/14/529  
Goodness-of-fit on F2    1.078  
Final R indexes [I>=2σ (I)]    R1 = 0.0686, wR2 = 0.1927  
Final R indexes [all data]    R1 = 0.0934, wR2 = 0.2104  
Largest diff. peak/hole / e Å-3    0.417/-0.280  
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Putative Biosynthetic Intermediate 43 (CCDC 862145) 
 
 
 
Identification code    rjkt1103  
Empirical formula    C19H23N3O2  
Formula weight    325.40  
Temperature/K    109.95(10)  
Crystal system    monoclinic  
Space group    P21/c  
a/Å    10.1662(4)  
b/Å    19.8479(7)  
c/Å    9.0230(4)  
α/°    90.00  
β/°    107.643(5)  
γ/°    90.00  
Volume/Å3    1735.01(13)  
Z    4  
ρcalcmg/mm
3    1.246  
m/mm-1    0.082  
F(000)    696.0  
Crystal size/mm3    0.2144 × 0.0643 × 0.0417  
2Θ range for data collection    5.68 to 55.94°  
Index ranges    -13 ≤ h ≤ 12, -25 ≤ k ≤ 14, -11 ≤ l ≤ 7  
Reflections collected    6967  
Independent reflections    3537[R(int) = 0.0445]  
Data/restraints/parameters    3537/0/221  
Goodness-of-fit on F2    1.069  
Final R indexes [I>=2σ (I)]    R1 = 0.0714, wR2 = 0.1780  
Final R indexes [all data]    R1 = 0.1084, wR2 = 0.2063  
Largest diff. peak/hole / e Å-3   0.31/-0.29  
10.1021/ol300039x r 2012 American Chemical Society
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ABSTRACT
The total synthesis of (()-janoxepin, a novel antiplasmodial D-leucine derived oxepine-pyrimidinone-ketopiperazine isolated from the fungus
Aspergillus janus, is described. The cornerstones of the synthetic route are pyrimidinone preparation, ring-closing metathesis, aldol introduction
of the enamide, and dihydro-oxepine elaboration. This synthetic route proved very efficient for the formation of a number of janoxepin analogues,
including dihydro-janoxepin and tetrahydro-janoxepin.
Janoxepin (1) was isolated from the fungus Aspergillus
janus in 2005 by Sprogøe and co-workers and shown to
display antiplasmodial activity against themalaria parasite
Plasmodium falciparum 3D7 (IC50 28 mg/mL).
1 Struc-
turally, janoxepin is fascinating, being based on anoxepine-
pyrimidinone-ketopiperazine tricyclic core derived from
D-leucine. The overall structure of janoxepin was deter-
mined by a combination of MS and NMR spectroscopy,
with the Z-configuration of the exocyclic enamide moiety
being confirmedby 1HNMRNOEcorrelations (Figure 1).
Examples of reduced oxepine-based natural products
such as the brevetoxin-like polyether marine metabolites2
and dihydro-oxepine epidithiodiketopiperazines3 are well-
known and have been the subject of synthetic studies.
However, examples containing a higher degree of unsat-
uration are rare.4 That said, janoxepin belongs to a small
family of pyrimidinone-annelated oxepine natural pro-
ducts including one very close relative in cinereain (2)5
and a number of other related compounds (oxepinamides
AD,6,7 brevianamides OP,8 protuboxepins AB,9
circumdatin A (asperloxin A),10 and circumdatin B).11
Figure 1. Structure of janoxepin (1).
(1) Sprogøe, K.; Manniche, S.; Larsen, T. O.; Christopherson, C.
Tetrahedron 2005, 61, 8718.
(2) For reviews see: Yamaguchi, S. Heterocycles 2009, 79, 243.
Snyder, N. L.; Haines, H. M.; Peczuh, M. W. Tetrahedron 2006, 62,
9301. Elliott, M. C. J. Chem. Soc., Perkin Trans. 1 2002, 2301.
(3) Codelli, J. A.; Puchlopek, A. L. A.; Reisman, S. E. J. Am. Chem.
Soc., DOI: 10.1021/ja209354e, Publication Date (Web): 24 Oct 2011.
(4) For naturally occurring dibenzo-oxepines and their synthesis, see:
Olivera, R.; San Martin, R.; Churruca, F.; Domınguez, E. Org. Prep.
Proced. Int. 2004, 36, 297.
(5) Cutler, H. G.; Springer, J. P.; Arrendale, R. F.; Arison, B. H.;
Cole, P. D.; Roberts, R. G. Agric. Biol. Chem. 1988, 52, 1725.
(6) Belofsky, G. N.; Anguera, M.; Jenson, P. R.; Fenical, W.; K€ock,
M. Chem.;Eur. J. 2000, 6, 1355.
(7) Lu, X.-H.; Shi, Q.-W.; Zheng, Z.-H.; Ke, A.-B.; Zhang, H.; Huo,
Y.; Ma, C.-H.; Ren, X.; Li, Y.-Y.; Lin, J.; Jiang, Q.; Gu, Y.-C.; Kiyota,
H. Eur. J. Org. Chem. 2011, 4, 802.
(8) Li, G.-Y.; Li, L.-M.; Yang, T.; Chen, X.-Z.; Fang, D.-M.; Zhang,
G.-L. Helv. Chim. Acta 2010, 93, 2075.
(9) Lee, S. U.; Asami, Y.; Lee, D.; Jang, J.-H.; Ahn, J. S.; Oh, H.
J. Nat. Prod 2011, 74, 1284.
(10) Ookura, R.; Kito, K.; Ooi, T.; Namikoshi, M.; Kusumi, T.
J. Org. Chem. 2008, 73, 4245. See also (erroneous structural assignment):
Rahbæck, L.; Breinholt, J.; Frisvad, J. C.; Christopherson, C. J. Org.
Chem. 1999, 64, 1689.
(11) Bode, H. B.; Bethe, B.; H€ofs, R.; Zeeck, A.ChemBioChem 2002,
3, 619.
Appendix VI.             Publications
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The oxepine natural products are not only of interest in
terms of their biological properties but are also intriguing
from a biosynthetic viewpoint: benzene epoxidation/rear-
rangement has been proposed as a biogenetic route to such
oxepine ring systems.1,7,11 Our interest, however, was to
develop a practical synthetic route to the oxepine-based
natural products, particularly to janoxepin and synthetic
analogues, and the benzene epoxidation route did not seem
well-suited to this objective. To the best of our knowledge,
there have been no syntheses, or synthetic approaches,
reported for janoxepin (1). Indeed, as far as we are aware,
no syntheses of any oxepine-based natural products lacking
benzannelationhave yet been reported (which is remarkable
as cinereain (2) was described as long ago as 1988).
The proposed retrosynthetic analysis (Scheme 1) was
based upon late-stage dihydro-oxepine elaboration pre-
ceded by introduction of the enamide using an aldol
condensation between dihydro-oxepine 3 and iso-butyral-
dehyde; dihydro-oxepine 3would thenbeprepared from the
diallyl pyrimidinone precursor 4 using ring-closing metath-
esis (RCM) with D-leucine being employed as the ultimate
starting material. This approach has the virtue of brevity,
and utility for analogue synthesis, but its speculative nature
needs emphasis;we couldnot finda single literature example
of oxepine synthesis proceeding by elaboration of the
corresponding dihydro-oxepine (see later discussion).
The synthetic study therefore commenced with the pre-
paration of the diallylated pyrimidinone 4 from commer-
cially available N-Boc-D-leucine 7 as shown in Scheme 2.
Mixed anhydride formation followed by coupling with
aminoacetonitrile and Boc deprotection gave the known
amine 8 in excellent yield.12Amine 8was next subjected to an
efficient, telescoped one-pot oximationhydrogenation cy-
clization sequence (based on a published procedure)13 to
furnish the desired novel amidine 5 {[R]D
22 47 (c 1.00,
MeOH)} in just 4 steps and64%overall yield fromD-leucine.
Condensation of cyclic amidine 5with the commercially
available allylmalonate 6usingNaOMeasbase and strictly
anhydrous conditions furnished the requiredpyrimidinone
9 in excellent yield (72%) on an 8 g scale, althoughwewere
disappointed to observe that racemization of the stereo-
genic center had occurred.14 The O-allylation of com-
pound 9 was investigated next, and the use of allyl
alcohol under Mitsunobu conditions (DIAD, PPh3) was
found to be optimal giving the required diallylated
pyrimidinone 4 in 73%yield.14 Interestingly, the use ofmore
conventional alkylating conditions (e.g., allyl bromide,
Bu4NI, K2CO3) gave much lower yields of product 4 with
substantial quantities of the bis-alkylated product 10 being
isolated (as a single diastereomer).
Having previously established that imidate-protected
amides were optimal substrates for aldol addition to the
ketopiperazine ring, it was found most efficient to protect
diallyl pyrimidinone 4 as imidate 11 prior to the key RCM
step. (whenRCMwas carriedout first, the basic conditions
needed for imidate formation also gave dihydro-oxepine
Scheme 1. Retrosynthetic Analysis
Scheme 2. Synthesis of Diallyl Pyrimidinone 14
(12) Frizler, M.; Lohr, F.; Furtmann, N.; Kl€as, J.; G€utschow, M.
J. Med. Chem. 2011, 54, 396.
(13) Kuse, M.; Kondo, N.; Ohyabu, Y.; Isobe, M. Tetrahedron 2004,
60, 835.
(14) {[R]D22þ 0.8 (c1.01,MeOH)}; confirmedbyHPLCanalysis of com-
pound 14 [ChiralpakAD-H, n-hexane/i-PrOH (9:1), 1 mLmin1; 14.15min,
47.3%; 15.10 min, 52.7% (ca. 5% ee)]; see Supporting Information.
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rearrangement products).15 Subsequent treatment of com-
pound 11 with the Grubbs second generation catalyst
(benzylidene[1,3-bis(2,4,6-trimethylphenyl)-2-imidazoli-
dinylidene]dichloro(tricyclohexylphosphine)ruthenium)
then provided dihydro-oxepine 12 in excellent yield as
shown in Scheme 3.
Wewerenow inaposition to effect the aldol elaboration.
This was achieved by deprotonation of imidate 12 with
LiHMDS and addition of iso-butyraldehyde, which pro-
vided aldol adduct 13 as a single diastereomer in excellent
yield (70%). Amesylationelimination sequence was then
employed togive enamine14asa single isomer.Next, imidate
hydrolysis gavedihydro-janoxepin15 in73%yield, againasa
single enamine isomer, which was confirmed to be in the
Z-configuration via 1H NMRNOE experiments. In pursuit
of other novel analogues, hydrogenation of dihydro-oxepine
intermediate 14 followed by imidate hydrolysis also provided
tetrahydro-janoxepin 16 as the Z-alkene.
The key step that remained in order to complete the
synthesis of janoxepin (1) was to convert one of the
dihydro-oxepine intermediates into the corresponding
oxepine. This proved to be extremely difficult, however.
Initial attempts centered around the formation of 1,2-
dibromides, or 1,2-diol-derived sulfonates, and then dou-
ble elimination to give the required diene. Unfortunately,
the elimination sequences all failed, possibly due to the
inherent strain of the oxepine (and the base-sensitivity of
dihydro-oxepines).15 After considerable experimentation,
an alternative sequence, illustrated in Scheme 4, was
devised in which the two alkenes are introduced in a
stepwise manner.
Treatment of dihydro-oxepine 14with selenium dioxide
gave allylic oxidation producing a mixture of allylic
alcohol 18 (50%, R:β= 1:1) along with a small amount
of the corresponding ketone 17 (10%), which could be
converted back into alcohol 18 (R:β=1:1) using sodium
borohydride. The 11,12-location of the double bond
was established from 1H NMR multiplicities (for a
single diastereomer, H-11 and H-12 were observed as
a doublet of doublets and doublet, respectively) and
was further confirmed by COSY, 13C and HSQC NMR
experiments.
Scheme 3. Dihydro-janoxepin 15 and Tetrahydro-janoxepin 16
Preparation
Scheme 4. Synthesis of Janoxepin (1)a
aX-ray structure of janoxepin (1) depicted using ORTEP-3 (CCDC
848130).
(15) Ramachary, D. B.; Ramakumar, K.; Bharanishashank, A.;
Narayana, V. V. J. Comb. Chem. 2010, 12, 855 and references therein.
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Following a screen of numerous methods for the dehy-
dration of allylic alcohol 18 to generate oxepine 20
(including sulfurane reagents, acid catalysis, Chugaev elim-
ination, Shapiro/BamfordStevens chemistry, selenide
oxidation, TsujiTrost elimination), it was found neces-
sary to proceed by way of the corresponding chloride 19
(R:β = 1:1) which was formed directly, and in near-
quantitative yield, using methanesulfonyl chloride in di-
chloromethane. Chloride 19 underwent TBAF-mediated
dehydrohalogenation16 to produce oxepine 20 in low
(10%), but entirely reproducible, yield which could not
be improvedupon followinganoptimization studyofbase,
solvent, and temperature. Although all starting material
was consumed in the reaction, no other products could be
identified from a complex mixture of polar byproducts. In
order to ascertain whether one diastereomer of chloride 19
was undergoing elimination preferentially, the diastereo-
mers of allylic alcohol 18 were separated and the two
compounds were subjected separately to the chlorination
conditions. However, in both cases an inseparable diaste-
reomeric mixture of chlorides 19 (R:β=1:1) was obtained
preventing further experimentation. The reasons for the
disappointing elimination yield leading to oxepine 20 are
not yet fully understood, although the base-sensitivity of
dihydro-oxepines15 and the acid and light sensitivity of
oxepines17 are well recognized. However, it must be em-
phasized that, to our knowledge, this is the first reported
preparation of an oxepine from the corresponding dihy-
dro-oxepine (although benzannelated oxepines18 and di-
hydro-analogues3 have been prepared by an eliminative
approach). Finally, imidate hydrolysis furnished janoxe-
pin (1) in near-quantitative yield. The 1H and 13C NMR
data for the synthetic material were in excellent agreement
with those published in the isolation paper (e.g., δC
(reported):1 C-9C-14, 142.9, 117.1, 127.6, 125.5, 110.3,
160.4). δC (found): C-9C-14, 143.0, 117.2, 127.8, 125.6,
110.5, 160.4). [See Supporting Information for a detailed
comparison.]
However, the melting point of synthetic janoxepin
(179180 C) did not match the reported value (88
89 C).1,19 This could be due to polymorphism or to the
fact that our material was racemic, but to provide unam-
biguous structural proof we subjected synthetic janoxepin
to X-ray crystallographic analysis. The first X-ray crystal
structure of janoxepin (1), shown in Scheme 4, confirmed
our structural assignment and indicated that it exists in two
oxepine conformers in the solid state.20
In principle, double deprotonation of racemic janoxepin
followed by enantioselective protonation21 of the resulting
enolate should provide a route to the enantioenriched
natural product.Unfortunately, usingbases suchas sec-BuLi
and a chiral proton source such as ()-ephedrine resulted in
complete decompositionof the substrate, anddecomposition
was also observed starting from imidate 20 (again demon-
strating the base-sensitivity of these oxepines).
In summary, we have completed the first total synthesis
of an oxepine-based natural product, and the first of any
oxepine-pyrimidinone natural product, the antiplasmodial
janoxepin (1), confirming the published1 structural assign-
ment by X-ray crystallography.
The synthesis of janoxepin (1) was accomplished in 13
steps from readily available Boc-D-leucine 7 using ring-
closing metathesis, aldol introduction of the enamide, and
oxepine elaboration as the key steps. The same synthetic
approach has been employed to prepare janoxepin ana-
logues including dihydro-janoxepin 15 and tetrahydro-
janoxepin 16. We are currently optimizing the route, in
particular the method of oxepine construction, as well as
investigating other enantioselective strategies. Ultimately,
this methodology will be employed to prepare other mem-
bers of the oxepine natural product family.
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Figure 1. Representative oxepine natural products.There is increasing fascination with the growing family of oxe-
pine-containing natural products, particularly in terms of their
structural determination, biological activity and biogenesis. We
have become interested in this area from a synthetic viewpoint
and recently reported the ﬁrst total synthesis of the anti-plasmo-
dial, oxepine-pyrimidinone-containing natural product janoxepin
(1) (Fig. 1).1
In terms of the biosynthesis of oxepine-containing natural prod-
ucts such as janoxepin (1) and related compounds, oxepinamide D
(2)2 and brevianamide O (3),3 a common proposal is that the oxe-
pine ring is generated via enzymatic arene-epoxidation of a pyraz-
ino[2,1-b]quinazoline-3,6-dione 4 followed by a rearrangement
and ring-opening sequence (Scheme 1).2–4
The pyrazino[2,1-b]quinazoline-3,6-dione skeleton seen in 4
can be found in numerous natural products with considerable bio-
logical potential. Many of this family, including acetylardeemin,5
ﬁscalin B6 and serantrypinone7 (amongst others8) have been the
subject of elegant syntheses. However, these compounds do not
bear the enamine moiety at C-4 present in 4 and the only natural
product examples with this structural feature are aurantiomide C
(6),9 verrucine F (7)10 and quinadoline A (8)11 ( Fig. 2), none of
which have succumbed to total synthesis to date. We therefore
decided to develop a synthetic route to prepare the putative
janoxepin precursor 4, both to aid biosynthetic studies in the
oxepine natural product area, and to provide an entry into the
pyrazino[2,1-b]quinazoline-3,6-dione natural products shown in
Figure 2.ll rights reserved.
fax: +44 (0)1904 324523.
ylor).The retrosynthetic analysis of 4 (Scheme 2) relied upon intro-
duction of the aliphatic enamine moiety via an aldol addition to
an imidate-protected version of the known12 pyrazino[2,1-b]qui-
nazoline-3,6-dione 9, followed by a selective elimination to furnish
the Z-enamine. The tricyclic intermediate 9 would itself be con-
structed by a double cyclisation of the novel amine 10, whilst an
amide coupling sequence starting from the inexpensive and readily
available isatoic anhydride (11), Fmoc-Gly-Cl 12 and D-leucine
methyl ester (13) would ultimately be employed to synthesise this
key intermediate.
The study therefore commenced with a modiﬁed coupling of
the commercially-available isatoic anhydride (11) and D-leucine
methyl ester (13) (Scheme 3) to furnish the known amide 14 in a
much improved yield to that previously reported (87% vs 32%13).
This was followed by a second coupling with the Fmoc-protected
glycine chloride 12 to furnish the novel intermediate 15. The Fmoc
protecting group was then removed by treatment of 15with piper-
idine to provide the key novel amine intermediate 10 in three207
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Scheme 1. Proposed biosynthesis of janoxepin (1).
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analysis).14
In order to effect the double cyclisation to convert amine 10
into pyrazino[2,1-b]quinazoline-3,6-dione 9 we utilised the Lewis
acid mediated cyclisation procedure reported by Chu and co-
workers.15 Thus, a solution of amine 10 in DMF was treated with
1 equiv of scandium triﬂate and irradiated in a microwave reac-
tor (CEM Discover) at 140 C, 50 W for 2 min as reported,15 but
only a trace of the desired tricycle 9 was observed along with
unreacted amine 10. However, microwave irradiation at the same
temperature for an extended period (10 min) gave pyrazino[2,1-
b]quinazoline-3,6-dione 9 in 62% yield (Scheme 3). This result
demonstrates that the Chu procedure15 is compatible with a sub-
stituent at C-1 on the ketopiperazine ring. Disappointingly
however, due either to the long reaction times, or simply the
base-sensitivity of the compounds, complete racemisation was
observed (9, 51:49 er) under the cyclisation conditions employed
here.16 Future work will investigate the effect of different side
chains at the C-1 position and screen alternative Lewis acids in
order to demonstrate the broader scope of this procedure. [Com-
pound 9 has previously been prepared by a four-step solid phaseFigure 3. X-ray crystallography of (±)-4. ORTEP representations shown with ellipsoids‘discrete’ synthesis in 53% overall yield from L-leucine-Wang re-
sin, anthranilic acid and Fmoc-Gly-Cl; no isolated mass reported,
optical purity unspeciﬁed.12 The long reaction times and large
excesses of anthranilic acid, Fmoc-Gly-Cl and iodine needed did
not lend this procedure to the gram scale preparation of 9
required in this context].
The key step now remaining was to install the enamine moiety.
Amide 9was ﬁrst converted into the novel imidate 16 using trieth-
yloxonium tetraﬂuoroborate. This choice of amide protection has
the virtue of facile subsequent removal under mild conditions,
whilst being stable to the basic conditions required for ketopiper-
azine deprotonation and further manipulations. Aldol addition
was effected by treatment of compound 16 with LiHMDS in THF
at 78 C followed by the addition of iso-butyraldehyde to afford
alcohol 17 as a single diastereomer and in good yield. Treatment
of 17 with methanesulfonyl chloride in pyridine, with heating to
50 C, gave enamine 18 directly (as a single isomer) via a one-pot
mesylation–elimination sequence. The preparation was completed
by imidate hydrolysis using aqueous acetic acid with heating to
50 C to furnish the target compound 4 in 43% overall yield over
the three steps in racemic form (Scheme 4).at 50% probability. A single enantiomer (R) is shown for clarity. CCDC 862145.18
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Table 1
Epoxidation conditions screened
Entry Oxidant Conditions
1 m-CPBA CH2Cl2/aq NaHCO3 (sat.), rt, 18 h
2 NaOCl n-Bu4NHSO4, CH2Cl2, rt, 18 h
3 DMDO Acetone, 0 C–rt, 18 h
2536 R. G. Doveston, R. J. K. Taylor / Tetrahedron Letters 53 (2012) 2533–2536The structure of 4 was conﬁrmed by 1H and 13C NMR spectros-
copy in conjunction with COSY and HSQC experiments.17 NOE cor-
relations (Scheme 4) conﬁrmed that the enamine was in the
desired Z-conﬁguration, and further proof of this was provided
by X-ray crystallographic analysis (Fig. 3).18
Preliminary, if speculative, experiments were carried out to
investigate whether chemical oxidation could be employed to ef-
fect the proposed biomimetic oxepine formation (Table 1). Pyrazi-
no[2,1-b]quinazoline-3,6-dione 9 was chosen as the substrate for
this study to preclude any problems with competing epoxidisation
of an enamine double bond. Unfortunately, there was no sign of the
hoped-for oxepine 19 (nor the intermediate epoxide) and only an
inseparable mixture of N-oxide compounds, starting material and
degradation products was observed (oxidation at the ketopiper-
azine C-4 position cannot be ruled out as this process has been re-
ported previously19). In order to remove the possibility of N-oxide
formation, the corresponding N-Boc derivative 20 was subjected to
the same reagents with similarly disappointing results. We plan to
investigate the chemical oxidation of the putative biosynthetic
intermediate 4 and its imidate precursor 18 in due course; how-
ever these preliminary results suggest that arene oxidation will
be difﬁcult to achieve synthetically.
In summary, the putative biosynthetic precursor to janoxepin
(1), pyrazino[2,1-b]quinazoline-3,6-dione 4, has been prepared in
an efﬁcient eight-step synthesis starting from readily available
and inexpensive starting materials. The methodology for installa-
tion of the enamine moiety, as well as that for pyrazino[2,1-b]qui-
nazoline-3,6-dione construction, not only has application in the
preparation of other oxepine biosynthetic precursors, but also in
the synthesis of pyrazino[2,1-b]quinazoline-3,6-dione natural
products 6–8 (Fig. 2). Strategies for the asymmetric synthesis of
compounds of this type are currently being investigated. With a
view to developing a biomimetic strategy for the synthesis of oxe-
pine natural products, a preliminary investigation of chemical
arene-epoxidation procedures was unsuccessful. However, an efﬁ-
cient route to these key biosynthetic precursors is now available to
underpin future studies using enzymatic epoxidative
biotransformations.
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Abbreviations 
 
Ac  Acetyl 
AcOH  Acetic acid 
AIBN  Azobis-iso-butyronitrile 
APCI  Atmospheric-pressure chemical ionisation 
app.  Apparent 
aq.  Aqueous 
Ar  Aryl 
BHT  Butylhydroxytoluene 
BIRO  Base induced ring opening 
Bmim  1-Butyl-3-methylimidazolium 
Bn  Benzyl 
Boc  tert-Butyloxycarbonyl 
br  Broad 
brsm  Based upon recovered starting material 
Bu  Butyl 
CAN  Cerium (IV) ammonium nitrate  
cat.  Catalytic 
CCDC  Cambridge Crystallographic Data Centre 
COSY  Correlation spectroscopy 
m-CPBA meta-Chloroperoxybenzoic acid 
18-crown-6 1,4,7,10,13,16-hexaoxacyclooctadecane 
δ  Chemical shift 
Δ  Heat 
d  Doublet, day 
D Stereochemically analogous to dextrorotatory enantiomer of 
glyceraldehyde 
DBAD di-tert-butyl azodicarboxylate 
DBN 1,5-Diazabicyclo[4.3.0]non-5-ene 
DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene 
DCM Dichloromethane 
DDQ 2,3-Dichloro-5,6-dicyanobenzoquinone 
de Diastereomeric excess 
DEAD Diethyl azodicarboxylate 
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DEPT Distortionless enhancement by polarization transfer 
DIAD Di-iso-propyl azodicarboxylate 
DIPEA Di-iso-propylethylamine 
DKP Diketopiperazine 
DMAP 4-Dimethylaminopyridine 
DME Dimethoxyethane 
DMF N,N-Dimethylformamide 
DMDO Dimethyldioxirane 
DMI 1,3-Dimethyl-2-imidazolidinone 
DMPU 1,3-Dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone 
DMSO  Dimethyl sulfoxide 
E  Entgegen, trans 
EDTA  Ethylenediaminetetraacetic acid 
ee  Enantiomeric excess 
eq.  Equivalent 
ESI  Electrospray ionisation 
Et   Ethyl 
g  Gram 
h  Hour(s)   
h  Planck’s constant 
HMBC Heteronuclear multiple bond correlation 
HMDS  Hexamethyldisilazane 
HPLC  High performance liquid chromatography 
HRMS  High resolution mass spectrometry 
HSQC  Heteronuclear single-quantum correlation 
HWE  Horner-Wadsworth-Emmons 
Hz  Hertz 
IC50  Median inhibition concentration 
IR  Infra-red 
IUPAC International Union of Pure and Applied Chemistry 
J  Coupling constant in Hz 
L Stereochemically analogous to levorotatory enantiomer of 
glyceraldehydes 
LDA Lithium di-iso-propylamide 
m Multiplet 
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M Molar 
Me  Methyl 
υmax Wavenumber of peak absorption 
mg Milligram 
MHz Megahertz 
mL Millilitre 
mmol Millimole 
min Minute(s) 
mp Melting point 
Ms Methane sulfonyl (mesyl) 
MS Molecular sieves 
MTBD  7-Methyl-1,5,7-triazabicyclo[4.4.0]dec-5-ene  
m/z Mass to charge ratio 
NBS N-Bromosuccinamide 
NMO N-Methylmorpholine-N-oxide 
NMP N-Methylpyrrolidone 
nOe Nuclear Overhauser effect 
NMR Nuclear magnetic resonance 
PCC Pyridinium chlorochromate 
PE Petroleum ether (that fraction which boils at 40 – 60 °C) 
Ph Phenyl 
pKa Acid disassociation constant 
PMB para-Methoxybenzyl 
ppm Parts per million 
Pr Propyl 
Py Pyridyl 
q Quartet 
quant. Quantitative 
sat. Saturated 
q Quartet 
R Unspecified group (aliphatic or aromatic) 
RCM Ring closing metathesis 
Rf Retention factor 
rsm Recovered starting material 
rt Room temperature 
214 
 
RTX  Resiniferatoxin 
s Singlet 
sept Septet 
sat. Saturated 
t Triplet 
t0.5 Half life 
TBAF Tetra-n-butylammonium fluoride 
TBAI Tetra-n-butylammonium iodide 
TBHP tert-Butyl hydrogen peroxide 
Teoc 2-(Trimethylsilyl)ethyl 4-nitrophenyl carbonate 
Tf Trifluoromethanesulfonyl (trifyl) 
TFA Trifluoroacetic acid 
TFDO Methyl(trifluoromethyl)dioxirane 
Tf2O Trifluoromethanesulfonic anhydride 
TfOH Trifluormethanesulfonic acid 
THF Tetrahydrofuran 
TLC Thin layer chromatography 
TMEDA Tetramethylethylenediamine 
TMS Trimethylsilane 
Tris 2,4,6-Tri-iso-propylbenzene 
Ts para-Toluenesulfonyl 
p-TSA para-Toluenesulfonic acid 
υ Frequency (Hz) 
μW Microwave 
Z Zusammen, cis 
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